संकलक (SANKALAK)

Status of National AIDS & STD Response

FIFTH EDITION
2023
© NACO, MoHFW, GoI, 2023

All rights reserved

You may copy, redistribute and adapt the publication for non-commercial purposes, provided the publication is
appropriately cited. In any use of this publication, there should be no suggestion that NACO endorses any specific
organization, products, or services. The use of the NACO logo is not permitted. If you adapt the publication, then you
must license your work allowing copy, redistribute and adapt the work for non-commercial purposes. If you create a
translation of this publication, you should add the following disclaimer: “This translation was not created by the NACO.
NACO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding
and authentic edition”

General disclaimers

NACO has made every effort to ensure the accuracy of data and verify the information contained in this publication.
However, errors and omissions excepted. The publication is being distributed without warranty of any kind, either
expressed or implied. Maps (if any), used in this publication, are only to provide visual impressions on the given
indicator. These are not for scale and must not be construed or used as a “Legal Description” of any State/UT/district.

Suggested citation

National AIDS Control Organisation (2023). Sankalak: Status of National AIDS & STD Response (Fifth edition, 2023).
New Delhi: NACO, Ministry of Health and Family Welfare, Government of India.

For additional information about Sankalak: Status of National AIDS & STD Response (Fifth edition, 2023),
please contact

Monitoring & Evaluation - Strategic Information Division

National AIDS Control Organisation (NACO)
Ministry of Health and Family Welfare, Government of India
6th and 9th Floor
Chanderlok Building, 36 Janpath, New Delhi, 110001
संकलक (SANKALAK)
Status of National AIDS & STD Response

FIFTH EDITION
2023
Sankalak: Status of National AIDS & STD Response (2023)
Sankalak: Status of National AIDS & STD Response (2023)
Sankalak: Status of National AIDS & STD Response (2023)
 Content

CONTENT

ABBREVIATIONS ...................................................................................................................15
EXECUTIVE SUMMARY .........................................................................................................19
1. INTRODUCTION ..........................................................................................................24
1.1 Background .....................................................................................................25
1.2 Organisation of the Report ..............................................................................25
2. STATUS OF THE EPIDEMIC ..........................................................................................28
2.1 Background .....................................................................................................29
2.2 Overview .........................................................................................................29
2.3 State/UT-wise level and trend ..........................................................................35
2.4 HIV Epidemic among High-risk groups ............................................................37
2.5 Syphilis seropositivity ......................................................................................43
3. PROGRESS ON 95-95-95 .............................................................................................46
3.1 Background .....................................................................................................47
3.2 National Progress ............................................................................................47
3.3 State/UT-wise progress ....................................................................................48
4. INFORMATION, EDUCATION & COMMUNICATION,
YOUTH AND MAINSTREAMING .................................................................................52
4.1 Background .....................................................................................................53
4.2 Mainstreaming & Partnership ..........................................................................53
4.3 Social Media ....................................................................................................55
4.4 National Toll-Free AIDS Helpline 1097 .............................................................56
4.5 Red Ribbon Club ..............................................................................................57
4.6 Adolescence Education Programme ................................................................57
4.7 Strengthening India’s response to the elimination of
HIV-related stigma and discrimination .............................................................58
5. PREVENTION OF NEW HIV/STI INFECTIONS AMONG
HIGH-RISK GROUPS AND BRIDGE POPULATION .......................................................60
5.1 Background .....................................................................................................61
5.2 Coverage of key population under TI: An overview ........................................63

Sankalak: Status of National AIDS & STD Response (2023) 11

Content

5.3 FSW coverage with Prevention Services in TI ..................................................64

5.4 MSM coverage with Prevention Services in TI .................................................67
5.5 H/TG persons coverage with Prevention Services in TI ....................................69
5.6 Migrants with Prevention Services in TI ...........................................................71
5.7 Truckers with Prevention Services in TI ............................................................73
5.8.1 IDUs with Prevention Services in TI .................................................................75
5.8.2 Opioid Substitution Therapy (OST) ..................................................................77
5.9 Prison Interventions .........................................................................................79
5.10 Link Workers Scheme (LWS) .............................................................................82
6. MANAGEMENT OF SEXUALLY TRANSMITTED
INFECTIONS/REPRODUCTIVE TRACT INFECTIONS ...................................................84
6.1 Background .....................................................................................................85
6.2 Service delivery model ....................................................................................85
6.3 Management of cases of STI/RTI ......................................................................87
6.4 Laboratory diagnosis at DSRC .........................................................................90
7. HIV COUNSELING AND TESTING SERVICES ..............................................................92
7.1 Background .....................................................................................................93
7.2 HIV Counselling and Testing Service (HCTS) Facilities .....................................93
7.3 HCT services uptake ........................................................................................94
7.4 HIV Sero-Positives and Sero-Positivity .............................................................98
7.5 Gender difference in HIV testing ...................................................................100
7.6 Spouse/partner testing among HIV positive at-risk population .....................100
8. INITIATION AND RETENTION ON ART .....................................................................102
8.1 Background ...................................................................................................103
8.2 Facilities .........................................................................................................104
8.3 PLHIV on ART ................................................................................................105
8.4 ART initiation and retention ...........................................................................107
8.5 Differentiated care model ..............................................................................109
9. HIV-TB CO-INFECTION MANAGEMENT ...................................................................112
9.1 Background ...................................................................................................113
9.2 HIV-TB co-infection management ..................................................................113
10. LABORATORY SERVICES ...........................................................................................116
10.1 Background ...................................................................................................117
10.2 CD4 testing ...................................................................................................118

12 Sankalak: Status of National AIDS & STD Response (2023)

 Content

10.3 Quality assurance under NACP ......................................................................120

10.4 Viral Load EQA ..............................................................................................122
10.5 Accreditation .................................................................................................123
10.6 Certificate of Excellence to ICTC ...................................................................124
10.7 Early Infant diagnosis (EID):
HIV-1 PCR laboratories tests for children under 18 months............................126
11. ELIMINATION OF VERTICAL TRANSMISSION OF HIV AND SYPHILIS (EVTHS) .......128
11.1 Background ...................................................................................................129
11.2 HIV and Syphilis testing coverage among pregnant women .........................131
HIV and Syphilis testing and sero-positivity ...................................................132
Estimated vs detected pregnant WLHIV ........................................................133
Syphilis infected pregnant women .................................................................135
11.3 HIV and Syphilis treatment coverage among pregnant women .....................136
HIV Treatment coverage ................................................................................136
Syphilis treatment coverage ..........................................................................138
95-95-95 Status of EVTHS .............................................................................138
11.4 Care of exposed infants/children ...................................................................139
Care of HIV exposed infants/children ............................................................139
Final EID at 18 months ...................................................................................142
Care of Syphilis exposed infants/children ......................................................143
12. SCORECARD ..............................................................................................................144
12.1 Background ...................................................................................................145
12.2 Methodology .................................................................................................145
12.3 Performance of SACS in Programme Implementation ...................................148
13. FACTSHEETS ..............................................................................................................152
14. INDICATOR GLOSSARY .............................................................................................368
15. REFERENCES .............................................................................................................378

Sankalak: Status of National AIDS & STD Response (2023) 13

14 Sankalak: Status of National AIDS & STD Response (2023)
 Abbreviations

ABBREVIATIONS

4s 4 Symptoms screening for TB

AAP Annual Action Plan
ADM Advance Disease Management
AEP Adolescence Education Programme
AIDS Acquired Immune Deficiency Syndrome
ANC Antenatal Care
ANHI Annual New HIV Infection
ANI Andaman & Nicobar Islands
ANM Auxiliary Nurse & Midwife
ARD Anorectal Discharge
ART Anti-Retroviral Treatment / Anti-Retroviral Therapy
ARV Anti-Retroviral
ATT Anti-Tuberculosis Treatment
CARG Community ART Refill Group
CBO Community Based Organisation
CD4 Clusters of differentiation 4 cells
CHC Community Health Centre
CI Confidence Interval
CLHIV Children Living with HIV
CoE Centres of Excellence
CPT Co-trimoxazole Preventive Therapy
CSC Care & Support Centres
CST Care Support and Treatment
DACS District AIDS Control Society
DIC Drop -In-Centre
DSRC Designated STI/RTI Clinic
EID Early Infant Diagnosis
EVTHS Elimination Vertical Transmission of HIV and Syphilis
FI-ICTC Facility Integrated Counselling and Testing Centre
FSW Female Sex Worker
FY Financial Year
GC General Client
GUD Genital Ulcer Disease
GUD-H Genital Ulcer Disease-Herpetic
GUD-NH Genital Ulcer Disease-Non-Herpetic
H/TG Hijra / Transgender person
HBV Hepatitis B Virus
HCTS HIV Counselling and Testing Service

Sankalak: Status of National AIDS & STD Response (2023) 15

Abbreviations

HCV Hepatitis C Virus

HIV Human Immunodeficiency Virus
HMIS Health Management Information System
HRG High-Risk Group
HSS HIV Sentinel Surveillance
HWC Health & Wellness Centre
IB Inguinal Bubo
ICTC Integrated Counseling and Testing Centre
IDU Injecting Drug User
IEC Information, Education & Communication
IMR Incidence Mortality Ratio
IPC Inter Personal Counselling
IPR Incidence Prevalence Ratio
JWG Joint Working Group
KK Kshamta Kendra
KP Key Population
LAC Link ART Centre
LAP Lower Abdominal Pain
LDT Long Distance Truckers
LFU Loss to Follow-Up
LWS Link Workers Scheme
M&E Monitoring & Evaluation
MMD Multi-Month Dispensation
MoHFW Ministry of Health and Family Welfare
MoU Memorandum of Understanding
MSM Men who have Sex with Men
MTCT Mother to Child Transmission
N/S Needle/Syringe
NACO National AIDS Control Organisation
NACP National AIDS & STD Control Programme
NCD Non-Communicable Disease
NCERT National Council of Educational Research and Training
NGO Non-Governmental Organization
NHM National Health Mission
NICU New-born Intensive Care Unit
NRL National Reference Laboratory
NTEP National Tuberculosis Elimination Programme
OCS Other Closed Settings
OI Opportunistic Infection
ORW Outreach Workers
OST Opioid Substitution Therapy
OVP Other Vulnerable Population
P&OCS Prison and Other Closed Setting intervention
PHC Primary Health Centres
PLHIV People Living with HIV
p-MPSE Programmatic Mapping and Population Size Estimation
PPP Public-Private Partnership

16 Sankalak: Status of National AIDS & STD Response (2023)

 Abbreviations

PPTCT Prevention of Parent to Child Transmission

PSS Painful Scrotal Swelling
PSU Public Sector Undertaking
PW Pregnant Women
PWID Person Who Injects Drug
RDT Rapid Diagnostic Test
RMNCHA+ Reproductive, Maternal, Neonatal, Child and Adolescent Healthcare
RPR Rapid Plasma Reagent
RRC Red Ribbon Club
RTI Reproductive Tract Infection
SACS State AIDS Control Society
SA-ICTC Stand-Alone ICTC
SBCC Social and Behavior Change Communication
SC Sub-Center
SDNS Secondary Distribution of Needle and Syringe
SIMS Strategic Information Management System
SMM Single Male Migrant
SNCU Special Newborn Care Unit
SOA Strengthening Outreach Activity
SOCH Strengthening Overall Care for HIV Beneficiary
SPD State Prisons Department
SSK Sampoorna Suraksha Kendra
SSS Sampoorna Suraksha Strategy
STD Sexually Transmitted Disease
TB Tuberculosis
TG Transgender
TI Targeted Intervention
TLD Tenofovir + Lamivudine + Dolutegravir
TNA-PCR Total Nucleic Acid-Polymerase Chain Reaction
ToR Terms of Reference
TPT TB Preventive Treatment
UD Urethral Discharge
UNAIDS The Joint United Nations Programme on HIV/AIDS
UT Union Territory
VBDD Voluntary Blood Donation Day
VCD Vagina Cervical Discharge
VDRL Venereal Disease Research Laboratory
VL Viral Load
WCD Women and Child Development
WHO World Health Organisation
WLHIV Women Living with HIV

Sankalak: Status of National AIDS & STD Response (2023) 17

18 Sankalak: Status of National AIDS & STD Response (2023)
 Executive Summary

EXECUTIVE SUMMARY

1. The year 2022–23 was the second year of phase-V of the National AIDS & STD Control Programme (NACP)
and the 31st year of the program since its launch in 1992. The national AIDS & STD response continues its
remarkable journey in 2022–2023. However, the additional epidemiological and programmatic contexts
were also noted that need to be addressed in the upcoming years to reach the objectives of NACP phase–V.

2. The HIV epidemic level continues to be low nationally with adult (15-49 yrs) HIV prevalence of 0.20% (0.17-
0.25%) and HIV incidence per 1000 uninfected population of 0.05 (0.03-0.08) in 2022. With around 24.67
lakh (20.84-29.52 lakh) people living with HIV (PLHIV), India has the second largest HIV epidemic in the
world, accounting for around 6.3% of all PLHIV worldwide. Annual new infections between 2010 and 2022
declined by 42% while annual AIDS-related deaths declined by 77% in India. Globally, the annual new
infections declined by 38% and AIDS-related deaths declined by 51% between the same period.

3. The level and trend of the HIV epidemic vary by State/UT. The prevalence was more than 1% in Mizoram
and Nagaland. In Manipur, the prevalence was slightly lower than 1% while almost twice the national
prevalence in Meghalaya (0.39%). Many States in the North-East India have seen increases in annual HIV
infections in 2022 vis-à-vis 2010. In Tripura, annual new HIV infections (ANHI) in 2022 increased by 300%
times vis-à-vis 2010. Similarly, in Arunachal Pradesh, ANHI increased by around 200%, in Meghalaya by
150% and in Assam by 75%. The level and trend of HIV prevalence and incidence in the northeastern
States in alarming.

4. The HIV prevalence among the high-risk groups continue to be much higher than the overall adult
prevalence. In comparison to the estimated national adult prevalence of 0.20% (0.17-0.25%) in 2022, the
observed HIV prevalence among high-risk groups is 9-43 times with 1.85% (95% CI: 1.75-1.96) among
female sex workers (FSW), 1.93% (95% CI: 1.75-2.12) among inmates in central jails, 3.26% (95% CI: 3.03-
3.48) among men who have sex with men (MSM), 3.78% (95% CI: 3.24-4.33) among hijra/transgender (H/
TG) persons and 9.03% (95% CI:8.69-9.37) among injecting drug users (IDU). Even among the migrants
and truckers, the HIV prevalence is observed to be 4 times (0.89%, 95%CI: 0.69-1.10) among single male
migrants and five times (1.00%, 95% CI: 0.78-1.21) among long-distance truckers than the national adult
prevalence.

5. Much higher prevalence is noted among high-risk groups in the northeastern States vis-à-vis national
average. Especially among the injecting drug users, the level and trend of HIV prevalence is concerning
in the northeastern States. This needs to be seen in the context of the density of the IDU population in
the northeastern States. The estimated size of IDUs relative to per 100,000 population ranged from 96 in
Meghalaya to 850 in Mizoram vis-à-vis the national average of 21.

6. Given the high rate of HIV prevalence among the high-risk groups, prevention of new infections amongst
the key populations remain key to national AIDS & STD response. As per the latest data on the size
of the HRGs through the exercise of programmatic mapping and population size estimation, India is
estimated to have around 9.95 lakh (9.03-10.89 lakh) FSW, 3.51 lakh (3.14-3.88 lakh) MSM, 0.96 lakh (0.85-
1.07 lakh) H/TG persons and 2.89 lakh (2.53-3.24 lakh) IDU. Against the point estimates, the coverage through
peer-led targeted intervention (TI) projects is 95% or more for the population of FSW and MSM population.
However, the coverage ranged between 68% to 72% for H/TG persons and IDU.

Sankalak: Status of National AIDS & STD Response (2023) 19

Executive Summary

7. However, State/UT-wise coverage of HRGs is uneven. In the emerging hotspots of Arunachal Pradesh,
Assam, Meghalaya and Tripura, the coverage for FSW ranged from 37% in Assam to 77% in Tripura
against the national average of ≥95%. In Mizoram, the State with the highest adult prevalence, only 70%
of estimated FSW are being covered through TI. For MSM, the coverage against the point estimate in
2022-23 was at 68% in Arunachal Pradesh, 30% in Assam, 58% in Meghalaya and 79% in Tripura. While not
even a single MSM was covered through TI in Sikkim. Coverage of H/TG persons in general is amongst the
lowest in the northeastern States. For IDU, coverage was at 73% in Arunachal Pradesh, 25% in Assam and
48% in Meghalaya.

8. Sub-optimum coverage of HRGs is also noted in other parts of the country. Coverage among IDU was at
65% In Uttar Pradesh, 40% in Rajasthan, 54% in Punjab, 39% in Karnataka, 31-44% in Haryana, Himachal
Pradesh and Jammu & Kashmir, 39% in Delhi and 63% in Bihar. For H/TG persons, the coverage was
in the range of 46%-52% in Uttar Pradesh, Uttarakhand and West Bengal, with 54% in Odisha, 60% in
Maharashtra, 42% in Karnataka and between 0-21% in Haryana, Himachal Pradesh and Jammu & Kashmir,
with 0% in Bihar. For MSM, coverage was at 64% in West Bengal, 65% in Uttar Pradesh, 64% in Punjab, 62%
in Odisha, 74% in Maharashtra, 62% in Haryana, 71% in Gujarat and 69% in Delhi. Among FSW, coverage
was 70% in Uttarakhand, 62% in Uttar Pradesh, 60% in Odisha, 48% in Jammu & Kashmir, 52% in Himachal
Pradesh, 72% in Haryana, 56% in Delhi and 63% in Bihar.

9. Opioid Substitution Therapy (OST) is a key harm reduction strategy to prevent HIV and other blood-
borne infections among IDUs since 2007. The OST program involves the treatment of patients with opioid
dependence for a certain duration of time through the sublingual route, in a dose which effectively
minimizes craving and withdrawals and thereby enables the patient to stop injecting drugs. Around 44.55
thousand IDU were on the OST program as on March 2023.

10. Integrated interventions for HIV and TB in prison and other close settings is being implemented since 2017
under NACP in a phased manner. The number of prisons covered has increased from 1150 prisons in 2021-
22 to 1262 in 2022-23. Around 14 lakh inmates were covered in 2022-23.

11. Management of Sexually Transmitted Infections (STI) and Reproductive Tract Infections (RTI) among HRGs
and other vulnerable populations is a key strategy for the attainment of two goals of NACP phase-V. The
STI/ RTI services in the country are provided through a network of Designated STI/RTI Clinics (DSRC,
branded as ‘Suraksha Clinic’) at the district and sub-district level under NACP. While the services below the
district/sub-district level are provided at Primary Health Centres (PHCs), Community Health Centres (CHCs)
and Sub-Centers (SCs) under the National Health Mission (NHM). There were 1,133 DSRCs operational
under NACO across the country as on March 2023. A total number of 58.2 lakh clinic visits were reported
to these DSRCs for various STI/RTI services and 35.85 lakh RPR tests were conducted for screening of
syphilis with seropositivity of 0.70% across the country in FY 2022-23. The States reporting seropositivity
of > 1% were Meghalaya (8.41%), Arunachal Pradesh (6.27%), Sikkim (6.11%), Kerala (3.67%), Goa (2.85%),
Chandigarh (2.03%), Gujarat (1.68%), West Bengal (1.61%), Assam (1.57%) and Nagaland (1.53%).

12. To augment the progress in the prevention of new infections, NACP phase-V envisions developing modalities
for the provision of comprehensive prevention, reduction of new infections and strengthen early detection
of HIV by reaching out to the population ‘at-risk’ for HIV and STIs, especially those not associated with
TI projects and LWS. Seventy five Sampoorna Suraksha Kendra (SSK) have been set up as an immersion
learning model to prioritize ‘at-risk’ HIV-negative clients through revised client flow, collaboration with
the National Health Mission and revision of counsellor’s job description by provisioning comprehensive
prevention packages to keep them negative. Around 10.20 thousand contacts were made with the ‘at-risk’
population through SSK in 2022-23.

13. HIV counselling and testing services (HCTS) was initiated in India in the year 1997 and are the key entry
point for the prevention of HIV infection, diagnosis, treatment and care of people who are infected with
HIV. The uptake of HCTS bounced back in 2022-23 to a level which was higher than the pre-COVID 19
pandemic period in 2022-23 after showing relatively low uptake in 2020-21 and 2021-22. In 2019-20,
almost 2.92 crore HIV tests were conducted among ‘at-risk’ clients (excluding pregnant women), which

20 Sankalak: Status of National AIDS & STD Response (2023)

 Executive Summary

dropped to 1.83 crore in 2020-21. The number of HIV tests conducted among ‘at-risk’ clients increased to
2.35 crore in 2021-22 but was still lower than pre- COVID 19 pandemic period. In comparison, 3.39 crore
HIV tests were conducted among ‘at-risk’ clients in 2022-23, which is the highest since the launch of HIV
counselling and testing services under NACP.

14. The overall HIV seropositivity among ‘at-risk’ clients was at 0.47% in 2022-23. The seropositivity was
highest among H/TG persons at 1.03% followed by 0.58% for males and 0.34% for females. Overall, nine
States/UTs recorded seropositivity of 1% or more including six of the northeastern States. In total, there
were around 1.60 lakh positive results for HIV tests conducted among ‘at-risk’ clients, almost two-thirds
(1.07 lakh) of them were among males.

15. Spouse/partner testing of newly detected HIV-positive persons is key to efficient and early detection of
PLHIV. In total, around 85.70 thousand spouses/partners for newly detected HIV-positive persons were
tested for HIV, indicating that 535 tests among partners/spouses of every 1000 newly detected HIV-positive
persons were conducted. The HIV seropositivity among spouses/partners tested was as high as 47.22%.
In 20 States/UTs, spouse/partner testing among newly diagnosed HIV-positive cases at HCTS facilities was
less than 50%. In Sikkim, Tripura, Andaman and Nicobar Islands, Arunachal Pradesh, Assam and Jammu &
Kashmir, the spouse/partner testing ranged between 10% and 20%.

16. HCTS facilities under NACP also anchor services on Goal 3: of the elimination of vertical transmission of
HIV and Syphilis (EVTHS). The country maintained its progress on EVTHS in 2022-23 with HIV testing
among pregnant women as high as 81% (after adjusting for repeat testing) and Syphilis testing at 71%.
The progress on syphilis testing was noteworthy which increased from 57% in 2021-22 to 71% in 2022-23.
Overall, 15,975 HIV-positive pregnant women were on lifelong ART, either newly initiated or already on
ART before the current pregnancy, in year 2022-23. This amounts to a treatment coverage of around 77%
against the point estimated number of around 20.74 thousand HIV-positive women giving birth in 2022-
23. With this coverage, the final vertical transmission rate of HIV was estimated at 19.91% (14.84-25.55) in
2022-23 including perinatal transmission and up to 36 months of breastfeeding. Among Syphilis positive
pregnant women, treatment coverage was at 89% nationally.

17. In twelve States/UTs, testing of HIV among pregnant women was less than 75% against the estimated size
of pregnant women. The HIV testing coverage among pregnant women was in the range of 52%-53% for
the States of Arunachal Pradesh and Himachal Pradesh. In Assam, Bihar, Dadra Nagar Haveli & Daman and
Diu, Delhi and Manipur, HIV testing coverage ranged between 60% and 70%. Madhya Pradesh, Nagaland,
Odisha, Rajasthan and Uttar Pradesh were other States with HIV testing coverage among pregnant women
less than 75%. It is important to note that in 10 States/UTs HIV testing coverage ranged between 105% to
144% indicating a high number of repeat tests conducted.

18. In the context of Syphilis testing among pregnant women, eight States/UT had testing coverage of less
than 75% in 2022-23. These included Arunachal Pradesh (59%), Assam (57%), Bihar (21%), Delhi (67%),
Himachal Pradesh (63%), Jammu & Kashmir (4%), Madhya Pradesh (71%) and Uttar Pradesh (45%).

19. There were 1,68,066 HIV-positive cases (including ‘at-risk’ clients and pregnant women) who were newly
diagnosed in 2022-23. In comparison, there were 1,60,608 PLHIV who were newly registered at anti-
retroviral treatment (ART) centres under NACP for the same time-period. This translates into 956 new
registrations at ARTC for every 1000 new detections at HCTS facilities. This reflects slightly lower progress
than in 2021-22 when 989 new registrations were made for every 1000 detections.

20. Overall, there were 16.80 lakh PLHIV (8.63 lakh male, 8.11 lakh female and 0.06 lakh H/TG people) on-ART
in March 2023 including 1.06 lakh PLHIV estimated to take ART from the private sector. There were also
1.80 lakh PLHIV who were lost to follow-up (LFU). For every 1000 PLHIV on-ART, 107 PLHIV were LFU (127
among male, 85 among females and 213 among H/TG persons). In 2021-22, there were 134 LFU for every
1000 PLHIV on-ART. This lower LFU number is also reflected in retention at 12 months which was at 81.80%
on 2022-23 vis-à-vis 79.57% as noted in 2021-22.

Sankalak: Status of National AIDS & STD Response (2023) 21

Executive Summary

21. While PLHIV retention at 12 months was more than 80% nationally, it was less than 80% in 22 States/UTs. In
Arunachal Pradesh, it was lowest at 41.50%, while the retention at 12-month was at 55.60% in Chhattisgarh
and around 58% in Goa. In Bihar, Mizoram, Rajasthan and Uttar Pradesh; retention at 12 months ranged
between 62% and 70%.

22. PLHIV attending ART centres (ARTC) are screened for TB on 4 symptoms (4S) every month as a core
component of providing integrated and comprehensive care. The percentage of PLHIV screened for TB has
increased from 94.7% in 2020-21 and has hovered around 97% in 2021-22 and 2022-23. In March 2023, 4S
screening of less than 95% was observed in seven States/UTs including Nagaland (78%), Meghalaya (85%),
Chhattisgarh (92%), Delhi (93%), Telangana (93%), Goa (88%) and Puducherry (91%).

23. Overall, 12.30 lakh viral load tests were conducted on-ART PLHIV at ARTC under NACP in 2022-23. This
works out to 781 tests conducted for every 1000 on-ART PLHIV which is an improvement from 712 tests
noted in 2021-22. In 14 States/UTs, the number of viral load tests per 1000 PLHIV on ART was less than
700. This was lowest in Andaman & Nicobar Islands (85) followed by Arunachal Pradesh (254), Tripura (273)
and Assam (358).

24. The quality assurance mechanism continues to be integral of various laboratory services under NACP,
wherein almost 8.44 crore various laboratory testing were conducted in 2022-23. Panel testing, where well-
characterized blinded panels are sent biannually from the Apex lab to National Reference Laboratories
(NRL), from NRL to State Reference Laboratories (SRL) and from SRL to SA-ICTC, is the cornerstone of
the quality assurance system under NACP. In FY 2022-23, 100% of NRL, 83% of SRL and 73% of SA-ICTC
participated in panel testing. No discordance was recorded in NRL while discordance of 1% was noted in
participating SRL and SA-ICTC.

25. NACP phase-V is operational under the overarching provisions of the HIV and AIDS (Prevention & Control)
Act, 2017. The Act reinforces and enacts provisions for reducing stigma and discrimination towards creating
an enabling environment for enhancing access to services. The Act also empowers a robust grievance
redressal mechanism in the form of an Ombudsman at the State level and a Complaints Officer at the
Establishment level aimed at providing speedy redressal of grivances.

26. As on March 2023, rules under the HIV and AIDS (Prevention & Control) Act, 2017 has been notified in all
States/UTs except for Dadra and Nagar Haveli and Daman and Diu, Goa, Haryana, Lakshadweep, Odisha,
Tamil Nadu, Telangana and Uttarakhand. Similarly, Ombudsman have been deputed/ designated in all
States/UTs except for Jammu & Kashmir and Ladakh, Kerala, Lakshadweep, Maharashtra, Telangana and
Tripura

27. As a result of a sustained, integrated and comprehensive response, more and more HIV-infected persons
were identified under the programme and initiated on ART. Overall, around 79% of estimated PLHIV
were aware of their HIV status as of March 2023. Fifteen States/UTs reported to have progress on the first 95
in the range of 50-75%. This included five north-eastern States including Arunachal Pradesh, Assam, Manipur,
Meghalaya and Nagaland. Bihar, Uttar Pradesh and Telangana were the other high-burden States in the group.

28. Among the PLHIV who know their HIV status, 86% were on-ART, higher than the 84% noted in 2021-
22. In 2022-23, less than 75% progress on second 95 was noted in the States of Delhi and Arunachal
Pradesh. The trend noted in State of Delhi is a cause of concern as it indicates a high number of PLHIV
being lost-to-follow-up (LFU) as a rising trend. While ART centres in Delhi also serve PLHIV for many of
the other States including like that in Bihar, yet a declining trend for second 95 need to be analysed and
suitably responded. Assam, Chhattisgarh, Nagaland, Puducherry and Uttarakhand were other States/UTs
with progress on second 95 less than 80% indicating towards higher rate of lost-to-follow-up PLHIV than
the national averages.

29. The viral load suppression was at 93% among on-ART PLHIV who were tested for viral load in 2022-
23. This is significantly higher than the 85% noted in 2021-22. As routine viral load testing gets fully

22 Sankalak: Status of National AIDS & STD Response (2023)

 Executive Summary

operational, no State/UT recorded viral suppression of less than 75%. In-fact, 10 States/UTs (Chandigarh,
Delhi, Goa, Kerala, Maharashtra, Manipur, Meghalaya, Puducherry, Sikkim and West Bengal) recorded viral
load suppression at 95% or more.

30. NACP phase-V have specific year-wise output and outcome targets. The table below summarises the
targets and achievements under the first two years of NACP phase-V.

S. 2021-22 2022-23
Indicator
No. Target Achievement Target Achievement

Physical and output targets

No. of calls received at
1 5.3 4.88 6.1 4.77
AIDS Helpline (1097) (In lakh)

2 No. of Targeted Interventions (TI) 1,663 1,512 1,735 1,543

No. of districts with the

3 165 146 175 168
Link Worker Scheme (LWS)

No. of HRG, bridge and the vulnerable

4 102.4 109.86 105.92 123.68
population covered through TI/LWS (In lakh)

5 No. of OST Centres 400 364 450 393

6 No. of IDU on OST (In lakh) 0.38 0.42 0.42 0.44

7 No. of ‘Sampoorna Suraksha’ Centres 25 0 75 75

No. of contacts with ‘at-risk’ population through

8 0.22 - 0.65 0.10
‘Sampoorna Suraksha’ Centres (In lakh)

9 No. of STI/RTI patients managed (In lakh) 100.16 50 106.7 99.27

No. of ‘at-risk’ population (excluding pregnant

10 252 235 265 339.79
women) tested for HIV (In lakh)

11 No. of pregnant women tested for HIV (In lakh) 252 248 265 238.07

No. of pregnant women tested for

12 176.4 169.4 190.8 208.65
Syphilis (In lakh)

13 No. of ART Centres 597 664 627 712

14 No. of Link ART Centres 1,294 1,261 1,324 1,261

15 No. of Care Support Centres 100 319 200 319

16 No. of PLHIV on ART (Cumulative)* (in lakh) 15.30 15.56 16.77 16.80

No. of viral load tests conducted among

17 11.0 10.32 13.50 12.30
PLHIV on ART (in lakh)

Outcome targets
1 Estimated PLHIV who know their HIV status (%) 79 75 82 79

PLHIV who know their HIV status and

2 84 84 87 86
are on ART (%)

PLHIV who are on ART and are virally

3 84 85 87 93
suppressed (%)

4 Estimated pregnant women tested for HIV (%) 84 84 88 81

* Including PLHIV on ART in the private sector

Sankalak: Status of National AIDS & STD Response (2023) 23

01
INTRODUCTION
 Introduction

INTRODUCTION

1.1 BACKGROUND Derived from the epidemiological data from

surveillance, programme monitoring and burden
estimations, Chapter 2 provides updates on
the magnitude and direction of the HIV and STI
First published in 2017, ‘Sankalak: Status of
epidemic in the country. Chapter 3 presents the
the national AIDS & STD response’ is the
progress of each State and UT on 95-95-95 for
annual publication under the National AIDS &
the past five years from 2018-19 to 2022-23.
STD Control Programme (NACP). The report
The information, education and communication
connects policymakers, programme managers,
(IEC) component of the NACP, including the
technical staff and other stakeholders including
1097 national helpline and the HIV and AIDS
community by capturing the progress as well as
(Prevention and Control) Act, 2017, is described
challenges towards the attainment of the stated
in Chapter 4. Chapter 5 focuses on the activities
targets and goals, thereby ensuring each can
for prevention of new infections among high-risk
design, implement and monitor evidence-based
groups and bridge population through targeted
programme. The current edition, fifth in the
intervention (TI) projects, link worker scheme
series, provides the status update for the year
(LWS) and prison interventions.
2022-23, the second year of the NACP phase-V
implementation, derived from the robust data
While Chapter 6 summarises the progress made
generated through the complementary systems
in the management of sexually transmitted
of monitoring, surveillance & epidemiology and
infections (STIs)/Reproductive Tract Infections
research & evaluation in the programme.
(RTIs), Chapter 7 details the progress made
under HIV counselling and testing services for
1.2 ORGANIZATION OF ‘at-risk’ clients. The care, support and treatment
THE REPORT services are covered in Chapter 8, whereas
the management of HIV-TB co-morbidities
is summarized in Chapter 9 and Chapter 10
provides an overview of the laboratory services,
As in previous editions, the fifth edition is also
such as viral load testing and external quality
organised in three broad sections: the narrative
assessment. Chapter 11 describes the progress
section, the factsheets and the indicators glossary.
made for the elimination of vertical transmission
The narrative section has a total of 12 chapters
of HIV and Syphilis. Chapter 12 presents the score
including ‘Introduction’. The factsheet presents the
sheet for each State/UT on their performance on
data for India and States/UTs across 11 domains
NACP implementation across all components.
mirroring the narratives chapter. At the end, the
section of the indicator glossary provides the
description, source and time reference of various
indicators being presented in the factsheet. The
readers are encouraged to go through the glossary
to have a comprehensive understanding of the
data presented.

Sankalak: Status of National AIDS & STD Response (2023) 25

Introduction

Figure 1.1 Chapters in fifth edition of ‘Sankalak’

01 Introduction 02 Status of the Epidemic

IEC, Youth,
03 Progress on 95-95-95 04 Mainstreaming
and the Act

Prevention among
05 HRG and bridge
population
06 STI/RTI Management

07 Early detection of HIV

infected people 08 Initiation and
retention of ART

09 HIV-TB co-infection
management 10 Laboratory services

11 EVTHS 12 Scorecard

26 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 27
02
STATUS OF
THE EPIDEMIC
 Status of the Epidemic

STATUS OF THE
EPIDEMIC

2.1 BACKGROUND 2.2 OVERVIEW

The year 2022-23 marked the implementation of India is estimated to have around 24.67 lakh
the second year of the NACP phase-V. Fully funded (20.84-29.52 lakh) people living with HIV (PLHIV)
as a Central Sector Scheme for the period of 1st in 2022 with an adult (15-49 years) prevalence of
April 2021 to 31st March 2026 with an outlay of 0.20% (0.17-0.25%). India has the second largest
Rs 15471.94 crore, the NACP phase-V aims to HIV epidemic in the world, accounting for around
reduce annual new HIV infections and AIDS-related 6.3% of all PLHIV worldwide (Figure 2.1), with an
mortalities by 80% by 2025-26 from the baseline estimated 3.9 crores HIV cases worldwide and 65
value of 2010. Robust strategic information, through lakh cases in Asia and the Pacific (UNAIDS 2023
complementary system of programme monitoring, Estimates). In terms of adult HIV prevalence, the
surveillance & epidemiology and research & global HIV prevalence (0.70%, 0.60-0.80%) is 3.5
evaluation of NACP indicates that the country has times that of national prevalence in India.
continued to make progress in terms of preventing
new infections and AIDS-related deaths. This has
been possible through the integrated approach of
prevention-detection-treatment of HIV, STIs and
related co-infections in the year 2022-23.

Figure 2.1. Percentage contribution of India in the global and regional HIV epidemic size estimates

A. India and rest of the world B. India and rest of the Asia and the Pacific

India
6.3% India
38.5%

Rest of the Asia

and the Pacific
Rest of 61.5%
the World
93.7%

The overall adult prevalence in India continues years, the impact on the magnitude and direction
to be low, wherein stabilization is noted in total of the epidemic is evident. After attaining a peak in
epidemic size in the recent years (Figure 2.2). As a year 2000, the HIV epidemic size started to decline.
successful National AIDS & STD Response, with the The decline in the size of the epidemic continued
incorporation of gamechanger initiatives in last 10 till 2015-18 and has been almost stable since then.

Sankalak: Status of National AIDS & STD Response (2023) 29

Status of the Epidemic

Figure 2.2. Level and trend of adult HIV prevalence (in %) and PLHIV size (1990-2022)

A. Adult HIV Prevalence (1990-2022) B. PLHIV Size Estimates

The stabilization observed in the magnitude of the of the expenditure incurred in FY 2014-15 and
epidemic is consistent with a new age of the AIDS 1.63 times of the expenditure incurred in whole
& STD response implemented since 2014 (Figure of NACP phase-IV Extension. The overall budget
2.3). This period was ushered in by policy measures, outlay of NACP phase-V is predominantly (around
particularly test and treat and universal viral load 93%) supported by the domestic budget. This is
testing, which was also enabled by the ground- indicative of mainstreaming of National AIDS &
breaking HIV and AIDS Prevention and Control STD Response as a public health responsibility of
Act, 2017. This assumes special significance given keeping 99.8% of the adult population free of HIV
the fact this new age is fully backed, financially but also for improving survival and the quality of
and politically by the Government of India. The life of persons infected and affected with HIV.
budget for the NACP phase-V is almost 12 times

Figure 2.3. Ten years of game changers (2014-2023)

Early Initiation on ART

Routine Viral
(Anti-Retroviral Therapy)
(CD4 <=500)
2015 2018 Load Testing

The HIV and AIDS

Launch of
(Prevention and
Control) Act
2017 2022 NACP phase - V

Integrated Health
Compaigns
Test and Treat 2017 2023 (HIV, Syphilis, Hep B,
Hep C and TB)

30 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

The rapid scale-up of treatment services uptake The consolidation of the prevention services and
contributed to both prevention of new infections scaling-up of the treatment services has led to
in general and reductions in AIDS-related a similar number of annual new HIV infections
mortality among PLHIV. As per 2022 round of and deaths among PLHIV. The point estimate
India HIV estimates, it was estimated that around for incidence-prevalence ratio (IPR) attained the
66.41 thousand (41.51-106.94 thousand) persons threshold value of 3 in the year 2019 and has
were newly infected with HIV in 2022 while 39.63 continued the declining trend since, indicating
thousand (25.79-61.95 thousand) HIV-infected that national AIDS & STD response is on track to
persons died due to AIDS-related illness. This attain the end of the HIV epidemic. However, the
amounts to around 182 (114-293) new infections incidence-mortality ratio (IMR) was more than 1
per day in 2022; almost 42% lower than the new in 2022, showing a rising trend. Going forward, if
infections noted in 2010 (Figure 2.4). In the same the new infections continue to be higher than the
period, the AIDS-related mortality declined by deaths among PLHIV along with the scale up of
around 77%. Globally, the annual new infections treatment programme, the size of PLHIV would
declined by 38% and AIDS-related deaths grow.
declined by 51% between 2010 and 2022
(UNAIDS 2023 Estimates).

Figure 2.4. HIV epidemic transition in India, 2000-2022

A. Trend in new HIV infections, deaths among PLHIV, total PLHIV size and on-ART PLHIV, 2000-2022

40.0 3.5

New HIV infec�ons and deaths (In lakh)

35.0 3.0
30.0
2.5
PLHIV (In lakh)

25.0
2.0
20.0
1.5
15.0
1.0
10.0

5.0 0.5

0.0 0.0
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022

PLHIV Size PLHIV on-ART

New HIV Infec�ons Deaths among PLHIV

B. Trend in IPR, 2000-2022 C. Trend in IMR, 2000-2022

9.0 1.4
8.5
8.0
7.5 1.2
7.0
6.5 1.0
6.0
5.5
5.0 0.8
4.5
4.0 0.6
3.5
3.0
2.5 0.4
2.0
1.5 0.2
1.0
0.5
0.0 0.0
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022

IPR IPR (Target) IMR IMR (Target)

Sankalak: Status of National AIDS & STD Response (2023) 31

Status of the Epidemic

Figure 2.5. Overview of HIV/AIDS epidemic in India, key statistics, 2022

Adults
(15-49 years) 0.20% 0.22% (0.18-0.27) 0.19% (0.16-0.23)
HIV (0.17-0.25) among men among women
Prevalence

People 23.99 lakh

Living with 24.67 lakh 10.86 lakh (9.19-12.94)
(20.29-28.70)
(20.84-29.52) women (15+ years)
HIV 15+ PLHIV

Annual new 42.20% decline 62.28 thousand

HIV 66.41 thousand between 2010 (38.71-100.63)
(41.51-106.94)
infections and 2022 adults (15+ years)

Annual
AIDS 76.60% decline 37.44 (24.49-58.46)
39.63 thousand
related between 2010 thousand adults
(25.79-61.95) and 2022 (15+ years)
deaths

With policy decisions augmenting the uptake of Growing older with HIV has additional concerns
anti-retroviral treatment (ART) under NACP which from the perspective of public health planning
in-turn fast-tracked attainment of viral suppression and management. Even when the viral levels are
reducing mortality and increasing AIDS-free suppressed among HIV-infected persons, there is
survival, aging of HIV epidemic is being noted evidence that higher rates of inflammation among
(Figure 2.6.). In 2022, around 36% of the total HIV-positive individuals are linked to higher rates of
PLHIV were estimated to be in the age group of cardiovascular, renal, neurocognitive, oncological
50 years or older. This is significantly different from and osteoporotic illness. This explains the focus
the period when the ART component of NACP was of the strategy paper of the NACP phase-V on
yet to be launched. In 2000, as per the India HIV the integrated health care for STIs and related
Estimates 2022, only around 17% of the total PLHIV communicable and non-communicable morbidities
were aged 50 years or older. for HIV-positive individuals aiming to sustained
quality of life keeping individual and communities
in the centre.

32 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

Figure 2.6. Age-sex distribution of HIV-infected persons, 2000 and 2022

The change in the age-sex pattern, along with at 10% (7.05-13.31%) in the year 2022 indicating a
the declining fertility rates and improved uptake very significant role of the HIV transmission during
of ART services, has resulted in reduced vertical the breastfeeding period in the overall vertical
transmission of HIV. Around 20.74 thousand transmission rates in India.
(16.91-25.75 thousand) HIV-positive women were
estimated to give birth in the year 2022 and thus The final MTCT rate is calculated based on
in need of treatment and prophylaxis to prevent the average of the proportion in various
vertical transmission to the new-born. In FY 2022- prophylaxis/treatment group during the
23, a total of 15,975 HIV positive pregnant women perinatal or breastfeeding period and the
were on-lifelong ART, either newly initiated or corresponding probability of transmission. In
already on-ART before the current pregnancy. the UNAIDS recommended Spectrum model,
This amounts to a treatment coverage of around used for HIV estimations under NACP, the risk
77%. With this coverage, around 4,100 (2500- of vertical transmission is highest when the
6500) children are estimated to have acquired HIV infection in women occur while pregnant
HIV through vertical transmission, with a final or breastfeeding (incident infections). HIV-
transmission rate of 19.91% (14.84-25.55%) positive women on antiretroviral therapy prior
including perinatal transmission and up to 36 to pregnancy have the lowest peripartum and
months of breastfeeding (Figure 2.7). The vertical postnatal transmission probabilities.
transmission rate at 6 weeks was estimated to be

Sankalak: Status of National AIDS & STD Response (2023) 33

Status of the Epidemic

Figure 2.7. Vertical transmission rate for HIV, key statistics, 2022

20.74 thousand 15.98 thousand 4.10 thousand

Estimated number Number of HIV Number of Children

of HIV-positive positive PW on-ART, estimated to acquire
women to give birth either newly initiated HIV transmission through
(PMTCT need) or already on-ART vertical transmission

4500

4250

4000 Mother infected during

761 breas�eeding
3750
Did not receive ART during
3500 breas�eeding

3250 Started ART late in pregnancy: child

infected during breas�eeding
536
3000
Dropped off ART: child infected
during breas�eeding
2750
419 Started ART during pregnancy: child
2500 infected during breas�eeding
143
2250 Started ART before pregnancy: child
infected during breas�eeding
191
2000
Mother infected during pregnancy
1750
Did not receive ART during
1500 pregnancy
1224
1250 Started ART late in the pregnancy:
child infected during pregnancy
1000
Dropped off ART during pregnancy:
750 child infected during pregnancy

Started ART during the pregnancy:

500
child infected during pregnancy
710
250 Started ART before the pregnancy:
82 child infected during pregnancy
0

77% 10% 19.9%

Percentage of HIV Vertical Final transmission

PW on-ART transmission rate including perinatal
against the rate at 6 weeks transmission and up to
estimated need 36 months of breasfeeding

34 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

2.3 STATE/UT-WISE LEVEL is estimated to have an adult prevalence of around

0.30% with Tamil Nadu at 0.21%.
AND TREND
Though many of the north-eastern States have
the highest rates for adult prevalence and thus
While overall prevalence of HIV epidemic in India epidemiologically important, States in the rest of
continues to remain low, there are substantial the country are equally important as the size of the
variations in level and trend of the HIV epidemic epidemic is also important for the public health
by States/UTs (Figure 2.8 and 2.9). The magnitude response. Maharashtra (3.88 lakh), Andhra Pradesh
and direction of the HIV prevalence is a concern (3.22 lakh) and Karnataka (2.74 lakh); with adult
in especially the north east States of India against prevalence higher than the national rate, ranks
the national prevalence of 0.20%. The prevalence 1-3 from the PLHIV population size perspectives.
continues to be more than 1% in the States of Uttar Pradesh, with the adult prevalence almost
Mizoram and Nagaland. In Manipur, the prevalence half of the national rate, has the fourth highest
is slightly lower than 1% while almost twice of PLHIV population size in the country (1.95 lakh).
the national prevalence in Meghalaya (0.39%). In Tamil Nadu, with adult prevalence like the national
the remaining north-eastern States prevalence is rate, is estimated to have around 1.65 lakh PLHIV
similar to or lower than the national average, but followed by 1.59 lakh PLHIV in Telangana. Bihar,
shows a rising trend. with the adult prevalence slightly lower than the
national rate, has PLHIV population size almost
Besides the above-mentioned north-eastern States, the same as Telangana. Gujarat is another State
other States with prevalence two to three times of with the estimated size of PLHIV more than 1 lakh.
the national average are Andhra Pradesh (0.64%), These States together account for around 72% of
Telangana (0.45%) and Karnataka (0.43%). Among the total HIV epidemic in the country.
the erstwhile high-prevalence States, Maharashtra

Figure 2.8. Adult HIV prevalence (%) and PLHIV size, 2022

Adult HIV Prevalence (%) PLHIV Size

Different States/UTs in country are at different level Maharashtra, Manipur, Tamil Nadu and Telangana.
of HIV epidemic status (Figure 2.9). It is important These are the States where the HIV epidemic onset
to note that the declining number of the estimated and peak are believed to have occurred earlier than
number of PLHIV population size is going down the rest of the States/UTs in India. In each of these
only in the States of Andhra Pradesh, Karnataka, States, except Manipur, decline in new infections

Sankalak: Status of National AIDS & STD Response (2023) 35

Status of the Epidemic

was very strong with a bigger gap between deaths In the rest of the States/UTs, the estimated size of the
among PLHIV and new infections which perhaps epidemic is stable to rising. While in north-eastern
led to a strong decline in PLHIV population size States of Arunachal Pradesh, Assam, Meghalaya
between the years 2000 and 2015. However, and Tripura; the increasing size of epidemic is driven
in the recent past, with the scale-up of the ART by the rising number of new HIV infections. Even
programme, the gap between new infections and though in the States of Mizoram and Nagaland, like
PLHIV deaths is shrinking, leading to stabilization many other States, new infections show a stable to
of the PLHIV population size. declining trend, the PLHIV population size is still
increasing as the rate of new infections is higher
than the rate of mortality.

Figure 2.9. New infections, PLHIV size and deaths among PLHIV, 1990-2022

Andhra Pradesh Arunachal Pradesh Assam Bihar

800,000 160,000 1,600 200 35,000 3,000 180,000 12,000

700,000 140,000 1,400 180 160,000

30,000 2,500 10,000
160 140,000
600,000 120,000 1,200
140 25,000
2,000 120,000 8,000
500,000 100,000 1,000 120 20,000 100,000
400,000 80,000 800 100 1,500 6,000
15,000 80,000
300,000 60,000 600 80
1,000 60,000 4,000
60 10,000
200,000 40,000 400 40,000
40
5,000 500 2,000
100,000 20,000 200 20 20,000
0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021
Chha�sgarh Delhi Goa Gujarat
60,000 12,000 70,000 4,000 18,000 7,000 140,000 12,000

3,500 16,000
50,000 10,000 60,000 6,000 120,000 10,000
3,000 14,000
50,000 5,000 100,000
40,000 8,000 12,000 8,000
2,500
40,000 10,000 4,000 80,000
30,000 6,000 2,000 6,000
30,000 8,000 3,000 60,000
1,500
20,000 4,000 6,000 4,000
20,000 2,000 40,000
1,000 4,000
10,000 2,000 10,000 1,000 20,000 2,000
500 2,000
0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021
Himachal Pradesh Haryana Jharkhand Karnataka
8,000 1,400 60,000 4,500 30,000 1,800 700,000 160,000

7,000 4,000 1,600 140,000

1,200 50,000 25,000 600,000
6,000 3,500 1,400 120,000
1,000 500,000
40,000 3,000 20,000 1,200
5,000 100,000
800 2,500 1,000 400,000
4,000 30,000 15,000 80,000
600 2,000 800 300,000
3,000 60,000
20,000 1,500 10,000 600
400 200,000
2,000 1,000 400 40,000
200 10,000 5,000 100,000
1,000 500 200 20,000

0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021
Kerala Meghalaya Maharashtra Manipur
30,000 3,500 9,000 1,200 1,200,000 250,000 45,000 8,000
8,000 40,000 7,000
25,000 3,000 1,000 1,000,000
7,000 200,000 35,000 6,000
2,500
20,000 6,000 800 800,000 30,000
150,000 5,000
2,000 5,000 25,000
15,000 600 600,000 4,000
1,500 4,000 20,000
100,000 3,000
10,000 3,000 400 400,000 15,000
1,000
2,000 10,000 2,000
50,000
5,000 500 200 200,000
1,000 5,000 1,000

0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

Madhya Pradesh Mizoram Nagaland Odisha

80,000 12,000 25,000 1,800 25,000 3,000 60,000 7,000

70,000 1,600
10,000 2,500 50,000 6,000
20,000 1,400 20,000
60,000
5,000
8,000 1,200 2,000 40,000
50,000 15,000 15,000
1,000 4,000
40,000 6,000 1,500 30,000
800 3,000
30,000 10,000 10,000
4,000 600 1,000 20,000
2,000
20,000 400
5,000 5,000
2,000 500 10,000 1,000
10,000 200
0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

Punjab Rajasthan Sikkim Tamil Nadu

90,000 10,000 80,000 6,000 500 35 350,000 60,000
80,000 9,000 70,000 450
5,000 30 300,000 50,000
70,000 8,000 400
60,000
7,000 350 25 250,000
60,000 4,000 40,000
6,000 50,000 300
50,000 20 200,000
5,000 40,000 3,000 250 30,000
40,000 15 150,000
4,000 30,000 200
30,000 2,000 20,000
3,000 150 10 100,000
20,000 20,000
2,000 100
1,000 5 50,000 10,000
10,000 1,000 10,000 50
0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

Telangana Tripura U�ar Pradesh West Bengal

350,000 60,000 7,000 800 250,000 25,000 90,000 12,000

300,000 6,000 700 80,000

50,000 10,000
200,000 20,000
600 70,000
250,000 5,000
40,000 60,000 8,000
500 150,000 15,000
200,000 4,000 50,000
30,000 400 6,000
150,000 3,000 40,000
300 100,000 10,000
20,000 30,000 4,000
100,000 2,000
200
50,000 5,000 20,000
50,000 10,000 1,000 2,000
100 10,000
0 0 0 0 0 0 0 0
1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

1981
1983
1985
1987
1989
1991
1993
1995
1997
1999
2001
2003
2005
2007
2009
2011
2013
2015
2017
2019
2021

Note: PLHIV size (in maroon line) on primary ‘Y’ axis; new infections (in red line) and deaths among PLHIV
(in orange line) on secondary ‘Y’ axis; time-series on ‘X’ axis.

36 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

2.4 HIV EPIDEMIC AMONG Like the adult HIV prevalence, higher prevalence
is also noted among various sub-population in the
HIGH-RISK GROUPS north-eastern States vis-à-vis national average as
noted in the 2021 rounds of Surveillance. Especially
among the injecting drug users, the level and trend
In India, the HIV epidemic is concentrated in of the HIV prevalence is also of concern. The higher
nature, i.e., HIV prevalence and incidence is level of epidemic in the north-eastern States is also
well established in one or more of the defined reflected in the positivity noted in routine testing.
sub-populations but is not well established in
the general population. The traditional sub- Figure 2.10 presents the sero-positivity noted in
population with higher HIV prevalence/incidence different population groups during 2022-23 in India
rates in India are female sex workers (FSW), vis-à-vis select north-eastern States. Among ‘at-risk’
men who have sex with men (MSM), injecting clients, the national sero-positivity was at 0.47% in
drug users (IDU) and hijra/transgender (H/TG) comparison to sero-positivity of 0.81% to 3.16%
persons. People living in prisons and other closed in Manipur and Mizoram respectively. Similarly,
settings are also considered as a sub-population among pregnant women, the sero-positivity
at a higher risk of acquiring HIV infection in the in Assam, Sikkim, Arunachal Pradesh, Tripura,
Indian context. Besides, migrants and truckers Manipur, Meghalaya, Mizoram and Nagaland
are also considered as bridge population groups ranged from 0.04% to 0.84% in comparison to
facilitating the transmission of HIV from high-risk national average of 0.03%. While among prisoners,
groups to the low-risk general population. migrants and truckers, the annual sero-positivity in
select north-eastern States was much higher than
In comparison to the estimated national adult the national average. Among prisoners, the sero-
prevalence of 0.20% (0.17-0.25%) in 2022, positivity in Assam, Tripura, Nagaland and Mizoram
the observed HIV prevalence among high- was 5-12 times than the national average. In Assam
risk groups are 9-43 times (Table 2.1). In 2021, and Manipur, the sero-positivity among migrants
observed HIV prevalence was 1.85% (95% CI: was 7-8 times of the national average. In Assam,
1.75-1.96) among FSW, 1.93% (95% CI: 1.93% Nagaland and Tripura, the sero-positivity among
(95% CI: 1.75-2.12) among inmates in central truckers was 2-3 times of the national average. For
jails, 3.26% (95% CI: 3.03-3.48) among MSM, IDU, the sero-positivity noted in Assam, Tripura and
3.78% (95% CI: 3.24-4.33) among H/TG person Arunachal Pradesh was 7-8 times of the national
and 9.03% (95% CI:8.69-9.37) among IDUs. Even average. Assam, Tripura and Arunachal Pradesh also
among the migrants and truckers, the observed noted higher sero-positivity among MSM than the
HIV prevalence was 4 times (0.89%, 95%CI: national average. While the varying sero-positivity
0.69-1.10) among single male migrants and five noted in the programme may also be the outcome
times (1.00%, 95% CI: 0.78-1.21) among long of the coverage and testing practices being
distance truckers. followed in a particular State, however, the sero-
positivity provides a context to the epidemiological
scenarios being seen in a State or a region.

Sankalak: Status of National AIDS & STD Response (2023) 37

Status of the Epidemic

Figure 2.10. HIV sero-positivity noted in routine testing, 2022-23

Note: The sero-positivity in ‘at-risk’ groups, pregnant women, migrants, truckers and prisoners refers to the
annual sero-positivity. The sero-positivity in the FSW, MSM and IDU group refers to the sero-positivity noted in
October’22-March’23 period.

38 Sankalak: Status of National AIDS & STD Response (2023)

 Table 2.1.HIV prevalence among various population groups, 2021
State/UT Pregnant Women SMM LDT FSW Inmates H/TG person MSM IDU
ANI 0.06 (0-0.19) - - - - - - -
Andhra Pradesh 0.37 (0.27-0.47) 0.93 (0.25-1.62) 0.60 (0.00-1.28) 1.78 (1.32-2.23) 3.25 (2.02-4.48) 4.61 (1.82-7.40) 2.06 (1.26-2.86) 1.32 (0.41-2.23)
Arunachal Pradesh 0 (0-0) - - 0.27 (0.00-0.64) - - - 1.60 (0.04-3.16)
Assam 0.11 (0.05-0.17) 3.21 (1.02-5.40) 2.12 (0.82-3.42) 1.65 (1.19-2.11) 2.01 (1.03-2.98) - 3.61 (2.78-4.95) 11.24 (8.69-13.80)
Bihar 0.24 (0.15-0.32) - - 0.62 (0.12-1.11) 0.00 (0.00-0.00) - 0.41 (0.00-1.20) 2.86 (1.38-4.33)
Chandigarh 0.38 (0-0.8) 0.40 (0.00-0.95) - 0.80 (0.16-1.44) 3.47 (1.68, 5.25) - 1.61 (0.04-3.17) 2.80 (0.76-4.84)
Chhattisgarh 0.17 (0.09-0.25) 1.20 (0.00-2.55) 2.00 (0.77-3.23) 1.92 (1.16-2.68) 0.00 (0.00-0.00) 6.00 (3.06-8.94) 4.01 (2.29-5.73) 7.20 (5.35-9.05)
DNH&DD 0.08 (0-0.46) - - - - - - -
Delhi 0.41 (0.21-0.61) 0.75 (0.00-1.80) 0.80 (0.00-1.90) 0.81 (0.25-1.36) 2.45 (1.33-3.57) 3.60 (1.97-5.23) 2.59 (1.20-3.98) 15.87 (13.25-18.48)
Goa 0.25 (0-0.53) - - 0.60 (0.00-1.28) - - 2.40 (1.06-3.74) 0.00 (0.00-0.00)
Gujarat 0.27 (0.19-0.36) 0.13 (0.00-0.39) 0.30 (0.00-0.64) 1.34 (0.90-1.77) 0.88 (0.42-1.33) 3.60 (1.29-5.91) 4.61 (3.68-5.53) 2.00 (0.26-3.74)
Haryana 0.11 (0.03-0.18) - - 1.33 (0.70-1.96) 1.63 (0.75-2.50) - 6.89 (5.32-8.46) 9.24 (7.45-11.02)
Himachal Pradesh 0.06 (0-0.13) 0.00 (0.00-0.00) - 0.55 (0.00-1.18) 0.25 (0.00-0.74) - 1.56 (0.04-3.07) 4.40 (1.86-6.94)
Jammu & Kashmir
0.02 (0-0.05) - - 0.40 (0.19-0.90) - - - 0.50 (0.06-0.93)
Ladakh
Jharkhand 0.13 (0.06-0.19) - 0.00 (0.00-0.00) 0.55 (0.19-0.90) 0.00 (0.00-0.00) - 6.68 (4.29-9.07) -
Karnataka 0.29 (0.22-0.36) 0.20 (0.00-0.59) 1.20 (0.00-2.55) 3.01 (2.56-3.46) 0.67 (0.21-1.13) 3.20 (1.66-4.74) 2.81 (2.08-3.55) 0.00 (0.00-0.00)

Sankalak: Status of National AIDS & STD Response (2023)

Kerala 0.04 (0-0.1) 0.00 (0.00-0.00) 1.20 (0.00-2.55) 0.44 (0.18-0.70) 0.50 (0.00-1.19) 0.56 (0.01-1.10) 0.35 (0.09-0.61) 0.40 (0.00-0.85)
Madhya Pradesh 0.09 (0.05-0.13) 0.78 (0.00-1.85) 0.00 (0.00-0.00) 0.75 (0.40-1.11) 1.58 (0.88-2.29) - 1.84 (1.09-2.58) 2.96 (1.92-4.01)
Maharashtra 0.25 (0.2-0.31) 0.13 (0.00-0.39) 0.40 (0.00-0.95) 2.54 (2.10-2.98) 1.13 (0.61-1.64) 6.00 (3.06-8.94) 4.18 (3.05-5.32) 18.41 (13.05-23.77)
Manipur 0.33 (0.19-0.46) - - 1.13 (0.60-1.67) 2.26 (0.80-3.72) - 9.43 (6.68-12.17) 8.84 (7.87-9.82)
Meghalaya 0.58 (0.36-0.8) - - 10.92 (8.62-13.22) - - 9.09 (3.08-15.10) 11.48 (8.43-14.54)
Mizoram 1.13 (0.79-1.47) 4.80 (2.15-7.45) - 56.15 (47.62-64.68) 26.00 (21.70-30.30) - 12.80 (8.66-16.94) 32.08 (29.88-34.28)
Nagaland 1.61 (1.25-1.98) - 1.20 (0.00-2.56) 2.00 (0.26-3.74) 4.59 (1.66-7.52) - 3.06 (1.54-4.59) 2.53 (1.93-3.13)
Odisha 0.21 (0.13-0.29) 1.60 (0.04-3.16) 2.00 (0.26-3.74) 0.65 (0.35-0.96) 0.00 (0.00-0.00) 1.49 (0.52-2.46) 1.20 (0.00-2.55) 1.90 (1.05-2.75)
Puducherry 0 (0-0) 0.00 (0.00-0.00) - 0.50 (0.06-0.94) - - 0.00 (0.00-0.00) -
Punjab 0.18 (0.09-0.27) 3.01 (1.51-4.50) 2.33 (0.49-4.18) 3.38 (2.67-4.09) 7.49 (6.00-8.98) - 11.62 (9.32-13.91) 19.57 (18.22-20.93)
Rajasthan 0.14 (0.07-0.2) 0.39 (0.00-1.16) 0.00 (0.00-0.00) 2.75 (2.03-3.46) 0.67 (0.21-1.13) 3.60 (1.29-5.91) 6.40 (3.37-9.43) -
Sikkim 0.05 (0-0.15) - - 0.00 (0.00-0.00) - - - 0.20 (0.00-0.59)
Tamil Nadu 0.17 (0.13-0.22) 0.00 (0.00-0.00) 0.60 (0.00-1.28) 1.52 (1.21-1.84) 0.50 (0.10-0.90) 4.80 (2.15-7.45) 2.07 (1.60-2.54) -
Telangana 0.16 (0.09-0.23) 0.80 (0.00-1.90) 0.80 (0.02-1.58) 1.81 (1.39-2.24) 2.50 (0.97-4.03) 4.00 (0.86-7.14) 2.67 (1.66-3.68) 0.40 (0.00-1.18)
Tripura 0.38 (0.13-0.62) - - 2.90 (1.86-3.94) 1.00 (0.02-1.98) - - 18.00 (13.24-22.76)
Uttar Pradesh 0.17 (0.13-0.22) 0.67 (0.08-1.25) 0.70 (0.18-1.22) 1.04 (0.62-1.47) 0.13 (0.00-0.37) 3.60 (1.29-5.91) 1.10 (0.56-1.64) 5.45 (4.74-6.16)
Uttarakhand 0.05 (0-0.1) - 2.10 (0.28-3.92) 0.42 (0.00-0.88) 0.00 (0.00-0.00) - 2.68 (0.56-4.79) 9.77 (7.09-12.45)
West Bengal 0.08 (0.02-0.14) 3.20 (1.02-5.38) 2.01 (1.00-3.01) 1.27 (0.70-1.84) 0.84 (0.32-1.35) 9.15 (6.60-11.69) 4.36 (3.08-5.63) 7.40 (5.11-9.69)

39
India 0.22 (0.21-0.24) 0.89 (0.69-1.10) 1.00 (0.78-1.21) 1.85 (1.75-1.96) 1.93 (1.75-2.12) 3.78 (3.24-4.33) 3.26 (3.03-3.48) 9.03 (8.69-9.37)
Status of the Epidemic
Status of the Epidemic

The high prevalence of HIV among IDU in the north- are not mutually exclusive and can often overlap.
eastern States of Assam, Mizoram and Tripura is For example, a sex worker might be available at a
also seen in the context of the updated population physical venue looking for a client, but at the same
size estimates of high-risk group under NACP. time, he/she may also be in contact with a network
This update is the outcome of the community- operator for getting a client while also browsing a
led programmatic mapping and population size particular Mobile App to get a commercial/casual
estimation (p-MPSE) activity undertaken under the sexual partner.
national programme during 2020-2022. p-MPSE
provided updated size estimates for HRGs (FSW, The community-led p-MPSE attempted to
MSM, IDU and H/TG) for 735 districts across undertake size estimation of HRGs who were
the country. Except for the UTs of Andaman and either available at the physical hotspots or were
Nicobar Islands, Dadra and Nagar Haveli and linked to a network operator. To estimate the
Daman and Diu; the p-MPSE was implemented in size of venue-based HRGs, community-members
all States/UTs in the country. first listed all the venues in the knowledge of the
programme, visited each of them and interviewed
Currently, it has been observed that HRGs now typology specific consenting key stakeholders at
solicitate clients or meet sexual/ injecting partners the venue to understand the size (minimum and
through three different approaches (Figure 2.11). maximum) of the HRGs who visited the venue on
One approach is through the physical venues (e.g., a typical day. The key stakeholders at the venue
brothels, bars, streets) which are frequented by both were also probed about other venues in the nearby
of HRGs and their sexual clients (partners)/injecting area where HRGs may be found. New venues thus
partners/peddlers. In the second approach, the identified were visited and the whole process was
HRGs don’t visit the physical venues, but are repeated. In regards to the network operators, a list
linked to a person who is also known to the clients/ was first developed, followed by their interviews to
sexual partners)/injecting partners/peddlers. These understand the size of HRGs associated with them.
persons, referred to as network operators under These same network operators were then probed
the programme, help connect the HRGs with their on information of other network operators and
sexual clients (partners)/injecting partners/peddlers when a new operator was identified, he/she was
using various mediums like cell phones, WhatsApp contacted and interviewed, if they consented to
group, etc. In the third approach, the HRGs participate. The p-MPSE also listed the number of
directly meet their clients/sexual partners/injecting HRGs in villages under the link worker scheme of
partners, etc, by using Mobile Applications, NACP. In each of the approach, information was
without the need of physical hotspots or being also collected for duplication and overlaps which
connected to any network operator. It is important was then used for adjustment while estimating the
to note that these three approaches used by a HRG National and State size for each of the high-risk
population group.

Figure 2.11. Different approaches for soliciting The p-MPSE estimated around 9.95 lakh (9.03-
clients or meeting sexual/ injecting partners. 10.89 lakh) FSW, 3.51 lakh (3.14-3.88 lakh) MSM,
0.96 lakh (0.85-1.07 lakh) H/TG person and 2.89
lakh (2.53-3.24 lakh) IDU available at physical
venues and with network operators (Table 2.2). It
is important to note that these estimates refer only
to the venues or to the network operators reached
under p-MPSE as per the approved methodology.
While the updated estimates for MSM as per the
p-MPSE is similar to that of earlier estimates, the
estimates for FSW is around 15% (4-25%), H/TG is
around 37% (22-53%) and IDU is around 63% (43-
83%) higher than the last estimates as conducted
for NACP.

40 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

Figure 2.12. HRG size estimates per 100,000 population

Sankalak: Status of National AIDS & STD Response (2023) 41

Status of the Epidemic

Table 2.2. HRG size estimates, p-MPSE 2022

State/UT FSW H/TG person MSM IDU

Andhra Pradesh 1,19,367 (1,02,886 5,364 (4,419-6,309) 22,060 (18,565-25,555) 1,332 (1,060-1,604)
-1,35,848)

Arunachal Pradesh 6,941 (6,264 -7,618) 140 (112-168) 901 (810-991) 5,143 (4,677-5,608)

Assam 39,721 (34,891 -44,550) 2,481 (2,186-2,777) 16,667 (14,545-18,789) 26,156 (22,963-29,348)

Bihar 11,682 (11,020 -12,344) 846 (775-918) 2,376 (2,236-2,517) 4,585 (4,250-4,921)

Chandigarh 3,333 (2,997 -3,668) 164 (142-185) 2,569 (2,306-2,832) 1,908 (1,701-2,115)

Chhattisgarh 18,375 (16,859 -19,891) 1,118 (990-1,246) 2,889 (2,630-3,148) 3,923 (3,535-4,310)

Delhi 88,399 (87,811 -88,987) 17,907 (16,188-19,626) 27,026 (24,985-29,068) 32,481 (29,447-35,515)

Goa 5,040 (4,305 -5,776) 132 (116-148) 3,339 (2,787-3,891) 302 (247-356)

Gujarat 37,118 (33,445 -40,792) 2,605 (2,396-2,814) 34,299 (30,661-37,938) 779 (637-920)

Haryana 17,668 (16,084 -19,251) 1,435 (1,275-1,594) 8,022 (7,205-8,839) 19,025 (17,193-20,856)

Himachal Pradesh 13,210 (11,888 -14,533) 258 (223-293) 1,252 (1,081-1,423) 3,662 (3,214-4,109)

Jammu & Kashmir

4,634 (3,899 -5,369) 614 (531-696) 677 (548-805) 10,162 (8,022-12,302)
Ladakh

Jharkhand 11,860 (10,568 -13,152) 483 (421-544) 1,742 (1,494-1,991) 779 (641-916)

1,53,337 (1,40,576
Karnataka
-1,66,098) 10,926 (9,836-12,016) 45,631 (41,397-49,864) 4,331 (3,771-4,890)

Kerala 16,623 (14,316 -18,922) 2,604 (2,167-3,036) #N/A 3,276 (2,628-3,922)

Madhya Pradesh 53,455 (47,189 -59,721) 1,614 (1,424-1,803) 18,085 (15,782-20,387) 11,919 (10,446-13,392)

Maharashtra 95,351 (88,080 - 1,02,622) 10,323 (9,250-11,396) 40,187 (37,261-43,113) 1,096 (910-1,282)

Manipur 5,662 (4,484 -6,839) 468 (395-541) 1,507 (1,258-1,755) 24,985 (20,447-29,523)

Meghalaya 3,297 (2,756 -3,837) 110 (85-135) 344 (252-435) 3,175 (2,715-3,634)

Mizoram 1,434 (1,256 -1,611) - (---) 841 (717-965) 10,397 (8,928-11,867)

Nagaland 2,246 (1,766 -2,726) 82 (62-102) 1,239 (1,051-1,426) 16,802 (14,137-19,468)

Odisha 24,620 (21,529 -27,712) 7,209 (6,277-8,141) 5,977 (5,261-6,694) 4,526 (3,918-5,134)

Puducherry 2,514 (2,197 -2,832) 203 (177-229) 2,489 (2,179-2,798) 21 (13-28)

Punjab 27,304 (24,301 -30,307) 1,316 (1,167-1,464) 8,045 (7,015-9,075) 45,098 (40,325-49,872)

Rajasthan 21,034 (19,196 -22,871) 2,126 (1,883-2,369) 7,351 (6,512-8,190) 3,024 (2,711-3,336)

Sikkim 732 (635 -828) - (---) - (---) 821 (713-929)

Tamil Nadu 60,775 (54,633 -66,917) 9,211 (7,734-10,687) 38,284 (33,927-42,641) 115 (92-138)

Telangana 75,381 (68,300 -82,461) 995 (919-1,072) 16,427 (15,282-17,573) 816 (657-974)

Tripura 6,242 (5,750 -6,734) 159 (154-164) 876 (808-944) 6,500 (5,953-7,047)

Uttar Pradesh 40,480 (37,075 -43,885) 9,846 (8,880-10,813) 19,668 (17,776-21,561) 35,412 (31,670-39,155)

Uttarakhand 7,213 (6,387 -8,040) 321 (293-349) 2,883 (2,647-3,119) 3,835 (3,407-4,264)

West Bengal 20,452 (18,937 -21,968) 5,134 (4,731-5,538) 3,532 (3,234-3,830) 2,334 (1,997-2,670)

India 9,95,499 (9,02,277- 96,193 (85,206- 3,51,020 (3,13,860- 2,88,717 (2,53,025-

10,88,712) 1,07,174) 3,88,175) 3,24,408)

42 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

Figure 2.12 presents the HRGs size estimates considered to be low prevalence given the overall
relative to the total population size in a State/UT epidemic context. However, the density of HRG in
and nationally. As evident, the highest density these States/UTs demands for continuous vigil on
of the HRG population is from the States in the the level and trend of the HIV epidemic.
north-eastern region, wherein Manipur, Mizoram
and Nagaland are estimated to have at least
900 HRG per 100,000 population. In Arunachal
2.5 SYPHILIS
Pradesh, there are around 850 HRG per 100,000 SERO-POSITIVITY
population while Assam, Meghalaya, Sikkim and
Tripura are estimated to have around 200-350
HRG per 100,000 population. Given that the Sexually transmitted infections (STIs) are an
national average is around 126 HRG per 100,000 important public health concern due to their links
population, the higher density of HRG size in the to sexual and reproductive health, child health and
north-eastern States is well established. HIV transmission through intercourse. Accordingly,
management of Sexually Transmitted Infections
It is observed that in the north-eastern States, the (STI) is a key focus in NACP phase-V. While no
density is significantly higher than the national new data from the surveillance is available for
average across the population groups. Arunachal Syphilis, the evidence from the previous editions
Pradesh is estimated to have around 450 FSW per has been reproduced in the sections below to
100,000 population, highest in the country and build the context.
almost 6 times of the national average of 73. For
MSM, the density per 100,000 in Arunachal Pradesh, In HSS 2021, serum samples collected from
Manipur, Mizoram and Nagaland is 58,47,69 and pregnant women and inmates were tested for
56 respectively; 2-3 times of the national density Syphilis using non-treponemal Rapid Plasma
(26). For IDU, the estimated size relative to per Reagin (RPR) test. Two test protocol, i.e. first
100,000 population ranged from 96 in Meghalaya qualitative test and then the quantitative test, was
to 850 in Mizoram vis-à-vis national average of 21. used as in the past. Only samples with a reactive
Only for the H/TG person, the density in the north- result in the first qualitative test were subjected
eastern States is lower than the national average to the second quantitative test. Under HSS, RPR
except for in Manipur. quantitative tests are reported as “reactive” at
dilution of ≥1:8.
Besides the north-eastern States, there are 9
States/UTs with HRG population density at-least As per the preliminary analysis of data from HSS
twice of the national average. In Chandigarh, 2021, Syphilis sero-positivity was 0.10% (95% CI:
Delhi and Goa, the density is in range of 550- 0.09-0.11) among pregnant women and 0.34%
800 HRGs, while in Andhra Pradesh, Himachal (95% CI: 0.26-0.42) among inmates in central
Pradesh, Karnataka, Puducherry, Punjab and prisons (Figure 2.13). In 2019, Syphilis sero-
Telangana, there are around 250-325 HRGs per positivity was at 0.10% (95%CI: 0.08–0.11) among
100,000 population. Some of these States/UTs, like pregnant women and at 0.40% (95% CI: 0.30%-
Chandigarh, Himachal Pradesh, Puducherry are 0.50%) among prisoners.

Sankalak: Status of National AIDS & STD Response (2023) 43

Status of the Epidemic

Figure 2.13. Syphilis sero-positivity (%) by population group, 2017,2019 and 2021

State/UT-wise in 2021, Syphilis sero-positivity Among prison and closed setting inmates, sero-
among pregnant women was highest in positivity of more than 1% was noted in three
Meghalaya (0.77%) followed by Nagaland (0.71%). States: Nagaland, Telangana and Madhya Pradesh.
Chhattisgarh and Mizoram had Syphilis sero- In Chandigarh, Chhattisgarh and Punjab, Syphilis
positivity 3.5 times that of the national average, sero-positivity ranged between 0.75% and <1%.
while in Sikkim, Manipur and Madhya Pradesh,
Syphilis sero-positivity ranged between 0.22% to
0.25% (Table 2.3).

44 Sankalak: Status of National AIDS & STD Response (2023)

 Status of the Epidemic

Table 2.3. Syphilis sero-positivity among various groups, 2021

State/UT Pregnant Women Inmates

ANI 0.00 (0.00-0.00) -

Andhra Pradesh 0.02 (0.00-0.04) 0.00 (0.00-0.00)

Arunachal Pradesh 0.00 (0.00-0.00) -

Assam 0.01 (0.00-0.03) 0.50 (0.01-0.99)

Bihar 0.00 (0.00-0.00) 0.00 (0.00-0.00)

Chandigarh - 0.99 (0.02-1.96)

Chhattisgarh 0.36 (0.24-0.47) 0.98 (0.26-1.70)

DNH&DD 0.00 (0.00-0.00) -

Delhi - 0.41 (0.00-0.87)

Goa 0.00 (0.00-0.00) -

Gujarat 0.13 (0.05-0.2) 0.00 (0.00-0.00)

Haryana 0.01 (0.00-0.04) 0.00 (0.00-0.00)

Himachal Pradesh 0.06 (0.00-0.13) 0.00 (0.00-0.00)

Jammu & Kashmir

0.00 (0.00-0.00) -
Ladakh

Jharkhand 0.1 (0.04-0.16) 0.29 (0.00-0.70)

Karnataka 0.01 (0.00-0.02) 0.00 (0.00-0.00)

Kerala 0.00 (0.00-0.00) 0.00 (0.00-0.00)

Madhya Pradesh 0.22 (0.15-0.28) 1.08 (0.50-1.67)

Maharashtra 0.03 (0.01-0.05) 0.19 (0.00-0.40)

Manipur 0.23 (0.12-0.34) 0.00 (0.00-0.00)

Meghalaya 0.77 (0.52-1.02) -

Mizoram 0.35 (0.16-0.54) 0.00 (0.00-0.00)

Nagaland 0.71 (0.47-0.95) 3.57 (0.97-6.17)

Odisha 0.1 (0.04-0.15) 0.00 (0.00-0.00)

Puducherry 0.13 (0.00-0.37) -

Punjab 0.08 (0.02-0.14) 0.75 (0.26-1.24)

Rajasthan 0.03 (0.00-0.06) 0.13 (0.00-0.37)

Sikkim 0.25 (0.03-0.47) -

Tamil Nadu 0.09 (0.06-0.12) 0.08 (0.00-0.25)

Telangana 0.13 (0.06-0.19) 2.25 (0.80-3.70)

Tripura 0.13 (0.00-0.27) 0.50 (0.00-1.19)

Uttar Pradesh 0.02 (0.01-0.04) 0.25 (0.00-0.60)

Uttarakhand 0.00 (0.00-0.00) 0.00 (0.00-0.00)

West Bengal 0.03 (0.00-0.06) 0.08 (0.00-0.25)

India 0.10 (0.09-0.11) 0.34 (0.26-0.42)

Sankalak: Status of National AIDS & STD Response (2023) 45

03
PROGRESS ON
95-95-95
 Progress on 95-95-95

PROGRESS ON
95-95-95

3.1 BACKGROUND HIV and AIDS, 95-95-95 is a critical programmatic

pre-requisite for NACP phase-V goals i.e., Goal 1:
reduce annual new HIV infections by 80%, Goal 2:
reduce AIDS-related mortalities by 80% and Goal 3:
The NACP phase-V calls for the attainment of
eliminate vertical transmission of HIV and Syphilis.
ambitious targets of 95-95-95 by 2025, where 95%
This chapter describes the progress on 95-95-95 by
of all people living with HIV know their HIV status,
States/UTs.
95% of all people diagnosed with HIV infection
receive sustained antiretroviral therapy (ART) and
The method for calculating the progress on 95-
95% of all people receiving antiretroviral therapy
95-95 remains same as noted in previous editions.
achieve viral suppression by 2025. Consistent with
Table below summarises the numerator and
the United Nations Member States Resolution in
denominator for calculation of 95-95-95 (Table 3:1).
June 2021 as part of the new Political Declaration on

Table 3.1. Description of 95-95-95 calculation

Indicator Description Calculation details

Numerator Denominator
First 95 Percent of all PLHIV who Number of PLHIV who Estimated number of
know their HIV status. know their HIV status PLHIV
Second 95 Percent of PLHIV who Number of PLHIV who Number of PLHIV who
are on ART among are on ART know their HIV status
those who know their
HIV status.
Third 95 Percent of PLHIV on Number of PLHIV on Number of PLHIV on
ART who are virally ART who are virally ART who are tested for
suppressed. suppressed viral load

Full realization of 95-95-95 in totality would mean status as of March 2023. This means around 79%
that 86% of total PLHIV are virally suppressed, often of PLHIV (76% among men; 82% among women)
presented in terms of testing and treatment cascade were aware of their HIV status. Among the
which provides another way of measuring progress PLHIV who know their HIV status, 86% (84% men
on the testing-treatment-suppression aspect of the and 89% women) were on ART. The viral load
programme. In the testing and treatment cascade, suppression was at 93% among on-ART PLHIV
the denominator for each indicator remains the who were tested for viral load in 2022-23. Out of
same i.e., estimated PLHIV. the total estimated PLHIV, 68% of PLHIV (64% of
men and 73% of women) were on-ART and 63%
3.2 NATIONAL PROGRESS (59% of men and 68% of women) achieved viral
suppression (Figure 3.1). Globally, the progress
on 95-95-95 was at 86-89-93 while progress on
testing and treatment cascade was at 86-76-71
Of the estimated 24.67 lakh (20.84-29.52 lakh)
in 2022.
PLHIV, 19.48 lakh PLHIV were aware of their HIV

Sankalak: Status of National AIDS & STD Response (2023) 47

Progress on 95-95-95

Figure 3.1. 95-95-95 and HIV testing and treatment cascade, 2022-23

95-95-95 Testing and treatment cascade

There has been steady progress on 95-95-95 While the progress on first 95 and third 95 is
since 2018-19. Taking into account the PLHIV the last five years is commendable, the progress
population size from the 2022 round of estimates as on second 95 is relatively less. This challenge
denominator, percentage of PLHIV who know their for progress on second 95 needs to be seen
HIV status increased from 70% in 2018-19 to 79% in the context of the lifelong requirement of a
in 2022-23. In the same reference period, progress PLHIV to be on ART and therefore the need for
on second 95 hovered between 82% to 86%. While interventions to improve and ensure retention
the progress on third 95 changed from 72% in 2018- and adherence. These aspects also have a
19 to 93% in 2022-23 as testing numbers increased behavioural context which makes the progress
significantly with testing strategies transitioning on second 95 relatively more challenging than
from priority population to routine testing. the first 95.

Figure 3.2. Progress on 95-95-95 between 2018-19 to 2022-23

3.3 STATE/UT-WISE UT of Lakshadweep. Overall, complete data on 95-

95-95 is available for 35 States/UTs, which includes
PROGRESS the UT of Jammu and Kashmir and UT of Ladakh
wherein the data is presented together.

Under NACP, the data on 95-95-95 for the year The States/UTs of India have not been able to attain
2022 is available for all States/UTs, except for the complete progress on 95-95-95 as on 2022-23.

48 Sankalak: Status of National AIDS & STD Response (2023)

 Progress on 95-95-95

For the first 95 of PLHIV who know their HIV & Diu are also registered in the State of Gujarat.
status, the progress of ≥95% has been recorded The actual progress on the first 95 in these two
in the UT of Chandigarh. However, this data is to UTs may be higher than being reported. Fifteen
be interpreted keeping in mind, that Chandigarh’s States/UTs reported progress on the first 95 in
ART centres are also utilised by PLHIVs from the the range of 50-75%. This includes five north-
neighbouring States, resulting in a higher progress eastern States including Arunachal Pradesh,
as observed in the context of the first 95. Assam, Manipur, Meghalaya and Nagaland.
Bihar, Uttar Pradesh and Telangana were the high
In the UTs of Andaman & Nicobar Islands, Dadra & burden States in the group. The progress noted
Nagar Haveli and Daman & Diu, the progress on in the first 95 in 2022-23 is much higher than the
first 95 is less than 50%. It is important to mention progress noted in 2018-19. Overall, eight States/
that PLHIVs from Andaman & Nicobar Islands are UTs progress on first 95 was lower than 50% in
also registered in State of West Bengal. Similarly, 2018-19 while in twenty States/UTs, it ranged
PLHIVs from Dadra & Nagar Haveli and Daman between 50% to 75% (Figure 3.3).

Figure 3.3. State/UT-wise progress on first 95, 2018-19 and 2022-23

2018-19 2022-23

In 2018-19, there were six States/UTs (Andaman in Bihar, yet this sort of declining trend for second
& Nicobar Islands, Arunachal Pradesh, Haryana, 95 needs to be analysed and suitably responded.
Meghalaya, Nagaland and Puducherry) where Assam, Chhattisgarh, Nagaland, Puducherry
progress on second 95 was less than 75% (figure and Uttarakhand are States/UTs with progress
3.4). In 2022-23, less than 75% progress on second on second 95 less than 80% indicating towards a
95 was noted in the States of Delhi and Arunachal higher rate of LFU PLHIV than the national average.
Pradesh. The trend noted in the State of Delhi is The progress in Telangana on second 95 in 2022-
a cause of concern as it indicates a high number 23 must be interpreted with caution as it driven by
of PLHIV being lost-to-follow-up (LFU) with a rising a very high number of PLHIV estimated to be on
trend. While ART centres in Delhi also serve the ART in the private sector in the State.
PLHIV for many of the other States including like

Sankalak: Status of National AIDS & STD Response (2023) 49

Progress on 95-95-95

Figure 3.4. State/UT-wise progress on second 95, 2018-19 and 2022-23

2018-19 2022-23

In terms of third 95, comparison of the State/ West Bengal) recorded viral load suppression
UT-wise progress in 2022-23 vis-à-vis 2018-19 of 75% or more. In 2022-23, as routine viral
shows significant changes, similar to the national load testing approach was fully operational, no
averages (Figure 3.5). In 2018-19, when viral State/UT recorded viral suppression of less than
load testing scale-up was initiated and was still 75%. In fact, ten States/UTs (Chandigarh, Delhi,
following the priority population approach, only Goa, Kerala, Maharashtra, Manipur, Meghalaya,
twelve States/UT (Assam, Delhi, Goa, Jammu & Puducherry, Sikkim and West Bengal) recorded
Kashmir and Ladakh, Kerala, Manipur, Meghalaya, viral load suppression at 95% or more.
Mizoram, Odisha, Sikkim, Uttar Pradesh and

Figure 3.5. State/UT-wise progress on third 95, 2018-19 and 2022-23

2018-19 2022-23

50 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 51
04
INFORMATION,
EDUCATION &
COMMUNICATION
 Information, Education & Communication

INFORMATION,
EDUCATION &
COMMUNICATION

4.1 BACKGROUND in order to strengthen multi-sectoral response

primarily in reaching out to a large number of
people with information on HIV prevention; linkages
with services especially testing and Anti-Retroviral
Activities under Information, Education and
Treatment (ART) to those who need it; adoption of
Communication (IEC) have made significant progress
the HIV and AIDS Policy for Establishments, 2022
in promoting behaviour change, to encourage
to address stigma & discrimination against the
and sustain positive healthy behaviours among
protected persons and linking people infected and
individuals and communities. NACP undertakes HIV,
affected by HIV with Social Protection Schemes.
AIDS and STI related communication campaigns
Under the Mainstreaming & partnerships efforts,
through a mix model of mass-media, mid-media,
NACP focuses on strengthen the multi-sectoral
social-media and interpersonal behaviour change
response through systematized convergence
communication strategies.
with key ministries/departments of the Central
Government as well as State Governments in a
Under NACP phase-V, the programme aims
cost-neutral approach.
at developing and rolling out of tailored
communication campaigns focusing on risk
Till date, there are 18 Memoranda of
perception, HCTS uptake and treatment of HIV
Understanding (MoU) signed between NACO
and STIs. The new generation communication
and Key ministries and departments. Respective
strategy that has been rolled-out are suitable to
Joint Working Groups (JWG) have also been
current context on elimination of HIV/AIDS related
formed to prepare action plans and roll out
stigma and discrimination as well as maintain and
activities as provisioned in the MoU. The States
augment the behaviour change communications
are directed to constitute JWG at the State level
for the general population. Specifically tailored
for implementation of the MoU as well as to
communication messages have been disseminated
initiate activities within their organizations and
through different mediums aiming at the young
the surrounding communities. These efforts have
and ‘at-risk’ people focusing on risk perceptions
impacted positively in vulnerability reduction
and service uptake. The National Toll-Free AIDS
through inclusion in programme and policy,
Helpline – 1097 is also widely publicized for
awareness generation through training and
information dissemination and actively linking the
sensitization, expansion of HIV related services in
target population for access to services.
existing health facilities of non-health Ministries,
PSUs and extending social protection benefits
4.2 MAINSTREAMING & through active linkages of marginalized persons
PARTNERSHIP including people infected and affected by HIV
and AIDS.

Partnership with Ministries/ Departments has been

viewed as an important strategy under NACP

Sankalak: Status of National AIDS & STD Response (2023) 53

Information, Education & Communication

Figure 4.1. Mainstreaming under NACP-V

Reduction of
Risk Integration Social
stigma and
Reduction of Services Protection
discrimination

Build capacities for

Build and sustain Linking PLHIV and
reduction of stigma & Provide information
partnerships for affected population
discrimination against on prevention and
risk reduction with social protection
PLHIV and affected control of HIV/AIDS
interventions schemes
population

Government –
Civil Society, Ministry/
Private Sector
NGOs, CBOs, FBOs Department,
Public Sector Units

Department of Department
Tele- of Youth
Communications Affairs
Ministry of Ministry of Department of
Road Petroleum & Social Justice &
Transport & Natural Gas Empowerment
Highways
Ministry of
Ministry of Department Department Housing & Urban
Labour & of Defence of Sports Poverty
Employment North Alleviation
Eastern Department
Council, Ministry Ministry of of Higher
of Development Coal Education
of NorthEastern
Region Department of Department of
Department of Empowerment of
Electronics Rural
Persons with Development
& IT Disabilities

Department of Department Ministry of

Internal of Commerce Shipping
Security

54 Sankalak: Status of National AIDS & STD Response (2023)

 Information, Education & Communication

4.3 SOCIAL MEDIA issues related to the wellbeing of people living

with HIV and to eliminate the stigmatising and
discriminatory attitude against people living with
and affected by HIV.
Digital interventions in present times are the most
economic means of communication and certainly
In the year 2022-23, NACO focused more on
most powerful to increase the reach to the masses.
enhancing the performance of Social Media
To optimally utilize this opportunity, NACO is
Platforms of the States/UTs. For this, NACO
presently active on Facebook, X, Instagram &
conducted the first ever National Capacity
YouTube as @NACOINDIA. Through all its Social
Building Workshop for Social Media with the
Media Platforms, NACO has developed, uploaded
objective to provide handholding support to
and shared content around different themes such
State Officers and Social Media Teams to get the
as safe behaviour, condom usage, stigma and
right message through an all-inclusive approach.
discrimination, myths and misconceptions about
In order to cross-check the performance for each
HIV and AIDS, important health days observed
State/UT, the National Scorecard continues to
globally and days of other national and international
indicate the activeness and accuracy of the State
significance. The idea behind exploring these
AIDS Control Societies.
digital platforms has been to bring upfront the

(Figure 4.2: Social media approaches under NACP-V)

NACO is effectively using

Social Media Platforms to
reach out to Digital Population

@NACOINDIA

35000 followers 7038 followers

8660 followers 7334 followers

Sankalak: Status of National AIDS & STD Response (2023) 55

Information, Education & Communication

4.4 NATIONAL TOLL-FREE

AIDS HELPLINE 1097

Even in the current times, helplines are solicited

as first point of contact by help-seekers to obtain
information and access to relevant services.
Toll-free tele-health helplines are usually a mix
of telephone and web-based platforms set-up
through designated and easily accessible short-
codes. These helplines enable public to obtain
Even though majority of the calls on the helpline
information on health issues and the risks associated
number are being recorded from males, substantial
in a confidential and anonymous manner.
improvement in calls is noted from females across
the country. Constant promotion efforts by State
National Toll-Free AIDS Helpline – 1097 has been a
AIDS Control Societies resulted in improvement
24x7 toll free service since 2014 for general public
of call volume from newer telecom circles (Bihar
and high-risk groups for obtaining information,
+ Jharkhand and Odisha) in the country other
counselling, referral and feedback services related
than the circles (West Bengal + Kolkata, Haryana,
to HIV. Call support is provided in a total of 16
Andhra Pradesh and Telangana) which have been
languages (including four north-eastern languages:
constantly registering high call volume. Over the
Assamese, Nagamese, Manipuri and Mizo) by 51
years, the percentage of repeat callers to the
trained counsellors based at four regional locations
helpline increased noticeably, indicating that the
within the country.
callers are being benefitted by the services offered
though the helpline number. The circumstances
The helpline recorded more than 4.6 million calls
under which the callers use the helpline vary, but
till date. 4,76,660 calls were recorded during the
the call percentage with current service model is
period from 1st April 2022 to 31st March 2023.
reinforcing their calling behaviour.

Figure 4.3. New and repeat callers on 1097

56 Sankalak: Status of National AIDS & STD Response (2023)

 Information, Education & Communication

4.5 RED RIBBON CLUB (RRC) • Observance of important

(International Youth Day, Rally and
events

awareness of VBDD, World AIDS Day,

National Youth Day, College fest, etc.)
Through Red Ribbon Clubs, the targeted Youth
(15-29) are encouraged to learn about a safe and • Community outreach and mobilization of
healthy lifestyle. The Red Ribbon Clubs promote youth
and channelize access to information on HIV and
AIDS, further educating them on Voluntary Blood • Training of Peer Educators
Donation and safe sexual behaviours. Red Ribbon
• Constitution of the Joint Working Group
Clubs also educate the targeted youth on HIV and
Committee-Youth (JWG) at the State
AIDS and associated topics so they can further act
as change agents for the HIV programme.
The aim of the Red Ribbon Club is to educate
the youth with correct, concise and adequate
Currently, there are more than 13,000 Red Ribbon
information and increase their level of
clubs constituted/functional in colleges under the
awareness about HIV/AIDS/STI/sexuality and
programme. Activities undertaken by the members
other related issues.
of RRCs are:

Figure 4.4. Colleges with Operational Red Ribbon Club (RRC) in States/UTs (As on 31st March 2023)1

4.6 ADOLESCENCE adolescents; to help them cope with negative peer

pressure, develop positive behaviour, improve
EDUCATION sexual health and prevent HIV infections. The
PROGRAMME (AEP) objective of the program is to provide opportunities
for the reinforcement of existing positive behaviour
and strengthening of life skills that enable young
The Adolescence Education Programme (AEP) by people to protect themselves from risky situations
NACO is a key intervention to build ‘life skills’ of they encounter in their lives.

1
ANI refers to Andaman and Nicobar Islands.

Sankalak: Status of National AIDS & STD Response (2023) 57

Information, Education & Communication

AEP is implemented in government schools in be seen in Figure 4.5. and Table 4.1. While AEP is
collaboration with NCERT. A 16-hour curriculum suspended in Maharashtra, there are schools with
is imparted to adolescent students of class IX and operational adolescent education program under
XI in more than 54,000 schools in the country. Mumbai DACS.
The status of the level of functioning of AEP can

Figure 4.5. Status of AEP implementation (As on March 2023)

Non-functional: Delhi, Mizoram

Suspended: Maharashtra, Uttar Pradesh,

Madhya Pradesh

Program Integrated in School Curriculum:

Andaman and Nicobar, Andhra Pradesh, Arunachal
Pradesh, Assam, Bihar, Chandigarh, Chhattisgarh,
Dadra & Nagar Haveli and Daman & Diu, Delhi,
Goa, Gujarat, Haryana, Himachal Pradesh, Jammu
& Kashmir, Ladakah Karnataka, Kerala, Madhya
Pradesh, Manipur, Meghalaya, Nagaland, Odisha,
Puducherry, Punjab, Rajasthan, Sikkim, Tamil Nadu,
Telangana, Tripura, Uttarakhand, West Bengal.

Suspended: Requires revival of the programme with

special interventions and advocacy

4.7 STRENGTHENING in establishments, prevent transmission of HIV

infection amongst workers, protect rights of those
INDIA’S RESPONSE infected with and affected by HIV and AIDS.
TO THE ELIMINATION OF
HIV-RELATED STIGMA AND It also mandates ensuring a safe non-stigmatised
and non-discriminatory working environment and
DISCRIMINATION maintaining the confidentiality of HIV-related data
for protected persons.

The HIV and AIDS (Prevention & Control) Act, The HIV and AIDS (Prevention & Control) Act,
2017 is a central legislation which came into force 2017 reinforces and enacts provisions for reducing
on September 10, 2018. The Act’s core thrust is stigma and discrimination towards creating an
based on prevention and to control the spread enabling environment for enhancing access to
of HIV and AIDS and to strengthen the legal and services. It provides diagnostic facilities related
human rights of persons infected with and affected to ART and opportunistic infection management
by HIV and AIDS, while also protecting the rights for people living with HIV and AIDS. The Act also
of healthcare providers. As per Section 12 of the empowers a robust grievance redressal mechanism
HIV and AIDS (Prevention and Control) Act, 2017, in the form of an Ombudsman at the State level
the Central Government has also notified the HIV and a Complaints Officer at the establishment level
and AIDS Policy for Establishments, 2022, which aimed at providing speedy redressal of grievances.
mandates generating awareness on HIV and AIDS

58 Sankalak: Status of National AIDS & STD Response (2023)

 Information, Education & Communication

Figure 4.6. State/UT-wise status of Rules notification and

placement of Ombudsman & Complaints Officer

Rules to be notified: Dadra Ombudsman to be deputed/ Complaints officer to be

and Nagar Haveli and Daman designated: Jammu & deputed/ designated:
and Diu, Goa, Haryana, Kashmir and Ladakh, Kerala, Andhra Pradesh, Gujarat,
Lakshadweep, Odisha, Lakshadweep, Maharashtra, Kerala, Lakshadweep,
Tamil Nadu, Telangana Telangana and Tripura Mizoram,Telangana,
and Uttarakhand and Tripura

Sankalak: Status of National AIDS & STD Response (2023) 59

05
PREVENTION
OF NEW HIV/
STI INFECTIONS
AMONG HIGH-
RISK GROUPS
AND BRIDGE
POPULATION
PREVENTION OF NEW
Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

HIV/STI INFECTIONS
AMONG HIGH-RISK
GROUPS AND BRIDGE
POPULATION
5.1. BACKGROUND route, which effectively minimizes craving and
withdrawals, and thereby enables the IDUs to stop
injecting drugs. OST has been demonstrated as
a successful intervention in reducing drug-related
Targeted Interventions (TI) projects and Link
harms including transmission of HIV, HBV and
Worker Schemes (LWS) are the major prevention
HCV. NACP provides OST primarily as a “Directly
interventions under National AIDS & STD Control
Observed Treatment” in a clinic-based setting
Programme (NACP) phase-V. These interventions
known as OST Centre under the supervision of a
focus primarily on providing services to the High-
Medical Officer. There is also provision for take-
Risk Groups (HRGs) and Bridge Populations who
home dosage for clinically stable clients satisfying all
are at risk of acquiring HIV and STI infections. High
the criteria provided. The OST program is provided
Risk Groups (HRGs) includes Female Sex Workers
through three models, namely the Collaborative
(FSW), Men who have Sex with Men (MSM),
model at public health facilities, the NGO based
Injecting Drug Users (IDU) and Hijra/Transgender
model provided at Targeted Intervention (TI) NGOs
(H/TG) persons whereas Migrants and Truckers
and the Satellite Model which includes provision of
are covered as proxy of bridge population.
OST at Prison and other closed settings.
TI and LWS are implemented in partnership
with Non-Governmental Organisations (NGOs)
A comprehensive package of services across the
and Community Based Organisations (CBOs)
prevention, testing and treatment spectrum are
contracted through State AIDS Control Societies
provided to HRGs through a peer-led and robust
(SACS) under the Social Contracting Mechanism of
outreach-based service delivery model. Focus is
NACP. The subgroups of population covered under
given on new registration of HRGs, strengthening
TI and the strategic geographical locations for TI
outreach activity (SOA) by going beyond the
interventions are decided based on the evidence
TI catchment areas, spouse and partner testing
of mapping and population size estimation and the
of HRGs, index testing, peer navigation to
field intelligence.
ensure linkages of PLHIV HRGs to ART centre,
establishment of satellite OST centres, secondary
Opioid Substitution Therapy (OST) is provided
distribution of needle & syringes (SDNS) sites
as a key harm reduction strategy to prevent HIV
and the periodical programmatic mapping and
infections among IDUs under NACP. The OST
population size estimation (p-MPSE). The key
service involves treating opioid-dependent IDUs
components and service delivery framework of TI
with a long –acting opioid agonist medication for an
is placed in the table below:
extended duration of time through the sublingual

Sankalak: Status of National AIDS & STD Response (2023) 61

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.1. Components and Service Delivery Framework of Targeted Interventions

Strategic Places /
Components Modalities of Service Delivery locations of Service
Delivery
Interpersonal Communication (IPC), Counselling, One-
Behaviour Change
to-One, One-to-Group Sessions, Use of SBCC Materials,
Communication • Drop-In Centre (DIC)
NACO Help Line
• Static Clinic
Syndromic Case Management, Syphilis Screening
(Biannual), Regular Medical Checkups, Counselling • Preferred Public
Clinical Services and Follow-up visits, Partner management, Opioid Providers (PPP)
Substitution Therapy (OST) for IDU, Abscess • Health Camps
Management
• Hotspots
Commodity
Condoms, Lubes, Clean Needle/Syringes etc. • Congregation Sites /
Provision Halt Points
Referral to ICTC, ART, DSRC, Preferred Providers, • OST Centers (Public
Referral and
TB, Other referred Centres as per the demand of the Health Facility/ NGO
Linkages
Community run OST center)
Advocacy, Liaison with Key Stakeholders such as • Satellite OST Centers
Enabling
Community Gater Keepers like Dera Heads, Police, • Secondary
Environment
Lawyers etc. Networking Distribution of
Needle/Syringe Sites
Community Creation of Community Groups, Formation of CBOs, • Referred Centers
Mobilization Strengthening Community Systems

*Modalities of service delivery and locations/places of service delivery varies based on the types of
subgroups of population covered under TI

Prevention interventions also cover priority Kshamta Kendra established through The Global
populations such as people living in Prisons and Fund support (The State/UT-wise locations of
Other Closed Settings (P&OCS), people who Kshamta Kendra is placed at Table 5.2). Besides
are operating through virtual platforms, spa the above, external evaluation of NGOs/CBOs
and massage parlours and new and young key that implement TI/LWS are conducted by third
populations living in hard-to-reach and uncovered party through an institutional mechanism with the
geographies. Comprehensive HIV service package support of The Global Fund Grant.
rolled out for P&OCS has achieved significant
milestones by exponentially increasing the The significance of prevention programme is best
frequency and intensity of its interventions in known for keeping a Large proportion of these
majority of prisons across the States/UTs with the key population (FSW, MSM, H/TG persons & IDU)
support of The Global Fund grant (2021-2024). as HIV negative in spite of changing dynamics
of solicitation, locations of outreach and use of
The NGOs/CBOs engaged in TI programme have technology. However, there is a pressing need
been trained through various capacity building to scale-up prevention interventions in the areas
initiatives conducted by Kshamta Kendra (TI of risk and vulnerability, to ensure that the at-risk
training institute). Till March 2023, there were 19 populations and vulnerable groups are reached.

62 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.2 State/UT-wise Distribution of Kshamta Kendra

Location of Kshamta Language

State/UT Kendra (KK) Competency
Andhra Pradesh Vijayawada Telugu
Assam, Meghalaya, Arunachal Pradesh, Sikkim, Mizoram Guwahati Assamese, Hindi, English
Bihar, Chhattisgarh, Jharkhand Patna Hindi
Chandigarh, Himachal Pradesh, J&K, Ladakh, Punjab Mohali Hindi, Punjabi
Delhi, Haryana, Uttarakhand Delhi Hindi
Gujarat, Daman & Diu, Dadra and Nagar Haveli Kutch Gujarati
Karnataka Mysore Kannada
Kerala, Lakshadweep Thiruvananthapuram Malayalam
Madhya Pradesh Bhopal Hindi
Maharashtra Nagpur Marathi
Manipur Imphal English
Mumbai, Goa Mumbai Hindi
Nagaland Kohima English
Odisha Sundargarh Odia
Rajasthan Jaipur Hindi
Tamil Nadu, Puduchery Dindigul Tamil
Telangana Warangal Telugu
Uttar Pradesh Prayagraj Hindi
West Bengal, Tripura Kolkata Bengali

5.2 COVERAGE OF KEY

POPULATION UNDER TI: AN OVERVIEW
The number of TIs and population coverage against the mapping estimates during FY 2022-23 is presented in
the Table 5.3 below.

Table 5.3 Typology wise number of TI and population coverage against estimation
Mapping
2022-23 Percentage
Estimates
Coverage
against the
Typology (in Lakh) []
a
Total Unit Coverage
Through Mapping
Exclusive Estimates
Compositeb
(Exclusive +
(in Lakh)
Composite)c
Female Sex Workers 9.95 301 557 858 9.70 ≥95
Men Having Sex with Men 3.51 91 502 593 3.35 ≥95
Intravenous Drug Users 2.89 204 233 437 2.07 72
Hijra/Transgender 0.96 43 263 306 0.65 68
Migrants 72.00 207 32 239 74.47 ≥95
Truckers 20.00 77 39 116 10.64 53
Core Composite - 620 - - - -
Total 109.32 1543 - - 100.88 92

a
Last mapping and population size estimates of FSW, MSM, IDU and H/TG population conducted in 2020-22. For Migrant
and Trucker’s population, the size estimates are from 2008-09.
b
Under composite interventions more than one typology are covered in a TI
c
Total units are the total number of interventions implemented either through exclusive or composite interventions.

Sankalak: Status of National AIDS & STD Response (2023) 63

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.3 above shows that during the financial year for the programme is around 13% among FSW,
2022-23, a total of 1,543 TIs were on board against 63% among IDU and around 37% among H/
a total sanctioned 1,596 TIs as per Annual Action TG population. There is a marginal decrease
Plan (AAP) for the year 2022-23. Coverage among among MSM population standing at around 2%.
the HRGs and bridge population has varied against Therefore, the overall coverage of HRGs as per
the estimated number of population. Coverage the new population size estimation is more than or
among truckers was lowest at 53%, while that of equals to 95% among FSW and MSM population,
other populations was more than 65%. It may be whereas 72% among IDUs and 68% among H/TG
noted that the percentage increase of estimated population. Details of last six-year achievements of
population among HRGs as per new mapping number of TIs and population covered under TI is
and population size estimation conducted in presented in Figure 5.1 below:
2022-23 to that of mapping conducted last time

Figure 5.1 Year-wise number of TIs and overall coverage of populations in TIs (2018– 2023)

The above figure highlights that the number of

TIs and the overall coverage of HRGs and bridge
5.3 FSW COVERAGE WITH
population has increased over the last five years. PREVENTION
Low coverage witnessed during 2020-21 was due SERVICES IN TI
to COVID-19 pandemic despite an increase in the
number of TIs. However, the pace of coverage has
increased in subsequent years to a tune of 40% In 2022-23, around 9.70 lakh FSW were covered,
in 2021-22 and 56% in 2022-23. The revamping wherein the coverage of FSW in 2022-23 has
strategy with a focus on reaching out new and increased to a tune of approx. 80 thousand more
unreached population within the catchment than in the previous year 2021-22. (Figure 5.2).
area and beyond has attributed to an increase in Higher coverage is also reflected in clinic visits,
coverage of the programme. HIV testing, HIV positive case detection and
linkage to ART.
Coverage of subgroups of HRGs with different
prevention services such as clinical services, STI
episodes treated, HIV testing, linkages to ART
and commodities distributed (condoms and clean
needle/syringes) in the last six years is placed in the
subsequent sections.

64 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Figure 5.2 Key prevention services provided to FSW, 2017-18 to 2022-23

a. Coverage, clinic visits and HIV testing b. Clinic visits (average) and STI episodes treated

5 60
30.00

25.00 4 50

Episodes in 1,000
20.00 40

Clinic visits
3
In lakhs

15.00 30
2
10.00 20
5.00 1 10
0.00
0 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Coverage Clinic visit HIV screening Average visits to clinic STI episodes treated

c. Condom Distribution among FSW d. HIV Positivity and put on Treatment

0.14 92
300 25.0
0.12 90
250
20.0
Average Condom

0.10
88
Condom in crore

HIV Posi�vity %

Linked to ART
200
15.0 0.08
150 86
0.06
10.0
100 84
0.04
5.0
50 82
0.02
0 0.0
0.00 80
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23

Average condom Condom Distribu�on HIV Posi�vity % Linked to ART %

Revamping activities with a focus on new Overall, there were twelve States/UTs which
registration of FSWs has attributed to an increase reported coverage of 95% or more against the
in coverage. Each HRG in a TI is provided free estimated FSW population. Assam has reported
medical check-ups/clinic visit once in a quarter. the lowest coverage of FSW population at 37%.
Average clinic visits by FSW has increased from 1.9 Mizoram has shown highest HIV sero positivity
visits in 2020-21 to 2.7 visits in 2022-23, wherein (2.20%) among all FSWs tested for HIV. There are
approx. 1.3% of the total FSWs who visited nine State/UTs wherein 100% linkages to ART
clinics were treated for STI during 2022-23. HIV has been ensured. Through the peer-navigation
Sero positivity was at 0.11% at national level and approach, efforts are also made to link all
continue to remain low, below 0.2% in the last six identified HIV positive HRGs to ART centres. The
years. Overall, 1456 new HIV positive FSW were State/UT-wise distribution of coverage of FSW
detected during 2022-23 and 85% of them were in key service parameters during 2022-23 as
linked to ART. In the context of 95-95-95, efforts presented above is given in the Table 5.4.
are being made to achieve 100% ART linkage and
their retention to achieve viral load suppression.
Provision of free condoms has increased over the
years and on an average 200 pcs of condom were
distributed per FSW during 2022-23.

Sankalak: Status of National AIDS & STD Response (2023) 65

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.4 State/UT wise coverage of FSWs on key service parameters, 2022-23

Percentage
Coverage
Clinical Syphilis Detected Condom HIV Tested ART
Total against STI Linked
State/UT Visits screening syphilis Distribution Testing HIV Linkage
Coverage estimated Treated to ART
(Lakh) (in Lakh) positive (Lakh) (Lakh) positive (%)
population
(%)

Andhra
156625 ≥95 4.37 1815 1.82 7 374.91 2.23 116 76 66
Pradesh

Arunachal
5045 73 0.15 140 0.08 46 5.81 0.08 3 3 100
Pradesh

Assam 14823 37 0.42 1092 0.20 23 30.55 0.21 87 67 77

Bihar 7348 63 0.22 210 0.10 3 9.86 0.11 21 19 90

Chandigarh 4867 ≥95 0.12 149 0.06 0 11.86 0.06 1 2 200

Chhattisgarh 19912 ≥95 0.62 2249 0.30 73 74.33 0.32 117 92 79

Delhi 49629 56 1.48 2450 0.72 10 22.06 0.76 54 46 85

Goa 5860 ≥95 0.19 192 0.06 2 17.74 0.10 1 0 0

Gujarat 30626 83 1.08 1497 0.54 34 130.27 0.54 41 39 95

Haryana 12678 72 0.38 664 0.20 14 38.72 0.20 74 51 69

Himachal
6852 52 0.22 747 0.11 3 16.41 0.11 10 10 100
Pradesh

Jammu and
2209 48 0.06 222 0.00 0 2.00 0.04 1 1 100
Kashmir

Jharkhand 16758 ≥95 0.53 396 0.26 2 24.95 0.29 13 14 108

Karnataka 134609 88 3.67 2724 1.87 12 174.83 1.85 100 98 98

Kerala 45488 ≥95 0.51 560 0.17 27 21.56 0.28 8 11 138

Madhya
46598 87 1.41 3186 0.74 33 75.84 0.74 60 54 90
Pradesh

Maharashtra 86428 91 2.84 5030 1.37 43 260.64 1.36 215 199 93

Manipur 6692 ≥95 0.25 41 0.09 2 14.30 0.09 10 7 70

Meghalaya 2047 62 0.06 344 0.03 35 3.03 0.03 13 12 92

Mizoram 997 70 0.03 13 0.01 3 1.40 0.01 29 16 55

Nagaland 3657 ≥95 0.12 144 0.06 12 6.72 0.06 11 9 82

Odisha 14829 60 0.45 1341 0.22 32 30.68 0.22 19 18 95

Puducherry 3940 ≥95 0.09 46 0.05 2 6.62 0.05 3 3 100

Punjab 21683 79 0.55 886 0.28 22 36.66 0.28 58 45 78

Rajasthan 19269 92 0.50 1026 0.18 15 41.09 0.26 19 16 84

Sikkim 1069 ≥95 0.03 77 0.02 1 2.39 0.02 0 0 0

Tamil Nadu 58903 ≥95 1.06 760 0.68 41 99.42 0.77 28 28 100

Telangana 136303 ≥95 2.98 1676 1.13 26 241.21 1.65 206 191 93

Tripura 4777 77 0.11 265 0.05 6 5.66 0.06 13 13 100

Uttar Pradesh 25173 62 0.70 1753 0.37 13 71.21 0.37 79 62 78

Uttarakhand 5021 70 0.17 677 0.09 2 12.40 0.09 5 4 80

West Bengal 19230 94 0.54 427 0.29 43 57.88 0.28 41 38 93

India 9,69,945 ≥95 25.90 32,799 12.16 587 1922.99 13.54 1456 1244 85

66 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.4. MSM COVERAGE WITH the programme in 2022-23 than the previous year
coverage 2021-22 (Figure 5.3). The total number
PREVENTION SERVICES of MSM covered under TI against the estimated
IN TI population has increased over the years. Due
to COVID 19 pandemic coverage was slightly
low during 2020-21, however has increased
Around 3.35 lakh MSM ≥95% of the estimated significantly in subsequent years, with more than
population were covered during 2022-23. 95% MSMs being covered in 2022-23.
Approximately 14 thousand MSMs were added in

Figure 5.3 Key prevention services provided to MSM, 2017-2018 to 2022-2023

a. Coverage, clinic visits and HIV testing b. Average clinic visits and STI episodes treated

5 16
10.00 14
9.00 4
12

Episodes in 1,000
8.00
7.00

Clinic visits
3 10
6.00
In lakhs

8
5.00
4.00 2 6
3.00 4
2.00 1
1.00 2
0.00 0 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Coverage Clinic visit HIV screening Average visits to clinic STI episodes treated

c. Condom Distribution among MSM d. HIV Positivity and put on Treatment

0.35 94
92
250 7 0.30
90
6 0.25
Average Condom

200 88
HIV Posi�vity %

Linked to ART
Condom in crore

5 86
0.20
150 4 84
0.15
3 82
100
0.10 80
2
50 78
1 0.05
76
0 0 0.00 74
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23

Average condom Condom Distribu�on HIV Posi�vity % Linked to ART %

Around 9.04 lakhs clinic visits were made by MSM Overall, there were fourteen States/UT that
during 2022-23, out of which approx. 0.75% of reported coverage of 95% or more against the
total clinic attendees were treated for STI. HIV sero estimated MSM population. Assam has reported
positivity among MSMs was found at 0.30 % and the lowest coverage of MSM population at 30%,
continue to remain low, below 0.30% in last six while Arunachal Pradesh has shown highest HIV
years. A total of 1,442 new HIV positive MSM were sero positivity (1.73%) among all MSM tested for
detected during 2022-23. Linkages to ART of all HIV. There were twelve States/UTs wherein 100%
detected positive cases was increased to 92% in linkage to ART has been ensured. Through the Peer
2022-23 than the last year achievement of 86% in Navigation approach, efforts are made to link all
2021-22. Linking to ART through peer navigation identified HIV positive HRGs to ARTC. The State/
has resulted in increase in linking cases to ART in UT-wise distribution of coverage of MSM in key
2022-23. Around 190 pcs of condom per MSM was service parameters during 2022-23 as presented
provided during 2022-23. above is given in the Table 5.5.

Sankalak: Status of National AIDS & STD Response (2023) 67

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.5 State/UT wise coverage of MSM on key service parameters, 2022-23

Percentage
Coverage
Clinical Syphilis Detected Condom HIV Total Total ART
Total against STI
State/UT Visits screening syphilis Distribution Testing tested linked Linkage
Coverage estimated Treated
(Lakh) (in Lakh) positive (Lakh) (Lakh) positive to ART (%)
population
(%)

Andhra
30681 ≥95 0.87 207 0.34 14 72.50 0.46 74 57 77
Pradesh

Arunachal
609 68 0.02 34 0.01 32 0.94 0.01 19 19 100
Pradesh

Assam 5074 30 0.15 133 0.07 16 9.03 0.07 55 58 105

Bihar 2210 93 0.06 76 0.03 0 2.25 0.03 14 14 100

Chandigarh 2989 ≥95 0.08 73 0.04 6 6.18 0.04 8 7 88

Chhattisgarh 3494 ≥95 0.11 163 0.05 35 12.79 0.06 62 55 89

Delhi 18781 69 0.55 191 0.28 14 34.51 0.30 71 66 93

Goa 4164 ≥95 0.13 122 0.03 2 8.64 0.07 6 4 67

Gujarat 29525 71 1.09 1242 0.52 153 83.04 0.53 125 117 94

Haryana 4934 62 0.16 197 0.08 32 12.81 0.08 72 57 79

Himachal
1084 87 0.03 142 0.01 1 1.84 0.01 10 10 100
Pradesh

Jammu and
742 ≥95 0.02 77 0.00 0 0.16 0.01 3 3 100
Kashmir

Jharkhand 2212 ≥95 0.07 84 0.04 0 2.88 0.04 8 8 100

Karnataka 48192 ≥95 1.25 393 0.67 36 76.83 0.66 139 135 97

Kerala 24707 ≥95 0.41 213 0.15 99 17.27 0.22 30 30 100

Madhya
16944 94 0.52 744 0.27 64 20.51 0.27 82 80 98
Pradesh

Maharashtra 29645 74 1.01 1113 0.49 127 68.68 0.48 142 130 92

Manipur 1902 ≥95 0.06 7 0.03 7 2.56 0.03 8 8 100

Meghalaya 201 58 0.01 1 0.00 1 0.26 0.00 1 1 100

Mizoram 879 ≥95 0.03 11 0.01 10 0.66 0.01 7 6 86

Nagaland 2642 ≥95 0.06 12 0.03 12 4.74 0.03 20 17 85

Odisha 3679 62 0.11 273 0.05 18 7.03 0.05 15 14 93

Puducherry 3555 ≥95 0.10 12 0.05 9 6.98 0.05 0 0 0

Punjab 5131 64 0.17 163 0.08 77 10.23 0.08 82 72 88

Rajasthan 6858 93 0.18 205 0.07 30 11.82 0.10 45 42 93

Sikkim 0 0 0.00 0 0.00 0 0.00 0.00 0 0 0

Tamil Nadu 41941 ≥95 0.76 193 0.50 368 73.78 0.56 103 103 100

Telangana 23743 ≥95 0.55 64 0.19 18 53.29 0.30 91 84 92

Tripura 692 79 0.02 11 0.01 4 0.60 0.01 9 9 100

Uttar
12770 65 0.37 543 0.19 36 28.67 0.19 131 103 79
Pradesh

Uttarakhand 2306 80 0.08 294 0.04 6 5.14 0.04 9 9 100

West Bengal 2263 64 0.06 17 0.04 38 3.85 0.04 40 39 98

India 3,34,549 ≥95 9.05 6,788 4.39 1265 642.93 4.83 1442 1322 92

68 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.5. H/TG PERSONS has increased over the years with an addition of
nearly 3 thousand H/TG population during 2022-23
COVERAGE WITH than the last year coverage. The total H/TG persons
PREVENTION covered under TI against the estimated population

SERVICES IN TI has increased over the years. Revamping activities

with a focus on new registration of H/TG persons
has attributed to this increase in coverage.

Around 65 thousand H/TG persons were covered

during 2022-23 (Figure 5.4). The overall coverage

Figure 5.4 Key prevention services provided to H/TG, 2017-2018 to 2022-2023

a. Coverage, clinic visits and HIV testing b. Average clinic visits and STI episodes treated

2.00 5 3
1.80
1.60 4 2

Episodes in 1,000
1.40 Clinic visits
1.20 3 2
In lakhs

1.00
0.80 2 1
0.60
0.40 1 1
0.20
0.00
0 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Coverage Clinic visit HIV screening Average visits to clinic STI episodes treated

c. Condom Distribution among H/TG d. HIV Positivity and put on Treatment

0.60 100

350 2.00
0.50
1.80 95
300
Average Condom

1.60
Condom in crore

0.40
250
HIV Posi�vity %

1.40

Linked to ART
90
200 1.20
0.30
1.00
150 85
0.80
0.20
100 0.60
0.40 80
50 0.10
0.20
0 0.00
0.00 75
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Average condom Condom Distribu�on HIV Posi�vity % Linked to ART %

All H/TG persons covered under TI are provided to around 91% during 2022-23. In the context of
clinical services once in a quarter, wherein approx. 95-95-95, efforts are being done to achieve 100%
0.97% of total clinic attendees were treated for STI ART linkage and their retention to achieve viral
during 2022-23. Around 1.85 lakhs clinic visits by load suppression. Provision of free condoms has
H/TG person were made, out of which around 1790 increased over the years, wherein around 270 pcs
episodes of STI were treated. HIV sero positivity of condom per H/TG person was distributed in
among H/TG persons was at 0.40% and continue year 2022-23.
to remain low, below 0.60% in the last six years.
Overall, a total of 392 new HIV positive H/TG Overall, there were eight States/UTs reporting
persons were detected during 2022-23 which was coverage of 95% or more against the estimated
around 21% higher than the total number of HIV H/TG population. Himachal Pradesh has reported
sero positive cases detected last year in 2021-22. the lowest coverage of H/TG population at 19%,
Linkages to ART of all detected positive case is while Goa has shown the highest HIV sero positivity
more than 83% in all six years, however it increased (2.11%) among all H/TG persons tested for HIV.

Sankalak: Status of National AIDS & STD Response (2023) 69

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

There were eight States/UT where 100% linkages UT-wise distribution of coverage of H/TG perons in
to ART centre was ensured. Through the Peer key service parameters during 2022-23 are given in
Navigation approach, efforts are made to link all the Table 5.6.
identified HIV positive HRGs to ARTC. The State/

Table 5.6 State/UT-wise coverage of H/TG person on Key service parameters

Percentage
Coverage Total
Clinical Syphilis Detected Condom HIV Total ART
Total against STI linked
State/UT Visits screening syphilis Distribution Testing tested Linkage
Coverage estimated Treated to
(Lakh) (in Lakh) positive (Lakh) (Lakh) positive (%)
population ART
(%)

Andhra
4557 91 0.14 27 0.05 3 13.46 0.07 25 15 60
Pradesh

Arunachal
92 66 0.00 3 0.00 3 0.24 0.00 2 2 100
Pradesh

Assam 674 27 0.02 11 0.01 7 1.23 0.01 8 7 88

Bihar 0 0 0.00 0 0.00 0 0.00 0.00 0 0 0

Chandigarh 232 ≥95 0.01 0 0.00 0 0.49 0.00 0 0 0

Chhattisgarh 1191 ≥95 0.04 64 0.02 26 4.97 0.02 32 29 91

Delhi 11786 66 0.34 144 0.18 26 23.34 0.18 32 31 97

Goa 109 83 0.00 10 0.00 3 0.87 0.00 2 1 50

Gujarat 1785 69 0.07 23 0.03 6 3.51 0.03 8 8 100

Haryana 305 21 0.01 8 0.01 0 0.71 0.01 4 2 50

Himachal
50 19 0.00 0 0.00 0 0.11 0.00 0 0 0
Pradesh

Jammu and
0 0 0.00 0 0.00 0 0.00 0.00 0 0 0
Kashmir

Jharkhand 539 ≥95 0.02 7 0.01 0 0.56 0.01 0 0 0

Karnataka 4596 42 0.17 40 0.09 14 12.68 0.09 29 29 100

Kerala 3405 ≥95 0.07 37 0.04 20 3.99 0.04 4 5 125

Madhya
969 60 0.03 13 0.02 5 1.00 0.02 7 7 100
Pradesh

Maharashtra 8670 84 0.29 712 0.14 78 35.66 0.13 88 86 98

Manipur 154 33 0.00 0 0.00 0 0.16 0.00 0 0 0

Meghalaya 28 25 0.00 0 0.00 0 0.03 0.00 0 0 0

Mizoram 0 0 0.00 0 0.00 0 0.00 0.00 0 0 0

Nagaland 105 ≥95 0.00 3 0.00 0 0.29 0.00 1 0 0

Odisha 3885 54 0.12 336 0.06 99 10.07 0.06 34 31 91

Puducherry 276 ≥95 0.01 0 0.00 2 0.70 0.00 0 0 0

Punjab 1087 83 0.04 31 0.02 14 2.72 0.02 10 5 50

Rajasthan 1475 69 0.04 44 0.01 3 2.44 0.02 4 4 100

Sikkim 0 0 0.00 0 0.00 0 0.00 0.00 0 0 0

Tamil Nadu 9131 ≥95 0.15 17 0.10 65 18.65 0.12 34 35 103

Telangana 3124 ≥95 0.07 19 0.03 4 26.39 0.04 15 13 87

Tripura 0 0 0.00 0 0.00 0 0.00 0.00 0 0 0

Uttar Pradesh 4694 48 0.15 181 0.08 5 11.31 0.08 24 16 67

Uttarakhand 168 52 0.01 41 0.00 1 0.38 0.00 0 0 0

West Bengal 2367 46 0.07 19 0.04 34 4.36 0.03 29 29 100

India 65,454 68 1.85 1790 0.94 418 180.32 0.99 392 355 91

70 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.6. MIGRANTS WITH (Figure 5.5). Due to COVID 19 pandemic, there

was a decline in coverage in 2020-21, however,
PREVENTION SERVICES this has subsequently improved. Around 9.53 lakh
HIV tests were conducted among migrants, with
HIV sero positivity at 0.12%. HIV testing per 1000
Around 74.47 lakh migrants were covered during population among migrant has increased from 125
2022-23, which is the highest coverage of migrants tests in 2021-22 to 128 tests in 2022-23.
against the estimated population in the last six years

Figure 5.5 Key prevention services provided to Migrants, 2017-2018 to 2022-2023

a. Coverage and HIV testing b. HIV Positivity and put on Treatment

0.25 100
90
80.00
0.20 80
70.00
70
60.00

HIV Posi�vity %

Linked to ART
0.15 60
50.00
In lakhs

50
40.00
0.10 40
30.00
30
20.00
0.05 20
10.00
10
0.00
0.00 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Coverage HIV screening HIV Posi�vity % Linked to ART %

Around 88% of total HIV positive cases detected among all migrants tested for HIV, followed by
were linked to ART. Since 2018-19, there has been Assam (0.84%). In seven States 100% linkages to
a significant increase in linkages to ART over past ART has been ensured. Under revamped strategy,
four years which is in the range of 87%-90%. efforts are made to link all identified HIV positive
HRGs to ARTC by way of prioritising the HRGs and
Around twenty States/UTs reported coverage linking them through navigation.
more than 95% of the total estimated population
(Table 5.7). Andhra Pradesh has reported the The State/UT-wise distribution of coverage of
lowest coverage of migrant population at 21%. HIV Migrant in key service parameters during 2022-23
sero positivity found 0.12% at national level, while as presented above are given in the Table 5.7.
Manipur has shown highest sero positivity (0.89%)

Sankalak: Status of National AIDS & STD Response (2023) 71

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.7 State/UT-wise wise coverage of Migrants on key service parameters

Percentage
HIV Total Total
Total Coverage against ART
State/UT Testing positive linked to
Coverage the estimated Linkage (%)
(Lakh) detected ART
population
Andhra Pradesh 42124 21 0.50 19 16 84

Arunachal Pradesh 70523 ≥95 0.11 31 26 84

Assam 16426 82 0.07 55 38 69

Bihar 0 0 0.00 0 0 0

Chandigarh 68034 ≥95 0.12 6 4 67

Chhattisgarh 222114 ≥95 0.31 20 14 70

Delhi 746883 ≥95 0.64 104 84 81

Goa 92376 ≥95 0.07 8 6 75

Gujarat 910728 69 0.62 56 52 93

Haryana 192280 ≥95 0.22 38 31 82

Himachal Pradesh 65251 45 0.05 14 14 100

Jammu and Kashmir 32970 ≥95 0.06 0 0 0

Jharkhand 83667 ≥95 0.13 0 0 0

Karnataka 359678 ≥95 0.46 50 47 94

Kerala 429793 ≥95 0.70 53 53 100

Madhya Pradesh 288852 ≥95 0.30 19 15 79

Maharashtra 2444621 ≥95 2.85 492 454 92

Manipur 6644 42 0.02 14 13 93

Meghalaya 0 0 0.00 0 0 0

Mizoram 66291 ≥95 0.07 27 24 89

Nagaland 25029 ≥95 0.03 4 4 100

Odisha 47730 52 0.54 33 27 82

Puducherry 26846 ≥95 0.10 3 3 100

Punjab 162047 ≥95 0.17 28 22 79

Rajasthan 224689 ≥95 0.22 19 19 100

Sikkim 0 0 0.00 0 0 0

Tamil Nadu 224273 ≥95 0.28 20 17 85

Telangana 87992 ≥95 0.32 12 11 92

Tripura 22703 63 0.06 1 1 100

Uttar Pradesh 97626 30 0.12 18 14 78

Uttarakhand 326421 ≥95 0.28 16 16 100

West Bengal 62673 ≥95 0.12 5 4 80

India 7447280 ≥95 9.53 1165 1029 88

72 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.7. TRUCKERS WITH the HIV sero positivity at 0.12%. HIV testing among
Truckers has increased over the years. Due to
PREVENTION SERVICES COVID-19 pandemic, testing had become slightly
low in 2020-21, however it increased significantly in
the successive year. HIV tests per 1000 population
Around 10.64 lakh truckers (53% of total estimation) has increased from 240 tests in 2021-22 to 274
were covered during 2022-23. Approx. 2.91 lakh tests in 2022-23.
HIV tests were conducted among the truckers, with

Figure 5.6 Key prevention services provided to Truckers, 2017-2018 to 2022-2023

a. Coverage and HIV testing b. HIV Positivity and put on Treatment

0.25 85

16.00
0.20 80
14.00
12.00

HIV Posi�vity %

Linked to ART
0.15 75
10.00
In lakhs

8.00
0.10 70
6.00
4.00
0.05 65
2.00
0.00
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 0.00 60
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Coverage HIV screening HIV Posi�vity % Linked to ART %

Around 80% of diagnosed HIV positive cases were positivity (0.52%) among all truckers tested for
linked to the ART and remains in the range of 70% HIV. In nine States, 100% linkages of all HIV case
to 81% in the last six year. Around twelve States/ detected to ART centre has been ensured.
UTs reported coverage more than 95% of the total
estimated population (Table 5.8). Goa has reported The State/UT-wise distribution of coverage of
the lowest coverage of trucker population at 43%, trucker in key service parameters during 2022-23
whereas Haryana has shown the highest sero as presented above are given in the Table 5.8.

Sankalak: Status of National AIDS & STD Response (2023) 73

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.8 State/UT- wise coverage of Truckers on key service parameters

Percentage
HIV Total Total
Total Coverage against ART
State/UT Testing positive linked to
Coverage the estimated Linkage (%)
(Lakh) detected ART
population
Andhra Pradesh 30000 57.3 0.18 11 4 36

Arunachal Pradesh 0 0.0 0.00 0 0 0

Assam 25000 ≥95 0.07 19 7 37

Bihar 10000 66.7 0.02 3 3 100

Chandigarh 10000 65.2 0.04 0 0 0

Chhattisgarh 55000 88.7 0.27 43 35 81

Delhi 35000 58.3 0.06 4 2 50

Goa 10000 43.5 0.02 0 0 0

Gujarat 55000 45.8 0.06 14 14 100

Haryana 55000 ≥95 0.08 42 27 64

Himachal Pradesh 10000 71.4 0.02 5 4 80

Jammu and Kashmir 35000 ≥95 0.07 12 12 100

Jharkhand 22500 64.3 0.09 1 1 100

Karnataka 80000 ≥95 0.11 16 11 69

Kerala 30000 ≥95 0.13 20 18 90

Madhya Pradesh 68500 80.6 0.33 13 12 92

Maharashtra 205000 ≥95 0.52 61 53 87

Manipur 0 0.0 0.00 0 0 0

Meghalaya 0 0.0 0.00 0 0 0

Mizoram 0 0.0 0.00 0 0 0

Nagaland 10000 ≥95 0.02 7 2 29

Odisha 20000 ≥95 0.11 5 5 100

Puducherry 0 0.0 0.00 0 0 0

Punjab 25000 0.0 0.07 10 11 110

Rajasthan 20000 52.2 0.04 3 3 100

Sikkim 0 0.0 0.00 0 0 0

Tamil Nadu 50000 ≥95 0.15 18 15 83

Telangana 46400 ≥95 0.04 4 1 25

Tripura 5000 ≥95 0.03 11 11 100

Uttar Pradesh 57000 79.2 0.19 19 18 95

Uttarakhand 40000 ≥95 0.07 5 4 80

West Bengal 55000 91.7 0.13 16 16 100

India 10,64,400 53.2 2.91 362 289 80

74 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.8.1. IDUs WITH sexually transmitted infections, abscess prevention

and management, condom programmes for IDUs
PREVENTION and their sexual partners, targeted information,
SERVICES IN TI education and communication for IDUs and their
sexual partners and prevention, diagnosis and
treatment of tuberculosis. Around 2.07 lakh IDUs
Under the targeted intervention projects , IDUs are were covered during 2022-23 with the increase of
provided a package of harm reduction services that approx. 27 thousand IDUs than the total coverage
includes Needle and syringe programmes, Opioid of previous year 2021-22. Overall, a total of 72% of
Substitution Therapy, HIV testing and counselling, IDUs were covered during 2022-23 against the new
Antiretroviral therapy, prevention and treatment of size estimation.

Figure 5.7 Key prevention services provided to IDU, 2017-2018 to 2022-2023

a. Coverage, clinic visits and HIV testing b. Average clinic visits and STI episodes treated

5.0 1.4
7.00 1.2
4.0
6.00

Episodes in 1,000
1.0
5.00
Clinic visits

3.0 0.8
In lakhs

4.00
3.00 2.0 0.6

2.00 0.4
1.00 1.0
0.2
0.00
0.0 0.0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Coverage Clinic visit HIV screening Average visits to clinic STI episodes treated

c. N/S Distribution among IDU d. HIV Positivity and put on Treatment

300.00 4.50 1.60 100

4.00 1.40 90
250.00 80
3.50 1.20
70
HIV Posi�vity %

200.00 3.00

Linked to ART
Average N/S

N/S in crore

1.00 60
2.50
150.00 0.80 50
2.00
0.60 40
100.00 1.50 30
0.40
1.00 20
50.00 0.20
0.50 10
0.00 0.00 0.00 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23 2017-18 2018-19 2019-20 2020-21 2021-22 2022-23

Average N/S N/S Distribu�on HIV Posi�vity % Linked to ART %

Revamping activities with a focus on new registration among IDUs was at 1.34 % during 2022-23 and
of IDUs has attributed to this increase in coverage it has continuously remained below 1.50 % in last
among the IDU population. Overall, there were six years. Across the States/UT, Tripura has shown
twelve States/UTs which reported coverage of 95 highest sero-positivity (8.06%) among all IDUs
% or more against the estimated IDU population, tested for HIV. There are eight States/UTs wherein
while Assam reported the lowest coverage of IDU 100 % linkages to ART was achieved. Overall, a
population at 25%. total of 3,721 new IDU PLHIV were detected, out
of which around 76 % are linked to ART. Through
Around 0.22% of total attendees were treated for the Peer Navigation approach, efforts are made to
STI during 2022-23. STI /RTI diagnosed and treated link all identified HIV positive HRGs to ART centres.
in TIs has remained below 0.4 % of the total clinic Linkages to ART of all detected positive case was
attendees over the six years. HIV Sero-positivity more than 75 % in all the six years.

Sankalak: Status of National AIDS & STD Response (2023) 75

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Provision of free distribution of Needle/Syringe average of approx. 270 pcs of needle/syringe per
has increased over the years. Around 4.16 crore IDU per year during 2022-23.
Needle/Syringes (N/S) were distributed at an

Table 5.9 State/UT-wise coverage of IDU on key service parameters

Percentage
Coverage Needle/
Clinical Syphilis Detected Condom HIV Total Total ART
Total against STI Syringe
State/UT Visits screening syphilis Distribution Testing tested linked Linkage
Coverage estimated Treated Distribution
(Lakh) (in Lakh) positive (Lakh) (Lakh) positive to ART (%)
population (Lakh)
(%)

Andhra
1895 ≥95 0.07 27 0.03 0 1.84 2.78 0.03 4 4 100
Pradesh

Arunachal
3733 73 0.09 51 0.05 39 0.79 2.44 0.05 284 130 46
Pradesh

Assam 6645 25 0.15 95 0.07 13 1.94 8.72 0.08 770 597 78

Bihar 2891 63 0.10 44 0.05 1 0.92 11.35 0.05 23 21 91

Chandigarh 2228 ≥95 0.07 9 0.04 0 0.96 5.52 0.04 4 3 75

Chhattisgarh 3679 94 0.11 156 0.05 9 1.20 6.83 0.05 22 17 77

Delhi 12525 39 0.40 44 0.19 1 1.46 48.96 0.20 120 99 83

Goa 524 ≥95 0.01 8 0.00 0 0.51 0.81 0.01 0 0 0

Gujarat 952 ≥95 0.03 0 0.02 0 0.14 1.43 0.02 3 2 67

Haryana 5937 31 0.17 27 0.09 2 2.05 16.51 0.09 170 114 67

Himachal
1849 50 0.05 14 0.02 0 0.62 2.65 0.03 11 7 64
Pradesh

Jammu and
4427 44 0.11 158 0.02 0 2.04 9.43 0.08 11 11 100
Kashmir

Jharkhand 1036 ≥95 0.04 1 0.02 1 0.47 3.57 0.02 3 3 100

Karnataka 1678 39 0.03 6 0.01 0 0.30 2.00 0.02 1 0 0

Kerala 7052 ≥95 0.08 0 0.04 2 0.25 3.97 0.04 1 1 100

Madhya
10758 90 0.32 53 0.16 3 4.33 13.58 0.16 61 53 87
Pradesh

Maharashtra 959 88 0.03 4 0.01 3 0.50 0.46 0.01 5 2 40

Manipur 28064 ≥95 0.76 10 0.34 0 20.63 53.23 0.35 76 69 91

Meghalaya 1516 48 0.04 15 0.02 10 0.36 2.60 0.02 25 14 56

Mizoram 13834 ≥95 0.42 13 0.18 14 5.09 18.97 0.14 289 223 77

Nagaland 28080 ≥95 0.71 57 0.30 15 12.63 17.94 0.34 149 118 79

Odisha 3389 75 0.11 127 0.05 1 1.08 3.70 0.06 8 8 100

Puducherry 0 0 0.00 0 0.00 0 0.00 0.00 0.00 0 0 0

Punjab 24446 54 0.76 58 0.34 9 7.02 37.41 0.33 625 456 73

Rajasthan 1209 40 0.04 5 0.02 1 0.32 4.63 0.02 9 9 100

Sikkim 1573 ≥95 0.04 4 0.02 0 0.58 3.93 0.02 1 1 100

Tamil Nadu 465 ≥95 0.01 0 0.01 0 0.05 0.16 0.01 0 0 0

Telangana 1108 ≥95 0.04 22 0.01 0 0.90 3.76 0.02 4 3 75

Tripura 6002 92 0.17 8 0.07 2 1.04 9.98 0.07 745 619 83

Uttar
23107 65 0.70 195 0.34 9 4.86 97.51 0.34 248 197 79
Pradesh

Uttarakhand 3191 83 0.09 89 0.05 1 1.05 11.65 0.05 40 34 85

West Bengal 1800 77 0.06 1 0.03 2 0.28 9.86 0.03 9 10 111

India 2,06,552 72 5.81 1301 2.67 138 76.23 416.33 2.78 3721 2825 76

76 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.8.2. OPIOID SUBSTITUTION NGO model: In this model, the OST centre is
located within an existing IDU TI project offering
THERAPY (OST) HIV prevention package such as needle syringe
exchange program and other clinical and outreach
services. In this model, the existing IDU-TI staff
The National AIDS & STD Control Programme such as Medical Doctor, Nurse, Counsellor, Data
(NACP) has adopted Opioid Substitution Therapy Manager and ORWs are trained on OST service
(OST) as a key harm reduction strategy to prevent delivery. As in the collaborative model, the NGO
HIV and other blood borne infections among IDUs OST centre is a full-fledged stand – alone centre
since 2007. The OST program involves treatment and the facility staffs are tasked with conducting
of patients with opioid dependence with a long- clinical assessment and diagnosis, prescription
acting opioid agonist medication for a certain of substitution treatment, daily dispensing of the
duration of time through sublingual route, in a dose medication, psycho- social counselling, follow up
which effectively minimizes craving and withdrawals and referrals and linkages. In the NGO model,
and thereby enables the patient to stop injecting there is a provision for additional ANM and ORW
drugs. Combined with extensive psycho-social to support the staffs outlined above.
intervention, the OST program has proved to be
relatively successful in reducing drug related harms Satellite OST model: The Satellite OST centre is
including transmission of HIV and HCV as well as basically a sub-centre of a full-fledged OST centre
opioid overdose. and is usually located away or at a distance from
the full-fledged main/parent centre. The purpose
Under NACP, OST is provided primarily as a of a satellite OST is to (a) provide OST services to
“Directly Observed Treatment” in a clinic-based clients residing/congregating at remote locations
setting known as OST centres under supervision of (more than 15-20 kms from the existing parent
a Medical Officer. There is also provision for “take OST centre, where clients have difficulty in access
home” dosage for clinically stable clients satisfying due to a longer travel time e.g., at least an hour
all the criteria and is given at the discretion of or more) and (b) to decongest the existing OST
the treating medical officer. The OST program centre with high daily client load so as to ensure
is provided through three models namely, the quality service delivery to each individual patient.
Collaborative model at public health facilities, The satellite OST centres are required to be linked
the NGO-based model provided at Targeted to a parent/main centre from any of the two models
Intervention (TI) NGOs and the Satellite Model mentioned above.
which includes Prison and other closed settings.
As on March 2023, there are 200 OST Centres in
Collaborative Model: In this model, the OST public health facilities settings and another 46 in
center is located in a government health care NGO settings. As part of the TI Revamped Strategy,
facility (medical college hospital, district hospital, 147 satellite OST centres have been set up to help
sub-divisional hospital, CHC, etc.). It is a full- de-congest the facilities with high client loads and
fledged stand-alone OST centre and the facility provide accessibility for clients in distant locations
staffs consist of a Nodal officer, a Medical Doctor, a from the main centre. Low threshold approaches
Nurse, Counsellor and a Data Manager. The facility such as take-home dosing for stable clients and
staff are tasked with conducting clinical assessment flexible timings have also been incorporated since
and diagnosis of opioid dependence, prescription 2021-22. The coverage of OST clients has been
of substitution treatment, daily dispensing of the steadily increasing from 29,090 in 2018-19 to
medication, psychosocial counselling, follow-up 44,553 in 2022-23 (Figure 5.8).
and referrals and linkages. The OST centre is linked
with a nearby IDU TI(s) to facilitate the service
uptake with demand generation activities and by
motivating and referring IDU clients in the project
area to the OST centre for treatment.

Sankalak: Status of National AIDS & STD Response (2023) 77

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Figure 5.8 OST centers and client coverage, 2018-19 to 2022-23

50 250
244 245
240
Client on OST(in 1000)

40 238
235
232 230
30 226 225
220
215 215
20
210
29.1

36.4

41.2

42.6

44.6
205
10 200
2018-19 2019-20 2020-21 2021-22 2022-23

Clients on-OST OST Centers

The coverage of OST clients has increased steadily (Figure 5.9). This can be attributed to the scale up
from 29 thousand active OST clients in 2018- of OST centers from 215 facilities in 2018-19 to 244
19 to 44 thousand active OST clients in 2022-23 facilities in 2022-23 within the six-year period.

Figure 5.9 On-OST IDU in TI (in 1,000) and % coverage

30 50

25 25
23 40
22 24
20
19 30
in 1,000

in %
15
44.6
42.6
41.2

20
36.4

10
29.1

5 10

0 0
2018-19 2019-20 2020-21 2021-22 2022-23

On OST( in 1000s) % of IDU on-OST

The proportion of IDUs on OST treatment i.e., total (19% of the active population) in 2018-19 to 44
clients on OST out of the total IDUs covered under thousand (23 % of the active population) in 2022-
the TI programme, has increased from 29 thousand 23. (Figure 5.9).

78 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.10 OST facilities and active population on OST (2022-23)

1.1. OSTC in Public 1.2. OSTC in 1.3 No. of Satellite

State/UT Active Population
Health Settings NGO Settings OST Centres
Andhra Pradesh 3 - - 548
Arunachal Pradesh 4 - - 444

Assam 6 - 4 1859

Bihar 2 - - 205

Chandigarh - 4 - 783

Chhattisgarh 6 - - 1047

Delhi 8 - - 1953

Goa - 1 - 68

Gujarat 2 - - 70

Haryana 10 2 - 1532

Himachal Pradesh 1 - 2 24

Jammu and Kashmir 2 - - 710

Jharkhand 2 - - 128

Karnataka 2 - - 86

Kerala 7 3 1 478

Madhya Pradesh 11 5 1 1497

Maharashtra 1 2 2 172

Manipur 19 7 26 4074

Meghalaya 2 3 4 972

Mizoram 13 4 69 2983

Nagaland 26 5 19 7949

Odisha 4 1 1 397

Puducherry - - - -

Punjab 26 8 6 9868

Rajasthan 3 - - 301

Sikkim 4 - 3 1661

Tamil Nadu 1 - - 39

Telangana - - - -

Tripura 6 - 4 1064

Uttar Pradesh 17 - 2 2237

Uttarakhand 5 - 494

West Bengal 7 1 3 900

India 200 46 147 44553

The collaborative or public health model is NACP phase-V leading to increased accessibility,
the mainstay of the OST program under NACP coverage and service uptake for OST treatment
phase-V with 200 centres in public health settings among the IDU population.
in comparison to 46 OST centres located in the TI
NGO settings in 2022-23 (Table 5.10). Additionally,
there are a total of 147 satellite OST centres linked
5.9. PRISON INTERVENTION
to the main OST centres. The establishment of
Satellite OST centres has proven to be one of NACO through respective SACS and in
the most effective revamped strategies under collaboration with State Prisons Departments

Sankalak: Status of National AIDS & STD Response (2023) 79

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

(SPD) and departments of Women and Child under the programme has increased from 1,150
Development (WCD) has been implementing HIV prisons in 2021-22 to 1,262 in 2022-23 (Figure
and TB intervention in a phased manner across the 5.10). Around 14 lakh inmates were covered in
country since 2017. The number of prisons covered 2022-23.

Figure 5.10 Number of Prisons implementing HIV intervention, 2018-19 to 2022-23

1600
1393 1371 1371 1350
1400 1306 1262
1150
1200 1059
953
1000 805
800
600
400
200
0
2018-19 2019-20 2020-21 2021-22 2022-23
Total no. of Prisons No. of Prisons Covered

Around 12.45 lakh inmates were tested for HIV, with 19. Overall, a total of 5,894 HIV-positive inmates
the HIV sero positivity at 0.47%. HIV sero positivity were identified in 2022-23 and 84.8% of them were
was in the range of 0.43% to 0.62% since 2018- linked to ART.

Table 5.11 Prison inmates tested for HIV,

diagnosed HIV positive and linked to ART, 2018-19 to 2022-23

Indicators 2018-19 2019-20 2020-21 2021-22 2022-23

Inmates covered 4,12,500 4,13,572 9,06,806 7,08,544 14,24,763
Tested 2,78,705 2,77,015 4,79,880 6,56,749 12,45,209
HIV positive 1,330 1,728 2,122 2,886 5,894
Linked to ART 1,050 1,259 1,814 2,362 5,001

During 2022-23 (Table 5.12), there were eight There were twelve States/ UTs which reported HIV
States/UT which reported coverage of 95% or test of 95% or more against the total population
more against the estimated population. Mizoram covered. Karnataka, Punjab and West Bengal
has the lowest coverage of 32.1%, while Delhi have reported more than 95% of ART linkages of
reported the highest number of STI cases detected all identified HIV positive inmates.
and treated among the incarcerated population.

80 Sankalak: Status of National AIDS & STD Response (2023)

 Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

Table 5.12 State/UT-wise Coverage of Prison Inmates with Key Service Parameters

% STI Syphilis HIV % ART Hep C

State/ UT Coverage HIV Test ART link TB Screen
Coverage Treated Test +ve link Test

Andaman
1445 ≥95 0 0 485 0 0 0.0 127 0
Nicobar

Andhra Pradesh 41738 53.3 0 0 28145 101 99 98.0 28769 0

Arunachal
363 64.5 0 70 237 1 1 100.0 270 70
Pradesh

Assam 21465 ≥95 1 6264 20838 432 244 56.5 16833 713

Bihar 171201 88.6 0 1 163497 607 389 64.1 24550 3

Chhattisgarh 19498 36.3 0 0 19498 41 31 75.6 2285 0

Chandigarh 1457 55.5 0 826 1249 5 5 100.0 1282 1163

DNHDD 211 55.7 0 210 250 1 1 100.0 73 210

Delhi 22906 45.5 1222 2001 18857 341 279 81.8 19536 9892

Goa 1328 94.5 4 1 686 6 5 83.3 643 460

Gujarat 26770 43.2 44 11766 16773 42 34 81.0 11758 8528

Haryana 63091 ≥95 0 8115 58882 663 656 98.9 58889 23998

Himachal
5421 90.4 1 1065 4535 20 17 85.0 6023 2375
Pradesh

Jammu and
9235 ≥95 0 14 8311 14 11 78.6 10642 22
Kashmir

Jharkhand 23946 44.0 1 45 21081 21 21 100.0 18040 1646

Karnataka 42194 80.0 0 5499 40499 90 91 101.1 40847 1341

Kerala 35921 93.9 2 2159 32981 42 36 85.7 23335 10000

Ladakh 26 59.1 0 26 26 0 0 0.0 26 26

Maharashtra 76437 66.9 114 21045 63626 229 188 82.1 20562 17132

Manipur 1845 94.3 0 974 1053 6 4 66.7 1533 1031

Meghalaya 2162 76.0 0 1009 2022 11 10 90.9 2045 303

Mizoram 1701 32.1 4 420 1687 101 15 14.9 2747 95

Madhya Pradesh 168177 ≥95 2 81770 160886 173 147 85.0 164647 64075

Nagaland 820 48.7 5 379 583 24 35 145.8 189 273

Odisha 40752 52.4 1 13011 39876 81 72 88.9 29620 10212

Puducherry 988 94.4 372 879 914 0 0 0.0 914 10

Punjab 46471 73.8 0 17733 44795 960 932 97.1 43340 15412

Rajasthan 99076 86.6 0 15083 88389 249 214 85.9 78010 23810

Sikkim 570 77.3 0 0 390 0 0 0.0 255 126

Tamilnadu 68046 80.1 36 31162 65608 100 90 90.0 65419 11591

Telangana 42607 ≥95 0 0 29335 115 103 89.6 33401 898

Tripura 1545 37.8 0 924 1499 53 36 67.9 1179 204

Uttarakhand 27446 ≥95 0 13 13316 193 163 84.5 13255 2017

Uttar Pradesh 312149 75.1 10 28206 270780 1104 1005 91.0 274663 2988

West Bengal 45755 40.9 0 454 23620 68 67 98.5 13469 8789

India 14,24,763 75.4 1819 2,51,124 12,45,209 5894 5001 84.8 10,09,176 2,19,413

Sankalak: Status of National AIDS & STD Response (2023) 81

Prevention of new HIV/STI infections among
High-Risk Groups and Bridge population

5.10. LINK WORKERS enabling and stigma-free environment, increasing

access to information and services by linking them
SCHEME (LWS) to other departments/programmes. However, the
scheme itself does not create any service delivery
points in the programme villages. LWS are placed
The Link Workers Scheme (LWS) is implemented in high risk or vulnerable districts considering
in the priority districts and blocks/villages to cover the presence of HRGs, migration patterns, PLHIV
rural HRGs and other vulnerable populations. Apart burden, etc. One LWS scheme is implemented
from the rural HRGs, other vulnerable populations in one district or more than one district covering
covered under the scheme are antenatal mothers, approximately 60-100 villages.
spouse and partner of HRGs, migrants and truckers,
youth, persons diagnosed with TB and PLHIV. This Year-wise progress of on-boarding of number of LWS
scheme envisages creation of demand for various in districts and population covered under prevention
HIV and AIDS related services, linking the target services are presented in the figure below.
population to existing services, creation of an

Figure 5.11 LWS districts and population covered by the scheme, 2017-18 to 2022-23.

180 168 2500000

160 146

Popula on covered(in number)

138
District covered(in umber)

140 123 124 2000000

117
120
1500000
100
80
1000000
60
1621486

1465939

1619216

1693345

1928426

40 2283094 500000
20
0 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
Vulnerable popula on covered District covered under scheme

Figure above indicates an increase in the number Year-wise population coverage under LWS, 2017-
of districts covered under the programme. This 18 to 2022-23 is presented in the Table 5.13.
has also led to an increase in the coverage of total
population in the rural villages.

82 Sankalak: Status of National AIDS & STD Response (2023)

 Table 5.13 Year-wise coverage of population under LWS, 2017-18 to 2022-23

Coverage Total tested for HIV Number of positive detected Number of HIV+ve linked to
ART Centre
Ty-
pol-
ogy FY 17- FY 18- FY 19- FY 20- FY 21- FY 22- FY 17- FY 18- FY 19- FY 20- FY 21- FY 22- FY 17- FY 18- FY 19- FY 20- FY 21- FY 22- FY 17- FY 18- FY 19- FY 20- FY 21- FY 22-
18 19 20 21 22 23 18 19 20 21 22 23 18 19 20 21 22 23 18 19 20 21 22 23

FSW 67,470 50,311 65,699 69411 78,528 80,684 57,454 37,077 51,692 57,292 63652 71463 72 110 132 113 158 203 64 103 127 109 148 200

IDU 4,106 4,121 4,564 5770 10,412 15,658 3,696 3,696 4,234 4,603 7648 9734 41 107 178 123 598 956 30 92 163 113 560 865

MSM 7,247 5,100 7,611 9850 17,438 12,200 5,672 3,373 5,126 7,298 8835 9017 18 18 43 37 51 62 15 17 40 35 43 61

H/TG 297 226 471 642 1,047 1,021 122 139 313 435 634 747 8 3 5 7 5 26 6 2 5 7 5 18

Mi-
6,10,007 5,01,979 4,77,812 520985 5,94,729 6,98,015 3,10,956 2,78,341 2,87,763 2,76,957 342237 418020 477 500 494 372 463 814 442 467 463 347 444 789
grant

Trucker 98,547 78,772 97,539 105600 1,36,551 1,80,664 60,600 53,598 66,036 60,695 74097 92703 72 88 117 79 116 178 69 82 110 71 107 172

OVP 6,41,816 6,44,253 7,17,973 726303 7,97,957 9,69,641 3,20,897 3,75,968 4,20,402 3,63,878 429297 513145 514 719 915 583 859 1242 469 640 838 541 813 1232

TB
13,740 12,559 20,241 61132 17,439 82,703 9,317 8,935 16,214 41,350 11091 80153 23 55 51 12 25 29 21 49 31 11 19 21
Cases

Sankalak: Status of National AIDS & STD Response (2023)

ANC 1,54,349 1,46,981 1,93,795 151561 1,82,478 1,99,232 1,36,134 1,26,559 1,74,690 1,33,853 159010 167187 72 65 94 89 108 136 65 63 90 84 106 132

PLHIV 23,907 21,637 33,511 42091 41,822 43,276

83
High-Risk Groups and Bridge population
Prevention of new HIV/STI infections among
06
MANAGEMENT
OF SEXUALLY
TRANSMITTED
INFECTIONS AND
REPRODUCTIVE
TRACT INFECTIONS
MANAGEMENT OF Management of Sexually Transmitted Infections and
Reproductive Tract Infections

SEXUALLY TRANSMITTED
INFECTIONS AND
REPRODUCTIVE
TRACT INFECTIONS
6.1. BACKGROUND district/sub-district level are provided at Primary
Health Centers (PHCs), Community Health Centres
(CHCs) and Sub-Centers (SCs) under National
Health Mission (NHM).
The sexually transmitted infections (STI) encompass
a spectrum of infections that transmits through
These services are also provisioned for key and
sexual as well as close physical (intimate) contact
bridge populations at Targeted Intervention (TI)
and may get transmitted from an infected mother
Project clinics and PLHIV at ART Centres. The STI/
to her baby during pregnancy and the process of
RTI services are included in the essential services
childbirth. The reproductive tract infections (RTI)
under Sampoorna Suraksha Strategy (SSS) to cater
refer to any infection in the reproductive tract of
to the needs of ‘at-risk’ HIV negative population
a person and these infections may or may not
(not falling under the criteria of TI) and One Stop
transmit through sexual route. More than 30
Centres (OSC – a model for providing holistic care
microorganisms have been associated with various
to hijra/transgender persons and drug users). The
STI/RTI. Along with significantly increasing the
current service delivery framework is mentioned
risk of acquisition and transmission of HIV, these
in Figure 6.1.
infections are responsible for serious sexual and
reproductive morbidity (including infertility),
The syndromic approach has been considered
adverse pregnancy outcomes and various cancers.
as the backbone of these services along with
These infections may manifest differently in people
optimum utilization of available on-site diagnostics
living with HIV and can be associated with increased
facilities without delaying the prompt treatment
morbidity resulting in various complications and
of patients. The patients are provided on-site
increased infectiousness of people living with HIV
diagnostic services through co-located SA-ICTCs
(PLHIV). Hence, the prevention, management and
and laboratories under district hospital/ medical
control of STI and RTI is important to prevent HIV
colleges.
transmission and ensure sound sexual-reproductive
health and wellbeing. The National AIDS & STD
There are currently 1,133 DSRCs operational
Control Programme is committed to work towards
under NACO across the country (Figure 6.2).
strengthening STI and RTI services in India. The
More than 75% of DSRCs are located in fifteen
NACP phase-V aims to ensure universal access to
States/UTs – Uttar Pradesh (115), Tamil Nadu
quality STI/RTI services for at-risk and vulnerable
(106), Maharashtra (80), Gujarat (66), Madhya
population towards the attainment of dual
Pradesh (66), Andhra Pradesh (55), Karnataka (54),
elimination of vertical transmission HIV and Syphilis
Rajasthan (53), Telangana (50), West Bengal (48),
in the country.
Bihar (44), Odisha (40), Chhattisgarh (31), Haryana
(31) and Punjab (31).
6.2. SERVICE DELIVERY
MODEL

The STI/ RTI services in the country are provided

through a network of Designated STI/RTI Clinics
(DSRC, branded as ‘Suraksha Clinic’) at district
and sub-district level under National AIDS & STD
Control Program (NACP). The services below

Sankalak: Status of National AIDS & STD Response (2023) 85

Management of Sexually Transmitted Infections and
Reproductive Tract Infections

Figure 6.1. STI/RTI Service Delivery under NACP phase-V

STI/RTI
Services

GC/KP/PLHIV/
At-risk HIV (-)
At-risk HIV (-) KP PLHIV

Designated Targeted
Anti-retroviral
STI/RTI Sampoorna Intervention (TI)
therapy
Clinics or Suraksha Kendra Project Clinics &
centres
Suraksha (SSK) OSC (One Stop
(ARTC)*
Clinic Centres)

GC: General Clients; KP: Key Populations; PLHIV: People living with HIV
*Screening & referrals of PLHIV for STI/RTI services

Figure 6.2. Number of DSRCs operational in States/UTs under NACP phase-V

120 115
106

100

80
80
66 66

60 55 54 53
50 48
44
40
40
31 31 31
28 28 28 27
23
20 18 18
20 12 10 10 10
6 6 5 5 4 4
1
0
Madhya…

Arunachal…
Himachal…

Jammu &…
Tamil Nadu
Maharashtra

Karnataka
Gujarat

Andhra Pradesh

Kerala

Mizoram
Tripura

Manipur

DDDNH
Chandigarh
Puducherry
Telangana

Assam
Delhi

Sikkim

Goa
ANI
West Bengal

Odisha
Bihar

Haryana

Nagaland
Rajasthan

Jharkhand

Meghalaya
Punjab
U�ar Pradesh

Chha�sgarh

U�arakhand

86 Sankalak: Status of National AIDS & STD Response (2023)

 Management of Sexually Transmitted Infections and
Reproductive Tract Infections

6.3 MANAGEMENT OF country in FY 2022-23. Around 3/4th of the total

clinic visits was reported from ten States/UTs
CASES OF STI/RTI (Figure 6.3) - Uttar Pradesh (17.5%), Maharashtra
(12.4%), Madhya Pradesh (7.8%), Tamil Nadu
(7.1%), Andhra Pradesh (6.5%), Bihar (5.6%),
A total number of 58.2 lakh clinic visits were Karnataka (5.0%), Chhattisgarh (4.4%), Rajasthan
reported for various STI/RTI services across the (4.4%) and Punjab (3.6%).

Figure 6.3. Clinic Visits for STI/RTI services (FY 2022-23)

Rest of India U�ar Pradesh

38% 18%

Maharashtra
12%

Madhya
Pradesh
8%
Karnataka Tamilnadu
5% Bihar Andhra 7%
6% Pradesh
6%

Out of 58.2 lakh clients, 63.5% were females and Average number of client visits per day
0.8% were H/TG persons. The States/UTs reporting
per DSRC
highest footfall of women were Manipur (81.3%),
Chandigarh (79.8%), Sikkim (74.7%), Bihar (73.8%),
An average of 17 clients were managed per day
Uttarakhand (73.1%) and Andhra Pradesh (72.2%).
per DSRC across the country in FY 2022-23. Nine
States/UTs reported a higher average than the
national average (Figure 6.4) i.e. Maharashtra (30),
Uttar Pradesh (30), Chhattisgarh (28), Bihar (25),
Andhra Pradesh (23), Madhya Pradesh (23), Punjab
(23), Haryana (18) and Karnataka (18).

Sankalak: Status of National AIDS & STD Response (2023) 87

Management of Sexually Transmitted Infections and
Reproductive Tract Infections

Figure 6.4. Number of client visits per day per DSRC (FY 2022 – 23)

35
30 30
30 28
Number of Clients Managed per day per DSRC

25
25 23 23 23

20 18 18 17
16 16 15
14 14 14 13
15 12
9 9 8
10 7 7 7 7 6 6
5 5 5 5
5 3 2
1 1
0
Maharashtra

Karnataka

Kerala
Mizoram
Andhra Pradesh

Manipur
ANI

Tamilnadu

Puducherry

Tripura
Chandigarh
Madhya Pradesh

Delhi

Himachal Pradesh
Goa
Gujarat

J&K

Arunchal Pradesh
Sikkim
Haryana

Odisha

Assam

DNHDD
Bihar

Telangana
West Bengal

Jharkhand

Meghalaya

Nagaland
Punjab

Rajasthan
U�ar Pradesh

U�arakhand
Chha�sgarh

India

States

On the contrary, seventeen States/UTs reported an genital ulcer disease – non herpetic (GUD – NH),
average of less than 10 clients managed per day genital ulcer disease – herpetic (GUD – H), lower
per DSRC, namely, Goa (9), Gujarat (9), Assam (8), abdominal pain (LAP) and inguinal bubo (IB). The
Kerala (7), Mizoram (7), Puducherry (7), Uttarakhand clients accessing STI/RTI services at DSRC are also
(7), Jharkhand (6), Tripura (6), Chandigarh (5), screened for genital warts and other STI/RTI.
DNHDD (5), Jammu & Kashmir (5), Meghalaya (5),
Manipur (3), Nagaland (2), Arunachal Pradesh (1) More than 3.31 lakh episodes of syndromes were
and Sikkim (1). reported among males accessing STI/RTI services
at DSRC. Around half of the syndromes reported in
Syndromic Case Management males was UD (47%), followed by GUD-NH (27%)
and GUD – H (13%). Additionally, 4.48 lakhs other
A STI/RTI syndrome is defined as a group of STI/RTI including 0.23 lakh cases of genital warts
common symptoms and signs caused by one or were reported among males.
more than one sexually transmitted organism. The
STI/RTI syndromes reported in males are urethral More than 16.3 lakh syndromes were reported
discharge (UD), anorectal discharge (ARD), genital among females accessing STI/RTI services at DSRC.
ulcer disease – non herpetic (GUD – NH), genital The predominant syndrome reported was VCD
ulcer disease – herpetic (GUD – H), painful scrotal (62%) followed by LAP (34%). The distribution of
swelling (PSS) and inguinal bubo (IB). The STI/RTI syndromes reported in DSRC is presented in Figure
syndromes reported in females are vagino-cervical 6.5. Additionally, 3.84 lakhs other STI/RTI including
discharge (VCD), anorectal discharge (ARD), 0.13 lakh cases of genital warts were reported
among females.

88 Sankalak: Status of National AIDS & STD Response (2023)

 Management of Sexually Transmitted Infections and
Reproductive Tract Infections

Figure 6.5. Distribution of Syndromes among DSRC Client in FY 2022-23

GUD-H GUD-NH GUD - H

13% 2% 2%

UD LAP
34%
47%

GUD-NH
27%

VCD
62%
IB
0.10%
ARD
PSS 0.20%
IB ARD
8%
2% 3%

Male Female

UD remained the major syndrome diagnosed in Chandigarh (79%) and Delhi (42%). Moreover, Uttar
male clients at DSRC. The States/UTs reporting Pradesh (57%) and Kerala (40%) reported GUD-NH
highest proportion of UD were Arunachal Pradesh as the predominant syndrome among males. PSS
(92%), DNHDD (84%), Assam (80%), Tripura (79%) was reported to be in highest proportion in ANI
and Madhya Pradesh (77%). While, the States/UTs (45%) and Odisha (31%). (See Figure 6.6.)
reporting GUD-H as predominant syndrome were

Figure 6.6. State/UT-wise distribution of STI/RTI Syndromes (%) among males (2022-23)

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

UD ARD IB PSS GUD - NH GUD - H

Sankalak: Status of National AIDS & STD Response (2023) 89

Management of Sexually Transmitted Infections and
Reproductive Tract Infections

VCD has remained the predominant syndrome The States/UTs reporting high proportion of LAP
diagnosed among females attending DSRC. were Haryana (48%), Manipur (46%), Uttarakhand
The States/UTs reporting highest proportion of (45%), Jammu & Kashmir (44%), Bihar (43%) and
VCD were Mizoram (91%), Assam (77%), Goa Delhi (43%). (See Figure 6.7.)
(76%), Gujarat (75%) and Andhra Pradesh (74%).

Figure 6.7. State/UT wise distribution of STI/RTI Syndromes (%) among females (2022-23)

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

VCD ARD IB LAP GUD - NH GUD - H

6.4 LABORATORY overall syphilis positivity was reported to be 0.7%

at DSRC. The trend for test positivity of syphilis at
DIAGNOSIS AT DSRC DSRC continues to rise in 2022-23 when compared
with test positivity reported in 2020-21 (0.49%) and
2021-22 (0.60%). The test positivity is also reported
A total number of 35.85 lakhs RPR tests were to increase among males and females when
conducted for screening of syphilis amongst the compared with previous FY. (The test positivity
DSRC clients. The test positivity was reported to be among males and females was reported to be 1%
at 1.3%, 0.3% and 1.9% among males, females and and 0.28% respectively in 2021-22)
H/TG population respectively (see Table 6.1). The

90 Sankalak: Status of National AIDS & STD Response (2023)

 Management of Sexually Transmitted Infections and
Reproductive Tract Infections

Table 6.1. Syphilis Screening at DSRC, 2022-23

Males Females H/TG Total

Total number of RPR tests conducted 13,69,585 21,85,644 30,635 35,85,864
Total number of RPR tests reported reactive 17823 7352 595 25770
Test positivity (%) 1.3% 0.3% 1.9% 0.7%

The States/UTs reporting test positivity > 1% are (2.00%), Gujarat (1.68%), West Bengal (1.61%),
Meghalaya (8.41%), Arunachal Pradesh (6.27%), Assam (1.57%), Nagaland (1.53%) and DNHDD
Sikkim (6.11%), Kerala (3.67%), Goa (2.85%), (1.30%). (See Table 6.2.).
Chandigarh (2.03%), Delhi (2.00%), Puducherry

Table 6.2. Gender-wise Syphilis Seropositivity (in %) at DSRC, 2022-23

States/UTs Males Females H/TG Total

A & N Islands 0.50 0.16 0.00 0.32
Andhra Pradesh 0.45 0.10 1.10 0.21
Arunachal Pradesh 7.17 5.58 0.00 6.27
Assam 3.33 0.67 5.65 1.57
Bihar 1.41 0.63 0.00 0.81
Chandigarh 7.65 0.62 0.00 2.03
Chhattisgarh 0.55 0.20 0.54 0.37
DNHDD 1.75 0.89 0.00 1.30
Delhi 4.33 0.81 17.02 2.00
Goa 5.02 0.61 50.00 2.85
Gujarat 3.17 0.67 13.79 1.68
Haryana 1.02 0.13 0.00 0.38
Himachal Pradesh 0.34 0.10 0.00 0.20
J&K 0.74 0.07 100.00 0.23
Jharkhand 0.34 0.05 0.00 0.17
Karnataka 0.62 0.16 1.28 0.33
Kerala 6.27 1.44 7.94 3.67
Madhya Pradesh 0.81 0.20 2.05 0.40
Maharashtra 0.78 0.19 5.28 0.49
Manipur 1.78 0.16 17.65 0.58
Meghalaya 9.97 7.05 0.00 8.41
Mizoram 0.68 0.44 0.00 0.53
Nagaland 1.52 1.54 0.00 1.53
Odisha 1.29 0.43 4.09 0.96
Puducherry 4.46 0.71 3.51 2.00
Punjab 1.06 0.25 1.06 0.60
Rajasthan 1.59 0.25 8.51 0.62
Sikkim 13.16 3.72 0.00 6.11
Tamil Nādu 1.02 0.29 1.49 0.67
Telangana 1.64 0.31 7.44 0.75
Tripura 0.39 0.14 0.00 0.27
Uttar Pradesh 0.48 0.15 0.91 0.28
Uttarakhand 1.12 0.12 0.00 0.37
West Bengal 3.47 0.62 21.67 1.61
India 1.30 0.34 1.94 0.72

Sankalak: Status of National AIDS & STD Response (2023) 91

07
HIV
COUNSELLING
AND TESTING
SERVICES
 HIV Counselling and Testing Services

HIV COUNSELLING
AND TESTING
SERVICES

7.1. BACKGROUND of HIV-infected people in the country are aware of

their status so that they can adopt healthy lifestyles
and prevent the transmission of HIV to others.

HIV counselling and testing services (HCTS) play

a key role to achieve the first 95 of the fast-track 7.2. HIV COUNSELLING
target of 95-95-95. Its central role in reduction of AND TESTING SERVICE
(HCTS) FACILITIES
new infections makes it an imperative component
for prevention and control of HIV and STI in the
country. HIV counselling and testing services
were started in the year 1997 and serves as the
key entry point where in people have access to Under NACP, the healthcare facility for HIV
correct information about HIV prevention and care confirmation services are usually limited to district-
while undergoing HIV test in a supportive and level facilities while the NHM facilities have a
confidential environment. People who are found wider and more granular presence which extends
HIV-negative are counselled to reduce risks and to the sub-district level in the country. The focus
remain HIV-negative, while people who are found is on decentralization of HIV and STI screening
HIV-positive are provided psychosocial support and services while consolidating confirmatory services.
linked to treatment and care at the nearest NACP NACP phase-V collaborates with NHM to scale-up
facilities. HCTS are offered through facility, mobile the preventive and management services for HIV
and community-based facilities in the public and and STI, through existing NHM facilities including
private sectors throughout the country. Health and Wellness Centre (HWC) to decongest
the ICTCs so that consellors can focus on preventive
Under NACP phase-V, NACO is committed to services for at-risk clients to ensure that they remain
reduce the number of new HIV infections by 80%. HIV negative.
To achieve this target, NACO has listed a basket
of strategies tailored to the high-risk, at-risk and Furthermore, to enhance reporting from F-ICTCs,
low-risk population groups. NACO envisions there are indicators pertaining to HIV and STI
to develop the modalities for provision of testing which are incorporated in HMIS. States/UTs
comprehensive prevention, reduce new infections are directed to report FICTC HIV testing in HMIS
and strengthen early detection of HIV by reaching from FY 2023-24 instead of in the SOCH portal.
out to the population ‘at-risk’ for HIV and STIs,
who are not associated with NACP projects. The facilities through which HCTS services are
A total of 75 Sampoorna Suraksha Kendra (SSK) provided in public and private sectors are classified
have been set up as an immersion learning model in two categories; (1) HIV Confirmatory Facilities
to prioritize “at-risk HIV negative clients” through also known as Stand-Alone (SA) ICTC where HIV
revised client flow, collaboration with NHM and confirmation is done using three different kits with
revision of counsellor’s ToR with emphasis on different principle and (2) HIV Screening Facilities,
provision of comprehensive prevention packages where HIV screening is done using whole blood
to keep them negative. finger prick test (WBFPT). There are two types of
screening facilities: Facility Integrated ICTCs (FI-
New infections declined by 42% between 2010 to ICTC) or Community Based HIV Screening, at the
2022. As of March 2023, 79% of the people who screening facilities, besides the pre and post-test
are HIV positive in the country are aware of their counselling, all individuals found HIV reactive are
HIV status. The target is to ensure that at least 95% referred and linked to confirmatory facilities.

Sankalak: Status of National AIDS & STD Response (2023) 93

HIV Counselling and Testing Services

As on March 2023, there were 34,515 HCTS facilities of 3.39 crore of HIV testing were conducted in the
including 5,428 confirmatory facilities where a total country. (Figure 7.1).

Figure 7.1. Scale up of HCTS facilities 2012-13 to 2022-23

40000 4

No of At Risk Clients (Excl.Pw) Tested fo HIV (no.incrores)

3.39
35000 3.5
2829
2494 2616 2890
30000 4290
3852 3733 3557 3
2044
2.92
4290
25000 0 2.5
2.57
3780
0 2.35
20000 0 3434 2.1 1.83 2
0 2465
2377 1.92
22041 22637 22298
15000 0 1.62 21187
1.5
1977 1.5 18206
16168
0 1.3
1341 12067
13243
10000 1.04
8811
10645
1
7048

5000 0.5
4508 4818 5347 5521 5545 5546 5410 5330 5352 5408 5428

0 0

HIV confirma�on facility HIV Screening facility (Govt) HIV Screening facility (PPP) CBS No of At-risk clients tested (in Crore)

HCTS includes HIV diagnostic tests, interpersonal When moving towards ending the HIV epidemic
communication, HIV-TB cross-referral, linkages by 2030, one of the key challenges remains to
with TI, DSRC, general health system, positive ensure that PLHIV, especially those in HRG and
people with ART centres, outreach services and at-risk population who are aware of their status
peer support services, etc. NACO has provided are linked to life-saving antiretroviral treatment
a list of priority clients with testing targets to the (ART) to prevent HIV morbidity, mortality and
States/UTs. Priority clients include self-referred further transmission. The national HIV testing
clients, HRGs, spouse/partners of HRGs newly guidelines have been revised over the years to
identified PLHIV’s spouse/partners, clients referred keep pace with the World Health Organization
from STI/RTI centres, clients referred from NTEP/ (WHO) guidelines. The guidelines recommend
TB and prison/OCS inmates. In FY 2022–2023, client-initiated voluntary counselling and testing as
NACO counsellors received both virtual and in- well as provider-initiated testing and counselling
person training to improve their counselling skills for pregnant women, people infected with TB and
and to inform the newer strategies introduced STI patients. Figure 7.1 displays the results of HIV
under NACP phase-V. tests conducted over the last 11 years for at-risk
clients. As seen in figure 7.1, there was an impact
7.3. HCT SERVICES UPTAKE on HCTS services during the COVID 19 pandemic,
which have returned to pre-covid level since then.
During FY 2022-23, around 3.39 crore at-risk clients
received HIV counselling and testing against the
(Note: Under NACP, HCTS are provided to at-risk
target of 2.65 crores.
clients as well as pregnant women. The targets are
set for both these groups. This section describes
The Figure 7. 2 represent the testing at ICTC and
HCTS services provided to at-risk clients. The HIV
FICTC in FY 2022-23. The SA-ICTC contributed to
testing among pregnant women is discussed under
around 64% of total testing.
chapter 11 on EVTHS).

94 Sankalak: Status of National AIDS & STD Response (2023)

 HIV Counselling and Testing Services

Figure 7.2. ICTC Vs FICTC testing in FY 2022-23

100%

80%

60%

40%

20%

0%

SAICTC F-ICTC

Focussed counselling and testing services are initiated testing is seen to account for about 10%
provided to the sub populations who are more of the total testing. However, testing at FICTCs is
vulnerable or practise high-risk behaviour while mostly provider initiated.
providing the minimum essential package of
services to the general population at large not To enhance uptake of HCTS for at-risk clients,
at risk of HIV infection. These sub populations particularly walk in clients, NACO has initiated
include sex workers and their clients, men who various strategies such as SSK, awareness through
have sex with men (MSM), hijra/transgender IEC, counsellor outreach services and client
persons, injecting drug users (IDUs), truckers, prioritization.
migrant workers, spouses/partners and children
of PLHIV and persons who are prone to risky To fast-track priority clients and ensure uptake of
behaviour. HIV prevalence levels are typically preventive services, counsellors are trained to
higher among these sub populations than in the perform ‘risk assessment’ for all the clients identified
general population. The counsellors at ICTCs from Direct Referrals (self-referred, reactive cases
strive to identify at-risk/vulnerable populations referred from screening sites, spouse/partners of
and ensure access for them to HIV counselling PLHIV). Such assessment is performed on the basis
and testing services. This type of HIV testing is of NACO’s defined risk assessment questionnaire
referred to as “Client Initiated” HIV testing. consisting of 6 questions, which evaluates clients’
risk on the basis of their sexual behaviour, needle
Medical professionals also refer patients who injecting behaviour and STI symptoms. Further, in
have a history of risky behaviour or have signs and case of discordant couples, the risk assessment
symptoms suggestive of HIV/AIDS for counselling at the time of registration will also consider the
and testing to an ICTC which is referred to as Spouse/Partner’s HIV status and such HIV negative
“Provider Initiated” HIV testing. At ICTCs, client- spouse/partners will be considered as ‘at-risk’.

Sankalak: Status of National AIDS & STD Response (2023) 95

HIV Counselling and Testing Services

Figure 7.3. Provider initiated testing and client-initiated testing FY 2022-23

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

CI -SAICTC PI-SAICTC FI-ICTC

The figure 7.3 indicates State/UT wise client- clients tested/screened for HIV is 85% out of the
initiated testing and provider-initiated testing total clients tested/screened for HIV during 2022-
and positivity. 23. It also reveals that, the positivity is high (0.99%)
in client-initiated (Walk-in-Client) among the total
Clients Initiated testing (walk in clients) reported by positive cases reported during the FY 2022-23.
ICTCs accounts for 15% out of total HIV screening
and testing with positivity of 0.99%. Whereas The State/UT wise testing and positivity is
Provider Initiated testing reported by ICTC provided in Table 7.1. Among the States/UTs
accounts for 49% out of total HIV screening and Meghalaya reported highest client-initiated
testing with positivity of 0.38%. The proportion of positivity at 7.47% followed by Chandigarh
at risk clients screened for HIV at FICTCs is 36% (7.33%), Uttarakhand (5.37%) and Mizoram
out of the total testing reported during the FY (4.93%). The highest positivity of provider-
2022-23. The individuals tested at F-ICTC are also initiated testing reported in Mizoram (2.44%),
considered as Provider Initiated testing, in such followed by Arunachal Pradesh (2.43%).
a way the proportion of total provider-initiated

96 Sankalak: Status of National AIDS & STD Response (2023)

 Table 7.1. State/UT wise HCT facilities and Service uptake 2022-23
Proportion of HIV Testing among At
HIV Tested/Screened among at Risk Client At Risk Client Diagnosed HIV Positive Positivity
risk Clients by Facilities
States/UTs
S.No. CI Tested PI Tested Total Tested Tested at Total HIV CI SA-ICTC PI SA-ICTC FI-ICTC Total HIV Total HIV
CI Positive PI Positive CI Positive PI Positive*
at SAICTC at SA-ICTC At SA-ICTC F-ICTC Tested % Tested % Tested Tested % Positive Positive
1 ANI 6,295 17,064 23,359 4,765 28,124 22% 61% 17% 11 19 30 0.17% 0.09% 0.11%
2 Andhra Pradesh 1,91,408 8,46,870 10,38,278 8,29,688 18,67,966 10% 45% 44% 3,071 12,465 15,536 1.60% 0.74% 0.83%
3 Arunachal Pradesh 6,839 10,269 17,108 1,909 19,017 36% 54% 10% 255 296 551 3.73% 2.43% 2.90%
4 Assam 52,235 1,65,419 2,17,654 33,979 2,51,633 21% 66% 14% 1,604 2,163 3,767 3.07% 1.08% 1.50%
5 Bihar 2,13,351 4,63,101 6,76,452 8,41,575 15,18,027 14% 31% 55% 3,879 5,548 9,427 1.82% 0.43% 0.62%
6 Chandigarh 2,264 91,503 93,767 7 93,774 2% 98% 0% 166 592 758 7.33% 0.65% 0.81%
7 Chhattisgarh 90,112 3,62,651 4,52,763 1,24,429 5,77,192 16% 63% 22% 972 1,850 2,822 1.08% 0.38% 0.49%
8 DNH 1,882 26,094 27,976 15,470 43,446 4% 60% 36% 13 25 38 0.69% 0.06% 0.09%
9 Daman & Diu 1,095 9,569 10,664 2,489 13,153 8% 73% 19% 7 10 17 0.64% 0.08% 0.13%
10 Delhi 88,807 4,06,626 4,95,433 17,117 5,12,550 17% 79% 3% 2,618 3,554 6,172 2.95% 0.84% 1.20%
11 Goa 13,811 43,288 57,099 33,329 90,428 15% 48% 37% 85 169 254 0.62% 0.22% 0.28%
12 Gujarat 2,47,632 8,25,457 10,73,089 5,54,623 16,27,712 15% 51% 34% 3,012 4,396 7,408 1.22% 0.32% 0.46%
13 Haryana 2,08,916 6,01,045 8,09,961 97,592 9,07,553 23% 66% 11% 2,077 3,581 5,658 0.99% 0.51% 0.62%
14 Himachal Pradesh 49,553 1,37,636 1,87,189 20,463 2,07,652 24% 66% 10% 134 404 538 0.27% 0.26% 0.26%
15 Jammu & Kashmir 2,842 1,15,146 1,17,988 2,59,441 3,77,429 1% 31% 69% 69 321 390 2.43% 0.09% 0.10%
16 Jharkhand 75,240 1,43,138 2,18,378 1,35,023 3,53,401 21% 41% 38% 650 1,008 1,658 0.86% 0.36% 0.47%
17 Karnataka 3,45,376 16,65,487 20,10,863 13,12,502 33,23,365 10% 50% 39% 2,061 10,736 12,797 0.60% 0.36% 0.39%
18 Kerala 1,08,516 5,54,133 6,62,649 1,33,249 7,95,898 14% 70% 17% 314 840 1,154 0.29% 0.12% 0.14%

Sankalak: Status of National AIDS & STD Response (2023)

19 Ladakh 45 3,825 3,870 1,777 5,647 1% 68% 31% 0 5 5 0.00% 0.09% 0.09%
20 Lakshadweep 0 222 222 3,219 3,441 0% 6% 94% 0 0 0 #DIV/0! 0.00% 0.00%
21 Madhya Pradesh 2,40,747 7,04,727 9,45,474 7,72,184 17,17,658 14% 41% 45% 1,190 4,049 5,239 0.49% 0.27% 0.31%
22 Maharashtra 11,10,779 16,57,903 27,68,682 14,39,676 42,08,358 26% 39% 34% 6,888 7,468 14,356 0.62% 0.24% 0.34%
23 Mumbai 1,06,163 2,62,633 3,68,796 86,983 4,55,779 23% 58% 19% 1,424 1,948 3,372 1.34% 0.56% 0.74%
24 Manipur 14,859 68,509 83,368 33,970 1,17,338 13% 58% 29% 345 603 948 2.32% 0.59% 0.81%
25 Meghalaya 4,419 46,598 51,017 16,403 67,420 7% 69% 24% 330 849 1,179 7.47% 1.35% 1.75%
26 Mizoram 20,185 34,719 54,904 15,522 70,426 29% 49% 22% 995 1,227 2,222 4.93% 2.44% 3.16%
27 Nagaland 34,241 36,744 70,985 49,583 1,20,568 28% 30% 41% 957 887 1,844 2.79% 1.03% 1.53%
28 Odisha 1,70,317 7,70,574 9,40,891 4,23,147 13,64,038 12% 56% 31% 592 2,426 3,018 0.35% 0.20% 0.22%
29 Puducherry 5,752 82,675 88,427 61,635 1,50,062 4% 55% 41% 61 161 222 1.06% 0.11% 0.15%
30 Punjab 39,096 7,24,276 7,63,372 2,59,536 10,22,908 4% 71% 25% 1,560 10,390 11,950 3.99% 1.06% 1.17%
31 Rajasthan 1,01,131 8,71,472 9,72,603 10,88,586 20,61,189 5% 42% 53% 1,768 4,796 6,564 1.75% 0.24% 0.32%
32 Sikkim 5,705 19,008 24,713 5,233 29,946 19% 63% 17% 13 33 46 0.23% 0.14% 0.15%
33 Tamil Nadu 8,25,474 23,18,195 31,43,669 9,50,826 40,94,495 20% 57% 23% 2,541 5,151 7,692 0.31% 0.16% 0.19%
34 Telangana 1,26,616 4,29,798 5,56,414 1,44,585 7,00,999 18% 61% 21% 2,244 6,391 8,635 1.77% 1.11% 1.23%
35 Tripura 27,525 47,794 75,319 69,507 1,44,826 19% 33% 48% 873 935 1,808 3.17% 0.80% 1.25%
36 Uttar Pradesh 3,40,672 10,88,983 14,29,655 10,68,418 24,98,073 14% 44% 43% 6,249 8,607 14,856 1.83% 0.40% 0.59%
37 Uttarakhand 4,971 1,18,812 1,23,783 1,99,931 3,23,714 2% 37% 62% 267 908 1,175 5.37% 0.28% 0.36%
38 West Bengal 2,79,850 8,41,898 11,21,748 10,92,011 22,13,759 13% 38% 49% 2,082 3,828 5,910 0.74% 0.20% 0.27%

97
India 51,64,721 1,66,13,861 2,17,78,582 1,22,00,382 3,39,78,964 15% 49% 36% 51,377 1,08,639 1,60,016 0.99% 0.38% 0.47%
HIV Counselling and Testing Services

*Provider Initiated Client includes the confirmed positive among the screened reactive referred from F-ICTC and the denominator included the individual tested at F-ICTC.
HIV Counselling and Testing Services

7.4. HIV SERO-POSITIVES pre-COVID 19 period as seen in Figure 7.4. During

FY 2022-23, a total of 160,016 HIV positive cases
AND SERO-POSITIVITY were identified with sero-positivity of 0.47%. As
we proceed towards bridging the gap of first 95,
NACO lays emphasis on identification of new cases
During FY 2022-23, HIV testing among at-risk and has directed States/UTs to focus on index
clients was reported high while the yield in terms testing as discussed in the subsequent section.
of HIV positive cases identified was still lower than

Figure 7.4. HIV sero-positive and Positivity (%) 2017-18 to 2022-23

200,000 1

180,000 0.9
182,397
177,564
0.87
160,000 167,754 0.8
160,016

140,000 0.7
0.69
120,000 0.6
122,588
0.55
0.57
100,000 0.52 0.5
100,918
0.47
80,000 0.4

60,000 0.3

40,000 0.2

20,000 0.1

0 0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23

HIV posi�ve Posi�vity

The testing coverage among at at-risk clients Similarly, the top ten States/UTs that identified 68%
varied between the States/UTs. The top ten of newly identified PLHIV are Maharashtra, Andhra
States/UTs contributed to around three fourth of Pradesh, Uttar Pradesh, Karnataka, Punjab, Bihar,
total HIV tested in India i.e. 74%, which includes Telangana, Tamil Nadu, Gujarat and Rajasthan
Maharashtra, Tamil Nadu, Karnataka, Uttar Pradesh, (Figure 7.5 b).
West Bengal, Rajasthan, Andhra Pradesh, Madhya
Pradesh, Gujarat and Bihar (Figure 7.5 a).

98 Sankalak: Status of National AIDS & STD Response (2023)

 HIV Counselling and Testing Services

Figure 7.5. State/UT-wise distribution (in%) of total

HIV testing conducted and HIV Positive detected, FY 2022-23

States wise propor�onate distribu�on of HIV Tesing among At-Risk client

during FY 2022-23

Maharashtra
Rest of India
13.73%
20.68%

Tamil Nadu
12.05%
Odisha
4.01%

Bihar
4.47%
Karnataka
Gujarat 9.78%
4.79%

Madhya Pradesh
5.06% U�ar Pradesh
7.35%
Andhra Pradesh West Bengal
5.50% Rajasthan 6.52%
6.07%
(Figure 7.5 a).

States wise propor�onate distribu�on of HIV Posi�ve case diagnosed

among At-Risk client during FY 2022-23

Maharashtra
11.08%
Rest of India
29.64%
Andhra Pradesh
9.71%

U�ar Pradesh
9.28%

Rajasthan
4.10% Karnataka
8.00%
Gujarat
4.63%
Tamil Nadu
Punjab
4.81%
Telangana Bihar 7.47%
5.40% 5.89%
(Figure 7.5 b).

Sankalak: Status of National AIDS & STD Response (2023) 99

HIV Counselling and Testing Services

As seen in Table 7.1, States/UTs reporting higher

positivity than the national average were Mizoram
7.6. SPOUSE/PARTNER
(3.16%), Arunachal Pradesh (2.90%), Meghalaya TESTING AMONG
(1.75%), Nagaland (1.53%), Assam (1.50%), Tripura HIV POSITIVE AT-RISK
POPULATION
(1.25%), Telangana (1.23%), Delhi (1.20%), Punjab
(1.17%), Andhra Pradesh (0.83%), Chandigarh
(0.81%), Manipur (0.81%), Mumbai (0.74%), Haryana
(0.62%), Bihar (0.62%), Uttar Pradesh (0.59%) and
Chhattisgarh (0.49%). The high positivity may be Spouse/Partner testing is a process through
contributed due to high prevalence and/or due to which all exposed sexual and injecting partners
focused testing. E.g. North-Eastern States have of PLHIVs (index case) are identified and offered
higher prevalence. However, States like Andhra HIV testing services. Through this process, the
Pradesh and Arunachal Pradesh which have previously undiagnosed positive partners of
focused index testing have resulted in higher yield. an index client are identified and placed on
Index testing is discussed later in this chapter. treatment. Likewise, those tested negative among
the exposed clients of index case are offered
State/UT-wise increase in uptake of HCTS has not comprehensive prevention services such as HIV
necessarily resulted into more detection of HIV education, condoms, STI care and harm reduction.
positive persons, for example, Telangana, DNH & By offering testing to all exposed spouse/partners
DD and Sikkim reported lesser identification than of index case and providing treatment to positive
FY 2020-21. individuals and prevention services to negative
individuals, will result in stopping and breaking
the chain of disease transmission. Considering
7.5. GENDER DIFFERENCE the positivity rate amongst those tested, spouse/
IN HIV TESTING partner testing has always been the priority
strategy for NACO and is reflected in all related
guidelines and trainings programs.
India conducted around 43% testing for female,
56.5% for males and 0.5% for transgender in FY There has been an increase in spouse /partner
2022-23. A total of 1.6 lakh HIV positives were testing of PLHIV from 45.58% in 2021-22 to 54%
identified, out of which 66.6%, 32.7%, 0.7% male, in 2022-23 compared with total PLHIV identified.
females and transgender persons respectively with In 2022-23, the sero-positivity was 47.22% as
a sero-positivity rate of 0.58% in male, 0.34% in compared to 52% in 2021-22.
females and 1.03% in transgender population.

100 Sankalak: Status of National AIDS & STD Response (2023)

 HIV Counselling and Testing Services

Various studies suggests that the spouse/partner per Pradesh reported the highest achievement against
PLHIV varies from 1.5-2.5%. Hence, from program NACO spouse/partner testing targets set by NACO.
implementation perspective, States/UTs have been
given spouse partner testing target as 200% of The figure 7. 6 explains States/UTs wise distribution
total new PLHIV identified in earlier year and test of Spouse/partner testing and sero positivity for
performance is monitored accordingly. Arunachal the period of 2022-23.

Figure 7.6. HIV sero-positivity among partners tested

70.0
100%
69.3
65.6 67.0 60.0
80% 57.6
55.2 56.3 54.7 50.0
53.0 53.1 52.5
51.6 50.7 50.752.4 50.8
47.2 48.0
60% 44.6 45.5 40.0
44.0 42.6 42.9
41.5 41.4
82%
98%

38.2 37.9 38.1

36.1 36.2 35.6 30.0
40% 33.2
76%
74%
66%
59%

20.0
59%
58%

25.8
56%
55%
55%

24.6
54%
53%
52%
51%
49%
49%
49%
48%
47%
46%
45%
43%
41%
20% 20.00

36%
35%
35%
35%
31%
10.0

18%
17%
17%
16%
14%
11%
0%
0%
0% 0.0 0.000.00 0.0
Puducherry
Manipur

Jharkhand
Andhra Pradesh

Chha�sgarh

Maharashtra
West Bengal

Bihar

Rajasthan

Himachal Pradesh
Madhya Pradesh

India

Tamil Nadu
Karnataka

Mizoram
Punjab
Kerala

Telangana

Chandigarh

Arunachal Pradesh

Tripura
Jammu & Kashmir*

Ladak
Goa

Delhi
DNH&DD

Sikkim
Nagaland

Gujarat

Odisha
Meghalaya

Andaman & Nicobar

Assam
Haryana

U�arakhand
U�ar Pradesh

Lakshadweep
Spouse/Partner tes�ng Coverage (%) Posi�vity

Sankalak: Status of National AIDS & STD Response (2023) 101

08
INITIATION AND
RETENTION
ON ART
 Initiation and retention on ART

INITIATION AND
RETENTION ON ART

8.1. BACKGROUND launched free ART on 1st April 2004 at 8 centres

under the second phase of NACP. The programme
has come a long way (Figure 8.1) and has witnessed
several changes including the adoption of test
The ‘end of AIDS epidemic as a public health
and treat, introduction of viral load (VL) testing for
threat’ asks for the attainment of viral suppression
monitoring of PLHIV on ART, dolutegravir-based
among 86% of all PLHIV. With the increased
regimens for treatment optimization, advanced
suppression rate due to availability of potent and
disease management (ADM), implementation of
effective regimens, the focus continues to remain
patient-centric differentiated care models including
on maximum retention in the programme and
multi-month dispensation (MMD), expansion of
ensuring quality of life for People Living with HIV
Link ART centres (LAC) and Community ART Refill
(PLHIV). Recognising this need, NACP phase-V
groups (CARG). With this increased access to
aims to attain the target of 86% viral suppression
antiretroviral therapy (ART), HIV as a disease has
by 2025 through strategies like (i) maintaining
become a manageable chronic condition and has
existing care, support and treatment (CST) service
increased longevity with favourable treatment
models and expanding further in a sustainable
outcomes. With improved survival, PLHIV are
manner, (ii) continued provisions of high-quality
more likely to develop non-communicable
ARV through differentiated service delivery models
diseases (NCD). To cater to this burden of NCD,
improving access and retention to care, (iii) focus
NACP has taken a pivotal step in line with NACP
on rapid ART initiation and advanced HIV disease
phase-V strategies for integration with other health
management augmenting quality of care and (iv)
programmes to ensure that holistic services are
addressing linkage loss at all level. The objective
provided to enhance the quality of life for PLHIV.
is to attain 95–95–95 HIV testing and treatment
The existing Care, Support & Treatment Technical
targets leading to 80% and 90% reduction in AIDS-
Guidelines, 2021, has incorporated comprehensive
related mortality by 2025 and 2030 respectively.
approach on prevention, screening, referrals and
management of non-communicable diseases.
Care, support and treatment remains integral to
the AIDS & STD response in India since the early
The aim of the programme continues to remain
years of NACP phase-II. The provision of free Anti-
to ensure there is universal access to life-saving
Retroviral Therapy (ART) for PLHIV under NACP
ART for all PLHIV, along with lifelong retention and
has been a pivotal decision in the fight against
sustained viral load suppression.
HIV/AIDS in the country. The Government of India

Sankalak: Status of National AIDS & STD Response (2023) 103

Initiation and retention on ART

Figure 8.1. Evolution of ART services under NACP

ART centre in each Medical

LAC Plus and ART Plus College
Centres Multi month Dispensation
LAC and CoE; ART Initiation
Launch of ART Second Line ART at CD4<=500 Rapid ART
Programme Initiation
Test and Treat

2004 2006 2008 2009 2010 2011 2015 2016 2017 2018 2019 2020 2021

TRG of ART ART Initiation at CD Third Line ART Introduction of

and Pediatric care <=250; Dolutegravir
Targetted Viral Load
ART Initiation Targeted Routine Viral
at CD <=350 Load testing

Under NACP phase-V, PLHIV continue to have Over the years, the service delivery mechanism for
access to free diagnostic facilities; free first-line, ART services has evolved into a three-tier system
second and third-line ART; prevention, diagnosis; (Figure 8.2). As on March 2023, there were 712
and management of opportunistic infections ART centres including 85 ART-plus centres across
including management of Tuberculosis (TB) with the country; mostly located at medical colleges
daily anti-TB treatment through a single window and district hospitals. The ART centres are also
approach. NACP phase-V is committed to offering mapped to 18 (11 Adult and 7 Paediatric) Centres
integrated service delivery packages through of Excellence (CoE) established by NACO.
establishing referrals and linkages in coordination
with related national health programmes especially The number of ART centres have increased by
for management of non-communicable diseases. 48 vis-à-vis last year; mostly involving the private
NACO is also engaging with the private sector medical colleges to ensure that PLHIV have
for setting up ART centres wherein every teaching access to services to increase retention & viral
college will have an ART centre providing ART suppression. These ART centres are fundamental
services in line with the national guidelines. to this service delivery mechanism. Efforts are also
being made under NACP phase-V to expand CST
8.2. FACILITIES delivery points in a sustainable manner tapping
the public and private health sectors. In the last
three years, more than 150 ART centres have
been established. There were 553 ART centres
NACP phase-V calls for maintaining the existing
providing ART services in March 2020 which have
care, support and treatment (CST) service models
been significantly scaled up to 712 ART centres as
along with expansion in a sustainable manner. The
on March 2023 reflecting an increase of more than
objective is to have 703 ART centres, 1,400 Link
150 ART centres in last three years and achieving
ART Centres (LAC) and 400 Care and Support
the target of NACP phase-V.
Centres (CSC) by 2025-26.

104 Sankalak: Status of National AIDS & STD Response (2023)

 Initiation and retention on ART

Figure 8.2. ART service delivery mechanism, March 2023

CoE (18)

ART Plus (85)

ART Center (627)

LAC and LAC Plus (1,261)

CSC (319)

The PLHIV enter the CST service networks through The preferred 1st line regimen is a fixed-dose
ART centres and are subsequently linked with combination of Tenofovir + Lamivudine +
LACs and CSCs for decentralized dispensation/ Dolutegravir (TLD), which is also the preferred
refilling, counselling and follow-ups services. regimen for post-exposure prophylaxis as per the
Currently, decentralization of services is provided national guidelines on HIV care and treatment
through the establishment of 1,261 LAC/LAC plus (2021). This is aligned with the NACP phase-V goal
and 319 CSCs (including 9 funded by the State to reduce mortality by 80% through the continued
government and 100 under the domestic budget) provision of high-quality ARVs. Overall, 7.1% (1.11
which facilitate access to essential services, lakh) were on second-line ART while very few
leading to increasing treatment adherence and (around three thousand four hundred) were on the
reducing stigma and discrimination. third line of ART. There has been an increase of
around two thousand PLHIV on second line ART as
8.3. PLHIV ON ART compared to the last year.

The number of ‘Alive and on-ART’ PLHIV under

NACO’s supported facilities in March 2023 is almost
Overall, as on March 2023, around 15.74 lakh PLHIV
66% higher than the number in March 2017. The
were on lifelong free antiretroviral (ARV) medicines
‘Test and Treat’ policy was adopted in 2017. In the
from 712 ART centres supported by NACO. This
first year of the test and treat policy, the number of
works out to approximately 2,211 ‘Alive and on-
‘on-ART’ PLHIV increased by almost 1.50 lakh on
ART’ per centre. Around 8.09 lakh (51%) of ‘Alive
a year-to-year basis. The upward trend continued
and on-ART’ PLHIV were males, 7.59 lakh (48%)
till 2020-21 which coincided with the COVID-19
were females while around 5.8 thousand were hijra/
pandemic. However, the momentum was regained
transgender (H/TG) persons.
in 2021-22 with a net gain of around 70 thousand
in terms of ‘on-ART’ PLHIV and further significant
increase of 1.24 lakh on-ART PLHIV in 2022-23.

Sankalak: Status of National AIDS & STD Response (2023) 105

Initiation and retention on ART

Figure 8.3. Scale-up of ART facilities and PLHIV on ART at NACP facilities, 2005 to March 2023

18.00 800

15.74
16.00 712 700
664
620
14.00 553
544 14.50 600
537 13.88
12.00 525 531 13.80
12.02 12.93
475 10.50 500
PLHIV (in Lakhs)

ART Centers
10.00 425 9.40
400 8.52 400
7.68
8.00 355
300 6.32 300
6.00 269 5.16
211 4.05 200
4.00 147 3.16
107 2.23
2.00 54 1.41 100
25 0.69
0.07 0.37
0.00 0
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

No. of pa�ent on ART No of ARTC

Several PLHIV do avail ARV from the private health these eleven States/UTs accounted for more than
care providers. To estimate the size of PLHIV 80% of the total ‘Alive and on-ART’ PLHIV in the
availing ARV from the private sector, a study was country (Table 8.1).
undertaken in 2018. In the study, ARV-wise sales
data for the period 2013-17 was collected from On an average, Telangana had 4,096 ‘Alive and
the Association of Indian Origin Chemist and on-ART’ PLHIV per ART centre, the highest in
Distributors Pharma-soft tech. Only 2-drug or the country, followed by Andhra Pradesh (3,959).
3-drug combinations were considered to estimate Delhi, Maharashtra, Chandigarh, Chhattisgarh,
the number of patients. With a response rate of Punjab, Karnataka and Bihar were the other States
54%, it was estimated that PLHIV availing ARV with ‘Alive and on-ART’ PLHIV per ART centre
from the private sector may range from 1,05,767 higher than the national average. The average
to 1,95,864. Based on this assessment, for all ‘Alive and on-ART’ PLHIV per ART centre in these
reporting purposes, it has been assumed that States ranged between 2,345 in Chhattisgarh to
1,05,767 PLHIV are on ART in the private sector. 3,114 in Delhi. The average load of less than 1,000
This number has been considered fixed until ‘Alive and on-ART’ PLHIV per ART centre is in six
better evidence about PLHIV accessing ARV from States/UT including that of Himachal Pradesh,
the private sector emerges. Taking into account Uttarakhand, Sikkim, DNH&DD, Arunachal Pradesh
almost 1.06 lakh PLHIV are on ARV from the private and ANI. The average ranged between 165 (ANI) to
sector, there were approximately 16.80 lakh ‘Alive 956 (Uttarakhand) in these States (Figure 8.4, Table
and on-ART’ PLHIV in India as of March 2023. 8.1). In the previous year, there were ten States/
UTs with the average load of less than 1000 while
With around 2.70 lakh ‘Alive and on-ART’ PLHIV, currently there are only six States/UTs. The average
Maharashtra has the highest number of on-ART load has increased to >1000 PLHIV per ART centre
PLHIV in the country followed by Andhra Pradesh in States such as Tripura, Meghalaya, Mizoram and
(2.13 lakh), Karnataka (1.80 lakh), Tamil Nadu (1.26 Nagaland as compared to the last year.
lakh) and Uttar Pradesh (1.06 lakh). Telangana,
Gujarat, Bihar, Punjab, West Bengal and Rajasthan
were the other States with ‘Alive and on-ART’ in
the range of 50,000 to less than one lakh. Together,

106 Sankalak: Status of National AIDS & STD Response (2023)

 Initiation and retention on ART

Figure 8.4. States/UTs wise distribution of ART Centres and average PLHIV per ART centre, March 2023

PLHIV((Alive and on-ART) per ART centre)

100 4500
90 4000
80 3500
70
ART Centers

3000
60 2500
50
40 2000
30 1500
20 1000
10 500
0 0
Bihar
Gujarat

West Bengal

Odisha

Mizoram

Delhi

Assam

Puducherry
Sikkim
Tamil Nadu

Haryana

Jharkhand

ANI
Nagaland

Meghalaya

Goa

DNH&DD
Andhra Pradesh

Kerala
Rajasthan

Punjab
Telangana

Tripura

Ladakh
Maharashtra
Karnataka

Manipur

Jammu & Kashmir

Madhya Pradesh

Chandigarh
Himachal Pradesh

Arunachal Pradesh
U�ar Pradesh

Chha�sgarh

U�arankhand
ART Centres (March 2023) PLHIV (Alive and on-ART) per ART centre

8.4 ART INITIATION AND The progress on ART initiation and retention
has been demonstrated through indicators of
RETENTION (i) initiation of ART per 100 detections in ICTC
centres, (ii) 12 months retention among PLHIV (in
%) and (iii) lost-to-follow-up (LFU) per 100 PLHIV
The Government of India launched “Test and ‘Alive and on-ART’ (Figure 8.5). As evident, the
Treat” on 28th April 2017. The introduction of the initiation of ART for every 100 detections in ICTCs
policy aimed for rapid initiation of ART, including under the programme has improved significantly.
the offer of same-day initiation, unless clinically In 2017-18, the first year of the launch of ‘Test an
contraindicated otherwise. The retention and Treat’, 78 PLHIV were initiated on ART for every
adherence on-ART is also critical to achieving and 100 detections made. In comparison, >95 PLHIV
maintaining the status of adequate viral suppression were initiated on ART for every 100 detections
for the prevention of opportunistic infections and made in 2022-23. Similarly, 12 months of retention
maintaining a healthy life while also eliminating on-ART increased to 82% in comparison to 72% in
chances of further transmission of the virus. Under 2017-18. However, there is scope for improvement
NACP phase-V, focus on rapid ART initiation, to achieve the target of 86% of viral suppression.
advanced HIV disease management and focus on
adherence and retention on treatment augmenting For every 100 on-ART PLHIV, 25 were LFU in
the quality of care continue to be key priorities. 2017-18 and 2018-19. After assigning definitive
The objective is to improve the survival and quality outcomes to LFU under ‘Mission Sampark’ of the
of life for the HIV-infected person at the individual Government of India, the number of LFU per 100
level and to fast-track the country’s response to on-ART PLHIV decreased to 13 in 2019-20 and
achieve the “End of AIDS” at the population level. further decreased to 11 in 2022-23. There has
been consistent improvement with decrease of LFU
cases over a period of years (Figure 8.5).

Sankalak: Status of National AIDS & STD Response (2023) 107

Initiation and retention on ART

Figure 8.5. ART initiation, retention and LFU; 2017-18 to 2022-23

100 94
89 95
90 85 88
80 78 80 82
72 75 74 71
70
60
50
40
30 26 24
20 15
13 13
10 11
0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23

PLHIV ini�ated on ART per 100 detec�ons 12 months reten�on among PLHIV
LFU per 100 ‘Alive and on- ART’ PLHIV

There was State/UT-wise variations on aspects Chandigarh, Punjab and Rajasthan. Similarly for the
of initiation, retention and LFU (Table 8.1). In State of Bihar, Jharkhand, etc, perhaps PLHIV are
Puducherry and Chandigarh, there were only being initiated on ART who were diagnosed in other
39 and 60 initiations respectively for every 100 States/UT. Another reason may be associated with
detections; however, this needs to be viewed in the the fact that those PLHIV diagnosed in the previous
context of these particular UTs being utilised as the FY 2021-22 are being registered and initiated
centre for healthcare services by the neighbouring in FY 2022-23. However, it merits exploring the
States. Improvement have been observed in Sikkim, reasons for the gaps in these States/UTs to further
Assam, J&K and Arunachal Pradesh as compared strengthen the linkage from HIV case detection to
with the last financial year. Assam and Delhi were ART initiation (Table 8.1).
the only other States/UTs with ART initiation per
100 detections ranging between 75 to 89. In the States/UT with the largest number of PLHIV on ART
remaining States, the ART initiation was > 90%. (Maharashtra, Andhra Pradesh, Karnataka, Tamil
This reflects significant improvement in the ART Nadu and Uttar Pradesh) had 12 months retention
initiation of those detected at ICTC and initiated above/equivalent to the national average (Table
at ARTC. Focus has been given on prompt linkage 8.1). However, there were seven States/UTs with
and initiation, resulting in mitigation of the linkage 12-months retention of less than <75%, with the
loss from ICTC to ART centre. lowest retention rate noted in Chhattisgarh (56%).
The retention in Chhattisgarh has dropped further
Gaps between the detection and initiation on ART to 56% from 65% as compared to the last year.
in select States may be attributed to duplicate Similarly, retention in Goa has dropped from 73%
testing or registration in the ART centres of the to 58% and in Arunachal from 88% to 41% for the
neighbouring States and data recording and current financial year. Attention needs to be given
reporting issues. In the State of Haryana, Bihar, on these States to improve their retention through
Jharkhand and Sikkim there was high number of focus on uptake of the differentiated care models.
initiations compared to detections. Earlier, Haryana States/UTs like Andaman & Nicobar Islands,
had one ART centre in Rohtak while currently there Odisha, Nagaland, West Bengal and Sikkim have
are additional 16 ART centres. There are high shown improvement under this indicator.
number of transfer-in to these 16 ART centres from
ART centres of the neighbouring States/UT like

108 Sankalak: Status of National AIDS & STD Response (2023)

 Initiation and retention on ART

As linkage loss adversely impacts the progress

on all three ninety-five, responding to the issue
8.5 DIFFERENTIATED
of LFU is a key priority under NACP phase-V. The CARE MODEL
programme aims to mitigate linkage loss across
screening-confirmation-treatment-retention by
leveraging technology, strengthening outreach, Differentiated care is a person-centric approach
upskilling field resources, improving counselling that simplifies and adapts HIV services across the
and building synergies across service delivery treatment cascade and takes into consideration the
points. These initiatives, in turn, will promote preferences and expectations of various groups of
retention and adherence towards rapid viral load PLHIV while reducing unnecessary burdens on the
suppression. Further, providing MMD to stable health system. Since each person’s specific needs
PLHIV along with community-based dispensation are unique, differentiated care aims to improve
through patient centric models such as CARG and the experience and treatment outcomes while
LAC has supported mitigation of linkage loss over ensuring that the health system is functioning
a period of years. both in a medically accountable and efficient
manner. General considerations for differentiated
Mission Sampark, launched on 1st December 2017, ART service delivery are based on three elements
was a key initiative under NACP to trace those who such as the clinical characteristics of the patient
were LFU and bring them back under the ART (e.g. stable, unstable, comorbidity/coinfection),
services. As on March 2023, Tamil Nadu, Kerala the sub-population (e.g. adults, children and
and Andhra Pradesh had 3,4 and 5 LFU respectively adolescents, pregnant and breastfeeding women,
for every 100 PLHIV on ART. Bihar, Chandigarh, key populations, men) and the context (e.g.
Haryana, Himachal, Jharkhand, Manipur, Mizoram, difficult terrains and hard to reach areas). The
Rajasthan, Sikkim and Uttar Pradesh were the differentiated care models (MMD, LAC, CARG etc.)
other States/UTs with LFU PLHIV lesser than 10 helps to improve patient outcomes, motivate and
for every 100 on-ART PLHIV. Assam, Chhattisgarh, empower patients to take responsibility, enhance
Nagaland, Uttarakhand, West Bengal, Meghalaya the quality of care and access to treatment for
and Delhi have LFU ranging from 20-40 for every PLHIV and effective resource management. Under
100 PLHIV on ART. There were 16 States/UT with a NACP phase-V, these models are being piloted and
much higher number of LFU for every 100 PLHIV on scaled up not only to bring services closer to the
ART than the national average (Table 8.1). PLHIV but also to decongest ART centres. This will
improve adherence and facilitate the attainment of
viral load suppression.

Sankalak: Status of National AIDS & STD Response (2023) 109

Initiation and retention on ART

Table 8.1. State/UT-wise progress on ARV treatment services, 2021-22a

PLHIV (Alive
PLHIV PLHIV 12 LFU
ART and on-ART) LFU Baseline
(Alive and initiated months per 100
Centres in NACP PLHIV CD4 test
State/UT on-ART) on ART retention ‘Alive and
(March supported (March per 100
per ART per 100 among on-ART’
2023) facilities 2023) registrations
centre detections PLHIV (%) PLHIV
(March 2022)

ANI 1 165 165 13 90 61 100 8

Andhra Pradesh 54 2,13,796 3959 10,467 ≥95 80 86 5

Arunachal Pradesh 1 543 543 58 90 12 41 11

Assam 9 11,970 1330 2,928 89 33 70 24

Bihar 27 76,160 2821 6,276 ≥95 36 67 8

Chandigarh 2 5,151 2576 447 60 93 79 9

Chhattisgarh 8 18,761 2345 4,121 90 34 56 22

DNH&DD 1 340 340 0 ≥95 100 85 0

Delhi 12 37,368 3114 14,562 80 83 76 39

Goa 2 3,246 1623 444 ≥95 90 58 14

Gujarat 47 79,424 1690 9,730 ≥95 68 72 12

Haryana 16 28,677 1792 2,512 ≥95 63 79 9

Himachal Pradesh 6 5,253 876 398 91 70 76 8

Jammu & Kashmir

3 3,399 1133 537 91 66 81 16
Ladakh

Jharkhand 13 14,515 1117 785 ≥95 52 78 5

Karnataka 71 1,80,509 2542 18,304 94 88 80 10

Kerala 15 15,923 1062 625 ≥95 46 82 4

Madhya Pradesh 30 36,402 1213 5,182 ≥95 82 79 14

Maharashtra 97 2,70,088 2784 44,101 ≥95 94 82 16

Manipur 13 14,492 1115 1,046 ≥95 61 78 7

Meghalaya 4 4,863 1216 1,135 93 46 62 23

Mizoram 14 14,357 1026 1,154 91 68 90 8

Nagaland 12 12,091 1008 2,722 ≥95 58 81 23

Odisha 19 24,654 1298 3,506 ≥95 58 81 14

Puducherry 1 1,318 1318 59 39 100 77 4

Punjab 24 56,542 2356 7,542 94 81 67 13

Rajasthan 36 55,445 1540 3,945 93 99 73 7

Sikkim 1 298 298 22 ≥95 100 88 7

Tamil Nadu 60 1,26,524 2109 3,922 ≥95 99 77 3

Telangana 23 94,210 4096 16,739 ≥95 84 77 18

Tripura 3 4,351 1450 515 91 36 70 12

Uttar Pradesh 55 1,06,677 1940 4,870 ≥95 74 80 5

Uttarakhand 6 5,738 956 1,394 ≥95 63 79 24

West Bengal 26 51,066 1964 10,059 ≥95 88 85 20

India 712 15,74,316 2211 1,80,120 ≥95 76 82 11

1
No ART centre in Lakshadweep

110 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 111
09
HIV-TB
CO-INFECTION
MANAGEMENT
 HIV-TB Co-infection Management

HIV-TB
CO-INFECTION
MANAGEMENT

9.1 BACKGROUND 9.2 HIV-TB CO-INFECTION

MANAGEMENT
Provision of an integrated package of services
keeping beneficiaries and communities in At the ART centres, PLHIV who are attending
the centre is the first guiding principle of ARTC are screened for TB for 4S every month. The
NACP phase-V. This is being done through percentage of PLHIV screened for TB has increased
institutionalized convergence with the existing from 94.7% in 2020-21 and has hovered around
schemes of the Central Government including 97% in 2021-22 & 2022-23. In the monthly report of
synergies with other National health programmes. March 2023, 4S screening of less than 95% PLHIV
was noted in seven States/UT including Nagaland
Tuberculosis (TB), the commonest opportunistic (78%), Meghalaya (85%), Chhattisgarh (92%), Delhi
infection (OI), is the leading cause of hospitalization (93%), Telangana (93%), Goa (88%) and Puducherry
and death among PLHIV, accounting for one in (91%). Except for Delhi, less than 95% screening
five HIV-related deaths. Given the context, HIV- has been reported again in 2022-23 for the rest of
TB cross-referral has been a focus under NACP the six states.
since 2001. NACP phase-V aims to maintain and
augment programme collaboration with National Emphasis is also given on early ART initiation for
Tuberculosis Elimination Programme (NTEP) co-infected PLHIV. Combined use of ART and anti-
for HIV-TB cross-referrals and single-window TB treatment (ATT) reduces the impact of active TB
delivery at all ART centres. HIV-TB collaborative among PLHIV significantly. The National Guidelines
activities are being implemented in all service for HIV Care and Treatment (2021) recommends
delivery centres. The objective is to ensure early that ART should be initiated among PLHIV within
detection and prompt linkage of presumptive two weeks of initiating TB treatment, regardless of
TB cases as well as notified TB cases for care, CD4 cell count (except for PLHIV diagnosed with
support and treatment. TB meningitis). In 2022-23, out of those PLHIV
who were enrolled in the HIV-TB register, almost
all (99%) were initiated on anti-TB treatment (ATT),
95% on CPT and ART (Figure 9.1).

Sankalak: Status of National AIDS & STD Response (2023) 113

HIV-TB Co-infection Management

Figure 9.1. Percentage of screening and initiation under single window services, 2022-23

100 99% ATT ini�a�on in FY 2022-23

95

97% TB Screening 90 95 % CPT ini�a�on in FY 2022-23

85

80

95% IPT ini�a�on 95% ART ini�a�on in FY 2022-23

(since incep�on)

TB preventive treatment (TPT) is offered to PLHIV Pradesh, Maharashtra, Chandigarh, Himachal

and CLHIV after ruling out TB. Further, TPT is also Pradesh, J&K, Goa, Gujarat, Karnataka, Rajasthan,
provided as secondary prophylaxis to PLHIV in Jharkhand, Odisha, Puducherry, Tamil Nadu,
the programme. Till March 2023, overall, ≥95% of Telangana and Uttar Pradesh, where TPT has been
PLHIV in active care at NACO’s ART centres were provided to >95% of PLHIV (Figure 9.2). However,
initiated on TB preventive treatment since the there are states like Bihar, Uttarakhand, Mumbai,
inception of single window services at ART centres. Sikkim, Assam and Arunachal Pradesh where the
There were fifteen States /UTs such as Andhra TPT uptake was <55% as on March 2023.

Figure 9.2. State/UT-wise TPT initiation as on March 2023

100% 100%

90%

80%

70%

60%
55%
50%

40%

30%

20%

10%

0%

114 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 115
10
LABORATORY
SERVICES
 Laboratory Services

LABORATORY
SERVICES

10.1. BACKGROUND and transporting the sample to their linked viral

load lab and ensuring that the data is entered in
SOCH portal.
One of the strategy under Goal 2 of NACP V is to
In-addition, NACP phase-V endeavours to monitor
optimize the use of programme laboratories for
the progress on elimination of vertical transmission
viral load measurements. NACO had installed 64
of HIV and syphilis. Routine viral load testing has
viral load machines as part of efforts to strengthen
been recommended for all HIV-positive pregnant
programme laboratories. The laboratories were
women during 32 to 36 weeks of pregnancy
initially testing samples for co-located ARTCs but in
(regardless of duration of ART) for suitable ARV
phase-V, the viral load testing at these laboratories
prophylaxis administration to eliminate the risk of
has been optimized through systematic mapping
HIV transmission to the baby.
and linkages with all ARTCs. All the States/UTs have
hired sample transportation agency and samples
Viral load provides an early and more accurate
from non-co-located ARTCs are transported to
indication of treatment failure and the need to
their linked viral load lab in cold chain within the
switch to second/third-line drugs. This helps
defined turn-around-time (TAT). Figure 10.1 shows
to reduce the accumulation of drug-resistance
the distribution of programme viral load labs across
mutations and improves clinical outcomes of
India. As part of the scale-up, all the lab technician
the PHLIV on ART. Measuring viral load can also
of ART centres have been trained on viral load
help distinguish between treatment failure and
sample collection, separation of plasma, packaging
non-adherence.

Figure 10.1. Distribution of 64 programme viral load laboratories under NACP

Sankalak: Status of National AIDS & STD Response (2023) 117

Laboratory Services

Around 40.7 lakh viral load tests were done between It is to mention that the contract with the private
2018-19 and 2022-23 under NACP (Figure 10.2). lab conducting the HIV-1 viral load testing ended in
The number of viral load tests are rapidly increasing February 2023 and all the HIV- 1 viral load testing is
every year. In FY 2022-23, 12.3 lakh tests were done now being performed by programme labs.
cumulatively by both private and programme labs.

Figure 10.2. Viral load tests under NACP, 2018-19 to 2022-23

1400000
No. of Valid Viral load tests (in lakhs)

6,83,838
1200000
4,07,694
1000000
1,34,452
800000
97,893

600000

400000
0
200000
240408 578722 751716 624570 546411
0
FY 2018-19 FY 2019-20 FY 2020-21 FY 2021- 22 FY 2022-23
Viral Load Tes ng (MHL, Mumbai) Viral Load Tes ng (Programme VL labs)

10.2. CD4 TESTING 350 cells/cu mm and viral load count is less than
1000 copies/mL (when sample for both the tests is
drawn at the same time). However, CD4 testing can
be initiated if the patient has been switched to a
Though the routine viral load testing has been
different regimen due to treatment failure (plasma
adopted by the programme, CD4 testing is an
Viral Load ≥1000 copies/ml) or when deemed
important marker a) to know the baseline immune
necessary for clinical management by the Medical
status of the infected individual, b) as a marker of
Officer at any point in time.
treatment failure especially in case of HIV-2, c)
to monitor the likely emergence of opportunistic
There are 352 functional CD4 testing machines
infections (OI), to initiate prophylaxis for OIs
under NACP which are installed at 343 CD4 testing
and d) as a measure of disease progression.
centres. The machines are both lab based and
Therefore, CD4 testing and monitoring continues
point of care (PoC). Figure 10.3 shows the CD4
to be the mainstay for monitoring along with viral
testing over the last five years.
load testing.

State/UT-wise CD4 testing conducted during 2022-

As per the current testing guidelines, CD4
23 is shown in Table 10.1. A total of 9,35, 259 tests
monitoring can be discontinued for any patient
were done in FY 2022-23.
(except children aged <5 yrs. wherein CD4%
calculation is done), if CD4 count is more than

118 Sankalak: Status of National AIDS & STD Response (2023)

 Laboratory Services

Figure 10.3. CD4 tests done in last five years

25

20.3
No. of CD4 tests done (in lakhs)
20 18.8

15

10.9 11
9.3
10

0
FY 2018-2019 FY 2019-2020 FY 2020-2021 FY 2021-2022 FY 2022-2023

Table 10.1. States/UTs-wise CD4 and viral load tests done, 2022-23

Total number of CD4 tests Number of Viral Load test conducted private and
State/UT
conducted in FY 2022-23 at 64 programme VL Labs for FY 2022-23
ANI 151 14
Andhra Pradesh 108218 163708
Arunachal Pradesh 85 138
Assam 3967 4288
Bihar 17365 38867
Chandigarh 5798 6255
Chhattisgarh 3677 14346
DNH&DD - 212
Delhi 28477 27918
Goa 1326 3072
Gujarat 47247 74644
Haryana 10181 17797
Himachal Pradesh 2581 3857
Jammu & Kashmir
2692 2099
Ladakh
Jharkhand 4121 12276
Karnataka 128504 133320
Kerala 3854 11787
Madhya Pradesh 21249 22376
Maharashtra 183261 253713
Manipur 3323 12222
Meghalaya 1560 3210
Mizoram 5438 10198
Nagaland 6822 9493
Odisha 9779 13799
Puducherry 915 997
Punjab 23553 35724
Rajasthan 45427 45959
Sikkim 371 257
Tamil Nadu 124342 116649
Telangana 56747 77077
Tripura 1321 1187
Uttar Pradesh 48054 73605
Uttarakhand 4283 4318
West Bengal 30721 34867
India 9,35,259 12,30,249

Sankalak: Status of National AIDS & STD Response (2023) 119

Laboratory Services

10.3. QUALITY ASSURANCE The process of administering EQA for HIV serology
is done through two ways as depicted in the Figure
UNDER NACP 10.4 and the process is explained below-

The laboratories are categorized into four tiers, as

High quality laboratory systems are quintessential follows:
to ensure that prevention, care, support and
treatment services are accurate across the country. • Apex Laboratory (first tier) – Indian Council
Low quality laboratory diagnostics can lead to false of Medical Research (ICMR) National AIDS
positive and false negative results and may lead Research Institute (NARI), Pune
to stigma and discrimination as well as increased
vulnerabilities and therefore further transmission. • National level: 13 National Reference
This could significantly limit the ability to reach the Laboratories (NRLs) (second tier) including
primary goal of NACP. ICMR-NARI

Under NACP phase-V, maintaining and • State level: 117 State Reference Laboratories
expanding laboratory quality assurance system (SRLs) (third tier)
is one of the key strategies for reduction of
AIDS-related mortality by 80%. Delivering • Districts-level: Stand-Alone ICTC (SA-ICTC)
correct test results is fundamental to the success (fourth tier)
of any public health programme.
The EQA panels are indigenously prepared by
NACP phase-V continues to have a four tiered ICMR-NARI for HIV Serology, CD4 testing labs and
structure for external quality assurance (EQA) Viral load testing labs
for HIV serology as one of the key strategies.

Figure 10.4. EQA system for HIV Serology under NACP

20% of positive
samples and 5% 1
of negative
Pr

samples received Apex Lab

ofi

in the first week

c

(ICMR-NARI)
ie
nc

of each quarter Well

y

characterized
pa
ne

13 National Reference blind panels

lt

Laboratories (NRLs) are sent

es
tin
g
)
rly

(B
te

117 State Reference Laboratories (SRLs)

i-a
ua

nn
(q

ua
ng

l)
sti

5000+ Integrated Counselling and Testing Centres (ICTCs)

te
Re

120 Sankalak: Status of National AIDS & STD Response (2023)

 Laboratory Services

Panel testing and retesting/reverse testing are the Participation of SRL and SA-ICTC in panel testing
two mechanisms followed to check and ensure in last five years is depicted in Figure 10.5 below.
quality assured HIV testing services.
Among the SRLs participating in panel testing, a
a. Panel Testing: Well characterized blinded discordance of 1% was reported. Similarly, among
panels are sent biannually from the Apex lab to the participating ICTCs, discordance of 1% was
NRL (8-member panel), NRL to SRL (8-member reported. However, root cause analysis was done
panel) and SRL to SA-ICTC (4-member panel). for the discordant results and corrective action was
In FY’ 2022-23, 100% NRL participated in panel taken accordingly.
testing with no discordance.

Figure 10.5. Participation in panel testing and discordant results, 2018 to 2022

a. SRL and ICTC participation in b. Discordance results at

panel testing (in %) SRL & ICTC (in %)

120.0 1.2
99.1 95.7
100.0 1 1
83.6 84.6 86.7 86.3 83.0
80.3 76.1
80.0 73.0 0.8
% Par�cipa�on

% Discordance
60.0 0.6

40.0 0.4

20.0 0.2 0.14

0.06 0.10 0.14
0.0 0 0 0 0 0
2018 2019 2020 2021 2022 2018 2019 2020 2021 2022

SRL Par�cipa�on ICTC Par�cipa�on SRL Discordance ICTC Discordance

b. Re-testing/reverse testing is a process where Table 10.2. Participation of ICTC in re-testing

ICTCs send already tested 20% positive and and discordant results, 2019-20 to 2022-23
5% negative samples in first seven working
days of each quarter (April, July, October,
January) to their linked SRL for re-confirmation/ Year % participation % discordance
re-checking of the results. 2019-20 88 0.03

All the labs also make entries on NACO Prayogshala 2020-21 77 0.1
for review. 2021-22 84 0.1
2022-23 91 0.05
Participation and performance of ICTCs in re-
testing has improved as compared with previous
years (Table 10.2).

Sankalak: Status of National AIDS & STD Response (2023) 121

Laboratory Services

Besides HIV serology, Indian Council of Medical and October-November. Each CD4 EQA panel
Research (ICMR) - National AIDS Research Institute contains two samples (of different levels). The
(NARI)-Pune is the apex laboratory for providing labs are supposed to test the samples within the
External Quality Assurance (EQA) to the testing defined timelines and submit the report to the
facilities and EQA programme is also conducted Apex lab for analysis. The entries are also made
for approx. 350 CD4 labs and 64 viral load labs. on NACO Prayogshala. In addition to CD4 EQA
programme, the GLP (Good Laboratory Practice)
CD4 EQA (External Quality Assurance) training for the ART center laboratory technicians
is also conducted every year.
NACO established CD4 EQA for the laboratories
linked to ART centers in 2005. The EQA round Around 78% of laboratories have participated in
is conducted twice in a year (once in every six EQA in the year 2023 with an average performance
months), mostly in the month of February-March of 75% Figure 10.7.

Table 10.3. Participation of CD4 laboratories in NEQA and results

Year Average % Participation Average % Performance

2018 79.4 79.2

2019 83.9 83.0

2020 96.0 95.4

2021 75.0 76.0

2022 70.0 80.0

2023 78.0 75.0

10.4. VIRAL LOAD EQA upload the results on ‘NACO Prayogshala’ portal
for further analysis.

In FY 2022-23, only one round was conducted.

ICMR-NARI, Pune conducts viral load EQA for all
All 64 labs participated in EQA of which 55 labs
64 VL laboratories under the National Programme.
secured satisfactory result. The percentage of
Two rounds are conducted every year where five
participation remained 100 % in the last two years
member panels are sent to the labs. The labs test
(Table 10.4).
the PT samples within the defined time frame and

122 Sankalak: Status of National AIDS & STD Response (2023)

 Laboratory Services

Table 10.4. Viral load EQA participation and results, 2020-21 to 2022-23

Labs Labs with Percentage Labs with

Total Labs
S. No. Year Round Ready for Satisfactory of satisfactory
Labs Participated
Participation Report Participation results (%)

1 Round-I 64 41 40 39 97.6 97.5

2020
2 Round-II 64 53 52 49 97.5 94.2

3 Round-I 64 63 63 59 100 93.7

2021
4 Round-II 64 64 64 62 100 96.9

5 2022 Round-I 64 64 64 55 100 85.9

10.5. ACCREDITATION Management System (QMS) for the HIV testing

reference network. As a result, 100% NRLs and
79% of SRLs are accredited as per ISO 15189
in FY 2022-23. Under NACP phase-V, the scope
Quality is an integral part of Lab Services Division
of accreditation is not limited to HIV Reference
and emphasis on quality assured laboratory service
laboratory but has been expanded to include
delivery is important for the success of NACP.
programme viral load laboratories. Out of 64
Laboratory Service Division has undertaken several
viral load laboratories, 35 VL labs are accredited
initiatives to strengthen the HIV testing reference
as per ISO 15189 which is a remarkable global
laboratory network of the country.
achievement. The figure 10.6 below depicts the
accreditation status of both viral load labs and HIV
NACO has provided technical assistance for the
Reference labs.
development and implementation of a Quality

Figure 10.6 a: Viral load lab accreditation status Figure 10.6 b: HIV Reference lab
accreditation status

Sankalak: Status of National AIDS & STD Response (2023) 123

Laboratory Services

10.6. CERTIFICATE OF Quality Systems Essentials (QSE) based on WHO

Laboratory Quality Management System Hand
EXCELLENCE TO ICTCs Book (2011), ISO 15189:2012 (third edition) and
National Guidelines for HIV Testing, NACO (2015).

National AIDS & STD Control Programme phase–V The checklist has four “Domains” – Operations,
addresses the need for quality assurance at all Technical, Monitoring and Evaluation (M&E) and
service delivery points. Hence, improvement of Logistics. Each of these domains has two or more
service quality across all the laboratories under sub elements which are termed as “attributes” and
its purview remains as a priority. The serological there are a total of 14 attributes. The maximum
testing done at the Integrated Counselling and overall score an ICTC can obtain is 246 where
Testing Centre (ICTC) is one among them. National the operation domain accounts for 78, technical
AIDS Control Organisation (NACO) aims at accounts for 90, M&E accounts for 50 while logistics
implementing a structured Quality Management accounts for 28.
System (QMS) at the ICTCs to ensure continuous
adherence to quality-assured testing practices In addition to the score, the centers were also
under NACP. graded from 1-5 (with 5 being the best possible
performance) based on the percentage of score
To ensure a uniform and unbiased audit process attained. These grades are calculated for the
an ICTC QMS checklist was developed. This overall performance as well as for each domain.
checklist was based on the NACO Operational
Guidelines for ICTC services (2007), CLSI As on date, 403 SA-ICTCs (Table 10.5) have
GP26-A4: A Quality Management System Model been approved by NACO for “Certification of
for Laboratory Services (Fourth Edition), National Excellence” who have achieved grade 5 or more
Health Mission Operational Guidelines for Quality than 90% score during the final assessment.
Assurance in Public Health facilities (2013), the 12

Table 10.5: State-wise status of Certificate of Excellence to ICTCs

S.No. Name of the State ICTCs awarded for Certificate of Excellence

1 Manipur 25

2 Mizoram 29

3 Nagaland 43

4 Mumbai 28

5 Maharashtra 70

6 Andhra Pradesh 60

7 Pondicherry 10

8 Tamil Nadu 19

9 Kerala 25

10 Uttar Pradesh 43

11 Telangana 30

12 Karnataka 10

13 West Bengal 11

Total 403

124 Sankalak: Status of National AIDS & STD Response (2023)

 Laboratory Services

Quality Assurance Scheme for Basic Level) through NABL under which SA-ICTCs are
encouraged to apply for M(EL)T certification.
Composite Medical Laboratories (Entry
The Entry Level QAS-BC certificate is issued to
Level) (M(EL)T certification) for SA-ICTCs: the laboratory with a validity of three years. The
scheme was introduced in the FY 2020-2021. The
Apart from NACO “Certificate of Excellence”, following Table 10.6 depicts the state wise status
Laboratory Services division has also introduced of ICTCs who have achieved M(EL)T certification by
Quality Assurance Scheme (QAS) for Basic NABL in FY 2020-21, FY 2021-22 and FY 2022-23.
Composite (BC) Medical Laboratories (Entry

Table 10.6. The state-wise data of number of ICTCs awarded M(EL)T certificate

Sl. No. State FY’ 2020-2021 FY’ 2021-22 FY’ 2022-23

1 Andaman & Nicobar 0 1 4

2 Andhra Pradesh 0 0 0

3 Arunachal Pradesh 0 0 0

4 Assam 0 0 2

5 Bihar 0 0 0

6 Chandigarh 0 0 0

7 Chhattisgarh 0 1 4

8 Delhi 0 3 4

9 Goa 0 0 9

10 Gujarat 0 0 0

11 Haryana 0 0 0

12 Himachal Pradesh 0 0 0

13 Jammu& Kashmir 0 0 6

14 Jharkhand 0 0 0

15 Karnataka 0 0 0

16 Kerala 13 28 14

17 Madhya Pradesh 0 0 0

18 Maharashtra 1 15 10

19 Manipur 0 0 2

20 Meghalaya 0 0 1

21 Mizoram 0 4 10

22 Mumbai 0 0 6

23 Nagaland 0 10 6

24 Odisha 0 1 1

25 Puducherry 0 5 4

26 Punjab 0 0 0

27 Rajasthan 0 0 0

28 Sikkim 0 0 1

29 Tamil Nadu 0 0 17

30 Telangana 1 0 5

31 Tripura 0 0 0

32 Uttar Pradesh 2 2 0

33 Uttarakhand 0 0 1

34 West Bengal 0 0 5

Total 17 70 112

Sankalak: Status of National AIDS & STD Response (2023) 125

Laboratory Services

10.7. EARLY INFANT Thus, in infants below 18 months, direct detection

tests for the virus must be conducted. The
DIAGNOSIS (EID): current test of choice is the HIV total nucleic acid-
HIV-1 PCR polymerase chain reaction (TNA-PCR) for which a

LABORATORIES network of 6 laboratories have been strengthened

for the purpose.
TESTS FOR CHILDREN
UNDER 18 MONTHS All 6 EID Laboratories (AIIMS-New Delhi, ICMR-
NARI-Pune, NIMHANS-Bengaluru, NIRT-Chennai,
Kasturba-Mumbai and NICED-Kolkata) participate
in EQA. This is a bi-annual activity. Dried Blood
The World Health Organisation (WHO) has
Spots (DBS) are issued with instructions to all
recommended the implementation of EID and
participating labs. The labs test the results
treatment among Human Immunodeficiency Virus
within the defined time and submit the report
type-1 (HIV-1) exposed infants. The Government of
on the portal. In FY 2022-23, all the Six EID labs
India initiated the implementation of EID services
successfully participated in the panel testing
under the NACP in 2010 with an objective to
programme with a score of 100%.
diagnose HIV-1 infection in infants and children
aged <18 months. HIV exposed infants cannot be
tested using standard HIV antibody tests due to The number of EID tests conducted at six EID
the presence of maternal antibodies (transferred laboratories over last five years is represented in
during pregnancy or breast feeding) and absence Figure 10.7.
of self-generated antibodies early in life.

Figure 10.7: No. of EID tests done from 2018-19 to 2022-23

18000
16260
15749
16000
13710
14000
No. of EID tests conducted

12545
12000

10000 9338

8000

6000

4000

2000

0
2018-19 2019-20 2020-21 2021-22 2022-23
Year

126 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 127
11
ELIMINATION
OF VERTICAL
TRANSMISSION
OF HIV &
SYPHILIS (EVTHS)
ELIMINATION OF Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

VERTICAL
TRANSMISSION
OF HIV & SYPHILIS
(EVTHS)
11.1 BACKGROUND NACO has taken a strong step by setting up task
force to revise EVTHS guidelines and planning
phase-wise implementation of EVTHS guidelines
in the year 2022. Though the data capturing
The NACP phase-V aims to attain the elimination
mechanism for the uptake of EVTHS services
of Vertical transmission of HIV and Syphilis (EVTHS)
particularly exposed infants is yet to be streamlined,
by 2025. The HIV infection in infants and young
NACO has constituted a sub-group for EVTHS M&E
children results in early mortality for many or creates
guidelines under Technical Working Group-EVTHS.
a lifelong chronic condition that greatly increases
By the time this report is published, the guidelines
morbidity, shortens life expectancy, imposes a
would already be published, with the first phase
great burden on the child and the family and further
of EVTHS intervention implementation initiated
exacerbate human, social and economic costs.
in seven high priority states viz Bihar, Karnataka,
Evidence suggests that without any intervention,
Maharashtra, Mizoram, Nagaland, Rajasthan and
the risk of transmission of HIV from infected
Uttar Pradesh as an immersion learning model.
pregnant woman to her children is estimated to
be around 20-45%. Over half of the pregnancies
The chapter is divided into three sections
among women with active syphilis result in stillbirth,
early neonatal death, a preterm or low-birth-weight
• HIV and Syphilis testing coverage among
infant or serious neonatal infection. The Prevention
pregnant women
from Parent to Child Transmission of HIV Program
(PPTCT) in India was launched in 2002 implementing
• HIV and Syphilis treatment coverage among
the usage of a single dose of Nevirapine. India also
pregnant women
rolled out interventions to eliminate parent to child
transmission of syphilis. Considering the impact,
• Care of exposed infants.
the guidelines for screening for syphilis during
pregnancy and prevention of congenital syphilis
was launched in 2014 and 2015 respectively. To measure progress towards EVTHS, NACO
monitors various impact and process indicators
such as standard indicators laid down by WHO as
In NACP phase V, India continues its commitment
well as indicators designed by NACO. The State/
towards EVTHS, with a dedicated goal of elimination
UT wise summary of key indicators is provided in
of vertical transmission of HIV & syphilis and detail
Table 11.1.
strategies to achieve the goal1.

1
Strategy Document National AIDS & STD Control Programme Phase-V (2021-2026), NACO

Sankalak: Status of National AIDS & STD Response (2023) 129

 Table 11.1. State/UT wise summary of key EVTHS indicators

130
FY 2022-2023
% ANC ART %ANC
Covered ART
State/UTs Estimated Coverage Syphilis Syphilis
# of Annual HMIS ANC against HIV Tested HIV Tested EMTCT PW Intiated (Population Coverage Syphilis Tested Syphilis Syphilis Treatment
registration Estimated Coverage Need Positive On ART (Facility Level Tested Reactive Treated
Pregnancies Level Against Coverage
Annual Denominator)
Denominator) Estimated
Pregnancies
ANI 4660 4989 ≥95% 4223 91% 4 2 2 50% 100% 5150 ≥95% 0 0 NA
Andhra
899900 832300 92% 956108 ≥95% 2014 1612 1607 80% 100% 981533 ≥95% 55 53 96
Pradesh
Arunachal
29540 31049 ≥95% 15256 52% 9 21 19 ≥95% 90% 17525 59% 337 189 56
Pradesh
Assam 816980 632934 77% 541021 66% 334 258 217 65% 84% 468014 57% 547 409 75
Bihar 3420990 3695535 ≥95% 2296978 67% 2446 911 689 28% 76% 730947 21% 63 47 75
Chandigarh 18190 32035 ≥95% 19188 ≥95% 16 42 41 256% ≥95% 23934 ≥95% 15 15 100
Chhattisgarh 717190 648576 90% 544987 76% 487 400 371 76% 93% 552940 77% 416 400 96
DNH & DD 24650 13708 56% 21216 86% 17 5 5 29% ≥95% 20728 84% 3 3 100
Delhi 353740 484813 ≥95% 243933 69% 394 373 299 76% 80% 238633 67% 115 109 95
Goa 20910 27072 ≥95% 29993 ≥95% 35 31 29 83% 94% 37932 ≥95% 11 11 100
Gujarat 1093130 1381865 ≥95% 1223697 ≥95% 1030 1025 966 94% 94% 1331495 ≥95% 571 536 94
Haryana 632900 582847 92% 596007 94% 475 546 449 95% 82% 631523 ≥95% 192 181 94
Himachal
125380 107571 86% 66409 53% 40 33 25 63% 76% 79503 63% 11 9 82
Pradesh
Jammu &
221900 247296 ≥95% 244962 ≥95% 58 25 25 43% 100% 8100 4% 7 7 100
Kashmir
Jharkhand 850800 969261 ≥95% 760097 89% 342 273 248 73% 91% 823022 ≥95% 98 96 98
Karnataka 1196210 1199522 ≥95% 1127067 94% 1707 1516 1470 86% 97% 1319493 ≥95% 131 131 100
Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Kerala 526340 418152 79% 417080 79% 114 99 90 79% 91% 444655 84% 83 74 89
Ladakh 4910 4622 94% 2505 51% 0 0 0 NA NA 94 2% 0 0 NA
Lakshadweep 1070 1282 ≥95% 1124 ≥95% 0 0 0 NA NA 1420 ≥95% 0 0 NA
Madhya
2223030 1899628 85% 1569667 71% 536 714 637 ≥95% 89% 1567322 71% 889 871 98
Pradesh
Maharashtra 2086620 2105207 ≥95% 2271394 ≥95% 2667 2013 1931 72% 96% 1673866 80% 276 268 97
Manipur 52390 58173 ≥95% 36912 70% 366 174 159 43% 91% 45009 86% 7 4 57
Meghalaya 80690 111158 ≥95% 62679 78% 234 284 267 ≥95% 94% 72940 90% 720 616 86
Mizoram 18760 24306 ≥95% 21337 ≥95% 328 256 244 74% 95% 22935 ≥95% 23 23 100
Nagaland 29830 35209 ≥95% 21883 73% 386 240 185 48% 77% 26142 88% 129 125 97
Odisha 927940 665678 72% 675073 73% 534 306 305 57% 100% 833637 90% 286 267 93
Puducherry 22670 52343 ≥95% 29734 ≥95% 30 7 6 20% 86% 35383 ≥95% 5 5 100
Punjab 483520 441818 91% 402125 83% 520 893 783 ≥95% 88% 481180 ≥95% 151 151 100
Rajasthan 2064990 1845767 89% 1476033 71% 788 835 842 ≥95% 101% 1580879 77% 855 743 87
Sikkim 11970 7776 65% 9210 77% 5 9 8 ≥95% 89% 9789 82% 26 19 73
Tamil Nadu 1170490 1000732 85% 1096396 94% 774 946 951 ≥95% 101% 1353547 ≥95% 127 126 99
Telangana 680790 689274 ≥95% 713858 ≥95% 1073 946 955 89% ≥95% 653775 ≥95% 51 42 82
Tripura 59310 57008 ≥95% 49010 83% 47 58 40 85% 69% 58555 ≥95% 24 23 96
Uttar Pradesh 6791420 7116158 ≥95% 4814907 71% 2186 1508 1569 72% ≥95% 3085549 45% 610 541 89
Uttarakhand 218460 188411 86% 170043 78% 97 70 40 41% 57% 197641 90% 85 42 49
West Bengal 1624570 1585212 ≥95% 1274917 78% 517 494 500 ≥95% ≥95% 1443893 89% 523 485 93

Sankalak: Status of National AIDS & STD Response (2023)

India 2,95,06,840 29199287 ≥95% 2,38,07,029 ≥95% 20610 16,927 15,975 78% 94% 2,08,64,812 71% 7444 6623 89
 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

11.2 HIV AND SYPHILIS first trimester, before or at the 12th week of
pregnancy. Data related to ANC registration is
TESTING COVERAGE captured in HMIS. MoHFW calculates estimated
AMONG PREGNANT pregnant women every year. ANC registration has

WOMEN increased from 96 % in FY 2017-18 to 99 % in FY

2022-23 (Figure 11.1).

Twenty-one States/UTs reported to have higher

Expanding HIV and Syphilis testing services among registration than the national average (> 95%).
pregnant women is critical for identifying those in These States/UTs include Andaman & Nicobar
need of follow-up care and providing subsequent Islands, Arunachal Pradesh, Bihar, Chandigarh,
interventions that can prevent vertical transmission. Delhi, Goa, Gujarat, Jammu & Kashmir, Jharkhand,
The HIV and Syphilis testing coverage is a Karnataka, Lakshadweep, Maharashtra, Manipur,
fundamental element of EVTHS with an objective Meghalaya, Mizoram, Nagaland, Pondicherry,
to achieve ≥95% coverage and is measured against Telangana, Tripura, Uttar Pradesh and West
the estimated pregnant women. Bengal (Table 11.1).

ANC Registration The details related to ANC registration (First 95)

and ANC testing for HIV and Syphilis (Second 95) is
Under RMNCHA+ program, all pregnant women placed in Figure 11. 1.
are registered at health facility preferably in the

Figure 11.1. ANC registration, HIV Testing, Syphilis Testing against estimated Pregnant Women

120
96 96 98 99 99
100 90
84 81
80 77 76
69 82
57 71
60 57 54
44
40 30

20

0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23
ANC Registra�on HIV Tes�ng Syphilis Tes�ng

Sankalak: Status of National AIDS & STD Response (2023) 131

Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

HIV AND SYPHILIS TESTING2 These facilities are supported by the nearest
HCTS confirmatory facilities. Over the years, HIV
AND SERO-POSITIVITY: and Syphilis screening of pregnant women has
expanded significantly. In FY 2022-23, HIV and
Syphilis screening against the estimated pregnant
HIV and Syphilis screening are conducted in the women was at 81% and 71% respectively (Figure
facilities that provide antenatal care (ANC) services, 11.1). Figure 11.2 (a) depicts State/UT wise HIV
such as various Public Health Facilities as well as tested and sero-positivity among pregnant women
Private Health Facilities including labour rooms. during FY 2022-23.

Figure 11.2 (a). State/UT wise HIV Testing among Pregnant Women and sero positivity

0.84
6000 0.90

0.80

0.71
5000
0.70

4000 0.60

0.50
3000
0.40
0.29

2000 0.30
0.14
0.13

0.13
0.20
0.08

0.08

1000
0.06
0.06
0.06

0.05
0.05

0.05
0.04
0.04
0.04

0.04
0.03

0.03
0.03

0.03
0.03

0.03

0.02

0.02
0.10
0.02

0.02
0.02

0.02
0.02

0.01
0.01

0.01

0.00
0.00
0 0.00
Maharashtra

Karnataka

Kerala

Tripura
Manipur

Mizoram
Tamil Nadu

Chandigarh
Madhya Pradesh

Gujarat

Andhra Pradesh

Himachal Pradesh

ANI
Goa
Pondicherry

Sikkim

Ladak
Bihar

Telangana
Odisha

Assam
Jharkhand

Jammu & Kashmir

Delhi

Meghalaya
Haryana
West Bengal

Nagaland
Rajasthan

Punjab

Dadar & Nagar Haveli

Arunachal Pradesh
U�ar Pradesh

U�arakhand
Chha�sgarh

Lakshadweep

HIV Tested(in thousasnds) HIV Posi�vity

Ten States/UTs reported higher HIV testing than the The HIV positivity among the pregnant women
national average ( >95%) . These States are Goa, was at 0.03% and it ranged between 0.01 % in
Puducherry, Mizoram, Gujarat, Jammu & Kashmir, J&K to 0.84 % in Nagaland. Nineteen States/
Maharashtra, Andhra Pradesh, Chandigarh, UTs reported higher HIV positivity than the
Lakshadweep and Telangana (Table 11.1). national average, namely Nagaland, Mizoram,

2
Repeat HIV testing among pregnant women: Repeated testing of the same pregnant woman may result in
overestimation of the numerator of the above indicator for HIV testing. Therefore, based on the available last
three years data in SIMS which indicates around 21% of repeat HIV testing at national level among pregnant
women at confirmatory facilities. Hence, the HIV testing among pregnant women is reported after 21%
deduction in this publication since last two years.

132 Sankalak: Status of National AIDS & STD Response (2023)

 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Figure 11.2 (b) depicts States/UT wise Syphilis testing and Sero-Positivity

3500 2.50%

1.92%
3000
2.00%
2500

2000 1.50%

0.99%
1500 1.00%

0.49%
1000

0.27%
0.50%

0.12%

0.10%

0.09%
0.08%

0.06%
0.06%
0.05%

0.05%
0.04%
0.04%

0.04%
0.04%

0.03%

0.03%
0.03%

0.03%
0.02%

0.02%
0.02%
0.02%

0.02%

0.01%
0.01%
0.01%
0.01%
0.01%

0.01%
0.01%
0.01%

0.00%
0.00%
0.00%
500

0 0.00%
Madhya Pradesh
Maharashtra

Gujarat
Karnataka

Himachal Pradesh
Tamil Nadu

Andhra Pradesh

Telangana

Assam

Meghalaya

Pondicherry
Rajasthan

Odisha
Jharkhand
Bihar

Haryana

Punjab

Tripura

Arunachal Pradesh
West Bengal

Kerala

Manipur

Mizoram

Sikkim

Ladak
Delhi

Goa

Dadar & Nagar Haveli

Nagaland
Chandigarh

Jammu & Kashmir

ANI
U�ar Pradesh

U�arakhand
Chha�sgarh

Lakshadweep
Syphilis Tested(in thousands) Sero posi�vity(%)

Meghalaya, Manipur, Punjab, Chandigarh, Delhi,

Tripura, Haryana, Mumbai, Telangana, Andhra
ESTIMATED VS DETECTED
Pradesh, Goa, Karnataka, Arunachal Pradesh, PREGNANT WLHIV:
Sikkim, Chhattisgarh, Gujarat and Assam. The
biennial HIV sero-surveillance by NACO also
reflects HIV epidemic heterogeneity among the The estimated pregnant WLHIV is calculated
pregnant women. using spectrum model every year. As per India
HIV Estimates 2021, it was estimated that around
As seen in Table 11.1, the national average of 20.6 thousand pregnant WLHIV may need EVTHS
syphilis testing among pregnant women was at services for HIV. Two categories of Pregnant WLHIV
71% of the estimated pregnancies. Twenty Seven are seen in the program: First category where the
States/UTs reported higher syphilis testing than known pregnant WLHIV who are aware of their HIV
the national average. The average syphilis sero- status become pregnant. Second category is newly
positivity was 0.04% and ranged between 0.01 diagnosed pregnant WLHIV where the women are
% in Himachal Pradesh to 1.92 % in Arunachal diagnosed with HIV during the current pregnancy.
Pradesh. Ten States/UTs reported higher Syphilis
positivity than the national average, like in The pattern over the last six years indicates the
States of Arunachal Pradesh (1.92%), Assam highest annual detection in FY 2022-23 (Figure
(0.12%), Sikkim (0.27%), J&K (0.09%), Chandigarh 11.3). A total of 8877 (52%) known cases of WLHIV
(0.06%), Nagaland (0.49%), Meghalaya (0.99%), and 8050 (48%) newly diagnosed pregnant WLHIV
Delhi (0.05%), Chattisgarh (0.08%) and Madhya infections were reported in FY 2022–2023. Figure
Pradesh (0.06%). 11.4 shows the distribution of these cases by State
and UTs.

Sankalak: Status of National AIDS & STD Response (2023) 133

Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Figure 11.3. Pregnant WLHIV FY 2017-18 to FY 2022-23

18,000 16,927

16,000 15,106 15,112

14,342
13,799
14,000
11,744 8,877
12,000 5,288 5,630
4,792

10,000 7,079
4,925
8,000

6,000
9,550 9,818 9,482
4,000 8,050
6,819 6,720
2,000

0
2017-18 2018-19 2019-20 2020-21 2021-22 2022-23

New Diagnosis Known Posi�ve Total

Figure 11.4 State/UT wise Newly Diagnosed and

Known Pregnant WLHIV (percentage distribution), 2022-23

100%

14%
18%
23%
27%
33%
36%
36%
40%
40%

80%
41%
41%
41%
42%
43%
44%
45%
47%
48%
50%
50%
50%
50%
51%
52%
52%
56%
56%
57%
61%
63%
66%
67%
71%
73%
74%

60%
86%
82%

40%
77%
73%
67%
64%
64%
60%
60%
59%
59%
59%
58%
57%
56%
55%
53%
52%
50%
50%
50%
50%
49%
48%
48%
44%
44%
43%

20%
39%
37%
34%
33%
29%
27%
26%

0%

Newly Diagnosed Known

Note: Ladakh and Lakshadweep reported zero pregnant WLHIV

134 Sankalak: Status of National AIDS & STD Response (2023)

 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

The national average of known pregnant WLHIV wherein this accounts for 6.3 cases per 100 newly
reported was at 52%. The States/UTs reported diagnosed pregnant WLHIV. This could indicate
to have more known pregnant WLHIV than the that undiagnosed cases during pregnancy or new
national average were Tamil Nadu, Kerala, Manipur, infections cases during breastfeeding period and
Arunachal Pradesh, Andhra Pradesh, Karnataka, therefore, it is programmatically significant. These
Maharashtra, Puducherry, Telangana and Sikkim. women and their children are also provided with
EVTHS service packages to eliminate risk of HIV
Additionally, 509 WLHIV were diagnosed with transmission. The distribution of around 80% of
HIV after childbirth or during the breastfeeding total WLHIV cases diagnosed post childbirth in 11
period and where the child is less than 18 months, states is presented in the Figure 11.5.

Figure 11.5. Number of WLHIV cases diagnosed post childbirth where child is less than 18 months

Number (%) of HIV posi�ve cases diagnosed post child birth (PNC) where child is less than 18
months to the total cases reportedin FY 2022-23 (Total n=509 cases)

Rest of India, 107,

21% U�ar Pradesh,
126, 25%

Odisha, 19, 4%

Assam, 19, 4%
Madhya Pradesh,
Telangana, 20, 4% 43, 8%

Karnataka, 25, 5%
Rajasthan,
32, 6%
Haryana, 28, 5%
West Bengal,
Bihar, 29, 6% Punjab, 31, 6%
30, 6%

SYPHILIS INFECTED contributed to around 77% of the total syphilis cases

in India (Figure 11.6). These states are Madhya
PREGNANT WOMEN: Pradesh, Rajasthan, Meghalaya, Uttar Pradesh,
Gujarat, Assam, West Bengal, Chhattisgarh,
Arunachal Pradesh and Odisha.
During FY 2022-23, a total of 7444 syphilis infected
pregnant women were reported in India. Ten States

Sankalak: Status of National AIDS & STD Response (2023) 135

Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Figure 11.6. Top 10 States/UTs reporting syphilis infected pregnant women

Top 10 States/UTs Syphilis infected among no of Pregnant women(%) reported,

(n=7,444)

Madhya Pradesh, 889, 12%

Rest of the States,
1690, 23%

Rajasthan, 855, 11%

Odisha, 286, 4%
Meghalaya, 720, 10%
Arunachal Pradesh,
337, 4%

Chha�sgarh, 416, 6%
U�ar Pradesh, 610, 8%
West Bengal, 523, 7%
Gujarat, 571, 8%
Assam, 547, 7%

11.3 HIV AND SYPHILIS Similarly, all pregnant women screened reactive for
syphilis are treated immediately with at least one
TREATMENT dose of injection Benzathine Penicillin G at the
COVERAGE AMONG nearest health facility4.

PREGNANT WOMEN
HIV TREATMENT COVERAGE
India has adopted WHO guidelines of “Test and
Treat” for pregnant WLHIV since 2014. Services HIV treatment coverage for EVTHS is measured in
for Pregnant WLHIV includes linkage to ART two ways; Facility level denominator and Population
centre for rapid ART initiation, counselling for level denominator.
ART adherence and referral for plasma viral load
testing between 32-36 weeks of pregnancy to HIV treatment Coverage (Facility level
determine risk of transmission to the new-born. denominator): HIV treatment Coverage
Pregnant women are prioritized and fast tracked (Facility level denominator) compare ART
for service delivery at ART centres3. However, if coverage against diagnosed pregnant WLHIV. The
they are not able to come to ART centre regularly, formula used is as below:
options such as Multi Month dispensation, Linkage
to Link ART Centre or other differentiated service
delivery are explored.

3
National Operational Guidelines for ART services, 2021
4
Congenital Syphilis guidelines, 2015

136 Sankalak: Status of National AIDS & STD Response (2023)

 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Total Pregnant WLHIV

(Newly diagnosed + Known) initiated on ART
ART coverage = X 100
Total Pregnant WLHIV (Newly diagnosed +Known)

It provides clarity on the accessibility to HIV West Bengal, Andhra Pradesh, Odisha, Chandigarh,
treatment after diagnosis. Out of total 16927 Karnataka, Maharashtra and Mizoram.
detected pregnant WLHIV, a total of 15975 (94.4%)
were reported to be on ART/initiated on ART. HIV treatment coverage (Population level
denominator): HIV treatment coverage (Population
Ten States/UTs reported to have a higher HIV level denominator) compare ART coverage against
treatment coverage (Facility Level Denominator) the estimated pregnant WLHIV. It provides clarity
than the national average (Figure 11.7 a). These on possible incidences of vertical transmission.
states are Andaman & Nicobar, Jammu & Kashmir,
Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh, The formula used is as below:

Total Pregnant WLHIV

(Newly diagnosed + Known) initiated on ART
ART coverage = X 100
Total Estimated Pregnant WLHIV

HIV treatment coverage is presented in figure Punjab, Tamil Nadu, Madhya Pradesh, Meghalaya
11.7(a). Eight States/UTs detected more number and Rajasthan.
of pregnant WLHIV than the estimates, therefore
the ART Coverage (population level denominator) Out of the total 20610 estimated pregnant WLHIV5
is higher than ≥95% in these states. These States/ (2021), 15975 WLHIV were reported on ART/
UTs are Chandigarh, Arunachal Pradesh, Sikkim, initiated on ART.

Figure 11.7(a) State-wise distribution of HIV treatment coverage among

pregnant women against the population level denominators and facility, 2022-23

300%
256%

250%
211%

200%
160%

151%

150%
123%

119%

114%

107%

104%
101%

101%
101%
101%

100%

100%

100%
100%
100%
98%

97%
97%

96%
95%
95%

94%
94%
94%

94%

94%

93%

91%
91%

91%
90%

89%

89%
89%

88%

86%

86%
85%

84%
83%
82%

100%
80%
80%

79%

78%

77%
76%

76%

76%

76%

94%
74%

73%

72%

72%
69%

65%

63%

78%
57%
57%

50%

48%

43%

43%

41%

50%
29%

28%

20%

0%
0%
0%
0%

0%

ART Coverage (Popula�on Level Denominator) ART Coverage (Facility Level Denominator)
India-ART Coverage (Popula�on Level Denominator) India- ART Coverage (Facility Level Denominator)

5
HIV estimates 2021, NACO

Sankalak: Status of National AIDS & STD Response (2023) 137

Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

SYPHILIS TREATMENT (88.97%) were treated (Figure 11.7(b). A total of

eighteen States/UTs reported ≥95% treatment
COVERAGE coverage. These States/UTs are Chandigarh, DNH
& DD, Goa, Karnataka, Maharashtra, Mizoram,
Pondicherry, Punjab, J&K, Tamil Nadu, Madhya
The Syphilis treatment coverage is presented in Pradesh, Jharkhand, Nagaland, Andhra Pradesh,
Figure 11.7(b). Out of the total 7444 pregnant Chhattisgarh and Tripura.
women identified with syphilis infection, 6623

Figure 11.7(b) State wise distribution of Syphilis treatment coverage (in %) among pregnant women
100
100
100
100
100
100
100
100
99
98
98
97
97
96
96
96
95
94
94
93
100

93
89
89
89
87
86
82
82
75
75
73
80

57
56
60

49
40

20

0
0
0
0
Karnataka

Rajasthan

Himachal Pradesh

Ladak
Pondicherry
Chandigarh
DNH & DD

Mizoram

Punjab

Tamil Nadu

Jharkhand
Maharashtra

Andhra Pradesh

Tripura

Kerala

Bihar
Madhya Pradesh

West Bengal

Meghalaya
Telangana

Assam

Sikkim
Manipur
Goa

Jammu & Kashmir

Arunachal Pradesh
Odisha

India
Nagaland

Delhi

Gujarat
Haryana

ANI
U�arakhand
Chha�sgarh

U�ar Pradesh

Lakshadweep
Note: A&N reported zero syphilis infected pregnant women.

95-95-95 STATUS OF EVTHS gap could be early HIV and Syphilis testing during
pregnancy. It was also observed that strengthening
screening and reporting by screening facility may
contribute significantly to this gap. Therefore, Dual
The EVTHS status of 95-95-95 at national level is
(HIV & Syphilis) RDT kit at screening facilities and
presented in Figure 11.8. Even though the first
reporting of it in HMIS are recommended. This
95 target is reached, a gap is observed in the
is being strengthened by NACO and NHM as
second and third 95. The primary reason for this
discussed earlier in chapter 7.

Figure 11.8. EVTHS 95-95-95 status at national Level FY 2022-23

99%
100%
89%
81% 78%
80% 71%

60%

40%

20%

0%
ANC Registra�on HIV Tes�ng HIV treatment Cvoverage Syphils Tes�ng Syphils Treatment
(against es�ma�on) Coverage

138 Sankalak: Status of National AIDS & STD Response (2023)

 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

As highlighted in table 11.2, there is significant progress towards achieving the elimination of
scope for improvement in care cascade to achieve vertical transmission of HIV. Only Chandigarh and
the desired EVTHS goals. An in-depth review of Arunachal Pradesh achieved all three 95 targets
the programme as well as of the data will support under EVTHS program.
understanding the aspects related to fast-tracking

Table 11.2. EVTHS 95-95-95: State/UTs achieved 95

Indicators Name of the states

Daman & Diu, Pondicherry, Chandigarh, Meghalaya, Delhi, Mizoram,

Goa, Gujarat, Lakshadweep, Nagaland, Jharkhand, Jammu &
≥95% ANC registration
Kashmir, Manipur, Maharashtra, Bihar, Andaman & Nicobar Islands,
Arunachal Pradesh, Uttar Pradesh and Telangana
Daman & Diu, Goa, Pondicherry, Mizoram, Gujarat, Jammu &
Kashmir, Maharashtra, Andhra Pradesh Chandigarh, Lakshadweep,
≥95% HIV testing
Telangana, Karnataka Haryana, Tamil Nadu, Andaman & Nicobar
Islands, Jharkhand, Dadar & Nagar Haveli, Punjab and Tirupura
≥95% Treatment
Uttar Pradesh, West Bengal, Telangana, Rajasthan, Tamil Nadu,
coverage (Facility
Andaman & Nicobar Islands, Dadar & Nagar Haveli, Jammu &
level identified
HIV Kashmir, Andhra Pradesh, Odisha, Chandigarh, Karnataka and
Pregnant WLHIV as
Maharashtra
denominator)
≥95% Treatment
coverage (Estimated
Chandigarh, Arunachal Pradesh, Sikkim, Punjab, Tamil Nadu,
Pregnant WLHIV
Madhya Pradesh, Meghalaya, Rajasthan and West Bengal
Population as a
denominator)
Goa, Pondicherry, Lakshadweep, Chandigarh, Mizoram, Gujarat,
≥95% Syphilis testing Tamil Nadu, Andaman & Nicobar Islands, Karnataka, Andhra
Pradesh, Haryana, Punjab, Tripura, Jharkhand and Telangana
Syphilis Andhra Pradesh, Chandigarh, Chhattisgarh, Dadar & Nagar Haveli,
≥95% Syphilis Daman & Diu, Goa, Jammu & Kashmir, Jharkhand, Karnataka,
treatment coverage Madhya Pradesh, Maharashtra, Mizoram, Nagaland, Pondicherry,
Punjab, Tamil Nadu and Tripura

11.4 CARE OF EXPOSED CARE OF HIV EXPOSED

INFANTS/CHILDREN: INFANTS/CHILDREN

The infants/children exposed to HIV/Syphilis Under NACP, various interventions are provided
are at higher risk of morbidity and mortality. To to the HIV exposed Infants/Children such as
optimize care of exposed infants, NACO has ARV prophylaxis, OI prophylaxis, EID at defined
recommended ART centres as an anchoring intervals, close monitoring of Infant feeding, Growth
point of care for HIV exposed infants with SNCU/ & Development and early initiation of treatment
NICU/paediatric treatment unit as a care point to the children identified with HIV infection. Two
for syphilis exposed infants. critical interventions to address the response are
administration of ARV prophylaxis and the Early
Infant Diagnosis, as discussed below.

Sankalak: Status of National AIDS & STD Response (2023) 139

Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

(A) Antiretroviral (ARV) prophylaxis (B) Early Infant Diagnosis:

Postnatal antiretroviral drugs should be provided Early infant diagnosis (EID) of HIV is an integral
to all infants exposed to HIV to reduce the risk component of EVTHS under NACP, ensuring follow
of perinatal HIV transmission. Antiretroviral (ARV) up care of HIV exposed Infants/children (borne to
prophylaxis is defined as the administration of 1 HIV positive mother) for early detection of infection
or more antiretroviral drug(s) to a newborn infant and timely access to antiretroviral treatment.
without confirmed HIV infection to reduce the risk The services are offered through all stand-alone
of HIV acquisition6. The program offers single or ICTCs. EID is conducted at 6 weeks, 6 months, 12
Dual ARV prophylaxis based on maternal plasma months and 18 months or 3 months after cession
viral load at the time of 32-36 weeks of pregnancy. of breastfeeding whichever is later as per the EID
The babies are categorised as high risk and low risk algorithm provided in the national guidelines7.
based on the maternal viral load result. High risk Linkage between EID and HIV care cascade and
babies are prescribed with dual prophylaxis and low the proportion of children tested TNA positive who
risk babies are prescribed with single prophylaxis. are initiated on ART have improved significantly
over the last few years. The summary of EID testing
To address the supply chain issues, NACO has is provided in table 11.3.
decentralized procurement of Syp Zidovudine
and Syp Nevirapine at State level. Around 85-
90% pregnant WLHIV reported live births and of
the 12942 live births reported under the program
in FY 2022-23, 12901 (100%) babies were given
ARV prophylaxis.

Table 11.3. Summary of EID testing FY 2022-23

HIV Exposed Babies Age wise EID Testing data FY 2022-2023

Visit of Babies Tested Positive Positivity Initiated ART Initiation
(%) On ART (%)
First Visit (at 6 week ) 12714 94 0.74 77 82%
First Visit (2 Months -6months) 2495 82 3.29 58 71%
Second Visit (6 Months to 12 Months) 10092 74 0.73 62 84%
Third Visit (12 Months to 18 Months) 7359 46 0.63 43 93%
Fourth Visit ( 18 Months or later) 8765 280 3.19 240 88%
Total EID test 41425 576 1.39 486 84%

During FY 2022-23, a total of 41425 EID tests were First EID (6 weeks-2 months): During FY 2022-
conducted which led to the identification of 576 23, out of a total 13070 eligible infants, 12714
(1.39%) positive children. Out of them, a total of (97%) infants underwent first EID at 42 days. Out of
486 (84%) children were initiated on ART. above, a total of 94 (0.74%) infants were diagnosed
HIV positive. Among them, around 77 (82%) infants
However, at 18 months all the children are tested were linked to ART and initiated. The State/UT wise
for EID irrespective of their earlier EID status. distribution is presented in Figure 11.9.
Hence the positive reported may include children
diagnosed positive on earlier EID.

6
WHO guidelines 2018
7
ART Technical Guidelines, 2021

140 Sankalak: Status of National AIDS & STD Response (2023)

 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Figure 11.9. First EID at 6 weeks: Testing, positivity and ART initiation (%)

120% 7.00

100% 6.00

5.00
80%
EID TEs�ng (%)

Posi�vity(%)
4.00
60%
3.00
40%
2.00
20% 1.00

0% 0.00

Tested In�ated On ART Posi�vity

Note: ANI, Ladakh, Lakshadweep reported zero Second EID (6 months-12 months) and
eligible HIV exposed infants. States like Meghalaya,
Third EID (12 months- 18 months)
Uttarakhand, J&K, Pondicherry, Arunachal Pradesh,
Sikkim, DNH & DD, Chandigarh and Goa reported
The second EID and third EID are recommended
zero positive infants at 6 weeks.
at 6 months and 12 months respectively. Parents
are counselled accordingly to ensure uptake of EID
The States/UTs that reported higher positivity than
at the recommended intervals. However, the test is
the national average ( 0.74%) includes Himachal
offered whenever the parents approach the health
Pradesh, Tripura, Nagaland, Uttar Pradesh,
system for EID testing. During FY 2022-23, for
Jharkhand, Tamil Nadu, Manipur, Rajasthan, Delhi,
second EID testing at 6 to 12 months, 10,092 (94%)
Kerala, Odisha and Punjab (Fig 11.9).
test were conducted for eligible infants and 74
(0.73%) infants reported positive. Additional out of
Additionally, 2495 (84%) out of eligible (who
7359 (93%) eligible children tested at third EID, 46
were not tested at 6 weeks) underwent EID
(0.63%) infants reported positive. During second
testing within 6 months. 82 (3.3%) infants were
and third EID 62 (84%) and 43 (93%) infants were
identified as positive, 58 (71%) infants were linked
initiated on ART. State/UT wise positivity at second
to treatment (Table 11.3). It may be noted that
EID and third EID is depicted in figure 11.10.
the infants who were tested later (who were not
tested at 6 weeks but tested within 6 months)
reported higher positivity and hence counselling
and treatment adherence in these mother-baby
pair is more crucial.

Sankalak: Status of National AIDS & STD Response (2023) 141

Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

Figure 11.10. State/UT wise positivity at second and third EID FY 2022-23
12.0
10.5

10.0

8.0

6.0
5.4

4.9

4.6
4.0

3.0
2.8

2.7
2.5
2.4

2.0

2.0
1.7
1.6

1.6

1.4

1.5
1.3

1.2
1.1

1.0
1.0

1.0
0.8

0.8
0.8
0.8
0.8
0.6

0.6
0.6

0.6
0.5

0.4

0.3

0.2
0.2

0.1
0.1

0.1

0.0
0.0

0.0

0.0
0.0

0.0

0.0

0.0

0.0
0.0

0.0

0.0
0.0

0.0

0.0

0.0
0.0
0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0
0.0

0.0

0.0
0.0

0.0

0.0
0.0

0.0

0.0
0.0

0.0
0.0

0.0

2nd EID (6m-12m) Posi�vity 3rd EID (12m-18m) Posi�vity

The uptake of second and third EID indicate cessation of breastfeeding whichever is later.
slow progress. Considering this, NACO has Nationally, during FY 2022-23, there were 8,765
recommended aligning maternal ART re-fill and (94%) of eligible HIV exposed children who
follow up with EID so that mother-baby pair gets underwent antibody test at 18 months, 280 (3.2%)
HIV care through trained professionals at ART were confirmed HIV positive and 240 (88%) were
centres and collocated HCTS facilities. initiated on ART (Table 11.3)

FINAL EID AT 18 MONTHS The number of positive children in 18th months was
higher in Rajasthan and Uttar Pradesh as shown in
figure 11.11.
The HIV exposed child’s HIV status is confirmed
only at 18 months or 3 months after complete

Figure 11.11. Number of children tested and found positive at 18 months

1200 40

35
1000
30
800
25

600 20

15
400
10
200
5

0 0
Maharashtra

Karnataka

Gujarat

Madhya Pradesh
Andhra Pradesh

Tamil Nadu

Mizoram

Haryana
Rajasthan

Bihar

Meghalaya
Jharkhand

Andhaman
Mumbai

Manipur
Nagaland

Kerala
Delhi

Goa

Puducherry

Jammu & Kashmir

Daman & Diu

Lakshadweep
Assam

Arunachal Pradesh
Odisha

Chandigarh

Tripura

Dadra & Nagar Haveli

West Bengal
Chha�sgarh
Telangana

Punjab

Himachal Pradesh

Ladak
U�ar Pradesh

U�arakhand
Sikkim

No of Babies Tested for An�body No of Posi�ve Iden�ied

142 Sankalak: Status of National AIDS & STD Response (2023)

 Elimination of Vertical Transmission of HIV & Syphilis (EVTHS)

CARE OF SYPHILIS EXPOSED laboratory tests at birth (comparison of RPR/VDRL

titres with maternal titre at birth) and follow up
INFANTS/CHILDREN tests. In FY 2022-23, a total of 2583 (84%) infants
were treated for congenital syphilis (Table 11.4)

The diagnosis of congenital syphilis is made based

on clinical examination, radiology (if available) and

Table 11.4. States-UTs wise congenital syphilis treatment FY 2020-21 to FY 2022-23 (Source HMIS)

State Wise-Syphilis Exposed Babies Congenital Syphilis Treated details from 2020-2021 to 2022-2023

Number of babies found Number of Percentage of

Congenital Syphilis Babies Treated Babies Treated
S. No. State/UTs
2020- 2021- 2022- 2020- 2021- 2022- 2020- 2021- 2022-
2021 2022 2023 2021 2022 2023 2021 2022 2023
1 ANI 0 0 0 0 0 0 0% 0% 0%
2 Andhra Pradesh 67 125 6 67 75 6 ≥95% 60% ≥95%
3 Arunachal Pradesh 55 0 1 0 1 0 0% 0% 0%
4 Assam 1 1 15 1 1 15 ≥95% ≥95% ≥95%
5 Bihar 125 7 108 125 0 98 ≥95% 0% 91%
6 Chandigarh 3 3 0 1 3 0 33% 100% 0%
7 Chhattisgarh 75 156 65 22 48 14 29% 31% 22%
8 Dadar & Nagar Haveli 44 4 0 0 4 0 0% ≥95% 0%
9 Delhi 2 20 6 0 17 5 0% 85% 83%
10 Goa 1 0 0 1 0 0 ≥95% 0% 0%
11 Gujarat 1135 473 602 376 348 559 33% 74% 93%
12 Haryana 0 29 65 0 29 34 0% ≥95% 52%
13 Himachal Pradesh 3 2 0 3 2 2 ≥95% ≥95% 0%
14 Jammu & Kashmir 0 1 0 0 1 0 0% ≥95% 0%
15 Jharkhand 9 0 1 9 0 1 ≥95% 0% ≥95%
16 Karnataka 228 384 417 97 293 217 43% 76% 52%
17 Kerala 3 3 7 2 3 6 67% ≥95% 86%
18 Ladakh 0 0 0 0 0 0 0% 0% 0%
19 Lakshadweep 0 0 0 0 0 0 0% 0% 0%
20 Madhya Pradesh 19 48 18 11 23 8 58% 48% 44%
21 Maharashtra 477 17 399 476 14 375 ≥95% 82% 94%
22 Manipur 1 0 0 1 0 0 ≥95% 0% 0%
23 Meghalaya 74 114 80 68 90 73 92% 79% 91%
24 Mizoram 0 30 2 0 3 2 0% 10% ≥95%
25 Nagaland 0 1 2 0 1 1 0% ≥95% 50%
26 Odisha 4 9 5 1 8 4 25% 89% 80%
27 Pondicherry 0 0 0 0 0 0 0% 0% 0%
28 Punjab 5 2 5 5 0 5 ≥95% 0% ≥95%
29 Rajasthan 1104 461 477 1104 373 263 ≥95% 81% 55%
30 Sikkim 1 0 0 0 0 0 0% 0% 0%
31 Tamil Nadu 14 20 5 14 5 2 ≥95% 25% 40%
32 Telangana 38 155 66 32 21 66 84% 14% ≥95%
33 Tripura 1 0 1 1 0 1 ≥95% 0% ≥95%
34 Uttar Pradesh 1143 327 302 478 11 172 42% 3% 57%
35 Uttarakhand 0 8 3 0 5 0 0% 63% 0%
36 West Bengal 12 58 403 12 10 403 ≥95% 17% ≥95%
India 4644 2458 3061 4130 1554 2583 89% 63% 84%

Sankalak: Status of National AIDS & STD Response (2023) 143

12
SCORECARD
 Scorecard

SCORECARD

12.1 BACKGROUND The second scorecard for the financial year 2022-
23 was prepared using a set of 40 indicators.
This set comprised of the 39 indicators from the
first scorecard, with the inclusion of an additional
The “Scorecard of SACS” offers a comprehensive
indicator “Status on second 95.” The preparation of
overview of each State/UT’s performance in
this scorecard involves utilizing program data and
implementing the NACP across all facilities. It
other relevant information available as of March 31,
serves as a valuable tool for identifying areas that
2023, as detailed in the subsequent section.
require additional efforts to achieve the NACP
targets in the respective financial year.
12.2 METHODOLOGY
NACO prepares the Scorecard of SACS biannually
and shares with the States/UTs to assess and improve
their performances for the given indicators. The Each indicator was given equal weightage and
first scorecard is prepared for the first six months of were based on the program data and other relevant
programme implementation for April to September information for the financial year 2022-23.
in a given financial year. The second scorecard is
prepared for the whole year (12 months). The first
scorecard for FY 2022-23 was prepared in November
2022 based on a total of 39 indicators from across
various service categories under the programme.

Sankalak: Status of National AIDS & STD Response (2023) 145

Scorecard

Table 12.1. Details of the Indicators across different service categories under NACP
Sl. No. Indicators Numerator Denominator
1 First 95 Status Total PLHIV in Active care (as on March 2023) Estimated PLHIV (2022)
Total PLHIV alive and on ART
2 Second 95 Status Total PLHIV in Active care (as on March 2023)
(as on March 2023)
No. of PLHIV who were tested for VL
3 Third 95 Status No. of PLHIV Virally suppressed (F.Y 2022-23)
(F.Y 2022-23)
4 Frequency of Social Media updates - -
Status of Adolescence Education Programme
5 - -
(AEP) integration in State School curriculum
6 Status of State Council on AIDS (SCA) - -
7 Status of State Rules - -
8 Status of Ombudsman - -
9 Facilities onboarded (TI+LWS) No. of Facilities onboarded No. of facilities approved in AAP (TI, LWS)
No. of facilities approved in AAP
10 Facilities onboarded (OST) No. of Facilities onboarded
(OST, Satellite OST)
11 HIV testing among HRG (HIV1 &HIV2) HRG tested for HIV Total number of active HRG Population
12 IDU on OST Active client on OST 50% of IDU coverage in TI
Viral load suppression among HRG & Bridge
13 HRG and BP reported suppressed viral load HRG and BP tested for viral load
Population (BP)
HIV testing among partners of HRG & Bridge
14 HRG’s and BP’s partner tested for HIV 30% of MOU target
Population (BP)
HIV testing among spouse of HRG & Bridge
15 HRG’s and BP’s spouse tested for HIV 20% of MOU target
Population (BP)
16 HIV testing among prisoner HIV testing among prisoner Total estimation of prisoner in states
Availability of buffer stock of condoms (number
17 Condom availability out of 3 months
of months)
18 HIV testing against target-General Clients (GC) No. of HIV tests done among GC in the FY Target for HIV testing among GC in the FY
19 HIV testing against target-Pregnant Women (PW) No. of HIV tests done among PW in the FY Target for HIV testing among PW in the FY
Percentage of Pregnant women No of HIV Positive pregnant women initiated on Total no of HIV Positive pregnant women
20
who were initiated on ART ART (MPR data) reported (incl. Known Positive)
Percentage of TB suspected 10% of general clients excluding pregnant
21 Number of TB suspect cases referred to NTEP
cases referred to NTEP women received pre-test counselling.
22 Clients managed at DSRC against the target No. of Clients managed at DSRC Target for the FY
23 Clinic Visit of HRGs at TI-Clinics Total number of HRGs visited TI-clinics Total number of active HRG Population x 2
Percentage of pregnant
24 Total number of PW tested for Syphilis Estimated population of pregnant women
women screened for Syphilis
Total number of HRGs screened
25 Percentage of HRGs screened for Syphilis Total number of active HRG Population
for Syphilis at TI
Target for PLHIV on ART FY 2022-23 as per
Progress on PLHIV alive on Achievement as on March 23 including Pvt.
26 NACP-V strategy document
ART during the FY 2022-23 Sector (Alive and On-ART)
(Alive and on-ART)
27 LFU rate among new ART initiation FY 2022-23 LFU among new initiation FY 2022-23 PLHIV Initiated in FY 2022-23
28 ART Initiation FY 2022-23 ART Initiation in FY 2022-23 PLHIV registered in FY 2022-23
Number of CSC allotted for establishment to
29 Status on establishment of CSC Number of CSC established in state under AAP
state under AAP
30 % of SRL accredited No. of SRL accredited No. of SRL in the state
31 % Participation of ICTCs in Re-testing No. of ICTC participated in the state Total no. of ICTC in the state
Orientation of SOPs on NACP Data Management
32 - -
& Data Sharing to facility level staffs/officers
4 priority areas for
33 No. of research projects undertaken in FY 2021-22 No. of research projects undertaken Operational Research and
Evaluation
4 priority areas for
No. of research priority areas
34 No. of finalized Priority areas Operational Research and
finalised in FY 2022-23
Evaluation
4 priority areas for
Institute mapped against all 4 research Number of priority areas mapped with Research
35 Operational Research and
priority areas for FY 2022-23 Institutes
Evaluation
Utilisation with respect to funds
36 Utilization in the FY 2021-22 Funds release in FY 2021-22
released during FY 2021-22
Submission of EC/GB ratification for approval of
37 Date of receipt of requisite report/ document by 30-June 2021
Expenditure (FY 2020-21)
Submission of Utilization Certificate
38 Date of receipt of requisite report/ document by 30-June 2022
(in GFR 12A) for the FY 2021-22
39 Report Submission (BSD-SCM Report) No. of formats reported during the period Total no. of formats to be reported in the period
40 Report Submission (CST ARV-SCM Report) No. of formats reported during the period Total no. of formats to be reported in the period

146 Sankalak: Status of National AIDS & STD Response (2023)

 Scorecard

Performance on individual indicators were divided Poor: Red, 1 Mark, Not Applicable: No colour- No
into four categories as described in the below table score added in denominator]. Indicator wise details
[Good: Green, 3 Marks, Average: Yellow, 2 Marks, of performance categories are given in the table 12.2.

Table 12.2. Categorisation of performance of indicators

Categorization
Sl.
Indicators Good Average Poor
No.
(Green) (Yellow) (Red)
1 First 95 Status ≥95% ≥80% to <95% <80%
2 Second 95 Status ≥95% ≥80% to <95% <80%
3 Third 95 Status ≥95% ≥80% to <95% <80%

If SACS has been If the social media If the social media

able to cross 60 social update number falls update number
media updates in total, between 40-59 including falls between 20-39
including indigenous indigenous content, including indigenous
content, repost, retweet, repost, retweet, sharing. content, repost, retweet,
4 Frequency of Social Media updates
sharing. 30 updates 20+ updates on each sharing. 10+ updates
on each Social Media Social Media Platform on each Social Media
Platform in one quarter in last quarter i.e. Jan- Platform in last quarter
i.e. Jan-March, hence 60 March, hence 40+ for i.e. Jan-March, hence
for best two. best two. 20+ for best two.

Status of Adolescence Education Programme (AEP)

5 Yes No
integration in state School curriculum
Constituted and at least Not constituted/
6 Status of State Council on AIDS (SCA) one meeting held since Constituted and no
2017 meeting held since 2017
7 Status of State Rules Notified Not notified
Not appointed/
8 Status of Ombudsman Appointed/ designated
designated
9 Facilities onboarded (TI+LWS) ≥95% ≥90% to <95% <90%
10 Facilities onboarded (OST) ≥95% ≥90% to <95% <90%
11 HIV testing among HRG (HIV1 &HIV2) ≥95% ≥90% to <95% <90%
12 IDU on OST ≥95% ≥90% to <95% <90%
Viral load suppression among
13 ≥95% ≥90% to <95% <90%
HRG & Bridge Population (BP)
HIV testing among partners of
14 ≥50% ≥40% to <50% <40%
HRG & Bridge Population (BP)
HIV testing among spouse of
15 ≥50% ≥40% to <50% <40%
HRG & Bridge Population (BP)
16 HIV testing among prisoner ≥50% ≥40% to <50% <40%
17 Condom availability (in months) ≥3 months 1 to < 3months <1 month
18 HIV testing against target- General Clients (GC) ≥95% ≥80% to <95% <80%
19 HIV testing against target- Pregnant Women (PW) ≥95% ≥80% to <95% <80%
20 Percentage of Pregnant women who were initiated on ART ≥95% ≥80% to <95% <80%
21 Percentage of TB suspected cases referred to NTEP ≥95% ≥80% to <95% <80%
22 Clients managed at DSRC against the target ≥90% ≥75% to <90% <75%
23 Clinic Visit of HRGs at TI-Clinics ≥90% ≥75% to <90% <75%
24 Percentage of pregnant women screened for Syphilis ≥95% ≥80% to <95% <80%
25 Percentage of HRGs screened for Syphilis ≥90% ≥75% to <90% <75%
26 Progress on PLHIV alive on ART during the FY 2022-23 ≥95% ≥80% to <95% <80%
27 LFU rate among new ART initiation FY 2022-23 <2% ≥ 2% to <5% ≥5%
28 ART Initiation FY 2022-23 ≥95% ≥80% to <95% <80%
29 Status on establishment of CSC ≥95% ≥80% to <95% <80%
30 % of SRL accredited 100% ≥80% to <100% <80%
31 % Participation of ICTCs in Re-testing ≥95% ≥85% to <95% <85%
Orientation of SOPs on NACP Data Management & Data Sharing to
32 Conducted Not conducted
facility level staffs/officers
33 No. of research projects undertaken in FY 2021-22 4 2 to 3 <2
34 No. of research priority areas finalised in FY 2022-23 4 2 to 3 <2
35 Institute mapped against all 4 research priority areas for FY 2022-23 4 2 to 3 <2
36 Utilisation with respect to funds released during FY 2021-22 ≥90% ≥85% to <90% <85%
beyond 30-September
37 Submission of EC/GB ratification for approval of Expenditure (FY 2020-21) by 30-June 2021 by 30-September 2021
2021/not yet received
beyond 30-September
38 Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22 by 30-June 2022 by 30-September 2022
2022
Report Submission
39 ≥90% ≥75% to <90% <75%
(BSD-SCM Report)
Report Submission
40 ≥90% ≥75% to <90% <75%
(CST ARV-SCM Report)

Sankalak: Status of National AIDS & STD Response (2023) 147

Scorecard

12.3 PERFORMANCE OF Table 12.3. Change in overall ranks from the

first to the second scorecards of FY 2022-23
SACS IN PROGRAMME
IMPLEMENTATION Improved Rank Retained Deteriorated
Rank Rank
Karnataka (133), Chandigarh (11), Mumbai (36),
A. Comparison of November 2022 and Andhra Pradesh (165), Puducherry (22), Gujarat (79), West

June 2023 Scorecards Sikkim (147), Tamil Nadu (44), Bengal (411),
Kerala (1611), Goa (88), Meghalaya (914),
Among the 35 SACS, there were notable progress Uttarakhand (2211), Punjab (99), Mizoram (1219),
in the ranking of 14 SACS, while 7 SACS maintained Andaman & Nicobar Haryana (1414), Nagaland (619),
their existing positions. The table 12.3 provides the Islands (2116), J&K & Ladakh Madhya Pradesh
changes in SACS ranking from the first scorecard to Maharashtra (2617), (3333) (2324),
the second scorecard for the FY 2022-23 Manipur (1917), Tripura (1924),
Uttar Pradesh (2319), Rajasthan (1127),
Himachal Pradesh Chhattisgarh
B. Performance of SACS, FY 2022-23 (2522), (1628),
(April 2022 to March 2023) DNH & DD (3223), Jharkhand (2829),
Assam (2624), Odisha (2831),
As per the second scorecard of the FY 2022-23, Delhi (3530), Bihar (3134),
percentage of SACS in different zones for each of Telangana (3431) Arunachal Pradesh
the indicators are given in the figure 12.1. (3035)

148 Sankalak: Status of National AIDS & STD Response (2023)

 Scorecard

Figure 12.1. Performance of SACS for each indicator in percentage

Progress on PLHIV alive on ART, FY 2022-23 94

Report Submission (BSD-SCM Report) 91
Orientation of SOPs on NACP Data Management & Sharing 89
Status of AEP integration in state school curriculum 89
Status of ombudsman 88
No. of research priority areas finalised in FY 2022-23 86
HIV testing against Target-GC % 83
Status on establishment of CSC 81
Status of state rules 79
TI/LWS onboarding 74
HIV testing against target-PW 69
No. of research projects undertaken in FY 2021-22 69
Frequency of social media updates 69
ART Initiation, FY 2022-23 63
Institute mapped against all 4 research priority areas for… 63
% of SRL accredited 62
HIV tesing among prisoners 60
Utilisation with respect to funds released during 57
OST onboarding 56
LFU rate among new ART initiation, FY 2022-23 46
Percentage of pregnant women screened for Syphilis 46
% participation of ICTCs in re-testing 41
Status of SCA 41
% of pregnant women who initiated ART 40
Third 95 31
Report Submission (CST-SCM Report) 31
Submission of Utilization Certificate (in GFR 12A) for the… 17
Clients managed at DSRC against the target 14
IDU on OST 9
Second 95 9
Clinic visit of HRGs at TI-Clinics 6
Percentage of HRGs screened for Syphilis 6
Condom availbility in months 6
Viral load supression among HRG & BP 6
% of TB suspected cases referred to NTEP 6
First 95 3
HIV testing among HRG
Submission of EC/GB ratification for approval of…
HIV testing among spouse of HRG & BP
HIV testing among partners of HRG & BP

Sankalak: Status of National AIDS & STD Response (2023) 149

Scorecard

Figure 12.2. Distribution of State/UT wise score obtained (in percentage), FY 2022-23

150 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 151
FACT SHEET
INDIA
INDIA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 2.69
2. IMR - - 1.07
3. Adult (15-49 yrs) HIV Prevalence (%) 0.22 0.19 0.20
4. Estimated people living with HIV 13,48,804 11,18,173 24,66,977
5. ART coverage (%) 64.0 72.5 68.1
6. Estimated children living with HIV 35,669 32,367 68,036
7. Annual new HIV infections 38,335 28,073 66,408
8. Annual AIDS-related deaths (ARD) 27,202 12,422 39,624
9. Change in annual new HIV infections since 2010 (%) -42.1 -42.28 -42.2
10. Change in annual ARD since 2010 (%) -73.7 -81.06 -76.6
11. EMTCT need - 20,735 20,735

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 9,95,499 74.2 48.5 1.85
2. Men who have Sex with Men 3,51,020 55.3 46.9 3.26
3. Injecting Drug Users 2,88,717 50.0 85.5 9.03
4. Hijra/Transgender People 96,193 65.2 35.5 3.78
5. Migrants 72,00,000 - - 0.89
6. Truckers 20,00,000 - - 1.00
7. Prison inmates 21,94,364 49.2 39.6 1.93

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 30.7 21.6 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 28.5 20.1 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 74.3 70.9 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 69.2 64.3 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 3.8 0.5 -
5.1 Condom use during last higher-risk intercourse (%) 60 57.4 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 6.4 0.8 -
6.1 Condom use during last higher-risk intercourse (%) 60.6 62.8 -

2. Progress on 95-95-95 (2022-23)

82 84 83 84 86 84 85 85
93 Indicator (2022-23) Male Female Total
79
70 73 74 75 72
1. Estimated PLHIV size (2022) 13,48,804 11,18,173 24,66,977

2. PLHIV who know their HIV Status 10,25,995 9,14,594 19,48,465

3. PLHIV who know their HIV status and are on ART 8,62,720 8,11,227 16,80,083
PLHIV who know PLHIV who know PLHIV who are on
their HIV status (%) their HIV status and ART and virally 4. PLHIV who are on ART and tested for their viral load 5,42,079 5,39,162 10,84,218
are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 5,03,076 5,03,375 10,09,262
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 153

INDIA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 2,88,717
A. Information, Education, Communication,
2. Coverage (%) 72
Youth and Mainstreaming
3. Needles distributed 4,16,33,379
Indicator 2022-23 4. Syringes distributed 3,02,04,290
1. Schools with operational Adolescent Education 5. On OST 44,553
54,720
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,33,255
2. Colleges with operational Red Ribbon Clubs (RRC) 13,286 6.1. HIV sero-positive (%) 1.49
3. Persons trained under mainstreaming 4,87,915 6.1.1 Linked to ART 1,594
7. Tested for HIV (October 2022 -March 2023) 1,44,374
4. No. of calls received at helpline 4,76,660
7.1. HIV sero-positive (%) 1.20
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 1,231
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 1133 1. Estimated size 96,193
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 68
2. Total STI/RTI 3. Condoms distributed 1,80,31,836
42,95,660 54,56,762 1,74,299 99,26,721
Clients managed 4. Tested for HIV (April 2022-September 2022) 46,806
3. RPR Tests 4.1. HIV sero-positive (%) 0.47
13,69,585 21,85,644 30,635 35,85,864
conducted 4.1.1. Linked to ART 201
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 51,872
1.30 0.34 1.94 0.72
seropositivity (%)
5.1. HIV sero-positive (%) 0.33
5.1.1. Linked to ART 154
4. Prevention of new HIV infections among 6. Clinic Visits 1,84,808
high-risk group and bridge population
7. STI/RTI treated 1,790
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 7,262
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 1,543 Indicator 2022-23
2. OST centres 393 1. Estimated size 72,00,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 9,52,755
Indicator 2022-23
3.1. HIV sero-positive (%) 0.12
1. Estimated size 9,95,499
3.2. Linked to ART 3,490
2. Coverage (%) ≥95
3. Condoms distributed 19,22,99,332 G. Truckers
4. Tested for HIV (April 2022-September 2022) 6,46,210 Indicator 2022-23
4.1. HIV sero-positive (%) 0.11 1. Estimated size 20,00,000
4.1.1. Linked to ART 594 2. Coverage (%) 53
5. Tested for HIV (October 2022 -March 2023) 7,07,658 3. Tested for HIV 2,91,130
5.1. HIV sero-positive (%) 0.11 3.1. HIV sero-positive (%) 0.12
5.1.1. Linked to ART 650 3.2. On ART 289
6. Clinic Visits 25,90,450
H. Prison Inmates
7. STI/RTI treated 32,799
Indicator 2022-23
8. Presumptive treatment 1,14,429
1. Total prisons 1,319
C. Men who have Sex with Men 2. Prisons covered under programme 1,262
Indicator 2022-23 3. Total inmates admitted 21,25,147
1. Estimated size 3,51,020 4. Inmates Covered (%) 67
2. Coverage (%) ≥95 5. Tested for HIV 12,45,209
3. Condoms distributed 6,42,92,815 5.1. HIV sero-positive (%) 0.47
4. Tested for HIV (April 2022-September 2022) 2,30,163 5.2. On ART (%) 84.83
4.1. HIV sero-positive (%) 0.32
I. Link Worker Scheme
4.1.1. Linked to ART 615
5. Tested for HIV (October 2022 -March 2023) 2,52,874 Indicator 2022-23
5.1. HIV sero-positive (%) 0.28 1. Districts covered under scheme 168
5.1.1. Linked to ART 623 2. Vulnerable population covered 22,83,094
6. Clinic Visits 9,04,554 3. Tested for HIV 13,62,169
7. STI/RTI treated 6,788 3.1. HIV sero-positive (%) 0.27
8. Presumptive treatment 37,485 3.2. Linked to ART (%) 95.7

154 Sankalak: Status of National AIDS & STD Response (2023)

 INDIA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 393
1.1. OSTC in Public Health Settings 200 Indicator 2022-23
1.2. OSTC in NGO Settings 46 1. Viral load laboratories 64
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 35
2. IDU on OST 44,553
2. Viral load testing conducted 12,30,249
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 91.3

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 13
3.1 Accredited NRL 13
Indicator 2022-23
1. HCTC facilities 34,515 4. State reference laboratories (SRL) 117
1.1. Stand-Alone 5,428 4.1 Accredited SRL 92
1.2. Facility integrated (Govt.) 22,627 5. CD4 testing conducted 9,35,259
1.3. Facility integrated (PPP) 3,579
6. External Quality Assessment of ICTC
1.4. CBS 2,881
1.5. SSK 75 6.1 Average Participation (%) 91
6.2. Average Discordance (%) 0.05
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23
7.1 No. of ICTCs certified for M(EL)T certification 112
Male Female H/TG Total
1. Tested for HIV 1,85,15,374 1,53,50,380 1,13,210 3,39,78,964
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
1,06,593 52,261 1,162 1,60,016
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.58 0.34 1.03 0.47 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 2,95,06,840
partner testing of
41,701 43,577 388 85,666 2. HIV testing among PW 2,38,07,029
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 16,927
‘at-risk’ population
4,614 5,530 13 10,157 4.1 On life-long ART 15,975
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 12,942

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.68
infected people 6. Babies tested HIV (6 week- 6 month) 12,714
A. Treatment facilities 6.1 Babies confirmed HIV Positive 94
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 712 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 8,765
2.1. Centre of Excellence (Adult) 11
7.2 Babies confirmed HIV positive at 18 months 280
2.2. Centre of Excellent (Paediatric) 7
3. Link ART Centres 1,261 8. HIV positive babies initiated on ART 246

4. Care Support Centres 319

B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 2,08,64,812
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.04
1. HIV positive cases 3. Put on treatment 6,623
1,06,593 60,311 1,162 1,68,066
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 1,00,957 58,723 928 1,60,608 Stigma and Discrimination
centre
2.1 Initiated on ART 96,556 56,778 903 1,54,237 A. HIV
3. PLHIV alive and
8,62,720 8,11,227 6,136 16,80,083 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention 28
- - - 81.8 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 1,09,685 69,129 1,306 1,80,120 2. State designated/appointed ombudsman 29

Sankalak: Status of National AIDS & STD Response (2023) 155

INDIA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 8,68,348 2,89,568 1,13,513 57,508 4,93,440 1,81,127 20,03,504

Quarter 2 9,11,641 3,01,809 1,21,662 60,890 5,27,020 2,32,736 21,55,758

Screened for TB
Quarter 3 9,26,468 3,06,811 1,23,056 62,592 5,21,342 2,44,409 21,84,678

Quarter 4 9,80,923 3,26,112 1,35,489 65,990 5,46,085 2,55,868 23,10,467

Quarter 1 7,624 3,020 1,318 433 2,493 680 15,568

Quarter 2 9,137 4,207 1,752 654 2,914 818 19,482

Tested for TB
Quarter 3 8,669 4,116 1,424 704 3,076 908 18,897

Quarter 4 10,247 4,542 1,979 952 2,560 910 21,190

Quarter 1 105 35 54 12 81 9 296

Quarter 2 71 42 50 7 78 11 259
Diagnosed with TB
Quarter 3 64 46 33 11 56 14 224

Quarter 4 129 44 55 13 64 20 325

Quarter 1 94 28 44 12 75 8 261

Initiated on TB Quarter 2 67 38 46 5 74 7 237

treatment
Quarter 3 69 46 30 11 55 11 222

Quarter 4 106 45 49 13 58 13 284

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 20,73,736

1.1. HIV sero-positive (%) 0.80

1.2. ICTC clients referred to NTEP 14,64,132

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 8,15,316 7,93,657 35,718 32,363 2,616 14,417

May-22 8,37,369 8,12,736 39,255 32,953 2,705 15,295

Jun-22 8,45,587 8,06,147 39,752 33,729 2,604 16,239

Jul-22 8,37,989 8,14,268 40,519 34,886 2,433 17,014

Aug-22 8,44,455 8,21,606 39,293 34,183 2,397 16,285

Sep-22 9,69,760 9,34,955 43,711 36,266 2,473 19,334

Oct-22 9,75,863 9,47,983 39,353 33,004 2,066 17,067

Nov-22 10,34,806 10,06,489 48,162 38,221 2,379 20,807

Dec-22 10,30,660 9,98,703 47,538 37,249 2,365 19,250

Jan-23 9,47,879 9,10,516 39,189 35,217 2,257 14,626

Feb-23 9,08,323 8,77,812 36,402 32,945 2,328 10,493

Mar-23 10,46,870 10,17,642 38,061 35,220 2,510 10,775

April 2022-March 2023 36,847 34,866

156 Sankalak: Status of National AIDS & STD Response (2023)

Sankalak: Status of National AIDS & STD Response (2023) 157
ANDAMAN &
NICOBAR
ISLANDS
ANDAMAN &
NICOBAR ISLANDS

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.54
2. IMR - - 1.07
3. Adult (15-49 yrs) HIV Prevalence (%) 0.16 0.12 0.14
4. Estimated people living with HIV 270 182 452
5. ART coverage (%) 35.7 43.1 38.6
6. Estimated children living with HIV ≤50 ≤50 ≤50
7. Annual new HIV infections ≤50 ≤50 ≤50
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 ≤50
9. Change in annual new HIV infections since 2010 (%) -64.3 -64.71 -64.4
10. Change in annual ARD since 2010 (%) -35.7 -50.00 -40.9
11. EMTCT need - 4 4

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers - - - -
2. Men who have Sex with Men - - - -
3. Injecting Drug Users - - - -
4. Hijra/Transgender People - - - -
5. Migrants - - - -
6. Truckers - - - -
7. Prison inmates 619 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 34.7 14.9 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 37 14.8 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 37.0 66.5 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 64.4 72.9 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 3.8 0.1 -
5.1 Condom use during last higher-risk intercourse (%) 84.1 0 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 5.9 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 100.0 0.0 -

2. Progress on 95-95-95 (2022-23)

95 94 95 95 Indicator (2022-23) Male Female Total
83
75
1. Estimated PLHIV size (2022) 270 182 452

35 30 31 35 40 2. PLHIV who know their HIV Status 101 79 180

3. PLHIV who know their HIV status and are on ART 96 78 175
PLHIV who know PLHIV who know PLHIV who are on 4. PLHIV who are on ART and tested for their viral load 70 88 158
their HIV status their HIV status ART and virally
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 58 73 131
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 159

ANDAMAN & NICOBAR ISLANDS

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size -
A. Information, Education, Communication,
2. Coverage (%) -
Youth and Mainstreaming
3. Needles distributed -
Indicator 2022-23 4. Syringes distributed -
1. Schools with operational Adolescent Education 5. On OST -
120
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) -
2. Colleges with operational Red Ribbon Clubs (RRC) 14 6.1. HIV sero-positive (%) -
3. Persons trained under mainstreaming 4,011 6.1.1 Linked to ART -
7. Tested for HIV (October 2022 -March 2023) -
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) -
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART -
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 1 1. Estimated size -
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) -
2. Total STI/RTI 3. Condoms distributed -
1,998 2,426 5 4,429
Clients managed 4. Tested for HIV (April 2022-September 2022) -
3. RPR Tests 4.1. HIV sero-positive (%) -
1,998 2,426 5 4,429
conducted 4.1.1. Linked to ART -
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) -
0.50 0.16 0.00 0.32
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART -
4. Prevention of new HIV infections among 6. Clinic Visits -
high-risk group and bridge population
7. STI/RTI treated -
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment -
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 0 Indicator 2022-23
2. OST centres 0 1. Estimated size -
2. Coverage (%) -
B. Female Sex Workers
3. Tested for HIV -
Indicator 2022-23
3.1. HIV sero-positive (%) -
1. Estimated size -
3.2. Linked to ART -
2. Coverage (%) -
3. Condoms distributed - G. Truckers
4. Tested for HIV (April 2022-September 2022) - Indicator 2022-23
4.1. HIV sero-positive (%) 0.00 1. Estimated size -
4.1.1. Linked to ART 0 2. Coverage (%) -
5. Tested for HIV (October 2022 -March 2023) - 3. Tested for HIV -
5.1. HIV sero-positive (%) 0.00 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 0 3.2. On ART -
6. Clinic Visits -
H. Prison Inmates
7. STI/RTI treated -
Indicator 2022-23
8. Presumptive treatment -
1. Total prisons 4
C. Men who have Sex with Men 2. Prisons covered under programme 1
Indicator 2022-23 3. Total inmates admitted 885
1. Estimated size - 4. Inmates Covered (%) ≥95
2. Coverage (%) - 5. Tested for HIV 485
3. Condoms distributed - 5.1. HIV sero-positive (%) 0.00
4. Tested for HIV (April 2022-September 2022) - 5.2. On ART (%) -
4.1. HIV sero-positive (%) 0.00
I. Link Worker Scheme
4.1.1. Linked to ART -
5. Tested for HIV (October 2022 -March 2023) - Indicator 2022-23
5.1. HIV sero-positive (%) 0.00 1. Districts covered under scheme -
5.1.1. Linked to ART - 2. Vulnerable population covered -
6. Clinic Visits - 3. Tested for HIV -
7. STI/RTI treated - 3.1. HIV sero-positive (%) -
8. Presumptive treatment - 3.2. Linked to ART (%) -

160 Sankalak: Status of National AIDS & STD Response (2023)

 ANDAMAN & NICOBAR ISLANDS

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 1
1.1. OSTC in Public Health Settings 1 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 0
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 52
2. Viral load testing conducted 14
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 71

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 39 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 13 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 24 5. CD4 testing conducted 151
1.3. Facility integrated (PPP) 2
6. External Quality Assessment of ICTC
1.4. CBS -
1.5. SSK - 6.1 Average Participation (%) 100.0
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 4
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 16,244 11,875 5 28,124
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
21 9 - 30
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.13 0.08 0.00 0.11 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 4,660
partner testing of
3 2 - 5 2. HIV testing among PW 4,223
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 2
‘at-risk’ population
- - - - 4.1 On life-long ART 2
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 2

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) -
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 1 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months -
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres -
4. Care Support Centres -
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 5,150
Male Female H/TG Total 2. Sero-positivity (%) among tested -
1. HIV positive cases 3. Put on treatment -
21 10 - 31
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 19 9 - 28 Stigma and Discrimination
centre
2.1 Initiated on ART 19 8 - 27 A. HIV
3. PLHIV alive and
96 78 - 175 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 100.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 9 4 - 13 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 161

ANDAMAN & NICOBAR ISLANDS

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Screened for TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Tested for TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 964

1.1. HIV sero-positive (%) 0.21

1.2. ICTC clients referred to NTEP 1,134

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 97 97 1 1 - 3

May-22 - - - - - -

Jun-22 - - - - - -

Jul-22 - 80 - - - -

Aug-22 62 62 - - - 4

Sep-22 52 52 1 1 - 2

Oct-22 58 58 1 1 - 1

Nov-22 78 78 1 1 - 1

Dec-22 74 74 1 1 - 3

Jan-23 92 92 - - - 2

Feb-23 76 76 - - - 5

Mar-23 97 97 2 2 - 2

April 2022-March 2023 5 -

162 Sankalak: Status of National AIDS & STD Response (2023)

 ANDAMAN & NICOBAR ISLANDS

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT A & N Islands

Rank 16
Sl. No.
Max Marks 108

Obtained Marks (%) 76 (70)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) NA
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) G
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) NA
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) NA
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) Y
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) Y
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) Y
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) Y
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 163

ANDHRA
PRADESH
ANDHRA PRADESH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 1.63
2. IMR - - 0.53
3. Adult (15-49 yrs) HIV Prevalence (%) 0.65 0.62 0.64
4. Estimated people living with HIV 1,62,961 1,58,578 3,21,539
5. ART coverage (%) 62.6 79.2 71.0
6. Estimated children living with HIV 10,011 8,833 18,845
7. Annual new HIV infections 2,957 2,283 5,240
8. Annual AIDS-related deaths (ARD) 4,929 1,779 6,708
9. Change in annual new HIV infections since 2010 (%) -58.7 -59.17 -58.9
10. Change in annual ARD since 2010 (%) -76.9 -86.51 -80.6
11. EMTCT need - 1,863 1,863

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 1,19,367 73.1 56.7 1.78
2. Men who have Sex with Men 22,060 52 77.9 2.06
3. Injecting Drug Users 1,332 72.1 90.3 1.32
4. Hijra/Transgender People 5,364 37.8 - 4.61
5. Migrants 1,99,533 - - 0.93
6. Truckers 52,345 - - 0.60
7. Prison inmates 69,761 27 - 3.25

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 38.6 24.6 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 38.1 27.2 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 66.4 64.1 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 72.1 64.3 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 3.8 0.1 -
5.1 Condom use during last higher-risk intercourse (%) 31.3 0.0 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 5.2 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 42.9 NA -

2. Progress on 95-95-95 (2022-23)

86
93 Indicator (2022-23) Male Female Total
80 82 78 80 78 81 80 81 86
74 77 79
60 1. Estimated PLHIV size (2022) 1,62,961 1,58,578 3,21,539

2. PLHIV who know their HIV Status 1,21,810 1,42,041 2,64,757

3. PLHIV who know their HIV status and are on ART 1,01,947 1,25,611 2,28,289
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 73,029 66,381 1,39,758
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 68,367 61,623 1,30,315
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 165

ANDHRA PRADESH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 1,332
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 2,77,679
Indicator 2022-23 4. Syringes distributed 2,78,868
1. Schools with operational Adolescent Education 5. On OST 548
1,070
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,674
2. Colleges with operational Red Ribbon Clubs (RRC) 207 6.1. HIV sero-positive (%) 0.00
3. Persons trained under mainstreaming - 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 1,744
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.23
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 4
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 55 1. Estimated size 5,364
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 85
2. Total STI/RTI 3. Condoms distributed 13,46,065
2,76,782 6,54,759 15,387 9,46,928
Clients managed 4. Tested for HIV (April 2022-September 2022) 3,785
3. RPR Tests 4.1. HIV sero-positive (%) 0.40
50,061 1,21,464 1,729 1,73,254
conducted 4.1.1. Linked to ART 9
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 3,659
0.45 0.10 1.10 0.21
seropositivity (%)
5.1. HIV sero-positive (%) 0.27
5.1.1. Linked to ART 6
4. Prevention of new HIV infections among 6. Clinic Visits 14,103
high-risk group and bridge population
7. STI/RTI treated 27
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 604
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 96 Indicator 2022-23
2. OST centres 3 1. Estimated size 1,99,533
2. Coverage (%) 21
B. Female Sex Workers
3. Tested for HIV 49,511
Indicator 2022-23
3.1. HIV sero-positive (%) 0.04
1. Estimated size 1,19,367
3.2. Linked to ART 292
2. Coverage (%) ≥95
3. Condoms distributed 3,74,90,851 G. Truckers
4. Tested for HIV (April 2022-September 2022) 1,08,097 Indicator 2022-23
4.1. HIV sero-positive (%) 0.06 1. Estimated size 52,345
4.1.1. Linked to ART 42 2. Coverage (%) 57
5. Tested for HIV (October 2022 -March 2023) 1,14,832 3. Tested for HIV 18,169
5.1. HIV sero-positive (%) 0.04 3.1. HIV sero-positive (%) 0.06
5.1.1. Linked to ART 34 3.2. On ART 4
6. Clinic Visits 4,36,938
H. Prison Inmates
7. STI/RTI treated 1,815
Indicator 2022-23
8. Presumptive treatment 17,854
1. Total prisons 106
C. Men who have Sex with Men 2. Prisons covered under programme 81
Indicator 2022-23 3. Total inmates admitted 1,06,830
1. Estimated size 22,060 4. Inmates Covered (%) 39
2. Coverage (%) ≥95 5. Tested for HIV 28,145
3. Condoms distributed 72,49,505 5.1. HIV sero-positive (%) 0.36
4. Tested for HIV (April 2022-September 2022) 21,630 5.2. On ART (%) 98.02
4.1. HIV sero-positive (%) 0.22
I. Link Worker Scheme
4.1.1. Linked to ART 30
5. Tested for HIV (October 2022 -March 2023) 24,729 Indicator 2022-23
5.1. HIV sero-positive (%) 0.11 1. Districts covered under scheme 13
5.1.1. Linked to ART 18 2. Vulnerable population covered 1,87,326
6. Clinic Visits 87,090 3. Tested for HIV 1,43,633
7. STI/RTI treated 207 3.1. HIV sero-positive (%) 0.21
8. Presumptive treatment 3,483 3.2. Linked to ART (%) 96.4

166 Sankalak: Status of National AIDS & STD Response (2023)

 ANDHRA PRADESH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 3
1.1. OSTC in Public Health Settings 3 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 10
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 10
2. IDU on OST 548
2. Viral load testing conducted 1,63,708
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 91.7

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 1,958 4. State reference laboratories (SRL) 7
1.1. Stand-Alone 225 4.1 Accredited SRL 7
1.2. Facility integrated (Govt.) 1,451 5. CD4 testing conducted 1,08,218
1.3. Facility integrated (PPP) 169
6. External Quality Assessment of ICTC
1.4. CBS 113
1.5. SSK 12 6.1 Average Participation (%) 64.8
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 9,53,974 9,04,460 9,532 18,67,966
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
8,433 6,974 129 15,536
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.88 0.77 1.35 0.83 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 8,99,900
partner testing of
8,129 6,924 119 15,172 2. HIV testing among PW 9,56,108
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.06
5. No. of contacts with 4. HIV Positive PW (old + new detections) 1,612
‘at-risk’ population
- - - - 4.1 On life-long ART 1,607
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 1,162

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.48
infected people 6. Babies tested HIV (6 week- 6 month) 1,255
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 54 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 896
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 6
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 4
3. Link ART Centres 117
4. Care Support Centres 23
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 9,81,533
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 53
8,433 7,529 129 16,091
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 8,309 7,401 103 15,813 Stigma and Discrimination
centre
2.1 Initiated on ART 8,240 7,350 103 15,693 A. HIV
3. PLHIV alive and
1,01,947 1,25,611 730 2,28,289 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 86.3 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 5,647 4,728 92 10,467 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 167

ANDHRA PRADESH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 1,10,135 23,168 1,258 3,291 13,760 3,613 1,55,225

Quarter 2 1,18,353 25,734 2,000 3,610 13,943 3,262 1,66,902

Screened for TB
Quarter 3 1,23,117 26,865 1,496 3,747 13,702 3,371 1,72,298

Quarter 4 1,37,646 30,372 1,828 4,332 14,656 3,485 1,92,319

Quarter 1 629 161 7 21 222 10 1,050

Quarter 2 920 125 270 11 165 2 1,493

Tested for TB
Quarter 3 765 114 41 20 271 - 1,211

Quarter 4 611 94 41 10 93 1 850

Quarter 1 2 1 - 1 1 - 5

Quarter 2 2 1 - 1 1 2 7
Diagnosed with TB
Quarter 3 - 1 - 1 2 - 4

Quarter 4 - - 2 1 - - 3

Quarter 1 2 1 - 1 1 - 5

Initiated on TB Quarter 2 2 1 - 1 1 - 5
treatment
Quarter 3 - 1 - 1 2 - 4

Quarter 4 - - 2 1 - - 3

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 80,268

1.1. HIV sero-positive (%) 0.74

1.2. ICTC clients referred to NTEP 93,273

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 82,001 80,078 3,737 3,690 254 1,181

May-22 88,331 86,650 4,051 4,021 249 1,321

Jun-22 87,201 85,608 4,504 4,484 249 1,350

Jul-22 81,366 79,412 4,775 4,768 223 1,542

Aug-22 88,479 87,094 4,308 4,296 240 1,407

Sep-22 93,654 89,988 4,022 4,015 224 1,295

Oct-22 89,088 87,267 3,648 3,641 175 1,167

Nov-22 1,04,444 1,02,849 4,108 4,097 210 1,188

Dec-22 1,08,874 1,07,218 3,901 3,889 214 1,304

Jan-23 96,947 95,477 4,153 4,136 219 1,083

Feb-23 1,00,922 99,485 3,470 3,464 226 825

Mar-23 1,42,736 1,41,374 3,733 3,707 249 906

April 2022-March 2023 4,142 4,089

168 Sankalak: Status of National AIDS & STD Response (2023)

 ANDHRA PRADESH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Andhra Pradesh

Rank 5
Sl. No.
Max Marks 120

Obtained Marks (%) 91 (76)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) Y
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) Y
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) Y
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) G
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 169

ARUNACHAL
PRADESH
ARUNACHAL PRADESH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 12.61
2. IMR - - 5.77
3. Adult (15-49 yrs) HIV Prevalence (%) 0.15 0.11 0.13
4. Estimated people living with HIV 818 554 1,372
5. ART coverage (%) 53.3 21.7 40.6
6. Estimated children living with HIV 135 97 232
7. Annual new HIV infections 103 69 172
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 ≤50
9. Change in annual new HIV infections since 2010 (%) 186.1 187.50 188.3
10. Change in annual ARD since 2010 (%) 66.7 133.33 91.7
11. EMTCT need - 23 23

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 6,941 48.1 68.6 0.27
2. Men who have Sex with Men 901 - - -
3. Injecting Drug Users 5,143 62.5 87.9 1.6
4. Hijra/Transgender People 140 - - -
5. Migrants 40,500 - - -
6. Truckers - - - -
7. Prison inmates 599 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 33.4 12.3 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 35.4 15.5 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 67.9 56.7 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 59.3 50.3 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 7.4 2.0 -
5.1 Condom use during last higher-risk intercourse (%) 75.8 58.5 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 12.3 4.0 -
6.1 Condom use during last higher-risk intercourse (%) 80.0 62.2 -

2. Progress on 95-95-95 (2022-23)

85 Indicator (2022-23) Male Female Total
72 70 73 73 74 78
66 66
56 58 1. Estimated PLHIV size (2022) 818 554 1,372

25 27 24 26 2. PLHIV who know their HIV Status 584 176 765

3. PLHIV who know their HIV status and are on ART 436 120 557
PLHIV who know PLHIV who know PLHIV who are on
their HIV status (%) their HIV status and ART and virally 4. PLHIV who are on ART and tested for their viral load 70 52 122
are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 63 41 104
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 171

ARUNACHAL PRADESH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 5,143
A. Information, Education, Communication,
2. Coverage (%) 73
Youth and Mainstreaming
3. Needles distributed 2,44,316
Indicator 2022-23 4. Syringes distributed 2,44,316
1. Schools with operational Adolescent Education 5. On OST 444
300
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 2,341
2. Colleges with operational Red Ribbon Clubs (RRC) 57 6.1. HIV sero-positive (%) 1.62
3. Persons trained under mainstreaming 5,351 6.1.1 Linked to ART 30
7. Tested for HIV (October 2022 -March 2023) 2,960
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 8.31
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 100
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 18 1. Estimated size 140
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 66
2. Total STI/RTI 3. Condoms distributed 23,944
13,570 17,176 1,271 32,017
Clients managed 4. Tested for HIV (April 2022-September 2022) 58
3. RPR Tests 4.1. HIV sero-positive (%) 1.72
3,318 4,375 - 7,693
conducted 4.1.1. Linked to ART 1
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 65
7.17 5.58 - 6.27
seropositivity (%)
5.1. HIV sero-positive (%) 1.54
5.1.1. Linked to ART 1
4. Prevention of new HIV infections among 6. Clinic Visits 239
high-risk group and bridge population
7. STI/RTI treated 3
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 22
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 20 Indicator 2022-23
2. OST centres 4 1. Estimated size 40,500
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 11,316
Indicator 2022-23
3.1. HIV sero-positive (%) 0.27
1. Estimated size 6,941
3.2. Linked to ART -
2. Coverage (%) 72.68
3. Condoms distributed 5,81,272 G. Truckers
4. Tested for HIV (April 2022-September 2022) 4,057 Indicator 2022-23
4.1. HIV sero-positive (%) 0.02 1. Estimated size -
4.1.1. Linked to ART 1 2. Coverage (%) 0
5. Tested for HIV (October 2022 -March 2023) 4,305 3. Tested for HIV 0
5.1. HIV sero-positive (%) 0.05 3.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 2 3.2. On ART 0
6. Clinic Visits 14,647
H. Prison Inmates
7. STI/RTI treated 140
Indicator 2022-23
8. Presumptive treatment 818
1. Total prisons 2
C. Men who have Sex with Men 2. Prisons covered under programme 9
Indicator 2022-23 3. Total inmates admitted 723
1. Estimated size 901 4. Inmates Covered (%) 50
2. Coverage (%) 68 5. Tested for HIV 237
3. Condoms distributed 93,518 5.1. HIV sero-positive (%) 0.42
4. Tested for HIV (April 2022-September 2022) 508 5.2. On ART (%) 100.00
4.1. HIV sero-positive (%) 1.97
I. Link Worker Scheme
4.1.1. Linked to ART 10
5. Tested for HIV (October 2022 -March 2023) 590 Indicator 2022-23
5.1. HIV sero-positive (%) 1.53 1. Districts covered under scheme -
5.1.1. Linked to ART 9 2. Vulnerable population covered -
6. Clinic Visits 1,857 3. Tested for HIV -
7. STI/RTI treated 34 3.1. HIV sero-positive (%) -
8. Presumptive treatment 114 3.2. Linked to ART (%) -

172 Sankalak: Status of National AIDS & STD Response (2023)

 ARUNACHAL PRADESH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 4
1.1. OSTC in Public Health Settings 4 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 444
2. Viral load testing conducted 138
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 83.3

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 147 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 39 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 83 5. CD4 testing conducted 85
1.3. Facility integrated (PPP) 4
6. External Quality Assessment of ICTC
1.4. CBS 21
1.5. SSK - 6.1 Average Participation (%) 85.8
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 10,632 8,369 16 19,017
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
500 48 3 551
among tested A. HIV
3. HIV sero-positivity
(%) among tested
4.70 0.57 18.75 2.90 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 29,540
partner testing of
53 43 2 98 2. HIV testing among PW 15,256
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.05
5. No. of contacts with 4. HIV Positive PW (old + new detections) 21
‘at-risk’ population
- - - - 4.1 On life-long ART 19
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 5

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 7
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 1 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 4
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres 4
4. Care Support Centres -
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 17,525
Male Female H/TG Total 2. Sero-positivity (%) among tested 1.92
1. HIV positive cases 3. Put on treatment 189
500 55 3 558
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 338 50 2 390 Stigma and Discrimination
centre
2.1 Initiated on ART 335 44 2 381 A. HIV
3. PLHIV alive and
436 120 1 557 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 41.5 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 39 17 2 58 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 173

ARUNACHAL PRADESH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 2,446 422 2,853 48 7,862 - 13,631

Quarter 2 2,528 420 2,911 38 7,201 - 13,098

Screened for TB
Quarter 3 2,628 450 2,938 51 7,164 - 13,231

Quarter 4 2,898 471 3,315 56 7,112 - 13,852

Quarter 1 28 - 22 - 9 - 59

Quarter 2 12 - 30 - 2 - 44
Tested for TB
Quarter 3 16 - 22 - 8 - 46

Quarter 4 34 1 178 - 11 - 224

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,742

1.1. HIV sero-positive (%) 1.21

1.2. ICTC clients referred to NTEP 445

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 80 80 13 13 3 12

May-22 79 79 13 13 - 14

Jun-22 75 75 20 20 - 10

Jul-22 44 44 10 10 2 10

Aug-22 44 44 10 10 2 10

Sep-22 119 119 12 12 - 10

Oct-22 86 86 10 10 - 10

Nov-22 86 86 10 10 - 31

Dec-22 164 164 67 67 - 18

Jan-23 76 76 16 16 2 5

Feb-23 117 117 18 18 - 5

Mar-23 161 161 15 15 - 5

April 2022-March 2023 14 14

174 Sankalak: Status of National AIDS & STD Response (2023)

 ARUNACHAL PRADESH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Arunachal Pradesh

Rank 35
Sl. No.
Max Marks 117

Obtained Marks (%) 68 (58)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) R
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) R
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) R
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 175

ASSAM
ASSAM

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 9.42
2. IMR - - 3.33
3. Adult (15-49 yrs) HIV Prevalence (%) 0.12 0.10 0.11
4. Estimated people living with HIV 16,394 13,673 30,067
5. ART coverage (%) 49.5 32.4 41.8
6. Estimated children living with HIV 1,727 1,546 3,273
7. Annual new HIV infections 1,478 1,355 2,833
8. Annual AIDS-related deaths (ARD) 246 363 609
9. Change in annual new HIV infections since 2010 (%) 63.5 88.72 74.6
10. Change in annual ARD since 2010 (%) -31.5 31.05 -4.2
11. EMTCT need - 402 402

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 39,721 75.3 0 1.65
2. Men who have Sex with Men 16,667 33.8 17.9 3.61
3. Injecting Drug Users 26,156 48.9 87.6 11.24
4. Hijra/Transgender People 2,481 - - -
5. Migrants 20,000 - - 3.21
6. Truckers 25,000 - - 2.12
7. Prison inmates 37,621 22.2 68.5 2.01

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 25.3 19.2 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 27.4 19.0 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 75.6 76.1 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 69.1 72.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 1.1 0.3 -
5.1 Condom use during last higher-risk intercourse (%) 62.6 40.0 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 1.8 0.5 -
6.1 Condom use during last higher-risk intercourse (%) 69.2 25.0 -

2. Progress on 95-95-95 (2022-23)

87 88 89
94 Indicator (2022-23) Male Female Total
80 79 75 74 78 77
1. Estimated PLHIV size (2022) 16,394 13,673 30,067
54
46
40 43 43
2. PLHIV who know their HIV Status 10,506 5,541 16,088

3. PLHIV who know their HIV status and are on ART 8,119 4,425 12,570
PLHIV who know PLHIV who know PLHIV who are on
their HIV status (%) their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 2,508 1,605 4,116
and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 2,370 1,506 3,879
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 177

ASSAM

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 26,156
A. Information, Education, Communication,
2. Coverage (%) 25
Youth and Mainstreaming
3. Needles distributed 8,71,890
Indicator 2022-23 4. Syringes distributed 8,67,982
1. Schools with operational Adolescent Education 5. On OST 1,859
500
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 3,171
2. Colleges with operational Red Ribbon Clubs (RRC) 245 6.1. HIV sero-positive (%) 13.65
3. Persons trained under mainstreaming 24,487 6.1.1 Linked to ART 327
7. Tested for HIV (October 2022 -March 2023) 4,656
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 7.24
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 270
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 28 1. Estimated size 2,481
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 27
2. Total STI/RTI 3. Condoms distributed 1,22,602
34,936 63,302 2,014 1,00,252
Clients managed 4. Tested for HIV (April 2022-September 2022) 501
3. RPR Tests 4.1. HIV sero-positive (%) 0.40
19,404 38,469 124 57,997
conducted 4.1.1. Linked to ART 1
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 542
3.33 0.67 5.65 1.57
seropositivity (%)
5.1. HIV sero-positive (%) 1.11
5.1.1. Linked to ART 6
4. Prevention of new HIV infections among 6. Clinic Visits 2,151
high-risk group and bridge population
7. STI/RTI treated 11
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 219
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 52 Indicator 2022-23
2. OST centres 10 1. Estimated size 20,000
2. Coverage (%) 82
B. Female Sex Workers
3. Tested for HIV 6,520
Indicator 2022-23
3.1. HIV sero-positive (%) 0.84
1. Estimated size 39,721
3.2. Linked to ART 3
2. Coverage (%) 37.31
3. Condoms distributed 30,54,657 G. Truckers
4. Tested for HIV (April 2022-September 2022) 9,566 Indicator 2022-23
4.1. HIV sero-positive (%) 0.49 1. Estimated size 25,000
4.1.1. Linked to ART 37 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 11,504 3. Tested for HIV 6,833
5.1. HIV sero-positive (%) 0.35 3.1. HIV sero-positive (%) 0.28
5.1.1. Linked to ART 30 3.2. On ART 7
6. Clinic Visits 42,283
H. Prison Inmates
7. STI/RTI treated 1,092
Indicator 2022-23
8. Presumptive treatment 2,239
1. Total prisons 31
C. Men who have Sex with Men 2. Prisons covered under programme 32
Indicator 2022-23 3. Total inmates admitted 18,838
1. Estimated size 16,667 4. Inmates Covered (%) ≥95
2. Coverage (%) 30 5. Tested for HIV 20,838
3. Condoms distributed 9,02,798 5.1. HIV sero-positive (%) 2.07
4. Tested for HIV (April 2022-September 2022) 3,510 5.2. On ART (%) 56.48
4.1. HIV sero-positive (%) 0.57
I. Link Worker Scheme
4.1.1. Linked to ART 23
5. Tested for HIV (October 2022 -March 2023) 3,895 Indicator 2022-23
5.1. HIV sero-positive (%) 0.90 1. Districts covered under scheme 1
5.1.1. Linked to ART 31 2. Vulnerable population covered 2,255
6. Clinic Visits 15,326 3. Tested for HIV 820
7. STI/RTI treated 133 3.1. HIV sero-positive (%) 0.37
8. Presumptive treatment 1,043 3.2. Linked to ART (%) 100.0

178 Sankalak: Status of National AIDS & STD Response (2023)

 ASSAM

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 10
1.1. OSTC in Public Health Settings 6 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 4 1.1 Accredited Viral load laboratories -
2. IDU on OST 1,859
2. Viral load testing conducted 4,288
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 93.0

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 435 4. State reference laboratories (SRL) 3
1.1. Stand-Alone 109 4.1 Accredited SRL 3
1.2. Facility integrated (Govt.) 231 5. CD4 testing conducted 3,967
1.3. Facility integrated (PPP) 65
6. External Quality Assessment of ICTC
1.4. CBS 30
1.5. SSK 1 6.1 Average Participation (%) 98.1
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 2
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 1,46,631 1,04,634 368 2,51,633
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
3,233 522 12 3,767
among tested A. HIV
3. HIV sero-positivity
(%) among tested
2.20 0.50 3.26 1.50 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 8,16,980
partner testing of
214 406 5 625 2. HIV testing among PW 5,41,021
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.04
5. No. of contacts with 4. HIV Positive PW (old + new detections) 258
‘at-risk’ population
- - - - 4.1 On life-long ART 217
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 197

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 198
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 9 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 89
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 4
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 2
3. Link ART Centres 10
4. Care Support Centres 3
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 4,68,014
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.12
1. HIV positive cases 3. Put on treatment 409
3,233 734 12 3,979
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 2,851 682 12 3,545 Stigma and Discrimination
centre
2.1 Initiated on ART 2,629 644 12 3,285 A. HIV
3. PLHIV alive and
8,119 4,425 26 12,570 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 70.3 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 1,981 933 14 2,928 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 179

ASSAM

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 10,898 4,107 2,873 572 2,713 1,534 22,697

Quarter 2 11,946 4,543 3,769 831 4,189 2,848 28,126

Screened for TB
Quarter 3 13,450 4,758 5,256 859 3,997 3,271 31,591

Quarter 4 13,779 4,395 4,937 865 4,385 3,451 31,812

Quarter 1 12 7 70 - 9 - 98

Quarter 2 27 70 63 1 11 - 172
Tested for TB
Quarter 3 15 13 92 2 160 35 317

Quarter 4 4 216 125 47 9 - 401

Quarter 1 1 1 4 - - - 6

Quarter 2 3 8 - - 1 - 12
Diagnosed with TB
Quarter 3 2 - 1 - - - 3

Quarter 4 2 - - - - - 2

Quarter 1 1 1 - - - - 2

Initiated on TB Quarter 2 2 7 - - 1 - 10
treatment
Quarter 3 2 - 1 - - - 3

Quarter 4 2 - - - - - 2

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 21,335

1.1. HIV sero-positive (%) 2.20

1.2. ICTC clients referred to NTEP 7,415

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 4,263 4,259 90 43 16 132

May-22 4,472 4,472 82 28 13 57

Jun-22 4,178 4,178 121 38 20 36

Jul-22 4,759 4,759 75 37 15 74

Aug-22 4,595 4,595 81 32 23 128

Sep-22 4,515 4,515 105 48 32 74

Oct-22 4,775 4,775 66 26 13 55

Nov-22 5,051 5,051 82 51 30 43

Dec-22 4,849 4,849 94 56 30 61

Jan-23 5,263 5,263 97 46 20 32

Feb-23 4,772 4,709 104 56 25 15

Mar-23 5,063 5,063 89 41 15 13

April 2022-March 2023 336 269

180 Sankalak: Status of National AIDS & STD Response (2023)

 ASSAM

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Assam

Rank 24
Sl. No.
Max Marks 117

Obtained Marks (%) 79 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) R
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 181

BIHAR
BIHAR

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 5.88
2. IMR - - 2.39
3. Adult (15-49 yrs) HIV Prevalence (%) 0.19 0.15 0.17
4. Estimated people living with HIV 90,071 66,019 1,56,090
5. ART coverage (%) 48.6 56.2 51.9
6. Estimated children living with HIV 9,507 6,598 16,105
7. Annual new HIV infections 5,414 3,763 9,177
8. Annual AIDS-related deaths (ARD) 1,796 853 2,649
9. Change in annual new HIV infections since 2010 (%) -3.6 -3.54 -3.6
10. Change in annual ARD since 2010 (%) -23.1 -52.77 -36.1
11. EMTCT need - 2,525 2,525

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 11,682 - - 0.62
2. Men who have Sex with Men 2,376 - - 0.41
3. Injecting Drug Users 4,585 35.4 96.6 2.86
4. Hijra/Transgender People 846 - - -
5. Migrants - - - -
6. Truckers 15,000 - - -
7. Prison inmates 2,45,503 - - 0.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 25.1 10.3 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 25.3 10.1 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 81.5 76.7 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 65.2 68.6 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5 0.4 -
5.1 Condom use during last higher-risk intercourse (%) 50.9 23.4 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 9.0 0.6 -
6.1 Condom use during last higher-risk intercourse (%) 51.4 33.3 -

2. Progress on 95-95-95 (2022-23)

85 88 89 90 93 89 Indicator (2022-23) Male Female Total
81 85 83
67
1. Estimated PLHIV size (2022) 90,071 66,019 1,56,090
51 53 53 53 56
2. PLHIV who know their HIV Status 47,513 39,462 87,096

3. PLHIV who know their HIV status and are on ART 43,783 37,098 80,993
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 18,802 17,978 36,803
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 16,697 16,161 32,878
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 183

BIHAR

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 4,585
A. Information, Education, Communication,
2. Coverage (%) 63
Youth and Mainstreaming
3. Needles distributed 11,35,115
Indicator 2022-23 4. Syringes distributed 6,71,081
1. Schools with operational Adolescent Education 5. On OST 205
360
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 2,522
2. Colleges with operational Red Ribbon Clubs (RRC) 406 6.1. HIV sero-positive (%) 0.44
3. Persons trained under mainstreaming 4,092 6.1.1 Linked to ART 10
7. Tested for HIV (October 2022 -March 2023) 2,628
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.46
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 11
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 44 1. Estimated size 846
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 0
2. Total STI/RTI 3. Condoms distributed 0
95,110 2,49,251 776 3,45,137
Clients managed 4. Tested for HIV (April 2022-September 2022) 0
3. RPR Tests 4.1. HIV sero-positive (%) -
30,766 1,06,558 315 1,37,639
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 0
1.41 0.63 0.00 0.81
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 0
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 0
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 15 Indicator 2022-23
2. OST centres 2 1. Estimated size -
2. Coverage (%) 0
B. Female Sex Workers
3. Tested for HIV 0
Indicator 2022-23
3.1. HIV sero-positive (%) -
1. Estimated size 11,682
3.2. Linked to ART 29
2. Coverage (%) 62.90
3. Condoms distributed 9,86,173 G. Truckers
4. Tested for HIV (April 2022-September 2022) 5,655 Indicator 2022-23
4.1. HIV sero-positive (%) 0.18 1. Estimated size 15,000
4.1.1. Linked to ART 10 2. Coverage (%) 67
5. Tested for HIV (October 2022 -March 2023) 5,272 3. Tested for HIV 1,848
5.1. HIV sero-positive (%) 0.21 3.1. HIV sero-positive (%) 0.16
5.1.1. Linked to ART 9 3.2. On ART 3
6. Clinic Visits 22,349
H. Prison Inmates
7. STI/RTI treated 210
Indicator 2022-23
8. Presumptive treatment 845
1. Total prisons 59
C. Men who have Sex with Men 2. Prisons covered under programme 59
Indicator 2022-23 3. Total inmates admitted 2,52,149
1. Estimated size 2,376 4. Inmates Covered (%) 68
2. Coverage (%) 93 5. Tested for HIV 1,63,497
3. Condoms distributed 2,25,023 5.1. HIV sero-positive (%) 0.37
4. Tested for HIV (April 2022-September 2022) 1,571 5.2. On ART (%) 64.09
4.1. HIV sero-positive (%) 0.51
I. Link Worker Scheme
4.1.1. Linked to ART 8
5. Tested for HIV (October 2022 -March 2023) 1,542 Indicator 2022-23
5.1. HIV sero-positive (%) 0.39 1. Districts covered under scheme 4
5.1.1. Linked to ART 3 2. Vulnerable population covered 1,56,050
6. Clinic Visits 6,111 3. Tested for HIV 49,760
7. STI/RTI treated 76 3.1. HIV sero-positive (%) 0.06
8. Presumptive treatment 353 3.2. Linked to ART (%) 100.0

184 Sankalak: Status of National AIDS & STD Response (2023)

 BIHAR

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 2
1.1. OSTC in Public Health Settings 2 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 205
2. Viral load testing conducted 38,867
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 88.6

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 856 4. State reference laboratories (SRL) 2
1.1. Stand-Alone 209 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 543 5. CD4 testing conducted 17,365
1.3. Facility integrated (PPP) 45
6. External Quality Assessment of ICTC
1.4. CBS 59
1.5. SSK 8 6.1 Average Participation (%) 33.8
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 6,84,188 8,30,575 3,264 15,18,027
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
6,003 3,340 84 9,427
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.88 0.40 2.57 0.62 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 34,20,990
partner testing of
2,427 2,320 33 4,780 2. HIV testing among PW 22,96,978
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 911
‘at-risk’ population
- - - - 4.1 On life-long ART 689
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 825

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.39
infected people 6. Babies tested HIV (6 week- 6 month) 1
A. Treatment facilities 6.1 Babies confirmed HIV Positive
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 27 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 462
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 3
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 8
3. Link ART Centres 13
4. Care Support Centres 15
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 7,30,947
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 47
6,003 3,852 84 9,939
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 5,952 3,994 17 9,963 Stigma and Discrimination
centre
2.1 Initiated on ART 5,474 3,741 14 9,229 A. HIV
3. PLHIV alive and
43,783 37,098 113 80,993 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 67.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 3,745 2,521 10 6,276 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 185

BIHAR

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 5,614 1,638 2,859 - - 1,650 11,761

Quarter 2 5,894 1,768 2,971 - - 1,723 12,356

Screened for TB
Quarter 3 5,302 1,642 2,802 - - 1,898 11,644

Quarter 4 5,011 1,662 2,871 - - 1,592 11,136

Quarter 1 34 5 8 - - - 47

Quarter 2 38 9 21 - - 2 70
Tested for TB
Quarter 3 55 10 46 - - - 111

Quarter 4 44 3 69 - - - 116

Quarter 1 - - 1 - - - 1

Quarter 2 - - 1 - - - 1
Diagnosed with TB
Quarter 3 - - 1 - - - 1

Quarter 4 - 1 1 - - - 2

Quarter 1 - - 1 - - - 1

Initiated on TB Quarter 2 - - 2 - - - 2
treatment
Quarter 3 - - 1 - - - 1

Quarter 4 - 1 1 - - - 2

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 34,312

1.1. HIV sero-positive (%) 2.75

1.2. ICTC clients referred to NTEP 35,621

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 36,572 35,246 1,033 693 159 672

May-22 38,889 37,037 1,290 685 148 444

Jun-22 35,314 33,999 1,238 686 125 328

Jul-22 37,742 36,330 1,285 688 117 379

Aug-22 37,742 36,330 1,285 688 117 379

Sep-22 43,946 41,895 1,628 959 144 430

Oct-22 46,691 44,631 1,469 858 90 311

Nov-22 51,773 49,483 1,400 908 115 271

Dec-22 50,877 48,666 1,225 873 109 260

Jan-23 42,515 40,939 1,058 651 121 243

Feb-23 40,823 37,703 1,018 575 129 222

Mar-23 48,541 46,935 984 595 143 266

April 2022-March 2023 1,495 1,205

186 Sankalak: Status of National AIDS & STD Response (2023)

 BIHAR

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Bihar

Rank 34
Sl. No.
Max Marks 117

Obtained Marks (%) 69 (59)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) R
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) R
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 187

CHANDIGARH
CHANDIGARH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.23
2. IMR - - 2.66
3. Adult (15-49 yrs) HIV Prevalence (%) 0.29 0.18 0.24
4. Estimated people living with HIV 1,585 802 2,387
5. ART coverage (%) 229.3 247.2 236.4
6. Estimated children living with HIV 134 65 199
7. Annual new HIV infections 52 ≤50 76
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 ≤50
9. Change in annual new HIV infections since 2010 (%) -42.2 -41.46 -40.8
10. Change in annual ARD since 2010 (%) -54.2 -63.64 -57.1
11. EMTCT need - 17 17

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 3,333 87.4 61.4 0.8
2. Men who have Sex with Men 2,569 68.7 1.9 1.61
3. Injecting Drug Users 1,908 64.5 94.8 2.8
4. Hijra/Transgender People 164 - - -
5. Migrants 25,000 - - 0.4
6. Truckers 15,330 - - -
7. Prison inmates 3,706 72.7 26.7 3.47

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 54.1 20.3 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 43.2 21 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 88.4 65.8 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 76 48.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 1.8 0 -
5.1 Condom use during last higher-risk intercourse (%) 46.5 - -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 5.0 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 50.0 - -

2. Progress on 95-95-95 (2022-23)

95 95 95 95 95
87
94 95 90 94 91 93 93 95 Indicator (2022-23) Male Female Total

65 1. Estimated PLHIV size (2022) 1,585 802 2,387

2. PLHIV who know their HIV Status 3,950 2,046 6,025

3. PLHIV who know their HIV status and are on ART 3,634 1,985 5,644
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally
4. PLHIV who are on ART and tested for their viral load 1,416 2,464 3,895
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 1,368 2,402 3,785
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 189

CHANDIGARH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 1,908
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 5,52,163
Indicator 2022-23 4. Syringes distributed 3,16,785
1. Schools with operational Adolescent Education 5. On OST 783
150
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,743
2. Colleges with operational Red Ribbon Clubs (RRC) 25 6.1. HIV sero-positive (%) 0.06
3. Persons trained under mainstreaming 4,063 6.1.1 Linked to ART 1
7. Tested for HIV (October 2022 -March 2023) 1,911
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.16
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 2
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 5 1. Estimated size 164
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 48,534
1,895 6,582 - 8,477
Clients managed 4. Tested for HIV (April 2022-September 2022) 124
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
1,621 6,446 - 8,067
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 130
7.65 0.62 0.00 2.03
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 502
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 24
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 12 Indicator 2022-23
2. OST centres 4 1. Estimated size 25,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 11,794
Indicator 2022-23
3.1. HIV sero-positive (%) 0.05
1. Estimated size 3,333
3.2. Linked to ART -
2. Coverage (%) ≥95
3. Condoms distributed 11,86,027 G. Truckers
4. Tested for HIV (April 2022-September 2022) 3,041 Indicator 2022-23
4.1. HIV sero-positive (%) 0.03 1. Estimated size 15,330
4.1.1. Linked to ART 2 2. Coverage (%) 65
5. Tested for HIV (October 2022 -March 2023) 2,902 3. Tested for HIV 4,212
5.1. HIV sero-positive (%) 0.00 3.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0 3.2. On ART 0
6. Clinic Visits 11,504
H. Prison Inmates
7. STI/RTI treated 149
Indicator 2022-23
8. Presumptive treatment 422
1. Total prisons 1
C. Men who have Sex with Men 2. Prisons covered under programme 1
Indicator 2022-23 3. Total inmates admitted 2,416
1. Estimated size 2,569 4. Inmates Covered (%) 60
2. Coverage (%) ≥95 5. Tested for HIV 1,249
3. Condoms distributed 6,17,576 5.1. HIV sero-positive (%) 0.40
4. Tested for HIV (April 2022-September 2022) 1,919 5.2. On ART (%) 100.00
4.1. HIV sero-positive (%) 0.16
I. Link Worker Scheme
4.1.1. Linked to ART 2
5. Tested for HIV (October 2022 -March 2023) 1,970 Indicator 2022-23
5.1. HIV sero-positive (%) 0.25 1. Districts covered under scheme -
5.1.1. Linked to ART 4 2. Vulnerable population covered -
6. Clinic Visits 7,790 3. Tested for HIV -
7. STI/RTI treated 73 3.1. HIV sero-positive (%) -
8. Presumptive treatment 398 3.2. Linked to ART (%) -

190 Sankalak: Status of National AIDS & STD Response (2023)

 CHANDIGARH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 4
1.1. OSTC in Public Health Settings - Indicator 2022-23
1.2. OSTC in NGO Settings 4 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 1
2. IDU on OST 783
2. Viral load testing conducted 6,255
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 92.8

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 38 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 12 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 11 5. CD4 testing conducted 5,798
1.3. Facility integrated (PPP) 2
6. External Quality Assessment of ICTC
1.4. CBS 13
1.5. SSK 1 6.1 Average Participation (%) 100.0
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 50,815 35,752 7,207 93,774
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
592 165 1 758
among tested A. HIV
3. HIV sero-positivity
(%) among tested
1.17 0.46 0.01 0.81 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 18,190
partner testing of
84 184 - 268 2. HIV testing among PW 19,188
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.13
5. No. of contacts with 4. HIV Positive PW (old + new detections) 42
‘at-risk’ population
9 35 - 44 4.1 On life-long ART 41
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 48

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 44
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 2 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 15
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 4
3. Link ART Centres 4
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 23,934
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.06
1. HIV positive cases 3. Put on treatment 15
592 190 1 783
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 331 135 1 467 Stigma and Discrimination
centre
2.1 Initiated on ART 299 124 1 424 A. HIV
3. PLHIV alive and
3,634 1,985 25 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 78.8 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 330 115 2 447 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 191

CHANDIGARH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 2,882 1,926 1,603 118 2,881 2,476 11,886

Quarter 2 2,902 1,951 1,770 127 2,837 2,661 12,248

Screened for TB
Quarter 3 2,814 1,975 1,839 126 2,924 2,383 12,061

Quarter 4 2,906 1,991 1,894 131 2,906 2,486 12,314

Quarter 1 11 11 - 6 19 10 57

Quarter 2 9 10 - 3 28 19 69
Tested for TB
Quarter 3 3 7 - - 13 10 33

Quarter 4 3 8 2 - 35 15 63

Quarter 1 1 - - - 3 - 4

Quarter 2 1 - - - - 1 2
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - 1 - - 1 2

Quarter 1 1 - - - 3 - 4

Initiated on TB Quarter 2 1 - - - - 1 2
treatment
Quarter 3 - 1 - - - - 1

Quarter 4 - - 1 - - 1 2

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 7,348

1.1. HIV sero-positive (%) 1.29

1.2. ICTC clients referred to NTEP 107

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 2,640 2,640 19 19 6 24

May-22 2,358 2,358 32 32 5 29

Jun-22 2,531 2,531 27 27 4 20

Jul-22 2,608 2,608 21 21 7 30

Aug-22 2,341 2,341 28 19 7 32

Sep-22 2,661 2,661 40 27 10 52

Oct-22 2,394 2,394 23 18 4 35

Nov-22 2,352 2,352 37 29 9 83

Dec-22 2,566 2,566 44 44 13 132

Jan-23 2,378 1,728 57 45 13 123

Feb-23 2,318 2,318 51 39 7 78

Mar-23 2,700 2,700 32 29 8 31

April 2022-March 2023 176 162

192 Sankalak: Status of National AIDS & STD Response (2023)

 CHANDIGARH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Chandigarh

Rank 1
Sl. No.
Max Marks 120

Obtained Marks (%) 99 (83)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) G
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) Y
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) G
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) Y
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) G
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) G
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) R
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 193

CHHATTISGARH
CHHATTISGARH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.76
2. IMR - - 1.03
3. Adult (15-49 yrs) HIV Prevalence (%) 0.18 0.16 0.17
4. Estimated people living with HIV 21,634 19,158 40,792
5. ART coverage (%) 50.3 46.4 48.8
6. Estimated children living with HIV 1,892 1,854 3,746
7. Annual new HIV infections 769 766 1,535
8. Annual AIDS-related deaths (ARD) 579 548 1,128
9. Change in annual new HIV infections since 2010 (%) -47.8 -41.48 -44.8
10. Change in annual ARD since 2010 (%) -72.0 -64.58 -68.8
11. EMTCT need - 505 505

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 18,375 72.8 46.9 1.92
2. Men who have Sex with Men 2,889 29 6.5 4.01
3. Injecting Drug Users 3,923 67.1 92.3 7.2
4. Hijra/Transgender People 1,118 - - 6
5. Migrants 2,31,000 - - 1.2
6. Truckers 62,000 - - 2.00
7. Prison inmates 66,388 39.4 0 0.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 30.7 23 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 29.9 22 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 77.7 79.4 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 74.5 72.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5 0.5 -
5.1 Condom use during last higher-risk intercourse (%) 56 21.2 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 9.1 0.4 -
6.1 Condom use during last higher-risk intercourse (%) 54.8 16.7 -

2. Progress on 95-95-95 (2022-23)

85 86 90 Indicator (2022-23) Male Female Total
75 76 76 76 79 76
70
57 62 1. Estimated PLHIV size (2022) 21,634 19,158 40,792
48 52 53
2. PLHIV who know their HIV Status 14,172 10,992 25,315

3. PLHIV who know their HIV status and are on ART 10,889 8,896 19,920
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 5,280 5,343 10,668
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 4,732 4,862 9,635
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 195

CHHATTISGARH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 3,923
A. Information, Education, Communication,
2. Coverage (%) 94
Youth and Mainstreaming
3. Needles distributed 6,83,229
Indicator 2022-23 4. Syringes distributed 5,59,470
1. Schools with operational Adolescent Education 5. On OST 1,047
305
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 2,220
2. Colleges with operational Red Ribbon Clubs (RRC) 175 6.1. HIV sero-positive (%) 0.32
3. Persons trained under mainstreaming 7,115 6.1.1 Linked to ART 5
7. Tested for HIV (October 2022 -March 2023) 2,871
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.52
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 12
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 31 1. Estimated size 1,118
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 4,96,628
1,86,247 2,37,895 6,153 4,30,295
Clients managed 4. Tested for HIV (April 2022-September 2022) 946
3. RPR Tests 4.1. HIV sero-positive (%) 2.33
62,772 83,418 11,573 1,57,763
conducted 4.1.1. Linked to ART 17
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 1,014
0.55 0.20 0.54 0.37
seropositivity (%)
5.1. HIV sero-positive (%) 0.99
5.1.1. Linked to ART 12
4. Prevention of new HIV infections among 6. Clinic Visits 3,905
high-risk group and bridge population
7. STI/RTI treated 64
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 343
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 44 Indicator 2022-23
2. OST centres 6 1. Estimated size 2,31,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 30,715
Indicator 2022-23
3.1. HIV sero-positive (%) 0.07
1. Estimated size 18,375
3.2. Linked to ART 115
2. Coverage (%) ≥95
3. Condoms distributed 74,32,834 G. Truckers
4. Tested for HIV (April 2022-September 2022) 15,181 Indicator 2022-23
4.1. HIV sero-positive (%) 0.36 1. Estimated size 62,000
4.1.1. Linked to ART 40 2. Coverage (%) 89.00
5. Tested for HIV (October 2022 -March 2023) 17,078 3. Tested for HIV 27,403
5.1. HIV sero-positive (%) 0.37 3.1. HIV sero-positive (%) 0.16
5.1.1. Linked to ART 52 3.2. On ART 35
6. Clinic Visits 61,555
H. Prison Inmates
7. STI/RTI treated 2,249
Indicator 2022-23
8. Presumptive treatment 4,375
1. Total prisons 33
C. Men who have Sex with Men 2. Prisons covered under programme 33
Indicator 2022-23 3. Total inmates admitted 62,625
1. Estimated size 2,889 4. Inmates Covered (%) 31
2. Coverage (%) ≥95 5. Tested for HIV 19,498
3. Condoms distributed 12,79,436 5.1. HIV sero-positive (%) 0.21
4. Tested for HIV (April 2022-September 2022) 2,549 5.2. On ART (%) 75.61
4.1. HIV sero-positive (%) 1.33
I. Link Worker Scheme
4.1.1. Linked to ART 27
5. Tested for HIV (October 2022 -March 2023) 2,979 Indicator 2022-23
5.1. HIV sero-positive (%) 0.94 1. Districts covered under scheme 6
5.1.1. Linked to ART 21 2. Vulnerable population covered 71,855
6. Clinic Visits 10,539 3. Tested for HIV 58,886
7. STI/RTI treated 163 3.1. HIV sero-positive (%) 0.20
8. Presumptive treatment 1,302 3.2. Linked to ART (%) 97.5

196 Sankalak: Status of National AIDS & STD Response (2023)

 CHHATTISGARH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 6
1.1. OSTC in Public Health Settings 6 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 0
2. IDU on OST 1,047
2. Viral load testing conducted 14,346
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 90.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 844 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 147 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 643 5. CD4 testing conducted 3,677
1.3. Facility integrated (PPP) 11
6. External Quality Assessment of ICTC
1.4. CBS 43
1.5. SSK - 6.1 Average Participation (%) 75.7
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 4
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 2,73,061 3,02,823 1,308 5,77,192
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
1,857 931 34 2,822
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.68 0.31 2.60 0.49 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 7,17,190
partner testing of
745 1,344 6 2,095 2. HIV testing among PW 5,44,987
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.04
5. No. of contacts with 4. HIV Positive PW (old + new detections) 400
‘at-risk’ population
- - - - 4.1 On life-long ART 371
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 285

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 316
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 8 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 195
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 11
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 14
3. Link ART Centres 22
4. Care Support Centres 3
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 5,52,940
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.08
1. HIV positive cases 3. Put on treatment 400
1,857 1,158 34 3,049
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 1,678 1,067 22 2,767 Stigma and Discrimination
centre
2.1 Initiated on ART 1,436 949 21 2,406 A. HIV
3. PLHIV alive and
10,889 8,896 135 19,920 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 55.6 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 2,410 1,696 15 4,121 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 197

CHHATTISGARH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 10,825 2,010 2,194 833 7,992 5,540 29,394

Quarter 2 11,903 2,258 2,531 1,080 10,373 7,756 35,901

Screened for TB
Quarter 3 12,506 2,554 2,600 991 13,708 8,356 40,715

Quarter 4 15,531 3,141 3,159 1,140 19,486 17,912 60,369

Quarter 1 225 35 6 20 52 40 378

Quarter 2 308 45 13 20 128 91 605

Tested for TB
Quarter 3 246 32 8 17 66 65 434

Quarter 4 360 26 13 10 189 102 700

Quarter 1 14 - - - - 1 15

Quarter 2 11 3 - 2 1 - 17
Diagnosed with TB
Quarter 3 16 2 - - 1 1 20

Quarter 4 9 1 - - - - 10

Quarter 1 13 - - - - 1 14

Initiated on TB Quarter 2 10 - - - 1 - 11
treatment
Quarter 3 13 2 - - 1 1 17

Quarter 4 9 1 - - - - 10

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 23,543

1.1. HIV sero-positive (%) 1.31

1.2. ICTC clients referred to NTEP 28,059

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 9,100 8,775 328 234 46 111

May-22 9,410 9,211 320 262 56 54

Jun-22 8,776 8,476 344 327 35 60

Jul-22 9,567 9,446 330 294 35 93

Aug-22 10,621 10,371 313 257 30 93

Sep-22 10,868 10,620 306 280 27 58

Oct-22 11,722 11,299 335 269 30 56

Nov-22 11,737 11,227 357 261 24 121

Dec-22 10,904 10,704 442 259 41 305

Jan-23 10,713 10,232 383 247 26 260

Feb-23 10,935 10,343 230 216 29 44

Mar-23 10,441 9,566 296 271 45 21

April 2022-March 2023 509 469

198 Sankalak: Status of National AIDS & STD Response (2023)

 CHHATTISGARH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Chhattisgarh

Rank 28
Sl. No.
Max Marks 120

Obtained Marks (%) 80 (67)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) G
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) R
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 G
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) R

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 199

DAMAN & DIU
AND
DADRA &
NAGAR HAVELI
DAMAN & DIU
AND
DADRA &
NAGAR HAVELI
1. Status of HIV/AIDS Epidemic
A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 5.00
2. IMR - - 4.05
3. Adult (15-49 yrs) HIV Prevalence (%) 0.20 0.16 0.19
4. Estimated people living with HIV 1,233 466 1,699
5. ART coverage (%) 17.8 26.0 20.0
6. Estimated children living with HIV 135 ≤50 178
7. Annual new HIV infections 62 ≤50 85
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 ≤50
9. Change in annual new HIV infections since 2010 (%) 29.2 0.00 19.7
10. Change in annual ARD since 2010 (%) -50.0 -54.55 -51.6
11. EMTCT need - 10 10

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers - - - -
2. Men who have Sex with Men - - - -
3. Injecting Drug Users - - - -
4. Hijra/Transgender People - - - -
5. Migrants 1,34,800 - - -
6. Truckers 81,640 - - -
7. Prison inmates 485 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 28.1 25.3 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 31.1 24.6 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 55.7 82.3 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 77.4 73.5 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 7.3 0.0 -
5.1 Condom use during last higher-risk intercourse (%) 84 - -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 6.5 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 100.0 - -

2. Progress on 95-95-95 (2022-23)

95 95 Indicator (2022-23) Male Female Total
82 80
1. Estimated PLHIV size (2022) 1,233 466 1,699

2. PLHIV who know their HIV Status 219 121 340

15 20
0 0 0 0 0 0 0 0 0 3. PLHIV who know their HIV status and are on ART 219 121 340
PLHIV who know PLHIV who know PLHIV who are on
their HIV status (%) their HIV status and ART and virally 4. PLHIV who are on ART and tested for their viral load 127 72 199
are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 104 55 159
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 201

DAMAN & DIU AND DADRA & NAGAR HAVELI

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size -
A. Information, Education, Communication,
2. Coverage (%) -
Youth and Mainstreaming
3. Needles distributed 0
Indicator 2022-23 4. Syringes distributed 0
1. Schools with operational Adolescent Education 5. On OST 0
65
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 0
2. Colleges with operational Red Ribbon Clubs (RRC) 17 6.1. HIV sero-positive (%) -
3. Persons trained under mainstreaming 2,761 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 0
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) -
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 0
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 4 1. Estimated size -
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) -
2. Total STI/RTI 3. Condoms distributed 0
2,721 3,243 - 5,964
Clients managed 4. Tested for HIV (April 2022-September 2022) 0
3. RPR Tests 4.1. HIV sero-positive (%) -
2,624 2,910 - 5,534
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 0
1.75 0.89 - 1.30
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 0
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 0
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects - Indicator 2022-23
2. OST centres - 1. Estimated size 1,34,800
2. Coverage (%) 0.00
B. Female Sex Workers
3. Tested for HIV 0.00
Indicator 2022-23
3.1. HIV sero-positive (%) 0.00
1. Estimated size -
3.2. Linked to ART -
2. Coverage (%) -
3. Condoms distributed - G. Truckers
4. Tested for HIV (April 2022-September 2022) - Indicator 2022-23
4.1. HIV sero-positive (%) - 1. Estimated size 81,640
4.1.1. Linked to ART 0 2. Coverage (%) 0
5. Tested for HIV (October 2022 -March 2023) - 3. Tested for HIV 0
5.1. HIV sero-positive (%) - 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 0 3.2. On ART 0
6. Clinic Visits -
H. Prison Inmates
7. STI/RTI treated -
Indicator 2022-23
8. Presumptive treatment -
1. Total prisons 2
C. Men who have Sex with Men 2. Prisons covered under programme 2
Indicator 2022-23 3. Total inmates admitted 442
1. Estimated size - 4. Inmates Covered (%) 48
2. Coverage (%) - 5. Tested for HIV 250
3. Condoms distributed 0 5.1. HIV sero-positive (%) 0.40
4. Tested for HIV (April 2022-September 2022) 0 5.2. On ART (%) 100.00
4.1. HIV sero-positive (%) -
I. Link Worker Scheme
4.1.1. Linked to ART 0
5. Tested for HIV (October 2022 -March 2023) 0 Indicator 2022-23
5.1. HIV sero-positive (%) - 1. Districts covered under scheme -
5.1.1. Linked to ART 0 2. Vulnerable population covered -
6. Clinic Visits 0 3. Tested for HIV -
7. STI/RTI treated 0 3.1. HIV sero-positive (%) -
8. Presumptive treatment 0 3.2. Linked to ART (%) -

202 Sankalak: Status of National AIDS & STD Response (2023)

 DAMAN & DIU AND DADRA & NAGAR HAVELI

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres -
1.1. OSTC in Public Health Settings - Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST -
2. Viral load testing conducted 212
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 78.7

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 27 4. State reference laboratories (SRL) -
1.1. Stand-Alone 6 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 15 5. CD4 testing conducted -
1.3. Facility integrated (PPP) 4
6. External Quality Assessment of ICTC
1.4. CBS 2
1.5. SSK - 6.1 Average Participation (%) -
6.2. Average Discordance (%) -
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 -
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 32,020 24,579 - 56,599
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
40 15 - 55
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.12 0.06 - 0.10 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 24,650
partner testing of
18 14 - 32 2. HIV testing among PW 21,216
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 7
‘at-risk’ population
- - - - 4.1 On life-long ART 6
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 3

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 4
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 1 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 1
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres -
4. Care Support Centres -
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 26,857
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.02
1. HIV positive cases 3. Put on treatment 5
40 21 - 61
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 36 22 - 58 Stigma and Discrimination
centre
2.1 Initiated on ART 36 22 - 58 A. HIV
3. PLHIV alive and
219 121 - 340 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 85.4 Control Act (2017)
on ART (%)
5. Lost to follow-up cases - - - - 2. State designated/appointed ombudsman -

Sankalak: Status of National AIDS & STD Response (2023) 203

DAMAN & DIU AND DADRA & NAGAR HAVELI

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Screened for TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Tested for TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 2,719

1.1. HIV sero-positive (%) 0.04

1.2. ICTC clients referred to NTEP 331

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 218 218 1 1 1 -

May-22 225 225 1 1 1 -

Jun-22 209 209 1 1 1 3

Jul-22 - 228 - - - 3

Aug-22 232 232 - - - 2

Sep-22 245 245 2 2 2 12

Oct-22 60 60 - - - 2

Nov-22 107 107 - - - 3

Dec-22 113 113 - - - 6

Jan-23 118 118 - - - 4

Feb-23 223 223 - - - 3

Mar-23 249 249 2 2 4 6

April 2022-March 2023 9 7

204 Sankalak: Status of National AIDS & STD Response (2023)

 DAMAN & DIU AND DADRA & NAGAR HAVELI

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT DNH & DD

Rank 23
Sl. No.
Max Marks 84

Obtained Marks (%) 57 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) G
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) R
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) NA
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) NA
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) NA
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) NA
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) NA
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) NA
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) NA
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) NA
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) NA
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) NA
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) NA
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) R
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) R
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) R
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 205

DELHI
DELHI

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 5.06
2. IMR - - 2.06
3. Adult (15-49 yrs) HIV Prevalence (%) 0.37 0.26 0.32
4. Estimated people living with HIV 36,387 22,176 58,563
5. ART coverage (%) 70.6 61.9 68.1
6. Estimated children living with HIV 2,089 1,558 3,647
7. Annual new HIV infections 1,774 1,186 2,960
8. Annual AIDS-related deaths (ARD) 598 522 1,121
9. Change in annual new HIV infections since 2010 (%) -19.1 -8.06 -15.0
10. Change in annual ARD since 2010 (%) 1.2 57.70 21.6
11. EMTCT need - 383 383

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 88,399 58.6 68.3 0.81
2. Men who have Sex with Men 27,026 42.2 37 2.59
3. Injecting Drug Users 32,481 35.0 90.8 15.87
4. Hijra/Transgender People 17,907 48.9 - 3.6
5. Migrants 2,77,822 - - 0.75
6. Truckers 60,000 - - 0.80
7. Prison inmates 75,472 40.9 28.6 2.45

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 43.8 29.5 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 36.3 25.1 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 85.9 80 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 80.3 73.2 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 7.2 0.6 -
5.1 Condom use during last higher-risk intercourse (%) 72.8 86.5 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 11.4 0.8 -
6.1 Condom use during last higher-risk intercourse (%) 70.0 100.0 -

2. Progress on 95-95-95 (2022-23)

94 95 Indicator (2022-23) Male Female Total
84 90 89 90 87 88 88
75 74 71 72 72 75
1. Estimated PLHIV size (2022) 36,387 22,176 58,563

2. PLHIV who know their HIV Status 37,059 17,409 55,104

3. PLHIV who know their HIV status and are on ART 25,702 13,724 39,856
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 8,941 14,915 24,079
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 8,735 14,422 23,375
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 207

DELHI

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 32,481
A. Information, Education, Communication,
2. Coverage (%) 39
Youth and Mainstreaming
3. Needles distributed 48,96,034
Indicator 2022-23 4. Syringes distributed 24,49,493
1. Schools with operational Adolescent Education 5. On OST 1,953
-
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 8,908
2. Colleges with operational Red Ribbon Clubs (RRC) 84 6.1. HIV sero-positive (%) 0.77
3. Persons trained under mainstreaming 60 6.1.1 Linked to ART 59
7. Tested for HIV (October 2022 -March 2023) 10,840
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.47
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 40
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 28 1. Estimated size 17,907
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 66
2. Total STI/RTI 3. Condoms distributed 23,34,467
40,505 91,703 88 1,32,296
Clients managed 4. Tested for HIV (April 2022-September 2022) 8,739
3. RPR Tests 4.1. HIV sero-positive (%) 0.17
26,044 51,687 47 77,778
conducted 4.1.1. Linked to ART 13
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 9,574
4.33 0.81 17.02 2.00
seropositivity (%)
5.1. HIV sero-positive (%) 0.18
5.1.1. Linked to ART 18
4. Prevention of new HIV infections among 6. Clinic Visits 33,799
high-risk group and bridge population
7. STI/RTI treated 144
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 663
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 79 Indicator 2022-23
2. OST centres 8 1. Estimated size 2,77,822
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 63,830
Indicator 2022-23
3.1. HIV sero-positive (%) 0.16
1. Estimated size 88,399
3.2. Linked to ART -
2. Coverage (%) 56.14
3. Condoms distributed 22,05,686 G. Truckers
4. Tested for HIV (April 2022-September 2022) 36,976 Indicator 2022-23
4.1. HIV sero-positive (%) 0.08 1. Estimated size 60,000
4.1.1. Linked to ART 26 2. Coverage (%) 58
5. Tested for HIV (October 2022 -March 2023) 39,402 3. Tested for HIV 5,665
5.1. HIV sero-positive (%) 0.06 3.1. HIV sero-positive (%) 0.07
5.1.1. Linked to ART 20 3.2. On ART 2
6. Clinic Visits 1,47,551
H. Prison Inmates
7. STI/RTI treated 2,450
Indicator 2022-23
8. Presumptive treatment 4,581
1. Total prisons 16
C. Men who have Sex with Men 2. Prisons covered under programme 15
Indicator 2022-23 3. Total inmates admitted 63,161
1. Estimated size 27,026 4. Inmates Covered (%) 36
2. Coverage (%) 69 5. Tested for HIV 18,857
3. Condoms distributed 34,51,085 5.1. HIV sero-positive (%) 1.81
4. Tested for HIV (April 2022-September 2022) 13,800 5.2. On ART (%) 81.82
4.1. HIV sero-positive (%) 0.21
I. Link Worker Scheme
4.1.1. Linked to ART 24
5. Tested for HIV (October 2022 -March 2023) 16,043 Indicator 2022-23
5.1. HIV sero-positive (%) 0.26 1. Districts covered under scheme -
5.1.1. Linked to ART 39 2. Vulnerable population covered -
6. Clinic Visits 55,492 3. Tested for HIV -
7. STI/RTI treated 191 3.1. HIV sero-positive (%) -
8. Presumptive treatment 1,468 3.2. Linked to ART (%) -

208 Sankalak: Status of National AIDS & STD Response (2023)

 DELHI

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 8
1.1. OSTC in Public Health Settings 8 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 2
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 1
2. IDU on OST 1,953
2. Viral load testing conducted 27,918
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 95.1

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 2
3.1 Accredited NRL 2
Indicator 2022-23
1. HCTC facilities 618 4. State reference laboratories (SRL) 4
1.1. Stand-Alone 90 4.1 Accredited SRL 4
1.2. Facility integrated (Govt.) 416 5. CD4 testing conducted 28,477
1.3. Facility integrated (PPP) 30
6. External Quality Assessment of ICTC
1.4. CBS 82
1.5. SSK 5 6.1 Average Participation (%) 98.1
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 4
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 2,75,546 2,32,239 4,765 5,12,550
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
4,802 1,290 80 6,172
among tested A. HIV
3. HIV sero-positivity
(%) among tested
1.74 0.56 1.68 1.20 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 3,53,740
partner testing of
2,934 662 17 3,613 2. HIV testing among PW 2,43,933
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.08
5. No. of contacts with 4. HIV Positive PW (old + new detections) 373
‘at-risk’ population
- - - - 4.1 On life-long ART 299
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 189

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 98.41
infected people 6. Babies tested HIV (6 week- 6 month) 233
A. Treatment facilities 6.1 Babies confirmed HIV Positive 4
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 12 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 187
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 4
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 10
3. Link ART Centres -
4. Care Support Centres 5
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 2,38,633
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.05
1. HIV positive cases 3. Put on treatment 109
4,802 1,494 80 6,376
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 3,864 1,191 34 5,089 Stigma and Discrimination
centre
2.1 Initiated on ART 3,580 1,118 32 4,730 A. HIV
3. PLHIV alive and
25,702 13,724 430 39,856 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 75.6 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 10,840 3,495 227 14,562 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 209

DELHI

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 37,412 13,888 10,625 8,452 28,414 4,600 1,03,391

Quarter 2 38,892 14,219 10,927 8,054 31,137 4,552 1,07,781

Screened for TB
Quarter 3 39,090 14,951 10,850 8,333 29,367 4,594 1,07,185

Quarter 4 42,127 17,183 11,234 10,339 30,027 4,529 1,15,439

Quarter 1 269 53 35 3 109 66 535

Quarter 2 238 63 36 2 170 51 560

Tested for TB
Quarter 3 237 92 27 4 168 49 577

Quarter 4 327 70 50 5 163 37 652

Quarter 1 34 1 3 - 3 - 41

Quarter 2 12 - - - 2 - 14
Diagnosed with TB
Quarter 3 8 2 1 2 5 - 18

Quarter 4 43 2 3 2 8 - 58

Quarter 1 24 1 3 - 3 - 31

Initiated on TB Quarter 2 12 - - - 2 - 14
treatment
Quarter 3 12 2 1 2 5 - 22

Quarter 4 28 2 3 2 8 - 43

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 88,858

1.1. HIV sero-positive (%) 0.64

1.2. ICTC clients referred to NTEP 12,879

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 20,093 19,748 322 215 119 265

May-22 20,284 19,929 361 217 113 290

Jun-22 20,629 19,155 373 248 110 487

Jul-22 20,774 19,632 422 308 102 686

Aug-22 20,774 19,632 422 308 102 686

Sep-22 22,494 20,992 468 331 102 1,655

Oct-22 21,959 19,507 410 258 69 701

Nov-22 21,545 20,153 437 278 89 577

Dec-22 22,696 21,307 1,007 234 80 411

Jan-23 22,232 20,581 467 248 63 677

Feb-23 21,279 19,607 426 215 75 215

Mar-23 23,894 22,139 435 340 77 318

April 2022-March 2023 1,495 1,415

210 Sankalak: Status of National AIDS & STD Response (2023)

 DELHI

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Delhi

Rank 30
Sl. No.
Max Marks 117

Obtained Marks (%) 75 (64)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) Y
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) R
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) G
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) R
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 G
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) R

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 211

GOA
GOA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 2.44
2. IMR - - 1.42
3. Adult (15-49 yrs) HIV Prevalence (%) 0.31 0.29 0.30
4. Estimated people living with HIV 2,432 2,159 4,591
5. ART coverage (%) 73.0 78.6 75.7
6. Estimated children living with HIV 165 149 314
7. Annual new HIV infections 57 55 112
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 53
9. Change in annual new HIV infections since 2010 (%) -5.0 12.24 2.8
10. Change in annual ARD since 2010 (%) -89.0 -91.67 -90.0
11. EMTCT need - 33 33

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 5,040 81.8 10.5 0.6
2. Men who have Sex with Men 3,339 73.4 51.8 2.4
3. Injecting Drug Users 302 48.3 62.7 0
4. Hijra/Transgender People 132 - - -
5. Migrants 35,000 - - -
6. Truckers 23,000 - - -
7. Prison inmates 1,647 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 67.2 49 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 72.8 52.9 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 79.8 80.1 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 83 79.8 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 8.8 5.2 -
5.1 Condom use during last higher-risk intercourse (%) 96.6 100 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 15.1 2.8 -
6.1 Condom use during last higher-risk intercourse (%) 92.3 100.0 -

2. Progress on 95-95-95 (2022-23)

91 91 91 90 89
86 86 89
95 Indicator (2022-23) Male Female Total
81 85 79
74 77 77
1. Estimated PLHIV size (2022) 2,432 2,159 4,591

2. PLHIV who know their HIV Status 2,058 1,825 3,890

3. PLHIV who know their HIV status and are on ART 1,776 1,696 3,477
PLHIV who know PLHIV who know PLHIV who are on 4. PLHIV who are on ART and tested for their viral load 1,374 1,424 2,801
their HIV status (%) their HIV status ART and virally
and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 1,302 1,355 2,660
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 213

GOA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 302
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 80,844
Indicator 2022-23 4. Syringes distributed 80,844
1. Schools with operational Adolescent Education 5. On OST 68
520
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 399
2. Colleges with operational Red Ribbon Clubs (RRC) 169 6.1. HIV sero-positive (%) 0.00
3. Persons trained under mainstreaming 1,050 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 537
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.00
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 0
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 4 1. Estimated size 132
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 83
2. Total STI/RTI 3. Condoms distributed 87,334
24,552 23,176 179 47,907
Clients managed 4. Tested for HIV (April 2022-September 2022) 39
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
2,468 2,446 2 4,916
conducted 4.1.1. Linked to ART 1
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 56
5.02 0.61 50.00 2.85
seropositivity (%)
5.1. HIV sero-positive (%) 3.57
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 293
high-risk group and bridge population
7. STI/RTI treated 10
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 0
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 15 Indicator 2022-23
2. OST centres 1 1. Estimated size 35,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 7,416
Indicator 2022-23
3.1. HIV sero-positive (%) 0.11
1. Estimated size 5,040
3.2. Linked to ART -
2. Coverage (%) ≥95
3. Condoms distributed 17,73,810 G. Truckers
4. Tested for HIV (April 2022-September 2022) 4,748 Indicator 2022-23
4.1. HIV sero-positive (%) 0.02 1. Estimated size 23,000
4.1.1. Linked to ART 0 2. Coverage (%) 43
5. Tested for HIV (October 2022 -March 2023) 5,147 3. Tested for HIV 2,175
5.1. HIV sero-positive (%) 0.00 3.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0 3.2. On ART 0
6. Clinic Visits 18,886
H. Prison Inmates
7. STI/RTI treated 192
Indicator 2022-23
8. Presumptive treatment 486
1. Total prisons 1
C. Men who have Sex with Men 2. Prisons covered under programme 1
Indicator 2022-23 3. Total inmates admitted 1,677
1. Estimated size 3,339 4. Inmates Covered (%) 79
2. Coverage (%) ≥95 5. Tested for HIV 686
3. Condoms distributed 8,63,510 5.1. HIV sero-positive (%) 0.87
4. Tested for HIV (April 2022-September 2022) 3,447 5.2. On ART (%) 83.33
4.1. HIV sero-positive (%) 0.15
I. Link Worker Scheme
4.1.1. Linked to ART 3
5. Tested for HIV (October 2022 -March 2023) 3,701 Indicator 2022-23
5.1. HIV sero-positive (%) 0.03 1. Districts covered under scheme -
5.1.1. Linked to ART 0 2. Vulnerable population covered -
6. Clinic Visits 13,427 3. Tested for HIV -
7. STI/RTI treated 122 3.1. HIV sero-positive (%) -
8. Presumptive treatment 0 3.2. Linked to ART (%) -

214 Sankalak: Status of National AIDS & STD Response (2023)

 GOA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 1
1.1. OSTC in Public Health Settings - Indicator 2022-23
1.2. OSTC in NGO Settings 1 1. Viral load laboratories -
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 68
2. Viral load testing conducted 3,072
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 93.8

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 69 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 16 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 25 5. CD4 testing conducted 1,326
1.3. Facility integrated (PPP) 12
6. External Quality Assessment of ICTC
1.4. CBS 16
1.5. SSK - 6.1 Average Participation (%) 100.0
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 9
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 53,736 36,613 79 90,428
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
177 76 1 254
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.33 0.21 1.27 0.28 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 20,910
partner testing of
116 76 - 192 2. HIV testing among PW 29,993
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.05
5. No. of contacts with 4. HIV Positive PW (old + new detections) 31
‘at-risk’ population
- - - - 4.1 On life-long ART 29
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 28

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 24
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 2 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 13
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres 3
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 37,932
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.03
1. HIV positive cases 3. Put on treatment 11
177 92 1 270
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 172 88 1 261 Stigma and Discrimination
centre
2.1 Initiated on ART 156 78 - 234 A. HIV
3. PLHIV alive and
1,776 1,696 4 3,477 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 58.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 279 163 2 444 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 215

GOA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 4,433 2,210 302 54 2,243 2,424 11,666

Quarter 2 4,445 2,573 284 69 2,115 2,303 11,789

Screened for TB
Quarter 3 4,539 2,563 323 64 2,346 2,332 12,167

Quarter 4 4,203 2,456 419 64 2,365 1,976 11,483

Quarter 1 1 - - - - - 1

Quarter 2 3 2 - - - - 5
Tested for TB
Quarter 3 1 - - - - - 1

Quarter 4 - - - 1 - - 1

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - 1 - - 1

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - 1 - - 1

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 4,457

1.1. HIV sero-positive (%) 0.65

1.2. ICTC clients referred to NTEP 2,975

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 2,334 2,044 16 12 - 16

May-22 2,336 2,141 18 11 - 32

Jun-22 2,227 1,910 34 32 3 21

Jul-22 2,272 2,025 29 26 3 25

Aug-22 2,575 2,265 37 32 2 23

Sep-22 2,793 2,450 27 27 1 9

Oct-22 2,958 2,570 13 13 2 12

Nov-22 2,595 2,327 12 12 - 12

Dec-22 2,420 2,133 17 12 1 7

Jan-23 2,619 2,199 15 12 - 12

Feb-23 2,709 2,386 12 12 1 17

Mar-23 3,124 2,741 34 21 3 8

April 2022-March 2023 75 69

216 Sankalak: Status of National AIDS & STD Response (2023)

 GOA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Goa

Rank 8
Sl. No.
Max Marks 120

Obtained Marks (%) 87 (73)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) Y
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) Y
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) Y
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 217

GUJARAT
GUJARAT

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 2.09
2. IMR - - 1.24
3. Adult (15-49 yrs) HIV Prevalence (%) 0.20 0.16 0.18
4. Estimated people living with HIV 66,322 48,859 1,15,180
5. ART coverage (%) 75.5 70.5 73.7
6. Estimated children living with HIV 3,464 2,901 6,365
7. Annual new HIV infections 1,296 1,112 2,408
8. Annual AIDS-related deaths (ARD) 424 433 857
9. Change in annual new HIV infections since 2010 (%) -58.9 -56.63 -57.9
10. Change in annual ARD since 2010 (%) -74.3 -67.20 -71.1
11. EMTCT need - 1,120 1,120

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 37,118 69.6 67.7 1.34
2. Men who have Sex with Men 34,299 79.1 41.2 4.61
3. Injecting Drug Users 779 74.6 79.4 2
4. Hijra/Transgender People 2,605 67.6 - 3.6
5. Migrants 13,14,462 - - 0.13
6. Truckers 1,20,000 - - 0.30
7. Prison inmates 92,697 61.5 14.3 0.88

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 35.7 28.5 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 33.4 27.2 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 87.9 86.3 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 72.4 70.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5.5 0.7 -
5.1 Condom use during last higher-risk intercourse (%) 42.9 51.2 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 8.7 1.5 -
6.1 Condom use during last higher-risk intercourse (%) 45.5 52.2 -

2. Progress on 95-95-95 (2022-23)

85 88 87 85 86 87 86 85 84
93 Indicator (2022-23) Male Female Total
76 79 80 81 72
1. Estimated PLHIV size (2022) 66,322 48,859 1,15,180

2. PLHIV who know their HIV Status 58,189 39,213 97,867

3. PLHIV who know their HIV status and are on ART 50,067 34,440 84,887
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 30,127 33,473 63,767
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 27,798 31,269 59,224
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 219

GUJARAT

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 779
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 1,42,571
Indicator 2022-23 4. Syringes distributed 1,42,571
1. Schools with operational Adolescent Education 5. On OST 80
10,266
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 816
2. Colleges with operational Red Ribbon Clubs (RRC) 451 6.1. HIV sero-positive (%) 0.12
3. Persons trained under mainstreaming 17,797 6.1.1 Linked to ART 1
7. Tested for HIV (October 2022 -March 2023) 878
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.23
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 1
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 66 1. Estimated size 2,605
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 69
2. Total STI/RTI 3. Condoms distributed 3,51,388
3,70,010 2,07,076 6,201 5,83,287
Clients managed 4. Tested for HIV (April 2022-September 2022) 1,518
3. RPR Tests 4.1. HIV sero-positive (%) 0.33
59,021 88,010 116 1,47,147
conducted 4.1.1. Linked to ART 5
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 1,541
3.17 0.67 13.79 1.68
seropositivity (%)
5.1. HIV sero-positive (%) 0.19
5.1.1. Linked to ART 3
4. Prevention of new HIV infections among 6. Clinic Visits 6,601
high-risk group and bridge population
7. STI/RTI treated 23
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 148
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 95 Indicator 2022-23
2. OST centres 2 1. Estimated size 13,14,462
2. Coverage (%) 69
B. Female Sex Workers
3. Tested for HIV 62,065
Indicator 2022-23
3.1. HIV sero-positive (%) 0.09
1. Estimated size 37,118
3.2. Linked to ART 64
2. Coverage (%) 82.50
3. Condoms distributed 1,30,27,067 G. Truckers
4. Tested for HIV (April 2022-September 2022) 26,190 Indicator 2022-23
4.1. HIV sero-positive (%) 0.08 1. Estimated size 1,20,000
4.1.1. Linked to ART 18 2. Coverage (%) 46
5. Tested for HIV (October 2022 -March 2023) 27,486 3. Tested for HIV 6,455
5.1. HIV sero-positive (%) 0.08 3.1. HIV sero-positive (%) 0.22
5.1.1. Linked to ART 21 3.2. On ART 14
6. Clinic Visits 1,07,575
H. Prison Inmates
7. STI/RTI treated 1,497
Indicator 2022-23
8. Presumptive treatment 4,250
1. Total prisons 32
C. Men who have Sex with Men 2. Prisons covered under programme 31
Indicator 2022-23 3. Total inmates admitted 77,137
1. Estimated size 34,299 4. Inmates Covered (%) 35
2. Coverage (%) 86 5. Tested for HIV 16,773
3. Condoms distributed 85,51,816 5.1. HIV sero-positive (%) 0.25
4. Tested for HIV (April 2022-September 2022) 25,415 5.2. On ART (%) 80.95
4.1. HIV sero-positive (%) 0.20
I. Link Worker Scheme
4.1.1. Linked to ART 46
5. Tested for HIV (October 2022 -March 2023) 25,400 Indicator 2022-23
5.1. HIV sero-positive (%) 0.14 1. Districts covered under scheme 16
5.1.1. Linked to ART 37 2. Vulnerable population covered 1,07,107
6. Clinic Visits 1,05,040 3. Tested for HIV 56,212
7. STI/RTI treated 1,020 3.1. HIV sero-positive (%) 0.12
8. Presumptive treatment 3,390 3.2. Linked to ART (%) 91.4

220 Sankalak: Status of National AIDS & STD Response (2023)

 GUJARAT

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 1
1.1. OSTC in Public Health Settings 1 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 4
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 2
2. IDU on OST 28
2. Viral load testing conducted 74,644
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 90.1

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 2,753 4. State reference laboratories (SRL) 5
1.1. Stand-Alone 322 4.1 Accredited SRL 5
1.2. Facility integrated (Govt.) 2,066 5. CD4 testing conducted 47,247
1.3. Facility integrated (PPP) 198
6. External Quality Assessment of ICTC
1.4. CBS 167
1.5. SSK 13 6.1 Average Participation (%) 93.3
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 8,82,438 7,42,272 3,002 16,27,712
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
5,162 2,195 51 7,408
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.58 0.30 1.70 0.46 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 10,93,130
partner testing of
1,374 2,523 15 3,912 2. HIV testing among PW 12,23,697
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.04
5. No. of contacts with 4. HIV Positive PW (old + new detections) 1,025
‘at-risk’ population
349 583 1 933 4.1 On life-long ART 966
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 824

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 874
A. Treatment facilities 6.1 Babies confirmed HIV Positive 3
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 47 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 514
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 20
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 15
3. Link ART Centres 66
4. Care Support Centres 25
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 13,31,495
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.04
1. HIV positive cases 3. Put on treatment 536
5,162 2,697 51 7,910
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 4,973 2,605 59 7,637 Stigma and Discrimination
centre
2.1 Initiated on ART 4,625 2,468 56 7,149 A. HIV
3. PLHIV alive and
50,067 34,440 380 84,887 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 71.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 6,182 3,473 75 9,730 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 221

GUJARAT

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 19,997 23,040 807 1,670 30,799 11,655 87,968

Quarter 2 21,437 22,176 720 1,699 31,591 10,956 88,579

Screened for TB
Quarter 3 21,698 22,699 708 1,711 29,845 10,668 87,329

Quarter 4 24,483 23,702 807 1,795 31,171 12,283 94,241

Quarter 1 702 1,046 20 76 303 78 2,225

Quarter 2 757 1,390 14 133 325 95 2,714

Tested for TB
Quarter 3 829 1,348 12 135 389 99 2,812

Quarter 4 816 1,162 20 228 256 123 2,605

Quarter 1 5 5 - - 12 1 23

Quarter 2 - 1 - - 8 2 11
Diagnosed with TB
Quarter 3 1 6 1 1 11 - 20

Quarter 4 5 3 - - 6 - 14

Quarter 1 6 5 - - 9 1 21

Initiated on TB Quarter 2 - 1 - - 8 2 11
treatment
Quarter 3 1 6 1 1 10 - 19

Quarter 4 5 3 - - 7 - 15

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,57,289

1.1. HIV sero-positive (%) 0.42

1.2. ICTC clients referred to NTEP 1,05,537

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 44,120 43,838 2,991 2,977 209 601

May-22 44,112 43,463 3,223 3,201 232 563

Jun-22 46,488 45,658 3,412 3,124 235 758

Jul-22 45,477 44,801 3,304 3,255 182 754

Aug-22 43,365 42,593 3,202 3,166 161 664

Sep-22 56,623 55,222 3,371 3,310 175 616

Oct-22 54,607 53,855 2,971 2,896 152 362

Nov-22 56,868 56,289 3,790 3,735 205 565

Dec-22 59,507 58,486 3,844 3,610 188 607

Jan-23 57,709 56,669 3,407 3,371 160 589

Feb-23 52,632 52,108 3,312 3,300 184 512

Mar-23 56,951 56,410 3,599 3,531 183 511

April 2022-March 2023 2,581 2,436

222 Sankalak: Status of National AIDS & STD Response (2023)

 GUJARAT

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Gujarat

Rank 9
Sl. No.
Max Marks 117

Obtained Marks (%) 84 (72)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) R
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) Y
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) G
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 223

HARYANA
HARYANA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.87
2. IMR - - 2.59
3. Adult (15-49 yrs) HIV Prevalence (%) 0.28 0.17 0.23
4. Estimated people living with HIV 34,885 19,574 54,459
5. ART coverage (%) 52.0 59.7 54.9
6. Estimated children living with HIV 2,766 1,484 4,250
7. Annual new HIV infections 1,403 707 2,110
8. Annual AIDS-related deaths (ARD) 285 89 375
9. Change in annual new HIV infections since 2010 (%) -40.5 -41.33 -40.8
10. Change in annual ARD since 2010 (%) -79.7 -86.37 -81.8
11. EMTCT need - 512 512

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 17,668 66.2 37.8 1.33
2. Men who have Sex with Men 8,022 48.9 29.9 6.89
3. Injecting Drug Users 19,025 53.6 90.7 9.24
4. Hijra/Transgender People 1,435 - - -
5. Migrants 1,31,755 - - -
6. Truckers 15,000 - - -
7. Prison inmates 78,049 64.3 57.6 1.63

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 36.4 19.7 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 31.7 17.5 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 84.5 75.2 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 78.9 64.3 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 6.7 0.2 -
5.1 Condom use during last higher-risk intercourse (%) 70.1 35 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 10.9 0.4 -
6.1 Condom use during last higher-risk intercourse (%) 65.3 20.0 -

2. Progress on 95-95-95 (2022-23)

87 82 78 87 Indicator (2022-23) Male Female Total
77 72 80
70
63 63
54 51 1. Estimated PLHIV size (2022) 34,885 19,574 54,459
43 47
35
2. PLHIV who know their HIV Status 20,773 13,342 34,218

3. PLHIV who know their HIV status and are on ART 18,126 11,685 29,902
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 8,655 6,976 15,667
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 7,380 6,193 13,603
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 225

HARYANA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 19,025
A. Information, Education, Communication,
2. Coverage (%) 31
Youth and Mainstreaming
3. Needles distributed 16,50,686
Indicator 2022-23 4. Syringes distributed 9,83,242
1. Schools with operational Adolescent Education 5. On OST 1,532
3,322
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 4,199
2. Colleges with operational Red Ribbon Clubs (RRC) 369 6.1. HIV sero-positive (%) 1.50
3. Persons trained under mainstreaming 52,282 6.1.1 Linked to ART 42
7. Tested for HIV (October 2022 -March 2023) 4,854
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 2.20
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 72
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 31 1. Estimated size 1,435
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 21
2. Total STI/RTI 3. Condoms distributed 70,958
78,849 1,38,786 370 2,18,005
Clients managed 4. Tested for HIV (April 2022-September 2022) 269
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
42,007 1,03,645 166 1,45,818
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 295
1.02 0.13 0.00 0.38
seropositivity (%)
5.1. HIV sero-positive (%) 1.36
5.1.1. Linked to ART 2
4. Prevention of new HIV infections among 6. Clinic Visits 1,064
high-risk group and bridge population
7. STI/RTI treated 8
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 0
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 37 Indicator 2022-23
2. OST centres 12 1. Estimated size 1,31,755
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 21,566
Indicator 2022-23
3.1. HIV sero-positive (%) 0.18
1. Estimated size 17,668
3.2. Linked to ART -
2. Coverage (%) 17.75
3. Condoms distributed 38,72,348 G. Truckers
4. Tested for HIV (April 2022-September 2022) 9,639 Indicator 2022-23
4.1. HIV sero-positive (%) 0.21 1. Estimated size 15,000
4.1.1. Linked to ART 14 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 10,484 3. Tested for HIV 8,051
5.1. HIV sero-positive (%) 0.52 3.1. HIV sero-positive (%) 0.52
5.1.1. Linked to ART 37 3.2. On ART 27
6. Clinic Visits 37,898
H. Prison Inmates
7. STI/RTI treated 664
Indicator 2022-23
8. Presumptive treatment 1,030
1. Total prisons 19
C. Men who have Sex with Men 2. Prisons covered under programme 20
Indicator 2022-23 3. Total inmates admitted 62,252
1. Estimated size 8,022 4. Inmates Covered (%) ≥95
2. Coverage (%) 62 5. Tested for HIV 58,882
3. Condoms distributed 12,80,938 5.1. HIV sero-positive (%) 1.13
4. Tested for HIV (April 2022-September 2022) 4,125 5.2. On ART (%) 98.94
4.1. HIV sero-positive (%) 1.12
I. Link Worker Scheme
4.1.1. Linked to ART 31
5. Tested for HIV (October 2022 -March 2023) 4,131 Indicator 2022-23
5.1. HIV sero-positive (%) 0.63 1. Districts covered under scheme -
5.1.1. Linked to ART 17 2. Vulnerable population covered -
6. Clinic Visits 16,326 3. Tested for HIV -
7. STI/RTI treated 197 3.1. HIV sero-positive (%) -
8. Presumptive treatment 244 3.2. Linked to ART (%) -

226 Sankalak: Status of National AIDS & STD Response (2023)

 HARYANA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 12
1.1. OSTC in Public Health Settings 10 Indicator 2022-23
1.2. OSTC in NGO Settings 2 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 1,532
2. Viral load testing conducted 17,797
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 86.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 743 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 117 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 533 5. CD4 testing conducted 10,181
1.3. Facility integrated (PPP) 30
6. External Quality Assessment of ICTC
1.4. CBS 63
1.5. SSK 3 6.1 Average Participation (%) 68.6
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 5,16,253 3,90,255 1,045 9,07,553
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
4,265 1,366 27 5,658
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.83 0.35 2.58 0.62 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 6,32,900
partner testing of
1,083 1,346 2 2,431 2. HIV testing among PW 5,96,007
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.06
5. No. of contacts with 4. HIV Positive PW (old + new detections) 546
‘at-risk’ population
103 146 1 250 4.1 On life-long ART 449
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 398

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 449
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 16 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 205
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 9
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 3
3. Link ART Centres 11
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 6,31,523
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.03
1. HIV positive cases 3. Put on treatment 181
4,265 1,734 27 6,026
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 4,408 2,021 23 6,452 Stigma and Discrimination
centre
2.1 Initiated on ART 4,334 2,002 23 6,359 A. HIV
3. PLHIV alive and
18,126 11,685 92 29,902 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 79.2 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 1,582 922 8 2,512 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 227

HARYANA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 9,320 3,989 3,729 238 5,587 3,866 26,729

Quarter 2 8,971 3,936 3,985 270 6,879 5,849 29,890

Screened for TB
Quarter 3 9,138 4,098 3,944 276 7,200 5,618 30,274

Quarter 4 9,734 4,302 4,918 280 10,145 7,941 37,320

Quarter 1 9 23 24 - 9 5 70

Quarter 2 8 22 5 - 14 - 49
Tested for TB
Quarter 3 19 16 9 - 14 3 61

Quarter 4 5 31 6 8 19 16 85

Quarter 1 2 1 3 - - - 6

Quarter 2 3 - 1 - - - 4
Diagnosed with TB
Quarter 3 1 1 1 - - 1 4

Quarter 4 - 2 - - - 1 3

Quarter 1 2 1 3 - - - 6

Initiated on TB Quarter 2 3 - 1 - - - 4
treatment
Quarter 3 1 1 1 - - 1 4

Quarter 4 - 2 - - - 1 3

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 80,923

1.1. HIV sero-positive (%) 1.45

1.2. ICTC clients referred to NTEP 17,552

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 10,463 10,463 1,132 169 50 251

May-22 10,190 10,187 1,161 202 53 310

Jun-22 10,788 10,810 1,293 220 32 400

Jul-22 12,429 12,429 1,410 254 45 492

Aug-22 12,719 12,719 1,798 300 36 506

Sep-22 14,677 14,677 432 365 39 534

Oct-22 14,161 14,161 371 343 35 568

Nov-22 12,132 12,132 249 246 44 311

Dec-22 12,305 12,305 271 266 38 376

Jan-23 10,832 10,832 288 288 60 485

Feb-23 11,416 11,416 236 236 54 484

Mar-23 12,689 12,689 312 312 64 566

April 2022-March 2023 615 498

228 Sankalak: Status of National AIDS & STD Response (2023)

 HARYANA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Haryana

Rank 14
Sl. No.
Max Marks 117

Obtained Marks (%) 83 (71)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) G
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 229

HIMACHAL
PRADESH
HIMACHAL PRADESH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 2.30
2. IMR - - 0.92
3. Adult (15-49 yrs) HIV Prevalence (%) 0.12 0.09 0.11
4. Estimated people living with HIV 4,428 3,048 7,476
5. ART coverage (%) 65.5 88.5 74.9
6. Estimated children living with HIV 165 128 294
7. Annual new HIV infections 97 75 172
8. Annual AIDS-related deaths (ARD) 103 ≤50 113
9. Change in annual new HIV infections since 2010 (%) -61.4 -51.61 -57.7
10. Change in annual ARD since 2010 (%) -61.4 -85.92 -66.6
11. EMTCT need - 38 38

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 13,210 59.3 0.0 0.55
2. Men who have Sex with Men 1,252 61 8.5 1.56
3. Injecting Drug Users 3,662 36.3 92.8 4.4
4. Hijra/Transgender People 258 - - -
5. Migrants 1,45,880 - - 0
6. Truckers 14,000 - - -
7. Prison inmates 6,439 54.5 25 0.25

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 40.8 36.2 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 37.3 34 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 87.1 89.7 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 85.2 80.7 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5.9 0.2 -
5.1 Condom use during last higher-risk intercourse (%) 76.2 28.8 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 8.1 0.7 -
6.1 Condom use during last higher-risk intercourse (%) 66.7 33.3 -

2. Progress on 95-95-95 (2022-23)

94 95 92 93 94 Indicator (2022-23) Male Female Total
81 84 82
71 74 79 73
65 68 1. Estimated PLHIV size (2022) 4,428 3,048 7,476
56

2. PLHIV who know their HIV Status 3,158 2,775 5,937

3. PLHIV who know their HIV status and are on ART 2,900 2,700 5,604
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 1,627 1,776 3,403
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 1,314 1,469 2,783
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 231

HIMANCHAL PRADESH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 3,662
A. Information, Education, Communication,
2. Coverage (%) 50
Youth and Mainstreaming
3. Needles distributed 2,64,610
Indicator 2022-23 4. Syringes distributed 2,08,699
1. Schools with operational Adolescent Education 5. On OST 24
1,000
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,087
2. Colleges with operational Red Ribbon Clubs (RRC) 295 6.1. HIV sero-positive (%) 0.55
3. Persons trained under mainstreaming 5,712 6.1.1 Linked to ART 4
7. Tested for HIV (October 2022 -March 2023) 1,520
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.33
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 3
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 20 1. Estimated size 258
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 19
2. Total STI/RTI 3. Condoms distributed 11,330
32,703 49,990 - 82,693
Clients managed 4. Tested for HIV (April 2022-September 2022) 39
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
23,729 32,044 - 55,773
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 48
0.34 0.10 - 0.20
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 45
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 0
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 17 Indicator 2022-23
2. OST centres 3 1. Estimated size 1,45,880
2. Coverage (%) 45
B. Female Sex Workers
3. Tested for HIV 4,687
Indicator 2022-23
3.1. HIV sero-positive (%) 0.30
1. Estimated size 13,210
3.2. Linked to ART -
2. Coverage (%) 51.86
3. Condoms distributed 16,40,552 G. Truckers
4. Tested for HIV (April 2022-September 2022) 5,107 Indicator 2022-23
4.1. HIV sero-positive (%) 0.06 1. Estimated size 14,000
4.1.1. Linked to ART 3 2. Coverage (%) 71
5. Tested for HIV (October 2022 -March 2023) 5,724 3. Tested for HIV 2,268
5.1. HIV sero-positive (%) 0.12 3.1. HIV sero-positive (%) 0.22
5.1.1. Linked to ART 7 3.2. On ART 4
6. Clinic Visits 21,674
H. Prison Inmates
7. STI/RTI treated 747
Indicator 2022-23
8. Presumptive treatment 315
1. Total prisons 16
C. Men who have Sex with Men 2. Prisons covered under programme 16
Indicator 2022-23 3. Total inmates admitted 7,090
1. Estimated size 1,252 4. Inmates Covered (%) 76
2. Coverage (%) 87 5. Tested for HIV 4,535
3. Condoms distributed 1,84,115 5.1. HIV sero-positive (%) 0.44
4. Tested for HIV (April 2022-September 2022) 621 5.2. On ART (%) 85.00
4.1. HIV sero-positive (%) 0.64
I. Link Worker Scheme
4.1.1. Linked to ART 4
5. Tested for HIV (October 2022 -March 2023) 774 Indicator 2022-23
5.1. HIV sero-positive (%) 0.78 1. Districts covered under scheme -
5.1.1. Linked to ART 6 2. Vulnerable population covered -
6. Clinic Visits 2,795 3. Tested for HIV -
7. STI/RTI treated 142 3.1. HIV sero-positive (%) -
8. Presumptive treatment 51 3.2. Linked to ART (%) -

232 Sankalak: Status of National AIDS & STD Response (2023)

 HIMANCHAL PRADESH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 3
1.1. OSTC in Public Health Settings 1 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres 2 1.1 Accredited Viral load laboratories -
2. IDU on OST 24
2. Viral load testing conducted 3,857
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 79.0

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 175 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 49 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 77 5. CD4 testing conducted 2,581
1.3. Facility integrated (PPP) 19
6. External Quality Assessment of ICTC
1.4. CBS 30
1.5. SSK - 6.1 Average Participation (%) 93.5
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 1,19,572 88,080 - 2,07,652
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
380 158 - 538
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.32 0.18 - 0.26 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 1,25,380
partner testing of
82 106 - 188 2. HIV testing among PW 66,409
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 33
‘at-risk’ population
- - - - 4.1 On life-long ART 25
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 15

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 93.33
infected people 6. Babies tested HIV (6 week- 6 month) 16
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 6 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 6
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 1
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 3
3. Link ART Centres 5
4. Care Support Centres 2
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 79,503
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 9
380 174 - 554
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 343 162 - 505 Stigma and Discrimination
centre
2.1 Initiated on ART 312 149 - 461 A. HIV
3. PLHIV alive and
2,900 2,700 4 5,604 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 76.2 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 264 134 - 398 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 233

HIMANCHAL PRADESH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 4,881 446 775 36 5,134 1,731 13,003

Quarter 2 5,605 677 1,382 39 7,814 2,312 17,829

Screened for TB
Quarter 3 5,421 713 1,345 36 7,327 2,224 17,066

Quarter 4 5,726 800 1,577 45 10,010 2,165 20,323

Quarter 1 100 23 19 - 1 - 143

Quarter 2 143 27 167 - 6 - 343

Tested for TB
Quarter 3 110 12 114 - 8 3 247

Quarter 4 130 - 20 - 19 8 177

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - 1 - - - - 1

Quarter 4 - - - - 1 1 2

Quarter 1 1 - - - - - 1

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - 1 - - - - 1

Quarter 4 - - - - 1 1 2

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 10,459

1.1. HIV sero-positive (%) 4.31

1.2. ICTC clients referred to NTEP 7,397

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 2,525 2,515 30 30 3 34

May-22 2,404 2,389 36 36 7 45

Jun-22 2,520 2,509 45 45 7 53

Jul-22 2,107 2,095 36 36 13 49

Aug-22 2,350 2,338 52 52 12 42

Sep-22 3,003 2,985 78 78 11 45

Oct-22 2,907 2,893 56 56 4 25

Nov-22 2,894 2,883 69 69 3 36

Dec-22 2,576 2,560 48 48 4 47

Jan-23 2,041 2,029 32 32 5 38

Feb-23 2,219 2,205 48 48 2 25

Mar-23 2,006 1,991 53 41 5 33

April 2022-March 2023 104 98

234 Sankalak: Status of National AIDS & STD Response (2023)

 HIMANCHAL PRADESH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Himachal Pradesh

Rank 22
Sl. No.
Max Marks 120

Obtained Marks (%) 82 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) R
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) R
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) R
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 235

JAMMU &
KASHMIR,
AND LADAKH
JAMMU & KASHMIR,
AND LADAKH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.34
2. IMR - - 1.31
3. Adult (15-49 yrs) HIV Prevalence (%) 0.07 0.05 0.06
4. Estimated people living with HIV 4,023 2,646 6,669
5. ART coverage (%) 52.4 56.8 54.3
6. Estimated children living with HIV 267 193 460
7. Annual new HIV infections 130 93 223
8. Annual AIDS-related deaths (ARD) 91 ≤50 126
9. Change in annual new HIV infections since 2010 (%) -56.8 -41.88 -51.6
10. Change in annual ARD since 2010 (%) -20.2 9.38 -13.7
11. EMTCT need - 56 56

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 4,634 - - 0.4
2. Men who have Sex with Men 677 - - -
3. Injecting Drug Users 10,162 25.9 90.9 0.5
4. Hijra/Transgender People 614 - - -
5. Migrants 25,000 - - -
6. Truckers 20,000 - - -
7. Prison inmates 11,297 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 33.6 15.8 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 33.8 17.2 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 66.2 59.8 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 74.6 65 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 0.6 0.0 -
5.1 Condom use during last higher-risk intercourse (%) 66.1 - -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 0.5 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 66.7 - -

2. Progress on 95-95-95 (2022-23)

93 Indicator (2022-23) Male Female Total
84 79 83 86 87 84 90 90
76
54 60 58 58 63 1. Estimated PLHIV size (2022) 4,023 2,646 6,669

2. PLHIV who know their HIV Status 2,501 1,654 4,171

PLHIV who know PLHIV who know PLHIV who are on

3. PLHIV who know their HIV status and are on ART 2,108 1,501 3,622
their HIV status their HIV status ART and virally
(%) and are on ART (%) suppressed (%) 4. PLHIV who are on ART and tested for their viral load 1,084 792 1,877

5. PLHIV who are virally suppressed 1,002 740 1,743

2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 237

JAMMU & KASHMIR, AND LADAKH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 10,162
A. Information, Education, Communication,
2. Coverage (%) 44
Youth and Mainstreaming
3. Needles distributed 9,43,395
Indicator 2022-23 4. Syringes distributed 5,05,971
1. Schools with operational Adolescent Education 5. On OST 710
850
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 3,585
2. Colleges with operational Red Ribbon Clubs (RRC) 302 6.1. HIV sero-positive (%) 0.22
3. Persons trained under mainstreaming 1,690 6.1.1 Linked to ART 8
7. Tested for HIV (October 2022 -March 2023) 4,594
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.07
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 3
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 6 1. Estimated size 614
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 0
2. Total STI/RTI 3. Condoms distributed 0
15,408 10,728 1,301 27,437
Clients managed 4. Tested for HIV (April 2022-September 2022) 0
3. RPR Tests 4.1. HIV sero-positive (%) -
1,758 5,919 1 7,678
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 0
0.74 0.07 100.00 0.23
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 0
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 0
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 19 Indicator 2022-23
2. OST centres 2 1. Estimated size 25,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 6,208
Indicator 2022-23
3.1. HIV sero-positive (%) 0.00
1. Estimated size 4,634
3.2. Linked to ART -
2. Coverage (%) 47.67
3. Condoms distributed 1,99,633 G. Truckers
4. Tested for HIV (April 2022-September 2022) 1,938 Indicator 2022-23
4.1. HIV sero-positive (%) 0.00 1. Estimated size 20,000
4.1.1. Linked to ART 0 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 2,313 3. Tested for HIV 7,075
5.1. HIV sero-positive (%) 0.04 3.1. HIV sero-positive (%) 0.17
5.1.1. Linked to ART 1 3.2. On ART 12
6. Clinic Visits 5,980
H. Prison Inmates
7. STI/RTI treated 222
Indicator 2022-23
8. Presumptive treatment 728
1. Total prisons 16
C. Men who have Sex with Men 2. Prisons covered under programme 15
Indicator 2022-23 3. Total inmates admitted 11,439
1. Estimated size 677 4. Inmates Covered (%) 81
2. Coverage (%) ≥95 5. Tested for HIV 8,337
3. Condoms distributed 16,219 5.1. HIV sero-positive (%) 0.17
4. Tested for HIV (April 2022-September 2022) 456 5.2. On ART (%) 78.57
4.1. HIV sero-positive (%) 0.22
I. Link Worker Scheme
4.1.1. Linked to ART 1
5. Tested for HIV (October 2022 -March 2023) 722 Indicator 2022-23
5.1. HIV sero-positive (%) 0.28 1. Districts covered under scheme -
5.1.1. Linked to ART 2 2. Vulnerable population covered -
6. Clinic Visits 1,851 3. Tested for HIV -
7. STI/RTI treated 77 3.1. HIV sero-positive (%) -
8. Presumptive treatment 254 3.2. Linked to ART (%) -

238 Sankalak: Status of National AIDS & STD Response (2023)

 JAMMU & KASHMIR, AND LADAKH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 2
1.1. OSTC in Public Health Settings 2 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 710
2. Viral load testing conducted 2,099
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 91.0

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 669 4. State reference laboratories (SRL) 2
1.1. Stand-Alone 36 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 601 5. CD4 testing conducted 2,692
1.3. Facility integrated (PPP) 22
6. External Quality Assessment of ICTC
1.4. CBS 10
1.5. SSK - 6.1 Average Participation (%) 94.3
6.2. Average Discordance (%) 1.52
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 6
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 2,29,236 1,53,813 27 3,83,076
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
274 119 2 395
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.12 0.08 7.41 0.10 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 2,26,810
partner testing of
10 46 - 56 2. HIV testing among PW 2,47,468
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.01
5. No. of contacts with 4. HIV Positive PW (old + new detections) 25
‘at-risk’ population
- - - - 4.1 On life-long ART 25
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 21

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 18
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 3 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 5
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres 4
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 8,194
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.09
1. HIV positive cases 3. Put on treatment 7
274 134 2 410
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 244 127 3 374 Stigma and Discrimination
centre
2.1 Initiated on ART 234 121 2 357 A. HIV
3. PLHIV alive and
2,108 1,501 13 3,622 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 81.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 371 163 3 537 2. State designated/appointed ombudsman -

Sankalak: Status of National AIDS & STD Response (2023) 239

JAMMU & KASHMIR, AND LADAKH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 448 220 824 - 38 45 1,575

Quarter 2 465 291 973 - 505 198 2,432

Screened for TB
Quarter 3 431 242 1,257 - 1,055 545 3,530

Quarter 4 637 166 2,119 - 329 429 3,680

Quarter 1 1 - 14 - 1 - 16

Quarter 2 22 2 59 - 1 2 86
Tested for TB
Quarter 3 39 1 58 - - 3 101

Quarter 4 66 1 98 - - 7 172

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 248

1.1. HIV sero-positive (%) 2.02

1.2. ICTC clients referred to NTEP 1,085

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 2,486 2,486 4 2 2 48

May-22 2,462 2,462 6 6 6 42

Jun-22 3,000 3,000 10 10 6 28

Jul-22 1,670 1,670 12 12 5 21

Aug-22 2,240 2,240 24 17 4 32

Sep-22 2,259 2,259 19 19 7 32

Oct-22 1,959 1,959 11 11 6 32

Nov-22 1,926 1,926 25 25 12 44

Dec-22 2,282 2,282 13 13 2 13

Jan-23 2,208 2,208 10 10 4 20

Feb-23 2,065 2,065 8 8 2 30

Mar-23 2,227 2,227 18 18 3 31

April 2022-March 2023 68 62

240 Sankalak: Status of National AIDS & STD Response (2023)

 JAMMU & KASHMIR, AND LADAKH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT J&K & Ladakh

Rank 33
Sl. No.
Max Marks 120

Obtained Marks (%) 73 (61)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) Y
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) R
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) Y
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) R
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) Y
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) Y
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 241

JHARKHAND
JHARKHAND

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 4.67
2. IMR - - 2.31
3. Adult (15-49 yrs) HIV Prevalence (%) 0.09 0.08 0.08
4. Estimated people living with HIV 13,874 11,736 25,610
5. ART coverage (%) 57.8 62.9 60.3
6. Estimated children living with HIV 1,177 1,069 2,246
7. Annual new HIV infections 631 565 1,196
8. Annual AIDS-related deaths (ARD) 207 97 304
9. Change in annual new HIV infections since 2010 (%) -26.6 -16.91 -22.3
10. Change in annual ARD since 2010 (%) -42.2 -64.47 -51.8
11. EMTCT need - 348 348

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 11,860 46.2 39.1 0.55
2. Men who have Sex with Men 1,742 32.9 19.3 6.68
3. Injecting Drug Users 779 75.1 95.0 -
4. Hijra/Transgender People 483 - - -
5. Migrants 20,000 - - -
6. Truckers 35,000 - - 0.00
7. Prison inmates 67,153 0 0 0.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 31.1 13.8 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 28.4 15.2 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 86.2 77.2 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 75.3 67.5 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 3.6 0.4 -
5.1 Condom use during last higher-risk intercourse (%) 38.3 23.1 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 5.7 0.7 -
6.1 Condom use during last higher-risk intercourse (%) 35.6 30.0 -

2. Progress on 95-95-95 (2022-23)

85
94 89 91 92
86 Indicator (2022-23) Male Female Total
83 83
74 77
61 59 61 62 65 1. Estimated PLHIV size (2022) 13,874 11,736 25,610

2. PLHIV who know their HIV Status 8,790 7,864 16,701

3. PLHIV who know their HIV status and are on ART 8,017 7,378 15,439
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 5,407 5,335 10,760
(%) and are on ART (%) suppressed (%)
2018-19 2019-20 2020-21 2021-22 2022-23
5. PLHIV who are virally suppressed 4,601 4,680 9,297

Sankalak: Status of National AIDS & STD Response (2023) 243

JHARKHAND

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 779
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 3,57,108
Indicator 2022-23 4. Syringes distributed 2,98,378
1. Schools with operational Adolescent Education 5. On OST 128
2,108
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 901
2. Colleges with operational Red Ribbon Clubs (RRC) 321 6.1. HIV sero-positive (%) 0.11
3. Persons trained under mainstreaming 2,695 6.1.1 Linked to ART 1
7. Tested for HIV (October 2022 -March 2023) 959
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.21
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 2
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 28 1. Estimated size 483
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 55,923
19,267 27,817 8 47,092
Clients managed 4. Tested for HIV (April 2022-September 2022) 408
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
15,665 23,428 4 39,097
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 492
0.34 0.05 0.00 0.17
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 1,602
high-risk group and bridge population
7. STI/RTI treated 7
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 165
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 28 Indicator 2022-23
2. OST centres 2 1. Estimated size 20,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 12,789
Indicator 2022-23
3.1. HIV sero-positive (%) 0.00
1. Estimated size 11,860
3.2. Linked to ART -
2. Coverage (%) ≥95
3. Condoms distributed 24,94,642 G. Truckers
4. Tested for HIV (April 2022-September 2022) 14,179 Indicator 2022-23
4.1. HIV sero-positive (%) 0.03 1. Estimated size 35,000
4.1.1. Linked to ART 4 2. Coverage (%) 64
5. Tested for HIV (October 2022 -March 2023) 14,774 3. Tested for HIV 8,688
5.1. HIV sero-positive (%) 0.06 3.1. HIV sero-positive (%) 0.01
5.1.1. Linked to ART 10 3.2. On ART 1
6. Clinic Visits 52,553
H. Prison Inmates
7. STI/RTI treated 396
Indicator 2022-23
8. Presumptive treatment 1,294
1. Total prisons 32
C. Men who have Sex with Men 2. Prisons covered under programme 32
Indicator 2022-23 3. Total inmates admitted 57,082
1. Estimated size 1,742 4. Inmates Covered (%) 42
2. Coverage (%) ≥95 5. Tested for HIV 21,081
3. Condoms distributed 2,88,485 5.1. HIV sero-positive (%) 0.10
4. Tested for HIV (April 2022-September 2022) 1,780 5.2. On ART (%) 100.00
4.1. HIV sero-positive (%) 0.22
I. Link Worker Scheme
4.1.1. Linked to ART 4
5. Tested for HIV (October 2022 -March 2023) 2,144 Indicator 2022-23
5.1. HIV sero-positive (%) 0.19 1. Districts covered under scheme -
5.1.1. Linked to ART 4 2. Vulnerable population covered -
6. Clinic Visits 7,226 3. Tested for HIV -
7. STI/RTI treated 84 3.1. HIV sero-positive (%) -
8. Presumptive treatment 436 3.2. Linked to ART (%) -

244 Sankalak: Status of National AIDS & STD Response (2023)

 JHARKHAND

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 2
1.1. OSTC in Public Health Settings 2 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 0
2. IDU on OST 128
2. Viral load testing conducted 12,276
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 82.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 359 4. State reference laboratories (SRL) 3
1.1. Stand-Alone 66 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 211 5. CD4 testing conducted 4,121
1.3. Facility integrated (PPP) 24
6. External Quality Assessment of ICTC
1.4. CBS 58
1.5. SSK 1 6.1 Average Participation (%) 93.0
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 1,93,919 1,59,024 458 3,53,401
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
1,052 593 13 1,658
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.54 0.37 2.84 0.47 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 8,50,800
partner testing of
440 519 22 981 2. HIV testing among PW 7,60,097
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 273
‘at-risk’ population
- - - - 4.1 On life-long ART 248
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 175

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 152
A. Treatment facilities 6.1 Babies confirmed HIV Positive 3
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 13 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 120
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 9
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 9
3. Link ART Centres 11
4. Care Support Centres 5
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 8,23,022
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 96
1,052 729 13 1,794
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 1,103 761 13 1,877 Stigma and Discrimination
centre
2.1 Initiated on ART 1,052 746 13 1,811 A. HIV
3. PLHIV alive and
8,017 7,378 43 15,439 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 78.1 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 478 306 1 785 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 245

JHARKHAND

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 11,545 1,453 909 240 5,020 5,249 24,416

Quarter 2 12,669 1,686 941 341 6,074 5,653 27,364

Screened for TB
Quarter 3 13,476 1,940 952 518 5,946 5,646 28,478

Quarter 4 13,927 2,104 1,005 519 6,091 5,677 29,323

Quarter 1 42 - - - - - 42

Quarter 2 53 1 - - 1 - 55
Tested for TB
Quarter 3 62 6 - - - - 68

Quarter 4 66 - - - - - 66

Quarter 1 1 - - - - - 1

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 1 - - - - - 1

Quarter 1 1 - - - - - 1

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 1 - - - - - 1

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 19,785

1.1. HIV sero-positive (%) 1.88

1.2. ICTC clients referred to NTEP 15,937

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 6,971 6,586 182 146 29 102

May-22 7,696 7,150 181 166 33 174

Jun-22 8,564 8,003 198 177 30 152

Jul-22 8,238 7,756 175 163 35 122

Aug-22 8,756 8,413 187 169 23 132

Sep-22 10,020 9,485 246 216 20 128

Oct-22 10,188 9,676 221 202 26 276

Nov-22 11,781 10,850 231 197 28 600

Dec-22 10,541 10,306 211 184 22 327

Jan-23 10,104 9,757 237 196 22 162

Feb-23 10,085 9,774 225 179 22 88

Mar-23 10,585 10,228 276 201 31 91

April 2022-March 2023 350 319

246 Sankalak: Status of National AIDS & STD Response (2023)

 JHARKHAND

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Jharkhand

Rank 29
Sl. No.
Max Marks 120

Obtained Marks (%) 79 (66)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) R
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) Y
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) R

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 247

KARNATAKA
KARNATAKA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 1.25
2. IMR - - 0.37
3. Adult (15-49 yrs) HIV Prevalence (%) 0.41 0.46 0.43
4. Estimated people living with HIV 1,30,134 1,43,451 2,73,585
5. ART coverage (%) 66.1 74.5 70.7
6. Estimated children living with HIV 9,481 8,934 18,415
7. Annual new HIV infections 1,731 1,690 3,421
8. Annual AIDS-related deaths (ARD) 3,994 2,583 6,577
9. Change in annual new HIV infections since 2010 (%) -65.8 -65.76 -65.8
10. Change in annual ARD since 2010 (%) -74.3 -81.39 -77.6
11. EMTCT need - 1,604 1,604

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 1,53,337 85.2 32.5 3.01
2. Men who have Sex with Men 45,631 67.4 61.4 2.81
3. Injecting Drug Users 4,331 27.8 69.6 0
4. Hijra/Transgender People 10,926 73.4 - 3.2
5. Migrants 2,10,000 - - 0.2
6. Truckers 85,000 - - 1.20
7. Prison inmates 85,576 65.5 11.8 0.67

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 26.6 24.5 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 24.4 26.8 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 78.8 73.7 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 74.8 69.5 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 2.8 0.4 -
5.1 Condom use during last higher-risk intercourse (%) 59.2 74.6 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 4.2 0.1 -
6.1 Condom use during last higher-risk intercourse (%) 56.9 100.0 -

2. Progress on 95-95-95 (2022-23)

85 87 85 84 87 93 Indicator (2022-23) Male Female Total
78 82 79 81 81
71 73 75 68
1. Estimated PLHIV size (2022) 1,30,134 1,43,451 2,73,585

2. PLHIV who know their HIV Status 1,02,488 1,20,137 2,23,353

3. PLHIV who know their HIV status and are on ART 86,036 1,06,826 1,93,447
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally
(%) and are on ART (%) suppressed (%)
4. PLHIV who are on ART and tested for their viral load 60,058 60,381 1,20,686

2018-19 2019-20 2020-21 2021-22 2022-23

5. PLHIV who are virally suppressed 56,106 56,312 1,12,652

Sankalak: Status of National AIDS & STD Response (2023) 249

KARNATAKA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 4,331
A. Information, Education, Communication,
2. Coverage (%) 39
Youth and Mainstreaming
3. Needles distributed 1,99,566
Indicator 2022-23 4. Syringes distributed 99,783
1. Schools with operational Adolescent Education 5. On OST 86
7,200
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 800
2. Colleges with operational Red Ribbon Clubs (RRC) 1,536 6.1. HIV sero-positive (%) 0.13
3. Persons trained under mainstreaming 1,07,013 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 807
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.00
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 0
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 54 1. Estimated size 10,926
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 42
2. Total STI/RTI 3. Condoms distributed 12,68,306
1,36,577 2,32,544 6,549 3,75,670
Clients managed 4. Tested for HIV (April 2022-September 2022) 4,012
3. RPR Tests 4.1. HIV sero-positive (%) 0.20
62,824 1,23,555 2,901 1,89,280
conducted 4.1.1. Linked to ART 8
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 4,934
0.62 0.16 1.28 0.33
seropositivity (%)
5.1. HIV sero-positive (%) 0.43
5.1.1. Linked to ART 21
4. Prevention of new HIV infections among 6. Clinic Visits 16,934
high-risk group and bridge population
7. STI/RTI treated 40
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 481
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 77 Indicator 2022-23
2. OST centres 2 1. Estimated size 2,10,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 46,322
Indicator 2022-23
3.1. HIV sero-positive (%) 0.11
1. Estimated size 1,53,337
3.2. Linked to ART 296
2. Coverage (%) 87.78
3. Condoms distributed 1,74,83,314 G. Truckers
4. Tested for HIV (April 2022-September 2022) 90,138 Indicator 2022-23
4.1. HIV sero-positive (%) 0.05 1. Estimated size 85,000
4.1.1. Linked to ART 44 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 94,439 3. Tested for HIV 10,554
5.1. HIV sero-positive (%) 0.06 3.1. HIV sero-positive (%) 0.15
5.1.1. Linked to ART 54 3.2. On ART 11
6. Clinic Visits 3,66,669
H. Prison Inmates
7. STI/RTI treated 2,724
Indicator 2022-23
8. Presumptive treatment 20,753
1. Total prisons 57
C. Men who have Sex with Men 2. Prisons covered under programme 52
Indicator 2022-23 3. Total inmates admitted 62,989
1. Estimated size 45,631 4. Inmates Covered (%) 67
2. Coverage (%) ≥95 5. Tested for HIV 40,499
3. Condoms distributed 76,82,585 5.1. HIV sero-positive (%) 0.22
4. Tested for HIV (April 2022-September 2022) 30,795 5.2. On ART (%) 100.00
4.1. HIV sero-positive (%) 0.22
I. Link Worker Scheme
4.1.1. Linked to ART 63
5. Tested for HIV (October 2022 -March 2023) 35,207 Indicator 2022-23
5.1. HIV sero-positive (%) 0.20 1. Districts covered under scheme 11
5.1.1. Linked to ART 73 2. Vulnerable population covered 176,968
6. Clinic Visits 1,24,790 3. Tested for HIV 123,527
7. STI/RTI treated 393 3.1. HIV sero-positive (%) 0.25
8. Presumptive treatment 6,901 3.2. Linked to ART (%) 97.0

250 Sankalak: Status of National AIDS & STD Response (2023)

 KARNATAKA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 2
1.1. OSTC in Public Health Settings 2 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 7
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 4
2. IDU on OST 86
2. Viral load testing conducted 1,33,320
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 91.5

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 1
3.1 Accredited NRL 1
Indicator 2022-23
1. HCTC facilities 3,374 4. State reference laboratories (SRL) 10
1.1. Stand-Alone 473 4.1 Accredited SRL 10
1.2. Facility integrated (Govt.) 2,436 5. CD4 testing conducted 128,504
1.3. Facility integrated (PPP) 407
6. External Quality Assessment of ICTC
1.4. CBS 58
1.5. SSK 7 6.1 Average Participation (%) 84.5
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 1,732,875 1,569,538 20,952 3,323,365
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
7,412 5,308 77 12,797
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.43 0.34 0.37 0.39 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 1,196,210
partner testing of
2,593 3,698 3 6,294 2. HIV testing among PW 1,127,067
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.05
5. No. of contacts with 4. HIV Positive PW (old + new detections) 1,516
‘at-risk’ population
- - - - 4.1 On life-long ART 1,470
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 1,111

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.91
infected people 6. Babies tested HIV (6 week- 6 month) 1,098
A. Treatment facilities 6.1 Babies confirmed HIV Positive 2
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 71 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 881
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 24
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 3
3. Link ART Centres 305
4. Care Support Centres 36
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 13,19,493
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 131
7,412 5,868 77 13,357
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 6,843 5,627 80 12,550 Stigma and Discrimination
centre
2.1 Initiated on ART 6,645 5,501 79 12,225 A. HIV
3. PLHIV alive and
86,036 106,826 585 193,447 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 80.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 9,753 8,431 120 18,304 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 251

KARNATAKA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 186,408 67,221 777 11,547 49,496 16,172 331,621

Quarter 2 201,062 73,279 749 11,963 48,364 17,054 352,471

Screened for TB
Quarter 3 197,045 74,020 783 12,424 45,726 15,809 345,807

Quarter 4 202,077 77,927 771 13,280 46,221 9,360 349,636

Quarter 1 1,649 391 10 3 99 1 2,153

Quarter 2 2,066 683 8 5 122 - 2,884

Tested for TB
Quarter 3 1,922 693 - 6 107 1 2,729

Quarter 4 1,392 639 10 15 83 - 2,139

Quarter 1 9 1 - 2 - - 12

Quarter 2 8 5 8 - 2 - 23
Diagnosed with TB
Quarter 3 7 7 - - - - 14

Quarter 4 4 1 - - 1 - 6

Quarter 1 9 1 - 2 - - 12

Initiated on TB Quarter 2 5 5 1 - 2 - 13
treatment
Quarter 3 7 6 - - - - 13

Quarter 4 4 1 - - 1 - 6

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 110,796

1.1. HIV sero-positive (%) 0.64

1.2. ICTC clients referred to NTEP 169,711

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 100,554 98,071 4,729 4,519 246 1,574

May-22 102,162 98,975 7,038 4,832 248 1,312

Jun-22 104,628 101,659 5,364 5,212 258 1,583

Jul-22 103,563 100,343 5,841 5,685 249 1,387

Aug-22 98,961 96,534 5,519 5,403 255 1,164

Sep-22 100,800 97,766 5,522 5,392 310 1,175

Oct-22 110,742 107,991 4,932 4,719 257 1,269

Nov-22 128,013 124,344 9,485 5,585 294 1,160

Dec-22 136,973 132,244 9,874 5,897 319 1,411

Jan-23 128,653 124,767 5,837 5,697 267 1,293

Feb-23 122,630 118,987 4,575 4,416 246 929

Mar-23 135,378 131,725 4,464 4,276 275 727

April 2022-March 2023 3,841 3,764

252 Sankalak: Status of National AIDS & STD Response (2023)

 KARNATAKA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Karnataka

Rank 3
Sl. No.
Max Marks 117

Obtained Marks (%) 90 (77)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) Y
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 253

KERALA
KERALA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 1.25
2. IMR - - 0.80
3. Adult (15-49 yrs) HIV Prevalence (%) 0.06 0.05 0.06
4. Estimated people living with HIV 11,028 9,676 20,704
5. ART coverage (%) 84.0 80.2 82.3
6. Estimated children living with HIV 404 357 761
7. Annual new HIV infections 136 123 259
8. Annual AIDS-related deaths (ARD) 60 67 127
9. Change in annual new HIV infections since 2010 (%) -77.3 -77.43 -77.3
10. Change in annual ARD since 2010 (%) -86.1 -85.59 -85.8
11. EMTCT need - 99 99

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 16,623 67.3 50 0.44
2. Men who have Sex with Men 13,836 33.5 60.3 0.35
3. Injecting Drug Users 3,276 35.2 88.7 0.4
4. Hijra/Transgender People 2,604 51.3 - 0.56
5. Migrants 150,000 - - 0
6. Truckers 20,000 - - 1.20
7. Prison inmates 26,545 41.8 15.4 0.50

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 45.2 34.8 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 40.6 30.2 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 65.3 71 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 78.9 71.7 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 0.5 0 -
5.1 Condom use during last higher-risk intercourse (%) 47.9 NA -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 0.5 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 0.0 NA -

2. Progress on 95-95-95 (2022-23)

95 95 95 95 95 91 92 95 Indicator (2022-23) Male Female Total
75 77 79 81
86 83 89
1. Estimated PLHIV size (2022) 11,028 9,676 20,704

2. PLHIV who know their HIV Status 9,894 7,827 17,748

3. PLHIV who know their HIV status and are on ART 9,261 7,760 17,044
PLHIV who know PLHIV who know PLHIV who are on
their HIV status (%) their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 5,305 5,695 11,009
and are on ART (%) suppressed (%)

2018-19 2019-20 2020-21 2021-22 2022-23 5. PLHIV who are virally suppressed 5,121 5,509 10,639

Sankalak: Status of National AIDS & STD Response (2023) 255

KERALA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 3,276
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 3,97,010
Indicator 2022-23 4. Syringes distributed 2,23,781
1. Schools with operational Adolescent Education 5. On OST 478
1,500
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,889
2. Colleges with operational Red Ribbon Clubs (RRC) 280 6.1. HIV sero-positive (%) 0.00
3. Persons trained under mainstreaming 1,887 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 2,340
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.04
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 1
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 23 1. Estimated size 2,604
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 3,99,232
22,350 29,159 467 51,976
Clients managed 4. Tested for HIV (April 2022-September 2022) 2,005
3. RPR Tests 4.1. HIV sero-positive (%) 0.05
14,535 17,340 189 32,064
conducted 4.1.1. Linked to ART 2
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 1,964
6.27 1.44 7.94 3.67
seropositivity (%)
5.1. HIV sero-positive (%) 0.15
5.1.1. Linked to ART 3
4. Prevention of new HIV infections among 6. Clinic Visits 7,085
high-risk group and bridge population
7. STI/RTI treated 37
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 251
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 64 Indicator 2022-23
2. OST centres 11 1. Estimated size 1,50,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 70,261
Indicator 2022-23
3.1. HIV sero-positive (%) 0.08
1. Estimated size 16,623
3.2. Linked to ART -
2. Coverage (%) ≥95
3. Condoms distributed 2,156,352 G. Truckers
4. Tested for HIV (April 2022-September 2022) 12,081 Indicator 2022-23
4.1. HIV sero-positive (%) 0.03 1. Estimated size 20,000
4.1.1. Linked to ART 5 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 15,679 3. Tested for HIV 12,786
5.1. HIV sero-positive (%) 0.03 3.1. HIV sero-positive (%) 0.16
5.1.1. Linked to ART 6 3.2. On ART 18
6. Clinic Visits 51,477
H. Prison Inmates
7. STI/RTI treated 560
Indicator 2022-23
8. Presumptive treatment 2,115
1. Total prisons 56
C. Men who have Sex with Men 2. Prisons covered under programme 55
Indicator 2022-23 3. Total inmates admitted 56,527
1. Estimated size 13,836 4. Inmates Covered (%) 64
2. Coverage (%) ≥95 5. Tested for HIV 32,981
3. Condoms distributed 17,26,840 5.1. HIV sero-positive (%) 0.13
4. Tested for HIV (April 2022-September 2022) 10,499 5.2. On ART (%) 85.71
4.1. HIV sero-positive (%) 0.12
I. Link Worker Scheme
4.1.1. Linked to ART 13
5. Tested for HIV (October 2022 -March 2023) 11,762 Indicator 2022-23
5.1. HIV sero-positive (%) 0.14 1. Districts covered under scheme -
5.1.1. Linked to ART 16 2. Vulnerable population covered -
6. Clinic Visits 41,358 3. Tested for HIV -
7. STI/RTI treated 213 3.1. HIV sero-positive (%) -
8. Presumptive treatment 1,955 3.2. Linked to ART (%) -

256 Sankalak: Status of National AIDS & STD Response (2023)

 KERALA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 11
1.1. OSTC in Public Health Settings 7 Indicator 2022-23
1.2. OSTC in NGO Settings 3 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres 1 1.1 Accredited Viral load laboratories 0
2. IDU on OST 478
2. Viral load testing conducted 11,787
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 96.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 1
3.1 Accredited NRL 1
Indicator 2022-23
1. HCTC facilities 834 4. State reference laboratories (SRL) 5
1.1. Stand-Alone 150 4.1 Accredited SRL 5
1.2. Facility integrated (Govt.) 530 5. CD4 testing conducted 3,854
1.3. Facility integrated (PPP) 90
6. External Quality Assessment of ICTC
1.4. CBS 64
1.5. SSK - 6.1 Average Participation (%) 99.3
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 14
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 437,715 354,729 3,454 795,898
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
852 296 6 1,154
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.19 0.08 0.17 0.14 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 5,26,340
partner testing of
168 348 4 520 2. HIV testing among PW 4,17,080
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.01
5. No. of contacts with 4. HIV Positive PW (old + new detections) 99
‘at-risk’ population
- - - - 4.1 On life-long ART 90
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 63

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 66
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 15 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 48
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 1
3. Link ART Centres 14
4. Care Support Centres 7
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 4,44,655
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.02
1. HIV positive cases 3. Put on treatment 74
852 323 6 1,181
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 824 336 6 1,166 Stigma and Discrimination
centre
2.1 Initiated on ART 723 305 6 1,034 A. HIV
3. PLHIV alive and
9,261 7,760 23 17,044 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 82.5 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 500 122 3 625 2. State designated/appointed ombudsman -

Sankalak: Status of National AIDS & STD Response (2023) 257

KERALA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 11,513 8,986 2,042 1,780 26,564 4,018 54,903

Quarter 2 13,738 8,973 1,915 1,769 27,987 4,260 58,642

Screened for TB
Quarter 3 16,048 10,259 1,993 1,940 27,627 4,314 62,181

Quarter 4 16,310 11,169 2,516 2,048 28,192 5,879 66,114

Quarter 1 69 16 1 4 22 - 112

Quarter 2 33 1 26 9 54 - 123
Tested for TB
Quarter 3 83 23 13 6 72 - 197

Quarter 4 23 3 7 - 34 - 67

Quarter 1 - - - - - - -

Quarter 2 2 - 1 - - - 3
Diagnosed with TB
Quarter 3 1 - - - 1 - 2

Quarter 4 - - - - 2 - 2

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 2 - 1 - - - 3
treatment
Quarter 3 1 - - - 1 - 2

Quarter 4 - - - - 2 - 2

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 9,829

1.1. HIV sero-positive (%) 0.93

1.2. ICTC clients referred to NTEP 44,127

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 10,123 10,123 257 240 18 80

May-22 9,924 9,924 189 175 16 87

Jun-22 9,670 9,670 153 140 14 112

Jul-22 8,986 8,986 170 148 11 140

Aug-22 10,115 10,115 187 164 20 154

Sep-22 10,243 10,243 169 142 15 100

Oct-22 10,941 10,941 174 153 22 97

Nov-22 10,124 10,124 1,106 171 19 90

Dec-22 9,496 9,496 1,391 148 22 78

Jan-23 8,987 8,987 189 165 18 85

Feb-23 9,100 9,100 169 155 12 60

Mar-23 10,227 10,227 204 180 19 69

April 2022-March 2023 223 198

258 Sankalak: Status of National AIDS & STD Response (2023)

 KERALA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Kerala

Rank 11
Sl. No.
Max Marks 120

Obtained Marks (%) 86 (72)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) G
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) R
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 259

MADHYA
PRADESH
MADHYA PRADESH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 2.56
2. IMR - - 1.08
3. Adult (15-49 yrs) HIV Prevalence (%) 0.10 0.07 0.09
4. Estimated people living with HIV 36,195 22,252 58,446
5. ART coverage (%) 60.3 75.2 66.2
6. Estimated children living with HIV 2,789 1,881 4,670
7. Annual new HIV infections 985 514 1,499
8. Annual AIDS-related deaths (ARD) 659 160 820
9. Change in annual new HIV infections since 2010 (%) -57.6 -59.40 -58.3
10. Change in annual ARD since 2010 (%) -77.3 -88.72 -81.0
11. EMTCT need - 662 662

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 53,455 67 63.6 0.75
2. Men who have Sex with Men 18,085 39.6 71.6 1.84
3. Injecting Drug Users 11,919 41.3 85.7 2.96
4. Hijra/Transgender People 1,614 - - -
5. Migrants 1,25,834 - - 0.78
6. Truckers 85,000 - - 0.00
7. Prison inmates 1,90,301 40 30.8 1.58

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 26.2 18.7 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 23.7 17.3 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 73.9 71.5 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 60.7 59.6 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5.5 0.5 -
5.1 Condom use during last higher-risk intercourse (%) 56.9 40.5 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 10.2 1.0 -
6.1 Condom use during last higher-risk intercourse (%) 51.6 50.0 -

2. Progress on 95-95-95 (2022-23)

79 82 81 78 82 84 81 81 77
88 Indicator (2022-23) Male Female Total
74 73
67 70
58 1. Estimated PLHIV size (2022) 36,195 22,252 58,446

2. PLHIV who know their HIV Status 26,470 19,662 46,277

3. PLHIV who know their HIV status and are on ART 21,822 16,740 38,667
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 9,005 8,098 17,140
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 7,842 7,133 15,011
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 261

MADHYA PRADESH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 11,919
A. Information, Education, Communication,
2. Coverage (%) 90
Youth and Mainstreaming
3. Needles distributed 13,58,309
Indicator 2022-23 4. Syringes distributed 13,58,309
1. Schools with operational Adolescent Education 5. On OST 1,497
Suspended
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 7,480
2. Colleges with operational Red Ribbon Clubs (RRC) 700 6.1. HIV sero-positive (%) 0.57
3. Persons trained under mainstreaming 2,127 6.1.1 Linked to ART 34
7. Tested for HIV (October 2022 -March 2023) 8,597
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.21
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 19
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 66 1. Estimated size 1,614
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 60
2. Total STI/RTI 3. Condoms distributed 99,940
3,12,705 4,55,611 3,191 7,71,507
Clients managed 4. Tested for HIV (April 2022-September 2022) 646
3. RPR Tests 4.1. HIV sero-positive (%) 0.62
74,314 1,58,760 146 2,33,220
conducted 4.1.1. Linked to ART 4
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 894
0.81 0.20 2.05 0.40
seropositivity (%)
5.1. HIV sero-positive (%) 0.34
5.1.1. Linked to ART 3
4. Prevention of new HIV infections among 6. Clinic Visits 2,937
high-risk group and bridge population
7. STI/RTI treated 13
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 15
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 68 Indicator 2022-23
2. OST centres 17 1. Estimated size 1,25,834
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 30,240
Indicator 2022-23
3.1. HIV sero-positive (%) 0.06
1. Estimated size 53,455
3.2. Linked to ART 114
2. Coverage (%) 87.17
3. Condoms distributed 75,83,750 G. Truckers
4. Tested for HIV (April 2022-September 2022) 35,572 Indicator 2022-23
4.1. HIV sero-positive (%) 0.11 1. Estimated size 85,000
4.1.1. Linked to ART 34 2. Coverage (%) 81
5. Tested for HIV (October 2022 -March 2023) 38,824 3. Tested for HIV 32,512
5.1. HIV sero-positive (%) 0.06 3.1. HIV sero-positive (%) 0.04
5.1.1. Linked to ART 20 3.2. On ART 12
6. Clinic Visits 1,41,405
H. Prison Inmates
7. STI/RTI treated 3,186
Indicator 2022-23
8. Presumptive treatment 3,319
1. Total prisons 131
C. Men who have Sex with Men 2. Prisons covered under programme 131
Indicator 2022-23 3. Total inmates admitted 1,64,155
1. Estimated size 18,085 4. Inmates Covered (%) ≥95
2. Coverage (%) 94 5. Tested for HIV 1,60,886
3. Condoms distributed 20,51,064 5.1. HIV sero-positive (%) 0.11
4. Tested for HIV (April 2022-September 2022) 13,065 5.2. On ART (%) 84.97
4.1. HIV sero-positive (%) 0.31
I. Link Worker Scheme
4.1.1. Linked to ART 38
5. Tested for HIV (October 2022 -March 2023) 14,328 Indicator 2022-23
5.1. HIV sero-positive (%) 0.29 1. Districts covered under scheme 10
5.1.1. Linked to ART 40 2. Vulnerable population covered 1,26,040
6. Clinic Visits 52,277 3. Tested for HIV 1,15,022
7. STI/RTI treated 744 3.1. HIV sero-positive (%) 0.10
8. Presumptive treatment 766 3.2. Linked to ART (%) 100.0

262 Sankalak: Status of National AIDS & STD Response (2023)

 MADHYA PRADESH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 17
1.1. OSTC in Public Health Settings 11 Indicator 2022-23
1.2. OSTC in NGO Settings 5 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres 1 1.1 Accredited Viral load laboratories 0
2. IDU on OST 1,497
2. Viral load testing conducted 22,376
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 87.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 1,845 4. State reference laboratories (SRL) 4
1.1. Stand-Alone 199 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 1,436 5. CD4 testing conducted 21,249
1.3. Facility integrated (PPP) 55
6. External Quality Assessment of ICTC
1.4. CBS 155
1.5. SSK 16 6.1 Average Participation (%) 84.1
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 9,24,785 7,86,983 5,890 17,17,658
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
3,670 1,545 24 5,239
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.40 0.20 0.41 0.31 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 22,23,030
partner testing of
1,477 1,460 14 2,951 2. HIV testing among PW 15,69,667
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 714
‘at-risk’ population
1,300 1,002 1 2,303 4.1 On life-long ART 637
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 618

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.51
infected people 6. Babies tested HIV (6 week- 6 month) 560
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 30 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 279
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 17
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 12
3. Link ART Centres 36
4. Care Support Centres 11
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 15,67,322
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.06
1. HIV positive cases 3. Put on treatment 871
3,670 1,967 24 5,661
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 3,533 1,919 16 5,468 Stigma and Discrimination
centre
2.1 Initiated on ART 3,377 1,862 15 5,254 A. HIV
3. PLHIV alive and
21,822 16,740 105 38,667 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 78.6 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 3,174 1,981 27 5,182 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 263

MADHYA PRADESH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 34,718 13,712 7,630 682 21,964 16,279 94,985

Quarter 2 32,814 12,672 7,718 744 23,045 16,773 93,766

Screened for TB
Quarter 3 37,457 14,073 8,329 1,043 22,171 18,436 1,01,509

Quarter 4 42,910 15,478 8,664 963 21,586 19,952 1,09,553

Quarter 1 285 122 104 9 37 38 595

Quarter 2 413 115 143 5 134 44 854

Tested for TB
Quarter 3 465 186 168 4 21 35 879

Quarter 4 513 232 262 2 35 43 1,087

Quarter 1 5 2 4 - 8 2 21

Quarter 2 7 6 8 - 14 1 36
Diagnosed with TB
Quarter 3 9 7 1 - 2 - 19

Quarter 4 15 2 8 - 4 2 31

Quarter 1 5 2 4 - 8 1 20

Initiated on TB Quarter 2 6 5 8 - 14 1 34
treatment
Quarter 3 8 6 1 - 2 - 17

Quarter 4 14 2 8 1 4 2 31

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 68,854

1.1. HIV sero-positive (%) 0.98

1.2. ICTC clients referred to NTEP 46,568

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 12,325 11,456 840 749 80 271

May-22 13,200 12,452 1,697 812 95 326

Jun-22 14,147 13,766 2,066 750 107 251

Jul-22 14,147 13,766 2,066 750 107 251

Aug-22 14,147 13,766 2,066 750 107 251

Sep-22 15,817 15,777 2,195 858 107 318

Oct-22 16,936 16,935 2,348 885 124 574

Nov-22 17,732 17,732 1,854 922 69 544

Dec-22 17,019 17,019 1,270 740 81 327

Jan-23 18,386 18,386 2,173 1,052 85 346

Feb-23 16,360 16,327 1,479 691 73 639

Mar-23 17,780 17,482 1,473 762 90 580

April 2022-March 2023 1,352 1,234

264 Sankalak: Status of National AIDS & STD Response (2023)

 MADHYA PRADESH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Madhya Pradesh

Rank 24
Sl. No.
Max Marks 117

Obtained Marks (%) 79 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) Y
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 265

MAHARASHTRA
MAHARASHTRA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 1.15
2. IMR - - 0.44
3. Adult (15-49 yrs) HIV Prevalence (%) 0.31 0.30 0.30
4. Estimated people living with HIV 2,08,163 1,79,912 3,88,075
5. ART coverage (%) 68.6 81.0 74.6
6. Estimated children living with HIV 11,348 10,150 21,498
7. Annual new HIV infections 2,340 2,121 4,461
8. Annual AIDS-related deaths (ARD) 5,412 1,219 6,631
9. Change in annual new HIV infections since 2010 (%) -64.2 -60.05 -62.3
10. Change in annual ARD since 2010 (%) -77.3 -89.93 -81.6
11. EMTCT need - 2,334 2,334

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 95,351 80.1 11.3 2.54
2. Men who have Sex with Men 40,187 67.7 20.1 4.18
3. Injecting Drug Users 1,096 48.2 70.4 18.41
4. Hijra/Transgender People 10,323 - - 6
5. Migrants 13,74,914 - - 0.13
6. Truckers 2,05,000 - - 0.40
7. Prison inmates 1,47,481 55.1 8.3 1.13

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 42.6 34.4 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 37.2 35.2 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 78.8 75.4 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 74.1 71.2 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 4.4 0.4 -
5.1 Condom use during last higher-risk intercourse (%) 86.3 88.7 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 6.1 0.1 -
6.1 Condom use during last higher-risk intercourse (%) 91.2 100.0 -

2. Progress on 95-95-95 (2022-23)

92 95 Indicator (2022-23) Male Female Total
83 88 89 88 80 79 77 80 81
87 87 88
74
1. Estimated PLHIV size (2022) 2,08,163 1,79,912 3,88,075

2. PLHIV who know their HIV Status 1,81,432 1,72,789 3,55,652

3. PLHIV who know their HIV status and are on ART 1,42,799 1,45,640 2,89,410
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 1,09,965 1,09,466 2,20,023
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 1,04,882 1,04,490 2,09,939
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 267

MAHARASHTRA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 1,096
A. Information, Education, Communication,
2. Coverage (%) 87
Youth and Mainstreaming
3. Needles distributed 45,908
Indicator 2022-23 4. Syringes distributed 26,334
1. Schools with operational Adolescent Education 5. On OST 172
250
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 590
2. Colleges with operational Red Ribbon Clubs (RRC) 1,022 6.1. HIV sero-positive (%) 0.00
3. Persons trained under mainstreaming 1,93,743 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 806
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.62
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 2
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 80 1. Estimated size 10,323
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 84
2. Total STI/RTI 3. Condoms distributed 35,66,209
9,10,917 6,89,645 29,979 16,30,541
Clients managed 4. Tested for HIV (April 2022-September 2022) 6,495
3. RPR Tests 4.1. HIV sero-positive (%) 0.99
2,47,310 2,82,285 2,461 5,32,056
conducted 4.1.1. Linked to ART 63
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 6,887
0.78 0.19 5.28 0.49
seropositivity (%)
5.1. HIV sero-positive (%) 0.35
5.1.1. Linked to ART 23
4. Prevention of new HIV infections among 6. Clinic Visits 28,976
high-risk group and bridge population
7. STI/RTI treated 712
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 1,014
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 173 Indicator 2022-23
2. OST centres 5 1. Estimated size 13,74,914
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 2,85,205
Indicator 2022-23
3.1. HIV sero-positive (%) 0.17
1. Estimated size 95,351
3.2. Linked to ART 586
2. Coverage (%) 90.64
3. Condoms distributed 2,60,63,712 G. Truckers
4. Tested for HIV (April 2022-September 2022) 63,462 Indicator 2022-23
4.1. HIV sero-positive (%) 0.20 1. Estimated size 2,05,000
4.1.1. Linked to ART 119 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 72,353 3. Tested for HIV 51,945
5.1. HIV sero-positive (%) 0.12 3.1. HIV sero-positive (%) 0.12
5.1.1. Linked to ART 80 3.2. On ART 53
6. Clinic Visits 2,84,114
H. Prison Inmates
7. STI/RTI treated 5,030
Indicator 2022-23
8. Presumptive treatment 12,403
1. Total prisons 64
C. Men who have Sex with Men 2. Prisons covered under programme 42
Indicator 2022-23 3. Total inmates admitted 1,14,494
1. Estimated size 40,187 4. Inmates Covered (%) 67
2. Coverage (%) 74 5. Tested for HIV 63,626
3. Condoms distributed 68,68,083 5.1. HIV sero-positive (%) 0.36
4. Tested for HIV (April 2022-September 2022) 22,982 5.2. On ART (%) 82.10
4.1. HIV sero-positive (%) 0.38
I. Link Worker Scheme
4.1.1. Linked to ART 75
5. Tested for HIV (October 2022 -March 2023) 25,312 Indicator 2022-23
5.1. HIV sero-positive (%) 0.22 1. Districts covered under scheme 21
5.1.1. Linked to ART 54 2. Vulnerable population covered 4,89,863
6. Clinic Visits 1,00,715 3. Tested for HIV 4,32,035
7. STI/RTI treated 1,113 3.1. HIV sero-positive (%) 0.14
8. Presumptive treatment 3,083 3.2. Linked to ART (%) 98.2

268 Sankalak: Status of National AIDS & STD Response (2023)

 MAHARASHTRA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 2
1.1. OSTC in Public Health Settings 1 Indicator 2022-23
1.2. OSTC in NGO Settings 1 1. Viral load laboratories 13
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 7
2. IDU on OST 77
2. Viral load testing conducted 2,53,713
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 93.7

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 2
3.1 Accredited NRL 2
Indicator 2022-23
1. HCTC facilities 4,660 4. State reference laboratories (SRL) 16
1.1. Stand-Alone 565 4.1 Accredited SRL 16
1.2. Facility integrated (Govt.) 2,598 5. CD4 testing conducted 1,83,261
1.3. Facility integrated (PPP) 1,344
6. External Quality Assessment of ICTC
1.4. CBS 153
1.5. SSK 8 6.1 Average Participation (%) 99.5
6.2. Average Discordance (%) 0.18
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 10
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 25,44,891 21,04,516 14,730 46,64,137
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
10,661 6,933 134 17,728
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.42 0.33 0.91 0.38 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 20,86,620
partner testing of
3,769 5,510 20 9,299 2. HIV testing among PW 22,71,394
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 2,013
‘at-risk’ population
541 655 1 1,197 4.1 On life-long ART 1,931
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 1,840

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.57
infected people 6. Babies tested HIV (6 week- 6 month) 1,499
A. Treatment facilities 6.1 Babies confirmed HIV Positive 6
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 97 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 1,223
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 29
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 21
3. Link ART Centres 182
4. Care Support Centres 44
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 16,73,866
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.02
1. HIV positive cases 3. Put on treatment 268
10,661 7,711 134 18,506
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 10,321 7,477 125 17,923 Stigma and Discrimination
centre
2.1 Initiated on ART 9,906 7,227 121 17,254 A. HIV
3. PLHIV alive and
1,45,640 970 2,89,410 Indicator 2022-23
on ART 1,42,799
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 84.1 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 25,559 18,190 352 44,101 2. State designated/appointed ombudsman -

Sankalak: Status of National AIDS & STD Response (2023) 269

MAHARASHTRA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 66,700 22,560 654 6,686 83,837 40,830 2,21,267

Quarter 2 68,090 21,861 773 6,987 89,934 44,596 2,32,241

Screened for TB
Quarter 3 67,931 21,664 798 7,161 93,648 45,340 2,36,542

Quarter 4 72,640 23,917 752 7,201 1,02,012 47,577 2,54,099

Quarter 1 1,023 204 3 35 800 340 2,405

Quarter 2 1,071 293 6 90 855 395 2,710

Tested for TB
Quarter 3 1,193 328 8 73 853 394 2,849

Quarter 4 1,748 335 2 74 826 421 3,406

Quarter 1 13 3 - - 23 - 39

Quarter 2 8 5 2 1 24 2 42
Diagnosed with TB
Quarter 3 7 3 2 1 15 2 30

Quarter 4 7 2 - 2 19 - 30

Quarter 1 12 3 - - 23 - 38

Initiated on TB Quarter 2 8 4 2 1 24 1 40
treatment
Quarter 3 7 3 2 1 15 2 30

Quarter 4 4 2 - 1 17 2 26

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,12,824

1.1. HIV sero-positive (%) 1.30

1.2. ICTC clients referred to NTEP 2,70,667

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 1,56,466 1,50,687 9,752 9,515 431 3,209

May-22 1,51,682 1,44,213 8,899 8,693 437 2,977

Jun-22 1,50,942 1,44,362 9,041 8,836 417 3,472

Jul-22 1,52,904 1,46,526 9,393 9,154 372 3,055

Aug-22 1,53,525 1,48,227 9,214 8,965 378 3,023

Sep-22 2,06,007 1,94,658 13,743 9,866 401 4,810

Oct-22 2,03,759 1,98,319 9,896 9,547 345 4,752

Nov-22 2,07,513 2,02,221 11,711 11,499 431 8,203

Dec-22 1,97,181 1,90,730 13,366 11,421 377 7,552

Jan-23 1,65,675 1,55,641 9,985 9,658 443 3,582

Feb-23 1,47,753 1,43,987 9,696 9,422 424 2,047

Mar-23 1,78,164 1,72,784 10,260 10,024 386 1,917

April 2022-March 2023 5,722 5,500

270 Sankalak: Status of National AIDS & STD Response (2023)

 MAHARASHTRA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Maharashtra

Rank 17
Sl. No.
Max Marks 117

Obtained Marks (%) 81 (69)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) R
5 Status of AEP integration in state school curriculum (G=Yes, R=No) R
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) R
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) Y
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 271

MANIPUR
MANIPUR

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.25
2. IMR - - 1.08
3. Adult (15-49 yrs) HIV Prevalence (%) 0.94 0.93 0.94
4. Estimated people living with HIV 13,272 12,675 25,948
5. ART coverage (%) 57.1 61.6 59.8
6. Estimated children living with HIV 1,251 1,277 2,527
7. Annual new HIV infections 432 411 843
8. Annual AIDS-related deaths (ARD) 339 240 579
9. Change in annual new HIV infections since 2010 (%) -39.2 -35.28 -37.3
10. Change in annual ARD since 2010 (%) -66.0 -67.08 -66.5
11. EMTCT need - 314 314

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 5,662 54.4 28.5 1.13
2. Men who have Sex with Men 1,507 - - 9.43
3. Injecting Drug Users 24,985 53.2 82.8 8.84
4. Hijra/Transgender People 468 - - -
5. Migrants 16,000 - - -
6. Truckers - - - -
7. Prison inmates 2,392 50 25 2.26

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 55.9 50.6 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 48.4 48.7 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 87 82 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 85.9 85.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 3 0.1 -
5.1 Condom use during last higher-risk intercourse (%) 24.8 0 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 4.5 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 14.3 NA -

2. Progress on 95-95-95 (2022-23)

89 95 94 93 95 86 92 93
95 95 Indicator (2022-23) Male Female Total

57 56 57 60 63 1. Estimated PLHIV size (2022) 13,272 12,675 25,948

2. PLHIV who know their HIV Status 8,215 8,028 16,370

3. PLHIV who know their HIV status and are on ART 7,574 7,812 15,510
PLHIV who know PLHIV who know PLHIV who are
their HIV status their HIV status on ART and
4. PLHIV who are on ART and tested for their viral load 5,194 4,926 10,190
(%) and are on ART (%) virally
suppressed (%)
5. PLHIV who are virally suppressed 5,123 4,816 10,007
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 273

MANIPUR

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 24,985
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 53,22,967
Indicator 2022-23 4. Syringes distributed 52,89,662
1. Schools with operational Adolescent Education 5. On OST 4,074
175
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 17,321
2. Colleges with operational Red Ribbon Clubs (RRC) 51 6.1. HIV sero-positive (%) 0.26
3. Persons trained under mainstreaming 55 6.1.1 Linked to ART 42
7. Tested for HIV (October 2022 -March 2023) 17,708
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.18
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 27
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 10 1. Estimated size 468
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 33
2. Total STI/RTI 3. Condoms distributed 15,639
25,952 13,867 535 40,354
Clients managed 4. Tested for HIV (April 2022-September 2022) 54
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
1,349 4,465 17 5,831
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 87
1.78 0.16 17.65 0.58
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 356
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 13
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 54 Indicator 2022-23
2. OST centres 52 1. Estimated size 16,000
2. Coverage (%) 42
B. Female Sex Workers
3. Tested for HIV 1,574
Indicator 2022-23
3.1. HIV sero-positive (%) 0.89
1. Estimated size 5,662
3.2. Linked to ART 19
2. Coverage (%) ≥95
3. Condoms distributed 14,29,613 G. Truckers
4. Tested for HIV (April 2022-September 2022) 4,504 Indicator 2022-23
4.1. HIV sero-positive (%) 0.00 1. Estimated size -
4.1.1. Linked to ART 0 2. Coverage (%) -
5. Tested for HIV (October 2022 -March 2023) 4,475 3. Tested for HIV -
5.1. HIV sero-positive (%) 0.22 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 7 3.2. On ART -
6. Clinic Visits 25,466
H. Prison Inmates
7. STI/RTI treated 41
Indicator 2022-23
8. Presumptive treatment 587
1. Total prisons 5
C. Men who have Sex with Men 2. Prisons covered under programme 2
Indicator 2022-23 3. Total inmates admitted 1,755
1. Estimated size 1,507 4. Inmates Covered (%) ≥95
2. Coverage (%) ≥95 5. Tested for HIV 1,053
3. Condoms distributed 2,56,098 5.1. HIV sero-positive (%) 0.57
4. Tested for HIV (April 2022-September 2022) 1,206 5.2. On ART (%) 66.67
4.1. HIV sero-positive (%) 0.25
I. Link Worker Scheme
4.1.1. Linked to ART 3
5. Tested for HIV (October 2022 -March 2023) 1,300 Indicator 2022-23
5.1. HIV sero-positive (%) 0.38 1. Districts covered under scheme 9
5.1.1. Linked to ART 5 2. Vulnerable population covered 27,286
6. Clinic Visits 6,236 3. Tested for HIV 17,969
7. STI/RTI treated 7 3.1. HIV sero-positive (%) 0.11
8. Presumptive treatment 135 3.2. Linked to ART (%) 95.0

274 Sankalak: Status of National AIDS & STD Response (2023)

 MANIPUR

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 52
1.1. OSTC in Public Health Settings 19 Indicator 2022-23
1.2. OSTC in NGO Settings 7 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres 26 1.1 Accredited Viral load laboratories 1
2. IDU on OST 4,074
2. Viral load testing conducted 12,222
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 97.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 1
3.1 Accredited NRL 1
Indicator 2022-23
1. HCTC facilities 226 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 64 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 82 5. CD4 testing conducted 3,323
1.3. Facility integrated (PPP) 13
6. External Quality Assessment of ICTC
1.4. CBS 67
1.5. SSK - 6.1 Average Participation (%) 98.6
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 2
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 72,099 43,174 2,065 1,17,338
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
576 361 11 948
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.80 0.84 0.53 0.81 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 52,390
partner testing of
349 425 2 776 2. HIV testing among PW 36,912
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.14
5. No. of contacts with 4. HIV Positive PW (old + new detections) 174
‘at-risk’ population
- - - - 4.1 On life-long ART 159
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 119

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 115
A. Treatment facilities 6.1 Babies confirmed HIV Positive 2
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 13 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 51
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 2
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 10
3. Link ART Centres 15
4. Care Support Centres 4
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 45,009
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.02
1. HIV positive cases 3. Put on treatment 4
576 412 11 999
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 555 389 13 957 Stigma and Discrimination
centre
2.1 Initiated on ART 526 372 13 911 A. HIV
3. PLHIV alive and
7,574 7,812 124 15,510 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 77.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 639 401 6 1,046 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 275

MANIPUR

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 3,073 1,000 7,280 4 905 - 12,262

Quarter 2 3,893 966 7,855 5 1,135 - 13,854

Screened for TB
Quarter 3 3,793 954 8,035 3 1,279 - 14,064

Quarter 4 3,945 963 9,027 46 1,447 - 15,428

Quarter 1 41 24 61 - - - 126

Quarter 2 54 28 48 - 2 - 132
Tested for TB
Quarter 3 85 47 58 - 5 - 195

Quarter 4 39 18 79 - - - 136

Quarter 1 - - 4 - - - 4

Quarter 2 - - 1 - 1 - 2
Diagnosed with TB
Quarter 3 1 - - - - - 1

Quarter 4 - - 2 - - - 2

Quarter 1 - - 1 - - - 1

Initiated on TB Quarter 2 - - 1 - 1 - 2
treatment
Quarter 3 - - 1 - - - 1

Quarter 4 - - 2 - - - 2

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 223

1.1. HIV sero-positive (%) 11.21

1.2. ICTC clients referred to NTEP 655

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 8,377 8,377 48 48 3 190

May-22 8,254 8,254 69 62 15 430

Jun-22 8,459 8,459 119 119 15 568

Jul-22 8,588 8,544 66 64 17 620

Aug-22 8,588 8,544 66 64 17 620

Sep-22 7,912 7,912 50 47 7 150

Oct-22 8,738 8,738 47 47 12 184

Nov-22 8,535 7,333 47 47 6 529

Dec-22 9,109 7,166 56 54 5 538

Jan-23 8,394 7,248 46 46 12 199

Feb-23 8,759 7,570 39 39 4 35

Mar-23 7,006 6,565 49 43 7 24

April 2022-March 2023 186 175

276 Sankalak: Status of National AIDS & STD Response (2023)

 MANIPUR

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Manipur

Rank 17
Sl. No.
Max Marks 117

Obtained Marks (%) 81 (69)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) Y
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) Y
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) Y
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 277

MEGHALAYA
MEGHALAYA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 11.89
2. IMR - - 10.28
3. Adult (15-49 yrs) HIV Prevalence (%) 0.41 0.38 0.39
4. Estimated people living with HIV 4,436 4,125 8,560
5. ART coverage (%) 51.8 67.8 59.5
6. Estimated children living with HIV 682 656 1,337
7. Annual new HIV infections 524 495 1,019
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 66
9. Change in annual new HIV infections since 2010 (%) 135.0 169.02 150.1
10. Change in annual ARD since 2010 (%) -2.6 0.00 -1.5
11. EMTCT need - 305 305

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 3,297 51.5 40.2 10.92
2. Men who have Sex with Men 344 - - 9.09
3. Injecting Drug Users 3,175 19.7 76.9 11.48
4. Hijra/Transgender People 110 - - -
5. Migrants 50,300 - - -
6. Truckers 4,150 - - -
7. Prison inmates 2,910 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 15.9 14.5 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 14.3 13.4 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 67.2 64.5 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 37.5 27.3 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 2.6 1.1 -
5.1 Condom use during last higher-risk intercourse (%) 40.2 45.3 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 5.0 1.9 -
6.1 Condom use during last higher-risk intercourse (%) 40.7 46.2 -

2. Progress on 95-95-95 (2022-23)

89 90 92 88 95 Indicator (2022-23) Male Female Total
84
71 76 81 76 77
65 1. Estimated PLHIV size (2022) 4,436 4,125 8,560
58 57 61

2. PLHIV who know their HIV Status 2,895 3,199 6,096

3. PLHIV who know their HIV status and are on ART 2,297 2,797 5,095
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 1,305 1,764 3,070
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 1,228 1,691 2,920
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 279

MEGHALAYA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 3,175
A. Information, Education, Communication,
2. Coverage (%) 48
Youth and Mainstreaming
3. Needles distributed 2,60,460
Indicator 2022-23 4. Syringes distributed 2,60,471
1. Schools with operational Adolescent Education 5. On OST 972
50
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,040
2. Colleges with operational Red Ribbon Clubs (RRC) 86 6.1. HIV sero-positive (%) 0.77
3. Persons trained under mainstreaming 733 6.1.1 Linked to ART 4
7. Tested for HIV (October 2022 -March 2023) 1,011
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 1.68
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 10
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 10 1. Estimated size 110
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 25
2. Total STI/RTI 3. Condoms distributed 3,313
8,742 9,647 69 18,458
Clients managed 4. Tested for HIV (April 2022-September 2022) 9
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
7,155 8,207 2 15,364
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 10
9.97 7.05 0.00 8.41
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 68
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 3
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 11 Indicator 2022-23
2. OST centres 9 1. Estimated size 50,300
2. Coverage (%) 0
B. Female Sex Workers
3. Tested for HIV 0
Indicator 2022-23
3.1. HIV sero-positive (%) -
1. Estimated size 3,297
3.2. Linked to ART 18
2. Coverage (%) 62.09484874
3. Condoms distributed 3,02,764 G. Truckers
4. Tested for HIV (April 2022-September 2022) 1,246 Indicator 2022-23
4.1. HIV sero-positive (%) 0.56 1. Estimated size 4,150
4.1.1. Linked to ART 5 2. Coverage (%) 0
5. Tested for HIV (October 2022 -March 2023) 1,306 3. Tested for HIV 0
5.1. HIV sero-positive (%) 0.46 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 7 3.2. On ART 0
6. Clinic Visits 5,953
H. Prison Inmates
7. STI/RTI treated 344
Indicator 2022-23
8. Presumptive treatment 279
1. Total prisons 5
C. Men who have Sex with Men 2. Prisons covered under programme 5
Indicator 2022-23 3. Total inmates admitted 2,346
1. Estimated size 344 4. Inmates Covered (%) 92
2. Coverage (%) 58 5. Tested for HIV 2,022
3. Condoms distributed 26,147 5.1. HIV sero-positive (%) 0.54
4. Tested for HIV (April 2022-September 2022) 117 5.2. On ART (%) 90.91
4.1. HIV sero-positive (%) 0.85
I. Link Worker Scheme
4.1.1. Linked to ART 1
5. Tested for HIV (October 2022 -March 2023) 140 Indicator 2022-23
5.1. HIV sero-positive (%) 0.00 1. Districts covered under scheme 2
5.1.1. Linked to ART 0 2. Vulnerable population covered 1,028
6. Clinic Visits 513 3. Tested for HIV 953
7. STI/RTI treated 1 3.1. HIV sero-positive (%) 1.68
8. Presumptive treatment 18 3.2. Linked to ART (%) 112.5

280 Sankalak: Status of National AIDS & STD Response (2023)

 MEGHALAYA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 9
1.1. OSTC in Public Health Settings 2 Indicator 2022-23
1.2. OSTC in NGO Settings 3 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 4 1.1 Accredited Viral load laboratories -
2. IDU on OST 972
2. Viral load testing conducted 3,210
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 93.9

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 222 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 34 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 170 5. CD4 testing conducted 1,560
1.3. Facility integrated (PPP) 6
6. External Quality Assessment of ICTC
1.4. CBS 12
1.5. SSK - 6.1 Average Participation (%) 96.3
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 1
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 32,731 34,686 3 67,420
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
767 412 - 1,179
among tested A. HIV
3. HIV sero-positivity
(%) among tested
2.34 1.19 0.00 1.75 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 80,690
partner testing of
128 233 - 361 2. HIV testing among PW 62,679
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.29
5. No. of contacts with 4. HIV Positive PW (old + new detections) 284
‘at-risk’ population
- - - - 4.1 On life-long ART 267
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 269

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 236
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 4 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 178
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 7
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 5
3. Link ART Centres 2
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 72,940
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.99
1. HIV positive cases 3. Put on treatment 616
767 593 - 1,360
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 696 583 - 1,279 Stigma and Discrimination
centre
2.1 Initiated on ART 627 535 - 1,162 A. HIV
3. PLHIV alive and
2,297 2,797 1 5,095 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 62.5 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 652 482 1 1,135 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 281

MEGHALAYA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 1,127 112 1,130 15 - - 2,384

Quarter 2 1,196 140 1,115 14 - - 2,465

Screened for TB
Quarter 3 1,273 135 1,165 15 - - 2,588

Quarter 4 1,392 142 1,316 24 - - 2,874

Quarter 1 43 - 35 - - - 78

Quarter 2 34 - 2 - - - 36
Tested for TB
Quarter 3 30 - - - - - 30

Quarter 4 45 - - - - - 45

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 2,922

1.1. HIV sero-positive (%) 2.29

1.2. ICTC clients referred to NTEP 653

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 2,675 2,481 23 10 5 23

May-22 2,681 2,524 19 12 3 74

Jun-22 - 2,603 30 15 7 103

Jul-22 2,524 2,524 26 17 5 93

Aug-22 2,978 2,743 29 20 4 127

Sep-22 2,852 2,573 29 11 4 147

Oct-22 2,827 2,784 38 31 1 185

Nov-22 2,850 2,542 15 9 2 96

Dec-22 2,842 2,650 16 13 3 37

Jan-23 3,328 2,857 14 13 3 72

Feb-23 2,870 2,521 14 13 2 15

Mar-23 3,559 3,024 24 22 4 132

April 2022-March 2023 163 152

282 Sankalak: Status of National AIDS & STD Response (2023)

 MEGHALAYA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Meghalaya

Rank 14
Sl. No.
Max Marks 117

Obtained Marks (%) 83 (71)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) Y
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) G
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) Y
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) Y
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 283

MIZORAM
MIZORAM

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 4.80
2. IMR - - 4.10
3. Adult (15-49 yrs) HIV Prevalence (%) 2.61 2.05 2.34
4. Estimated people living with HIV 12,039 9,401 21,440
5. ART coverage (%) 74.9 66.1 71.0
6. Estimated children living with HIV 1,177 928 2,105
7. Annual new HIV infections 589 440 1,029
8. Annual AIDS-related deaths (ARD) 53 60 113
9. Change in annual new HIV infections since 2010 (%) -26.5 -25.93 -26.3
10. Change in annual ARD since 2010 (%) -85.4 -73.57 -80.8
11. EMTCT need - 288 288

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 1,434 37.7 43 56.15
2. Men who have Sex with Men 841 - - 12.8
3. Injecting Drug Users 10,397 53.1 79.5 32.08
4. Hijra/Transgender People - - - -
5. Migrants 50,300 - - 4.8
6. Truckers 15,000 - - -
7. Prison inmates 6,606 33.3 45.9 26.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 65.6 64.1 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 60 68.9 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 95.7 86.7 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 89.4 88.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 3.3 0.7 -
5.1 Condom use during last higher-risk intercourse (%) 29 7.1 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 2.4 0.7 -
6.1 Condom use during last higher-risk intercourse (%) 57.1 33.3 -

2. Progress on 95-95-95 (2022-23)

91 92 90 91 94 Indicator (2022-23) Male Female Total
84 87 88 88 82
73 78
68 1. Estimated PLHIV size (2022) 12,039 9,401 21,440
59 62

2. PLHIV who know their HIV Status 9,986 6,715 16,701

3. PLHIV who know their HIV status and are on ART 9,012 6,211 15,223
PLHIV who know PLHIV who know PLHIV who are on 4. PLHIV who are on ART and tested for their viral load 5,308 3,848 9,157
their HIV status their HIV status ART and virally
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 4,934 3,658 8,593
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 285

MIZORAM

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 10,397
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 18,96,514
Indicator 2022-23 4. Syringes distributed 18,96,855
1. Schools with operational Adolescent Education 5. On OST 2,983
-
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 7,105
2. Colleges with operational Red Ribbon Clubs (RRC) 44 6.1. HIV sero-positive (%) 2.58
3. Persons trained under mainstreaming 4,309 6.1.1 Linked to ART 129
7. Tested for HIV (October 2022 -March 2023) 6,449
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 1.64
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 94
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 10 1. Estimated size -
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) -
2. Total STI/RTI 3. Condoms distributed -
49,373 23,067 397 72,837
Clients managed 4. Tested for HIV (April 2022-September 2022) -
3. RPR Tests 4.1. HIV sero-positive (%) -
8,377 13,669 - 22,046
conducted 4.1.1. Linked to ART -
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) -
0.68 0.44 - 0.53
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART -
4. Prevention of new HIV infections among 6. Clinic Visits -
high-risk group and bridge population
7. STI/RTI treated -
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment -
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 36 Indicator 2022-23
2. OST centres 86 1. Estimated size 50,300
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 6,919
Indicator 2022-23
3.1. HIV sero-positive (%) 0.39
1. Estimated size 1,434
3.2. Linked to ART 60
2. Coverage (%) 69.55
3. Condoms distributed 1,39,866 G. Truckers
4. Tested for HIV (April 2022-September 2022) 591 Indicator 2022-23
4.1. HIV sero-positive (%) 2.20 1. Estimated size 15,000
4.1.1. Linked to ART 6 2. Coverage (%) 0
5. Tested for HIV (October 2022 -March 2023) 563 3. Tested for HIV 0
5.1. HIV sero-positive (%) 2.84 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 10 3.2. On ART 0
6. Clinic Visits 3,122
H. Prison Inmates
7. STI/RTI treated 13
Indicator 2022-23
8. Presumptive treatment 90
1. Total prisons 10
C. Men who have Sex with Men 2. Prisons covered under programme 9
Indicator 2022-23 3. Total inmates admitted 4,937
1. Estimated size 841 4. Inmates Covered (%) 34
2. Coverage (%) ≥95 5. Tested for HIV 1,687
3. Condoms distributed 66,061 5.1. HIV sero-positive (%) 5.99
4. Tested for HIV (April 2022-September 2022) 511 5.2. On ART (%) 14.85
4.1. HIV sero-positive (%) 0.98
I. Link Worker Scheme
4.1.1. Linked to ART 4
5. Tested for HIV (October 2022 -March 2023) 548 Indicator 2022-23
5.1. HIV sero-positive (%) 0.36 1. Districts covered under scheme 8
5.1.1. Linked to ART 3 2. Vulnerable population covered 11,589
6. Clinic Visits 2,661 3. Tested for HIV 9,559
7. STI/RTI treated 11 3.1. HIV sero-positive (%) 0.71
8. Presumptive treatment 52 3.2. Linked to ART (%) 88.2

286 Sankalak: Status of National AIDS & STD Response (2023)

 MIZORAM

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 86
1.1. OSTC in Public Health Settings 13 Indicator 2022-23
1.2. OSTC in NGO Settings 4 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 69 1.1 Accredited Viral load laboratories -
2. IDU on OST 2,983
2. Viral load testing conducted 10,198
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 92.1

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 161 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 41 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 64 5. CD4 testing conducted 5,438
1.3. Facility integrated (PPP) 12
6. External Quality Assessment of ICTC
1.4. CBS 44
1.5. SSK 1 6.1 Average Participation (%) 100.0
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 10
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 42,893 27,528 5 70,426
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
1,545 677 - 2,222
among tested A. HIV
3. HIV sero-positivity
(%) among tested
3.60 2.46 0.00 3.16 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 18,760
partner testing of
480 565 2 1,047 2. HIV testing among PW 21,337
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.71
5. No. of contacts with 4. HIV Positive PW (old + new detections) 256
‘at-risk’ population
196 202 - 398 4.1 On life-long ART 244
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 266

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 289
A. Treatment facilities 6.1 Babies confirmed HIV Positive 1
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 14 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 216
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 8
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres 4
4. Care Support Centres 3
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 22,935
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.10
1. HIV positive cases 3. Put on treatment 23
1,545 828 - 2,373
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 1,394 777 - 2,171 Stigma and Discrimination
centre
2.1 Initiated on ART 1,384 768 - 2,152 A. HIV
3. PLHIV alive and
9,012 6,211 - 15,223 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 90.3 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 755 399 - 1,154 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 287

MIZORAM

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 669 441 9,179 - 3,173 - 13,462

Quarter 2 745 749 10,498 - 3,620 - 15,612

Screened for TB
Quarter 3 794 726 9,645 - 4,534 - 15,699

Quarter 4 864 743 11,106 - 4,189 - 16,902

Quarter 1 3 - 18 - 1 - 22

Quarter 2 3 1 20 - - - 24
Tested for TB
Quarter 3 4 1 10 - - - 15

Quarter 4 5 - 17 - - - 22

Quarter 1 1 - 2 - - - 3

Quarter 2 - - 3 - - - 3
Diagnosed with TB
Quarter 3 - - 2 - - - 2

Quarter 4 - - 1 - - - 1

Quarter 1 1 - 2 - - - 3

Initiated on TB Quarter 2 - - 3 - - - 3
treatment
Quarter 3 - - 1 - - - 1

Quarter 4 - - 1 - - - 1

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,561

1.1. HIV sero-positive (%) 8.07

1.2. ICTC clients referred to NTEP 1,475

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 5,581 5,581 49 49 23 292

May-22 6,119 6,119 57 57 30 267

Jun-22 6,574 6,574 47 47 22 199

Jul-22 6,415 6,415 46 46 18 257

Aug-22 6,415 6,415 46 46 18 257

Sep-22 6,809 6,809 45 41 16 424

Oct-22 6,307 6,307 30 30 7 381

Nov-22 8,121 8,121 69 42 15 182

Dec-22 6,376 6,376 58 34 17 167

Jan-23 6,053 6,052 28 27 12 173

Feb-23 7,424 7,424 43 43 42 119

Mar-23 7,627 7,627 61 61 14 70

April 2022-March 2023 270 268

288 Sankalak: Status of National AIDS & STD Response (2023)

 MIZORAM

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Mizoram

Rank 19
Sl. No.
Max Marks 117

Obtained Marks (%) 80 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) Y
5 Status of AEP integration in state school curriculum (G=Yes, R=No) R
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) Y
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) R

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 289

NAGALAND
NAGALAND

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 4.73
2. IMR - - 2.64
3. Adult (15-49 yrs) HIV Prevalence (%) 1.37 1.31 1.34
4. Estimated people living with HIV 11,711 10,473 22,184
5. ART coverage (%) 54.1 62.2 58.0
6. Estimated children living with HIV 1,248 1,158 2,406
7. Annual new HIV infections 557 493 1,050
8. Annual AIDS-related deaths (ARD) 166 99 265
9. Change in annual new HIV infections since 2010 (%) -37.0 -32.09 -34.8
10. Change in annual ARD since 2010 (%) -68.0 -68.47 -68.2
11. EMTCT need - 278 278

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 2,246 80.2 0 2
2. Men who have Sex with Men 1,239 69.9 0 3.06
3. Injecting Drug Users 16,802 53.0 87.9 2.53
4. Hijra/Transgender People 82 - - -
5. Migrants 5,000 - - -
6. Truckers 5,000 - - 1.20
7. Prison inmates 2,137 50 31.8 4.59

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 40.1 25.6 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 31.9 21.1 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 64.8 63.4 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 63.7 56.8 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 8.8 2.3 -
5.1 Condom use during last higher-risk intercourse (%) 59.5 11.6 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 7.5 3.4 -
6.1 Condom use during last higher-risk intercourse (%) 66.7 6.3 -

2. Progress on 95-95-95 (2022-23)

93 Indicator (2022-23) Male Female Total
86 87 86
80 79 80 80
73
63 58 63 67 72 68 1. Estimated PLHIV size (2022) 11,711 10,473 22,184

2. PLHIV who know their HIV Status 7,949 8,055 16,013

3. PLHIV who know their HIV status and are on ART 6,337 6,515 12,859
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally
4. PLHIV who are on ART and tested for their viral load 3,912 4,383 8,304
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 3,532 4,161 7,702
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 291

NAGALAND

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 16,802
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 17,93,625
Indicator 2022-23 4. Syringes distributed 17,95,116
1. Schools with operational Adolescent Education 5. On OST 7,949
724
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 16,775
2. Colleges with operational Red Ribbon Clubs (RRC) 89 6.1. HIV sero-positive (%) 0.60
3. Persons trained under mainstreaming 6,541 6.1.1 Linked to ART 77
7. Tested for HIV (October 2022 -March 2023) 16,730
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.29
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 41
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 12 1. Estimated size 82
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 28,967
4,320 4,069 - 8,389
Clients managed 4. Tested for HIV (April 2022-September 2022) 21
3. RPR Tests 4.1. HIV sero-positive (%) 4.76
3,747 3,441 - 7,188
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 90
1.52 1.54 - 1.53
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 345
high-risk group and bridge population
7. STI/RTI treated 3
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 18
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 46 Indicator 2022-23
2. OST centres 50 1. Estimated size 5,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 2,699
Indicator 2022-23
3.1. HIV sero-positive (%) 0.15
1. Estimated size 2,246
3.2. Linked to ART 14
2. Coverage (%) ≥95
3. Condoms distributed 6,72,282 G. Truckers
4. Tested for HIV (April 2022-September 2022) 3,115 Indicator 2022-23
4.1. HIV sero-positive (%) 0.29 1. Estimated size 5,000
4.1.1. Linked to ART 8 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 3,047 3. Tested for HIV 2,361
5.1. HIV sero-positive (%) 0.07 3.1. HIV sero-positive (%) 0.30
5.1.1. Linked to ART 1 3.2. On ART 2
6. Clinic Visits 11,956
H. Prison Inmates
7. STI/RTI treated 144
Indicator 2022-23
8. Presumptive treatment 949
1. Total prisons 11
C. Men who have Sex with Men 2. Prisons covered under programme 12
Indicator 2022-23 3. Total inmates admitted 2,046
1. Estimated size 1,239 4. Inmates Covered (%) 40
2. Coverage (%) ≥95 5. Tested for HIV 583
3. Condoms distributed 4,73,831 5.1. HIV sero-positive (%) 4.12
4. Tested for HIV (April 2022-September 2022) 1,324 5.2. On ART (%) 145.83
4.1. HIV sero-positive (%) 0.98
I. Link Worker Scheme
4.1.1. Linked to ART 10
5. Tested for HIV (October 2022 -March 2023) 1,533 Indicator 2022-23
5.1. HIV sero-positive (%) 0.46 1. Districts covered under scheme 6
5.1.1. Linked to ART 6 2. Vulnerable population covered 4,799
6. Clinic Visits 6,052 3. Tested for HIV 2,078
7. STI/RTI treated 12 3.1. HIV sero-positive (%) 0.91
8. Presumptive treatment 227 3.2. Linked to ART (%) 73.7

292 Sankalak: Status of National AIDS & STD Response (2023)

 NAGALAND

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 50
1.1. OSTC in Public Health Settings 26 Indicator 2022-23
1.2. OSTC in NGO Settings 5 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 19 1.1 Accredited Viral load laboratories -
2. IDU on OST 7,949
2. Viral load testing conducted 9,493
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 91.5

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 269 4. State reference laboratories (SRL) 2
1.1. Stand-Alone 73 4.1 Accredited SRL 2
1.2. Facility integrated (Govt.) 125 5. CD4 testing conducted 6,822
1.3. Facility integrated (PPP) 14
6. External Quality Assessment of ICTC
1.4. CBS 57
1.5. SSK 1 6.1 Average Participation (%) 98.6
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 6
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 69,856 50,707 5 1,20,568
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
1,069 775 - 1,844
among tested A. HIV
3. HIV sero-positivity
(%) among tested
1.53 1.53 0.00 1.53 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 29,830
partner testing of
508 514 - 1,022 2. HIV testing among PW 21,883
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.84
5. No. of contacts with 4. HIV Positive PW (old + new detections) 240
‘at-risk’ population
27 35 - 62 4.1 On life-long ART 185
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 271

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 97.05
infected people 6. Babies tested HIV (6 week- 6 month) 160
A. Treatment facilities 6.1 Babies confirmed HIV Positive 5
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 12 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 99
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 5
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 6
3. Link ART Centres 8
4. Care Support Centres 3
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 26,142
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.49
1. HIV positive cases 3. Put on treatment 125
1,069 959 - 2,028
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 1,037 943 - 1,980 Stigma and Discrimination
centre
2.1 Initiated on ART 942 883 - 1,825 A. HIV
3. PLHIV alive and
6,337 6,515 7 12,859 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 80.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 1,419 1,302 1 2,722 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 293

NAGALAND

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 1,198 792 6,279 38 199 - 8,506

Quarter 2 1,243 887 7,167 50 525 - 9,872

Screened for TB
Quarter 3 1,253 605 6,556 59 646 - 9,119

Quarter 4 1,381 925 6,573 113 560 - 9,552

Quarter 1 12 2 27 - - - 41

Quarter 2 8 3 18 - 6 - 35
Tested for TB
Quarter 3 7 1 19 - - - 27

Quarter 4 15 - 36 - - - 51

Quarter 1 1 - - - - - 1

Quarter 2 - - - - 1 - 1
Diagnosed with TB
Quarter 3 - - 1 - - - 1

Quarter 4 - - 6 - - - 6

Quarter 1 1 - - - - - 1

Initiated on TB Quarter 2 - - - - 1 - 1
treatment
Quarter 3 - - 1 - - - 1

Quarter 4 - - 6 - - - 6

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,503

1.1. HIV sero-positive (%) 3.66

1.2. ICTC clients referred to NTEP 3,027

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 4,385 3,928 90 68 25 125

May-22 4,826 4,307 97 84 30 198

Jun-22 6,280 4,703 89 45 27 354

Jul-22 5,137 4,986 100 77 36 521

Aug-22 5,736 4,371 85 67 29 294

Sep-22 6,193 4,726 77 66 23 393

Oct-22 6,193 4,726 77 66 23 393

Nov-22 7,078 5,683 62 56 25 185

Dec-22 5,383 4,170 41 37 22 106

Jan-23 5,001 3,967 64 61 33 76

Feb-23 5,584 4,118 56 53 25 38

Mar-23 6,245 4,856 93 83 42 94

April 2022-March 2023 398 362

294 Sankalak: Status of National AIDS & STD Response (2023)

 NAGALAND

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Nagaland

Rank 19
Sl. No.
Max Marks 117

Obtained Marks (%) 80 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) Y
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) R
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 295

ODISHA
ODISHA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.49
2. IMR - - 0.91
3. Adult (15-49 yrs) HIV Prevalence (%) 0.14 0.13 0.14
4. Estimated people living with HIV 28,032 24,848 52,880
5. ART coverage (%) 51.6 45.9 49.7
6. Estimated children living with HIV 1,979 1,909 3,887
7. Annual new HIV infections 925 919 1,844
8. Annual AIDS-related deaths (ARD) 725 789 1,514
9. Change in annual new HIV infections since 2010 (%) -54.4 -48.63 -51.7
10. Change in annual ARD since 2010 (%) -52.8 -34.85 -44.9
11. EMTCT need - 499 499

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 24,620 60.6 72 0.65
2. Men who have Sex with Men 5,977 31.5 67.8 1.2
3. Injecting Drug Users 4,526 63.9 87.3 1.9
4. Hijra/Transgender People 7,209 70.7 - 1.49
5. Migrants 92,000 - - 1.6
6. Truckers 15,607 - - 2.00
7. Prison inmates 82,440 34.4 0 0.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 24.6 21.4 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 22.1 18.1 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 77.5 71.3 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 56.9 63.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 1.1 0.2 -
5.1 Condom use during last higher-risk intercourse (%) 39.3 2.7 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 1.8 0.4 -
6.1 Condom use during last higher-risk intercourse (%) 35.0 0.0 -

2. Progress on 95-95-95 (2022-23)

94 92 90 89 90 Indicator (2022-23) Male Female Total
84 87 85 87
76
55
1. Estimated PLHIV size (2022) 28,032 24,848 52,880
49 51
43 47
2. PLHIV who know their HIV Status 16,408 12,307 29,260

3. PLHIV who know their HIV status and are on ART 14,465 11,402 26,307
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 6,952 5,696 12,809
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 5,943 4,998 11,081
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 297

ODISHA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 4,526
A. Information, Education, Communication,
2. Coverage (%) 75
Youth and Mainstreaming
3. Needles distributed 3,69,657
Indicator 2022-23 4. Syringes distributed 6,31,597
1. Schools with operational Adolescent Education 5. On OST 397
364
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 2,619
2. Colleges with operational Red Ribbon Clubs (RRC) 640 6.1. HIV sero-positive (%) 0.11
3. Persons trained under mainstreaming 532 6.1.1 Linked to ART 3
7. Tested for HIV (October 2022 -March 2023) 2,889
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.17
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 5
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 40 1. Estimated size 7,209
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 54
2. Total STI/RTI 3. Condoms distributed 10,06,559
85,719 84,830 3,252 1,73,801
Clients managed 4. Tested for HIV (April 2022-September 2022) 2,611
3. RPR Tests 4.1. HIV sero-positive (%) 0.65
57,624 51,989 2,833 1,12,446
conducted 4.1.1. Linked to ART 17
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 2,972
1.29 0.43 4.09 0.96
seropositivity (%)
5.1. HIV sero-positive (%) 0.57
5.1.1. Linked to ART 14
4. Prevention of new HIV infections among 6. Clinic Visits 11,755
high-risk group and bridge population
7. STI/RTI treated 336
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 568
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 52 Indicator 2022-23
2. OST centres 6 1. Estimated size 92,000
2. Coverage (%) 52
B. Female Sex Workers
3. Tested for HIV 53,910
Indicator 2022-23
3.1. HIV sero-positive (%) 0.06
1. Estimated size 24,620
3.2. Linked to ART 126
2. Coverage (%) 60.23
3. Condoms distributed 30,68,438 G. Truckers
4. Tested for HIV (April 2022-September 2022) 10,803 Indicator 2022-23
4.1. HIV sero-positive (%) 0.09 1. Estimated size 15,607
4.1.1. Linked to ART 9 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 11,690 3. Tested for HIV 10,594
5.1. HIV sero-positive (%) 0.08 3.1. HIV sero-positive (%) 0.05
5.1.1. Linked to ART 9 3.2. On ART 5
6. Clinic Visits 44,877
H. Prison Inmates
7. STI/RTI treated 1,341
Indicator 2022-23
8. Presumptive treatment 2,089
1. Total prisons 92
C. Men who have Sex with Men 2. Prisons covered under programme 92
Indicator 2022-23 3. Total inmates admitted 94,753
1. Estimated size 5,977 4. Inmates Covered (%) 43
2. Coverage (%) 62 5. Tested for HIV 39,876
3. Condoms distributed 7,02,535 5.1. HIV sero-positive (%) 0.20
4. Tested for HIV (April 2022-September 2022) 2,629 5.2. On ART (%) 88.89
4.1. HIV sero-positive (%) 0.27
I. Link Worker Scheme
4.1.1. Linked to ART 6
5. Tested for HIV (October 2022 -March 2023) 2,864 Indicator 2022-23
5.1. HIV sero-positive (%) 0.28 1. Districts covered under scheme 6
5.1.1. Linked to ART 9 2. Vulnerable population covered 1,39,840
6. Clinic Visits 10,777 3. Tested for HIV 72,327
7. STI/RTI treated 273 3.1. HIV sero-positive (%) 0.18
8. Presumptive treatment 527 3.2. Linked to ART (%) 98.4

298 Sankalak: Status of National AIDS & STD Response (2023)

 ODISHA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 6
1.1. OSTC in Public Health Settings 4 Indicator 2022-23
1.2. OSTC in NGO Settings 1 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 1 1.1 Accredited Viral load laboratories -
2. IDU on OST 397
2. Viral load testing conducted 13,799
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 84.8

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 662 4. State reference laboratories (SRL) 3
1.1. Stand-Alone 216 4.1 Accredited SRL -
1.2. Facility integrated (Govt.) 217 5. CD4 testing conducted 9,779
1.3. Facility integrated (PPP) 83
6. External Quality Assessment of ICTC
1.4. CBS 146
1.5. SSK 3 6.1 Average Participation (%) 98.8
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 1
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 8,73,270 4,82,229 8,539 13,64,038
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
2,111 800 107 3,018
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.24 0.17 1.25 0.22 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 9,27,940
partner testing of
415 609 21 1,045 2. HIV testing among PW 6,75,073
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 306
‘at-risk’ population
- - - - 4.1 On life-long ART 305
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 212

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 208
A. Treatment facilities 6.1 Babies confirmed HIV Positive 2
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 19 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 209
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 12
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 2
3. Link ART Centres 19
4. Care Support Centres 12
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 8,33,637
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.03
1. HIV positive cases 3. Put on treatment 267
2,111 978 107 3,196
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 2,033 1,060 92 3,185 Stigma and Discrimination
centre
2.1 Initiated on ART 1,952 1,013 91 3,056 A. HIV
3. PLHIV alive and
14,465 11,402 440 26,307 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 80.7 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 2,158 1,253 95 3,506 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 299

ODISHA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 11,043 2,689 2,311 2,934 16,711 3,750 39,438

Quarter 2 11,272 2,684 2,630 2,704 17,504 4,098 40,892

Screened for TB
Quarter 3 11,514 2,903 2,264 2,966 17,510 4,470 41,627

Quarter 4 11,945 2,862 2,451 3,201 19,326 4,830 44,615

Quarter 1 940 156 304 134 630 34 2,198

Quarter 2 1,154 208 378 155 722 76 2,693

Tested for TB
Quarter 3 992 217 310 238 697 51 2,505

Quarter 4 912 187 357 263 692 42 2,453

Quarter 1 2 1 1 2 3 1 10

Quarter 2 - - - 1 4 - 5
Diagnosed with TB
Quarter 3 1 2 1 - 2 - 6

Quarter 4 4 - - - 6 - 10

Quarter 1 2 1 1 2 3 1 10

Initiated on TB Quarter 2 - - - 1 4 - 5
treatment
Quarter 3 1 2 1 - 2 - 6

Quarter 4 4 - - - 6 - 10

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 25,412

1.1. HIV sero-positive (%) 0.81

1.2. ICTC clients referred to NTEP 91,057

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 9,906 9,195 407 407 34 261

May-22 9,864 9,478 379 379 33 276

Jun-22 9,452 9,044 492 492 38 247

Jul-22 9,452 9,044 492 492 38 247

Aug-22 9,452 9,044 492 492 38 247

Sep-22 8,787 8,483 393 393 33 309

Oct-22 8,234 7,933 399 396 31 252

Nov-22 9,073 8,736 446 445 21 168

Dec-22 9,073 8,103 415 413 28 88

Jan-23 9,300 8,764 403 391 25 167

Feb-23 9,222 8,740 408 400 30 134

Mar-23 10,239 9,811 442 439 31 131

April 2022-March 2023 658 643

300 Sankalak: Status of National AIDS & STD Response (2023)

 ODISHA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Odisha

Rank 31
Sl. No.
Max Marks 120

Obtained Marks (%) 74 (62)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) Y
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) G
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) Y
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) R
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) R
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 301

PUDUCHERRY
PUDUCHERRY

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.49
2. IMR - - 1.05
3. Adult (15-49 yrs) HIV Prevalence (%) 0.22 0.19 0.21
4. Estimated people living with HIV 1,505 1,421 2,926
5. ART coverage (%) 46.5 49.9 48.3
6. Estimated children living with HIV 79 76 155
7. Annual new HIV infections 54 ≤50 102
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 74
9. Change in annual new HIV infections since 2010 (%) -55.4 -53.85 -54.7
10. Change in annual ARD since 2010 (%) 141.2 135.71 138.7
11. EMTCT need - 17 17

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 2,514 68.8 0 0.5
2. Men who have Sex with Men 2,489 85.9 0 0
3. Injecting Drug Users 21 - - -
4. Hijra/Transgender People 203 - - -
5. Migrants 15,000 - - 0
6. Truckers - - - -
7. Prison inmates 2,378 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 32.5 30.2 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 32.3 25.4 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 76.4 67.4 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 63.4 54.2 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 2.4 0.1 -
5.1 Condom use during last higher-risk intercourse (%) 60.5 0 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 0.0 0.0 -
6.1 Condom use during last higher-risk intercourse (%) - - -

2. Progress on 95-95-95 (2022-23)

95 Indicator (2022-23) Male Female Total
83 84 83 85 86 86 83
72 66
65 1. Estimated PLHIV size (2022) 1,505 1,421 2,926
57 56 57 57

2. PLHIV who know their HIV Status 855 801 1,664

3. PLHIV who know their HIV status and are on ART 699 709 1,413
PLHIV who know PLHIV who know PLHIV who are
their HIV status their HIV status on ART and 4. PLHIV who are on ART and tested for their viral load 410 471 886
(%) and are on ART (%) virally
suppressed (%)
5. PLHIV who are virally suppressed 391 450 845
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 303

PUDUCHERRY

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 21
A. Information, Education, Communication,
2. Coverage (%) 0
Youth and Mainstreaming
3. Needles distributed 0
Indicator 2022-23 4. Syringes distributed 0
1. Schools with operational Adolescent Education 5. On OST 0
325
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 0
2. Colleges with operational Red Ribbon Clubs (RRC) 70 6.1. HIV sero-positive (%) 0
3. Persons trained under mainstreaming 1,813 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 0
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 0
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 5 1. Estimated size 203
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 69,554
22,769 17,354 966 41,089
Clients managed 4. Tested for HIV (April 2022-September 2022) 187
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
4,059 8,034 228 12,321
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 172
4.46 0.71 3.51 2.00
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 721
high-risk group and bridge population
7. STI/RTI treated 0
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 21
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 5 Indicator 2022-23
2. OST centres 0 1. Estimated size 15,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 9,724
Indicator 2022-23
3.1. HIV sero-positive (%) 0.03
1. Estimated size 2,514
3.2. Linked to ART -
2. Coverage (%) ≥95
3. Condoms distributed 6,61,574 G. Truckers
4. Tested for HIV (April 2022-September 2022) 2,594 Indicator 2022-23
4.1. HIV sero-positive (%) 0.08 1. Estimated size -
4.1.1. Linked to ART 2 2. Coverage (%) -
5. Tested for HIV (October 2022 -March 2023) 2,718 3. Tested for HIV -
5.1. HIV sero-positive (%) 0.04 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 1 3.2. On ART -
6. Clinic Visits 9,411
H. Prison Inmates
7. STI/RTI treated 46
Indicator 2022-23
8. Presumptive treatment 572
1. Total prisons 4
C. Men who have Sex with Men 2. Prisons covered under programme 4
Indicator 2022-23 3. Total inmates admitted 1,551
1. Estimated size 2,489 4. Inmates Covered (%) 64
2. Coverage (%) ≥95 5. Tested for HIV 914
3. Condoms distributed 6,98,029 5.1. HIV sero-positive (%) 0.00
4. Tested for HIV (April 2022-September 2022) 2,712 5.2. On ART (%) -
4.1. HIV sero-positive (%) 0.00
I. Link Worker Scheme
4.1.1. Linked to ART 0
5. Tested for HIV (October 2022 -March 2023) 2,737 Indicator 2022-23
5.1. HIV sero-positive (%) 0.00 1. Districts covered under scheme -
5.1.1. Linked to ART 0 2. Vulnerable population covered -
6. Clinic Visits 10,015 3. Tested for HIV -
7. STI/RTI treated 12 3.1. HIV sero-positive (%) -
8. Presumptive treatment 524 3.2. Linked to ART (%) -

304 Sankalak: Status of National AIDS & STD Response (2023)

 PUDUCHERRY

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres -
1.1. OSTC in Public Health Settings - Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST -
2. Viral load testing conducted 997
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 93.7

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 81 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 12 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 48 5. CD4 testing conducted 915
1.3. Facility integrated (PPP) 16
6. External Quality Assessment of ICTC
1.4. CBS 5
1.5. SSK - 6.1 Average Participation (%) 97.9
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 4
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 88,536 61,001 525 1,50,062
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
132 90 - 222
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.15 0.15 0.00 0.15 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 22,670
partner testing of
60 63 - 123 2. HIV testing among PW 29,734
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.01
5. No. of contacts with 4. HIV Positive PW (old + new detections) 7
‘at-risk’ population
- - - - 4.1 On life-long ART 6
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 20

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 13
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 1 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 7
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres 1
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 35,583
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 5
132 93 - 225
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 45 42 - 87 Stigma and Discrimination
centre
2.1 Initiated on ART 42 41 - 83 A. HIV
3. PLHIV alive and
699 709 5 1,413 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 76.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 34 25 - 59 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 305

PUDUCHERRY

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 2,635 2,686 - 195 3,306 - 8,822

Quarter 2 2,672 2,807 - 211 3,525 - 9,215

Screened for TB
Quarter 3 2,710 2,873 - 205 3,575 - 9,363

Quarter 4 2,741 2,654 - 191 3,758 - 9,344

Quarter 1 16 3 - 1 1 - 21

Quarter 2 11 17 - 4 1 - 33
Tested for TB
Quarter 3 4 19 - - - - 23

Quarter 4 22 23 - 6 1 - 52

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 - - - - - - -

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,739

1.1. HIV sero-positive (%) 0.17

1.2. ICTC clients referred to NTEP 1,296

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 1,097 951 41 41 4 7

May-22 1,115 973 30 30 2 5

Jun-22 1,135 989 33 33 2 5

Jul-22 1,139 1,005 39 39 3 4

Aug-22 1,172 1,046 36 36 4 6

Sep-22 1,154 1,071 37 37 1 14

Oct-22 1,135 1,026 34 34 4 8

Nov-22 1,145 1,041 35 35 4 4

Dec-22 1,158 1,022 30 30 2 5

Jan-23 1,099 993 36 36 3 8

Feb-23 1,073 975 28 28 3 10

Mar-23 1,073 975 28 28 3 10

April 2022-March 2023 30 30

306 Sankalak: Status of National AIDS & STD Response (2023)

 PUDUCHERRY

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Puducherry

Rank 2
Sl. No.
Max Marks 114

Obtained Marks (%) 91 (80)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) R
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) NA
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) Y
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) NA
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) G
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) G
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 G
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 307

PUNJAB
PUNJAB

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 2.48
2. IMR - - 1.54
3. Adult (15-49 yrs) HIV Prevalence (%) 0.35 0.25 0.30
4. Estimated people living with HIV 48,719 32,069 80,788
5. ART coverage (%) 83.9 57.9 73.8
6. Estimated children living with HIV 2,747 1,867 4,614
7. Annual new HIV infections 1,183 818 2,001
8. Annual AIDS-related deaths (ARD) 232 393 625
9. Change in annual new HIV infections since 2010 (%) -61.3 -57.86 -60.0
10. Change in annual ARD since 2010 (%) -90.5 -65.86 -82.6
11. EMTCT need - 819 819

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 27,304 71.9 56.5 3.38
2. Men who have Sex with Men 8,045 55.1 14.6 11.62
3. Injecting Drug Users 45,098 64.6 86.7 19.57
4. Hijra/Transgender People 1,316 - - -
5. Migrants 1,31,850 - - 3.01
6. Truckers - - - 2.33
7. Prison inmates 75,276 60 44.8 7.49

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 37.5 20.6 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 33.3 17.5 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 79.8 77.2 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 67.5 66.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5.9 0.3 -
5.1 Condom use during last higher-risk intercourse (%) 56.9 30.1 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 8.5 0.6 -
6.1 Condom use during last higher-risk intercourse (%) 61.4 33.3 -

2. Progress on 95-95-95 (2022-23)

87 90 Indicator (2022-23) Male Female Total

76 81 79 76 82 85 83 84 79
67 72 70
57 1. Estimated PLHIV size (2022) 48,719 32,069 80,788

2. PLHIV who know their HIV Status 49,766 20,517 70,510

3. PLHIV who know their HIV status and are on ART 40,890 18,563 59,615
PLHIV who know PLHIV who know PLHIV who are
their HIV status their HIV status on ART and
(%) and are on ART (%) virally
4. PLHIV who are on ART and tested for their viral load 18,538 12,020 30,615
suppressed (%)
5. PLHIV who are virally suppressed 16,566 10,887 27,505
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 309

PUNJAB

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 45,098
A. Information, Education, Communication,
2. Coverage (%) 54
Youth and Mainstreaming
3. Needles distributed 37,40,675
Indicator 2022-23 4. Syringes distributed 27,04,194
1. Schools with operational Adolescent Education 5. On OST 9,868
6,057
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 16,723
2. Colleges with operational Red Ribbon Clubs (RRC) 700 6.1. HIV sero-positive (%) 2.21
3. Persons trained under mainstreaming 11,087 6.1.1 Linked to ART 316
7. Tested for HIV (October 2022 -March 2023) 16,616
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 1.53
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 140
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 31 1. Estimated size 1,316
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 83
2. Total STI/RTI 3. Condoms distributed 2,71,692
2,03,600 1,76,217 5,157 3,84,974
Clients managed 4. Tested for HIV (April 2022-September 2022) 760
3. RPR Tests 4.1. HIV sero-positive (%) 0.66
84,628 1,15,211 188 2,00,027
conducted 4.1.1. Linked to ART 3
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 991
1.06 0.25 1.06 0.60
seropositivity (%)
5.1. HIV sero-positive (%) 0.50
5.1.1. Linked to ART 2
4. Prevention of new HIV infections among 6. Clinic Visits 3,638
high-risk group and bridge population
7. STI/RTI treated 31
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 255
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 61 Indicator 2022-23
2. OST centres 40 1. Estimated size 1,31,850
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 16,718
Indicator 2022-23
3.1. HIV sero-positive (%) 0.17
1. Estimated size 27,304
3.2. Linked to ART 1,038
2. Coverage (%) 79.41
3. Condoms distributed 36,66,313 G. Truckers
4. Tested for HIV (April 2022-September 2022) 13,760 Indicator 2022-23
4.1. HIV sero-positive (%) 0.25 1. Estimated size -
4.1.1. Linked to ART 26 2. Coverage (%) 0
5. Tested for HIV (October 2022 -March 2023) 14,359 3. Tested for HIV 7,219
5.1. HIV sero-positive (%) 0.16 3.1. HIV sero-positive (%) 0.14
5.1.1. Linked to ART 19 3.2. On ART 11
6. Clinic Visits 54,759
H. Prison Inmates
7. STI/RTI treated 886
Indicator 2022-23
8. Presumptive treatment 1,678
1. Total prisons 26
C. Men who have Sex with Men 2. Prisons covered under programme 25
Indicator 2022-23 3. Total inmates admitted 76,999
1. Estimated size 8,045 4. Inmates Covered (%) 60
2. Coverage (%) 64 5. Tested for HIV 44,795
3. Condoms distributed 10,22,837 5.1. HIV sero-positive (%) 2.14
4. Tested for HIV (April 2022-September 2022) 4,102 5.2. On ART (%) 97.08
4.1. HIV sero-positive (%) 1.12
I. Link Worker Scheme
4.1.1. Linked to ART 36
5. Tested for HIV (October 2022 -March 2023) 4,066 Indicator 2022-23
5.1. HIV sero-positive (%) 0.89 1. Districts covered under scheme 7
5.1.1. Linked to ART 22 2. Vulnerable population covered 22,774
6. Clinic Visits 16,689 3. Tested for HIV 14,863
7. STI/RTI treated 163 3.1. HIV sero-positive (%) 7.32
8. Presumptive treatment 561 3.2. Linked to ART (%) 95.4

310 Sankalak: Status of National AIDS & STD Response (2023)

 PUNJAB

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 40
1.1. OSTC in Public Health Settings 26 Indicator 2022-23
1.2. OSTC in NGO Settings 8 1. Viral load laboratories 1
1.3. No. of Satellite OST Centres 6 1.1 Accredited Viral load laboratories 0
2. IDU on OST 9,868
2. Viral load testing conducted 35,724
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 88.1

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 845 4. State reference laboratories (SRL) 2
1.1. Stand-Alone 116 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 372 5. CD4 testing conducted 23,553
1.3. Facility integrated (PPP) 266
6. External Quality Assessment of ICTC
1.4. CBS 91
1.5. SSK 6 6.1 Average Participation (%) 94.3
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 6,13,777 4,08,032 1,099 10,22,908
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
10,273 1,653 24 11,950
among tested A. HIV
3. HIV sero-positivity
(%) among tested
1.67 0.41 2.18 1.17 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 4,83,520
partner testing of
3,020 2,422 16 5,458 2. HIV testing among PW 4,02,125
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.13
5. No. of contacts with 4. HIV Positive PW (old + new detections) 893
‘at-risk’ population
266 676 - 942 4.1 On life-long ART 783
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 625

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.68
infected people 6. Babies tested HIV (6 week- 6 month) 666
A. Treatment facilities 6.1 Babies confirmed HIV Positive 5
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 24 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 338
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 6
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 7
3. Link ART Centres 12
4. Care Support Centres 8
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 4,81,180
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.03
1. HIV positive cases 3. Put on treatment 151
10,273 2,180 24 12,477
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 9,494 2,188 23 11,705 Stigma and Discrimination
centre
2.1 Initiated on ART 9,395 2,170 23 11,588 A. HIV
3. PLHIV alive and
40,890 18,563 162 59,615 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 67.1 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 6,217 1,296 29 7,542 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 311

PUNJAB

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 12,727 3,920 19,013 743 6,726 4,247 47,376

Quarter 2 13,228 4,096 18,677 895 6,096 6,170 49,162

Screened for TB
Quarter 3 13,786 4,281 18,718 928 6,756 5,741 50,210

Quarter 4 13,869 4,066 20,614 1,069 6,686 5,545 51,849

Quarter 1 14 22 141 4 29 4 214

Quarter 2 12 13 75 4 11 1 116
Tested for TB
Quarter 3 16 19 38 5 17 4 99

Quarter 4 21 14 60 2 16 - 113

Quarter 1 - 2 6 3 5 - 16

Quarter 2 - - 5 1 3 - 9
Diagnosed with TB
Quarter 3 - 3 6 2 3 - 14

Quarter 4 - - 6 - 1 - 7

Quarter 1 - 2 6 3 5 - 16

Initiated on TB Quarter 2 - - 7 1 3 - 11
treatment
Quarter 3 - 3 5 2 3 - 13

Quarter 4 - - 6 - 1 - 7

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 46,786

1.1. HIV sero-positive (%) 2.86

1.2. ICTC clients referred to NTEP 25,755

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 26,290 26,275 422 379 92 649

May-22 26,648 26,667 417 361 97 695

Jun-22 24,742 24,725 447 385 83 1,157

Jul-22 25,513 25,493 335 311 60 1,330

Aug-22 25,513 25,493 335 311 60 1,330

Sep-22 31,846 31,844 463 456 53 1,339

Oct-22 37,348 37,348 2,767 356 51 691

Nov-22 34,928 34,926 2,583 412 53 519

Dec-22 34,271 33,961 329 286 50 393

Jan-23 34,760 34,750 844 332 64 482

Feb-23 31,614 31,613 811 300 46 586

Mar-23 35,288 35,280 418 410 59 536

April 2022-March 2023 1,206 1,166

312 Sankalak: Status of National AIDS & STD Response (2023)

 PUNJAB

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Punjab

Rank 9
Sl. No.
Max Marks 117

Obtained Marks (%) 84 (72)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) Y
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) G
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) Y
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 313

RAJASTHAN
RAJASTHAN

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.36
2. IMR - - 2.36
3. Adult (15-49 yrs) HIV Prevalence (%) 0.13 0.09 0.11
4. Estimated people living with HIV 42,824 28,291 71,115
5. ART coverage (%) 73.7 96.6 82.9
6. Estimated children living with HIV 3,035 2,069 5,104
7. Annual new HIV infections 1,445 944 2,389
8. Annual AIDS-related deaths (ARD) 271 82 353
9. Change in annual new HIV infections since 2010 (%) -41.7 -35.12 -39.2
10. Change in annual ARD since 2010 (%) -76.4 -82.33 -78.1
11. EMTCT need - 929 929

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 21,034 62.6 40.7 2.75
2. Men who have Sex with Men 7,351 32.7 18.6 6.4
3. Injecting Drug Users 3,024 38.7 92.2 -
4. Hijra/Transgender People 2,126 - - 3.6
5. Migrants 1,10,000 - - 0.39
6. Truckers 38,340 - - 0.00
7. Prison inmates 1,18,516 50 7.7 0.67

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 36 26.8 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 34.3 27.6 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 76 76 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 78.2 72.4 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 6.4 0.9 -
5.1 Condom use during last higher-risk intercourse (%) 73.8 74.6 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 11.6 2.1 -
6.1 Condom use during last higher-risk intercourse (%) 74.2 76.5 -

2. Progress on 95-95-95 (2022-23)

82 84 86
90 91 89 88 89 92
82 83 85
91 Indicator (2022-23) Male Female Total
77
59 1. Estimated PLHIV size (2022) 42,824 28,291 71,115

2. PLHIV who know their HIV Status 34,357 29,386 63,849

3. PLHIV who know their HIV status and are on ART 31,563 27,335 58,988
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 18,292 18,596 36,928
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 16,402 17,020 33,460
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 315

RAJASTHAN

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 3,024
A. Information, Education, Communication,
2. Coverage (%) 40
Youth and Mainstreaming
3. Needles distributed 4,63,066
Indicator 2022-23 4. Syringes distributed 2,74,499
1. Schools with operational Adolescent Education 5. On OST 301
500
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 927
2. Colleges with operational Red Ribbon Clubs (RRC) 715 6.1. HIV sero-positive (%) 0.65
3. Persons trained under mainstreaming 5,660 6.1.1 Linked to ART 4
7. Tested for HIV (October 2022 -March 2023) 1,052
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.29
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 5
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 53 1. Estimated size 2,126
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 69
2. Total STI/RTI 3. Condoms distributed 2,43,730
1,56,592 2,29,669 2,920 3,89,181
Clients managed 4. Tested for HIV (April 2022-September 2022) 884
3. RPR Tests 4.1. HIV sero-positive (%) 0.34
51,102 1,36,048 47 1,87,197
conducted 4.1.1. Linked to ART 3
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 1,192
1.59 0.25 8.51 0.62
seropositivity (%)
5.1. HIV sero-positive (%) 0.08
5.1.1. Linked to ART 1
4. Prevention of new HIV infections among 6. Clinic Visits 3,676
high-risk group and bridge population
7. STI/RTI treated 44
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 196
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 41 Indicator 2022-23
2. OST centres 3 1. Estimated size 1,10,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 22,454
Indicator 2022-23
3.1. HIV sero-positive (%) 0.08
1. Estimated size 21,034
3.2. Linked to ART 3
2. Coverage (%) 91.61
3. Condoms distributed 41,09,304 G. Truckers
4. Tested for HIV (April 2022-September 2022) 12,306 Indicator 2022-23
4.1. HIV sero-positive (%) 0.04 1. Estimated size 38,340
4.1.1. Linked to ART 3 2. Coverage (%) 52
5. Tested for HIV (October 2022 -March 2023) 14,144 3. Tested for HIV 3,709
5.1. HIV sero-positive (%) 0.10 3.1. HIV sero-positive (%) 0.08
5.1.1. Linked to ART 13 3.2. On ART 3
6. Clinic Visits 49,600
H. Prison Inmates
7. STI/RTI treated 1,026
Indicator 2022-23
8. Presumptive treatment 2,511
1. Total prisons 144
C. Men who have Sex with Men 2. Prisons covered under programme 145
Indicator 2022-23 3. Total inmates admitted 1,23,169
1. Estimated size 7,351 4. Inmates Covered (%) 80
2. Coverage (%) 93 5. Tested for HIV 88,389
3. Condoms distributed 11,82,182 5.1. HIV sero-positive (%) 0.28
4. Tested for HIV (April 2022-September 2022) 4,346 5.2. On ART (%) 85.94
4.1. HIV sero-positive (%) 0.39
I. Link Worker Scheme
4.1.1. Linked to ART 14
5. Tested for HIV (October 2022 -March 2023) 5,445 Indicator 2022-23
5.1. HIV sero-positive (%) 0.51 1. Districts covered under scheme 1
5.1.1. Linked to ART 25 2. Vulnerable population covered 2,446
6. Clinic Visits 17,844 3. Tested for HIV 1,592
7. STI/RTI treated 205 3.1. HIV sero-positive (%) 0.19
8. Presumptive treatment 557 3.2. Linked to ART (%) 100.0

316 Sankalak: Status of National AIDS & STD Response (2023)

 RAJASTHAN

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 3
1.1. OSTC in Public Health Settings 3 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 3
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 0
2. IDU on OST 301
2. Viral load testing conducted 45,959
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 88.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 2,705 4. State reference laboratories (SRL) 6
1.1. Stand-Alone 184 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 2,280 5. CD4 testing conducted 45,427
1.3. Facility integrated (PPP) 149
6. External Quality Assessment of ICTC
1.4. CBS 92
1.5. SSK 15 6.1 Average Participation (%) 85.6
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 11,50,380 9,08,585 2,224 20,61,189
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
4,396 2,152 16 6,564
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.38 0.24 0.72 0.32 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 20,64,990
partner testing of
1,564 1,567 3 3,134 2. HIV testing among PW 14,76,033
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 835
‘at-risk’ population
- - - - 4.1 On life-long ART 842
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 723

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.28
infected people 6. Babies tested HIV (6 week- 6 month) 697
A. Treatment facilities 6.1 Babies confirmed HIV Positive 12
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 36 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 470
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 30
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 25
3. Link ART Centres 25
4. Care Support Centres 17
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 15,80,879
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.05
1. HIV positive cases 3. Put on treatment 743
4,396 2,568 16 6,980
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 4,036 2,462 17 6,515 Stigma and Discrimination
centre
2.1 Initiated on ART 3,942 2,429 17 6,388 A. HIV
3. PLHIV alive and
31,563 27,335 91 58,988 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 73.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 2,312 1,621 12 3,945 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 317

RAJASTHAN

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 19,546 7,795 1,848 1,514 37,590 11,535 79,828

Quarter 2 22,624 8,542 1,772 1,816 41,336 10,621 86,711

Screened for TB
Quarter 3 21,106 8,279 1,796 1,795 42,346 12,757 88,079

Quarter 4 22,510 8,158 1,959 1,935 42,538 12,760 89,860

Quarter 1 18 12 - - 24 2 56

Quarter 2 29 15 - 3 31 5 83
Tested for TB
Quarter 3 32 25 - - 34 11 102

Quarter 4 35 23 - - 39 18 115

Quarter 1 2 - - - 3 1 6

Quarter 2 - 2 - - 1 2 5
Diagnosed with TB
Quarter 3 - - - - 8 8 16

Quarter 4 1 3 - - 7 14 25

Quarter 1 2 - - - 2 1 5

Initiated on TB Quarter 2 - 2 - - 1 2 5
treatment
Quarter 3 - - - - 8 5 13

Quarter 4 1 3 - - 5 5 14

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 54,387

1.1. HIV sero-positive (%) 1.37

1.2. ICTC clients referred to NTEP 54,679

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 28,973 28,605 1,665 851 123 887

May-22 29,317 28,964 1,803 976 140 777

Jun-22 30,018 29,715 2,797 963 119 841

Jul-22 29,815 29,558 1,697 888 136 964

Aug-22 29,815 29,558 1,697 888 136 964

Sep-22 32,553 32,080 1,751 926 139 883

Oct-22 32,359 32,013 1,577 777 92 759

Nov-22 34,907 34,597 1,728 940 128 691

Dec-22 35,605 35,254 1,631 846 109 620

Jan-23 30,309 30,065 1,556 772 101 570

Feb-23 29,646 29,363 1,626 824 123 515

Mar-23 31,691 31,392 1,722 931 125 587

April 2022-March 2023 1,578 1,552

318 Sankalak: Status of National AIDS & STD Response (2023)

 RAJASTHAN

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Rajasthan

Rank 27
Sl. No.
Max Marks 120

Obtained Marks (%) 81 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) R
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) R
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) Y
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 319

SIKKIM
SIKKIM

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 4.27
2. IMR - - 3.17
3. Adult (15-49 yrs) HIV Prevalence (%) 0.09 0.07 0.08
4. Estimated people living with HIV 268 176 445
5. ART coverage (%) 68.7 73.7 70.7
6. Estimated children living with HIV ≤50 ≤50 ≤50
7. Annual new HIV infections ≤50 ≤50 ≤50
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 ≤50
9. Change in annual new HIV infections since 2010 (%) -38.9 -41.67 -36.7
10. Change in annual ARD since 2010 (%) -33.3 0.00 -25.0
11. EMTCT need - 9 9

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 732 - - 0
2. Men who have Sex with Men - - - -
3. Injecting Drug Users 821 28.6 89.7 0.2
4. Hijra/Transgender People - - - -
5. Migrants - - - -
6. Truckers - - - -
7. Prison inmates 944 - - -

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 18.5 23.9 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 15.1 29.3 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 64.1 74.4 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 67.4 73.1 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 12.8 3.6 -
5.1 Condom use during last higher-risk intercourse (%) 71.8 52.3 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 6.9 7.9 -
6.1 Condom use during last higher-risk intercourse (%) 42.9 58.3 -

2. Progress on 95-95-95 (2022-23)

92 91 87 87 89 86 87 89 91
95 Indicator (2022-23) Male Female Total
80
71
64 1. Estimated PLHIV size (2022) 268 176 445
56 60

2. PLHIV who know their HIV Status 208 147 355

3. PLHIV who know their HIV status and are on ART 184 130 315
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 129 101 230
(%) and are on ART (%) suppressed (%)

2018-19 2019-20 2020-21 2021-22 2022-23

5. PLHIV who are virally suppressed 124 98 222

Sankalak: Status of National AIDS & STD Response (2023) 321

SIKKIM

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 821
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 3,93,222
Indicator 2022-23 4. Syringes distributed 3,93,242
1. Schools with operational Adolescent Education 5. On OST 1,661
110
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,030
2. Colleges with operational Red Ribbon Clubs (RRC) 125 6.1. HIV sero-positive (%) 0.00
3. Persons trained under mainstreaming 2,260 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 1,145
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.09
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 1
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 6 1. Estimated size -
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) -
2. Total STI/RTI 3. Condoms distributed -
3,443 4,070 - 7,513
Clients managed 4. Tested for HIV (April 2022-September 2022) -
3. RPR Tests 4.1. HIV sero-positive (%) -
456 1,345 - 1,801
conducted 4.1.1. Linked to ART -
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) -
13.16 3.72 - 6.11
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART -
4. Prevention of new HIV infections among 6. Clinic Visits -
high-risk group and bridge population
7. STI/RTI treated -
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment -
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 6 Indicator 2022-23
2. OST centres 7 1. Estimated size -
2. Coverage (%) -
B. Female Sex Workers
3. Tested for HIV -
Indicator 2022-23
3.1. HIV sero-positive (%) -
1. Estimated size 732
3.2. Linked to ART -
2. Coverage (%) ≥95
3. Condoms distributed 2,38,831 G. Truckers
4. Tested for HIV (April 2022-September 2022) 823 Indicator 2022-23
4.1. HIV sero-positive (%) 0.00 1. Estimated size -
4.1.1. Linked to ART 0 2. Coverage (%) -
5. Tested for HIV (October 2022 -March 2023) 894 3. Tested for HIV -
5.1. HIV sero-positive (%) 0.00 3.1. HIV sero-positive (%) -
5.1.1. Linked to ART 0 3.2. On ART -
6. Clinic Visits 3,089
H. Prison Inmates
7. STI/RTI treated 77
Indicator 2022-23
8. Presumptive treatment 103
1. Total prisons 2
C. Men who have Sex with Men 2. Prisons covered under programme 2
Indicator 2022-23 3. Total inmates admitted 853
1. Estimated size - 4. Inmates Covered (%) 67
2. Coverage (%) - 5. Tested for HIV 390
3. Condoms distributed - 5.1. HIV sero-positive (%) 0.00
4. Tested for HIV (April 2022-September 2022) - 5.2. On ART (%) -
4.1. HIV sero-positive (%) -
I. Link Worker Scheme
4.1.1. Linked to ART -
5. Tested for HIV (October 2022 -March 2023) - Indicator 2022-23
5.1. HIV sero-positive (%) - 1. Districts covered under scheme -
5.1.1. Linked to ART - 2. Vulnerable population covered -
6. Clinic Visits - 3. Tested for HIV -
7. STI/RTI treated - 3.1. HIV sero-positive (%) -
8. Presumptive treatment - 3.2. Linked to ART (%) -

322 Sankalak: Status of National AIDS & STD Response (2023)

 SIKKIM

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 7
1.1. OSTC in Public Health Settings 4 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 3 1.1 Accredited Viral load laboratories -
2. IDU on OST 1,661
2. Viral load testing conducted 257
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 94.6

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 45 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 13 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 26 5. CD4 testing conducted 371
1.3. Facility integrated (PPP) -
6. External Quality Assessment of ICTC
1.4. CBS 6
1.5. SSK - 6.1 Average Participation (%) 80.1
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 1
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 16,730 13,212 4 29,946
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
33 13 - 46
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.20 0.10 0.00 0.15 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 11,970
partner testing of
2 3 - 5 2. HIV testing among PW 9,210
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.04
5. No. of contacts with 4. HIV Positive PW (old + new detections) 9
‘at-risk’ population
- - - - 4.1 On life-long ART 8
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 5

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 6
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 1 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 5
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART -
3. Link ART Centres 1
4. Care Support Centres -
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 9,789
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.27
1. HIV positive cases 3. Put on treatment 19
33 17 - 50
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 38 18 - 56 Stigma and Discrimination
centre
2.1 Initiated on ART 37 17 - 54 A. HIV
3. PLHIV alive and
184 130 - 315 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 87.5 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 16 6 - 22 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 323

SIKKIM

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 378 - 516 - - - 894

Quarter 2 415 - 533 - - - 948

Screened for TB
Quarter 3 437 - 533 - - - 970

Quarter 4 531 - 672 - - - 1,203

Quarter 1 6 - 9 - - - 15

Quarter 2 7 - 4 - - - 11
Tested for TB
Quarter 3 2 - 1 - - - 3

Quarter 4 5 - 4 - - - 9

Quarter 1 - - - - - - -

Quarter 2 - - - - - - -
Diagnosed with TB
Quarter 3 1 - - - - - 1

Quarter 4 1 - - - - - 1

Quarter 1 - - - - - - -

Initiated on TB Quarter 2 - - - - - - -
treatment
Quarter 3 1 - - - - - 1

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,292

1.1. HIV sero-positive (%) 10.45

1.2. ICTC clients referred to NTEP 77

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 138 138 2 2 - 1

May-22 120 120 3 3 - 1

Jun-22 127 127 5 5 1 -

Jul-22 163 163 - - - 2

Aug-22 110 110 - - - 1

Sep-22 135 135 - - - -

Oct-22 101 101 - - - -

Nov-22 144 144 2 - - 11

Dec-22 114 114 1 - - 5

Jan-23 145 145 2 1 - -

Feb-23 129 129 2 2 - -

Mar-23 121 121 2 2 - 1

April 2022-March 2023 8 4

324 Sankalak: Status of National AIDS & STD Response (2023)

 SIKKIM

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Sikkim

Rank 7
Sl. No.
Max Marks 117

Obtained Marks (%) 86 (74)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) G
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) Y
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) R
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 325

TAMIL NADU
TAMIL NADU

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 1.42
2. IMR - - 0.63
3. Adult (15-49 yrs) HIV Prevalence (%) 0.21 0.20 0.21
4. Estimated people living with HIV 85,133 79,522 1,64,656
5. ART coverage (%) 76.7 88.0 82.4
6. Estimated children living with HIV 4,059 3,639 7,698
7. Annual new HIV infections 1,272 1,062 2,334
8. Annual AIDS-related deaths (ARD) 1,507 510 2,017
9. Change in annual new HIV infections since 2010 (%) -57.6 -57.82 -57.7
10. Change in annual ARD since 2010 (%) -74.3 -86.49 -79.1
11. EMTCT need - 1,071 1,071

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 60,775 88.8 17.3 1.52
2. Men who have Sex with Men 38,284 59.5 21.2 2.07
3. Injecting Drug Users 115 - - -
4. Hijra/Transgender People 9,211 52.3 - 4.8
5. Migrants 1,95,127 - - 0
6. Truckers 47,000 - - 0.60
7. Prison inmates 63,039 84.6 16.7 0.50

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 26.6 23.6 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 23.2 23.9 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 65.7 56.4 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 52.2 41.5 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 0.8 0 -
5.1 Condom use during last higher-risk intercourse (%) 49.8 - -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 0.7 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 16.7 - -

2. Progress on 95-95-95 (2022-23)

92 88 90 89 89 90 93 Indicator (2022-23) Male Female Total
85 86 87 89 85 85 86
74
1. Estimated PLHIV size (2022) 85,133 79,522 1,64,656

2. PLHIV who know their HIV Status 75,075 75,617 1,51,291

3. PLHIV who know their HIV status and are on ART 65,311 69,964 1,35,735
PLHIV who know PLHIV who know PLHIV who are on
their HIV status (%) their HIV status and ART and virally 4. PLHIV who are on ART and tested for their viral load 52,917 50,806 1,04,032
are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 49,568 47,145 97,000
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 327

TAMIL NADU

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 115
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 16,474
Indicator 2022-23 4. Syringes distributed 16,474
1. Schools with operational Adolescent Education 5. On OST 39
9,830
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 135
2. Colleges with operational Red Ribbon Clubs (RRC) 2,329 6.1. HIV sero-positive (%) 0.00
3. Persons trained under mainstreaming 7,732 6.1.1 Linked to ART 0
7. Tested for HIV (October 2022 -March 2023) 450
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.00
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 0
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 106 1. Estimated size 9,211
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 99
2. Total STI/RTI 3. Condoms distributed 18,64,707
2,74,664 2,86,073 23,696 5,84,433
Clients managed 4. Tested for HIV (April 2022-September 2022) 5,655
3. RPR Tests 4.1. HIV sero-positive (%) 0.34
1,88,704 1,82,483 3,771 3,74,958
conducted 4.1.1. Linked to ART 18
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 5,931
1.02 0.29 1.49 0.67
seropositivity (%)
5.1. HIV sero-positive (%) 0.25
5.1.1. Linked to ART 17
4. Prevention of new HIV infections among 6. Clinic Visits 15,266
high-risk group and bridge population
7. STI/RTI treated 17
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 926
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 86 Indicator 2022-23
2. OST centres 1 1. Estimated size 1,95,127
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 28,262
Indicator 2022-23
3.1. HIV sero-positive (%) 0.07
1. Estimated size 60,775
3.2. Linked to ART 103
2. Coverage (%) ≥95
3. Condoms distributed 99,41,875 G. Truckers
4. Tested for HIV (April 2022-September 2022) 38,504 Indicator 2022-23
4.1. HIV sero-positive (%) 0.04 1. Estimated size 47,000
4.1.1. Linked to ART 16 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 38,766 3. Tested for HIV 14,859
5.1. HIV sero-positive (%) 0.03 3.1. HIV sero-positive (%) 0.12
5.1.1. Linked to ART 12 3.2. On ART 15
6. Clinic Visits 1,06,141
H. Prison Inmates
7. STI/RTI treated 760
Indicator 2022-23
8. Presumptive treatment 6,319
1. Total prisons 142
C. Men who have Sex with Men 2. Prisons covered under programme 142
Indicator 2022-23 3. Total inmates admitted 1,11,585
1. Estimated size 38,284 4. Inmates Covered (%) 61
2. Coverage (%) ≥95 5. Tested for HIV 65,608
3. Condoms distributed 73,77,924 5.1. HIV sero-positive (%) 0.15
4. Tested for HIV (April 2022-September 2022) 27,826 5.2. On ART (%) 90.00
4.1. HIV sero-positive (%) 0.19
I. Link Worker Scheme
4.1.1. Linked to ART 54
5. Tested for HIV (October 2022 -March 2023) 28,141 Indicator 2022-23
5.1. HIV sero-positive (%) 0.17 1. Districts covered under scheme 17
5.1.1. Linked to ART 49 2. Vulnerable population covered 4,11,372
6. Clinic Visits 75,783 3. Tested for HIV 26,184
7. STI/RTI treated 193 3.1. HIV sero-positive (%) 0.40
8. Presumptive treatment 5,130 3.2. Linked to ART (%) 97.2

328 Sankalak: Status of National AIDS & STD Response (2023)

 TAMIL NADU

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 1
1.1. OSTC in Public Health Settings 1 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 7
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 4
2. IDU on OST 39
2. Viral load testing conducted 1,16,649
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 91.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 2
3.1 Accredited NRL 2
Indicator 2022-23
1. HCTC facilities 2,987 4. State reference laboratories (SRL) 12
1.1. Stand-Alone 807 4.1 Accredited SRL 10
1.2. Facility integrated (Govt.) 1,876 5. CD4 testing conducted 1,24,342
1.3. Facility integrated (PPP) 199
6. External Quality Assessment of ICTC
1.4. CBS 105
1.5. SSK - 6.1 Average Participation (%) 99.8
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 17
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 23,22,161 17,60,061 12,273 40,94,495
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
4,779 2,863 50 7,692
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.21 0.16 0.41 0.19 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 11,70,490
partner testing of
1,557 2,242 3 3,802 2. HIV testing among PW 10,96,396
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 946
‘at-risk’ population
- - - - 4.1 On life-long ART 951
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 577

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 535
A. Treatment facilities 6.1 Babies confirmed HIV Positive 10
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 60 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 524
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 16
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 18
3. Link ART Centres 174
4. Care Support Centres 31
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 13,53,547
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 126
diagnosed (At ICTC) 4,779 3,106 50 7,935
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART
4,599 3,046 56 7,701 Stigma and Discrimination
centre
2.1 Initiated on ART 4,254 2,872 53 7,179 A. HIV
3. PLHIV alive and
65,311 69,964 460 1,35,735 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 76.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 2,450 1,438 34 3,922 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 329

TAMIL NADU

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 43,114 30,126 109 6,497 51,672 12,705 1,44,223

Quarter 2 43,015 29,715 163 6,536 48,691 13,422 1,41,542

Screened for TB
Quarter 3 42,483 28,841 309 6,440 38,441 18,458 1,34,972

Quarter 4 41,342 28,489 391 6,353 37,591 17,617 1,31,783

Quarter 1 394 384 - 74 6 33 891

Quarter 2 702 650 - 166 19 1 1,538

Tested for TB
Quarter 3 602 493 - 142 37 97 1,371

Quarter 4 785 848 8 146 - 6 1,793

Quarter 1 - 2 - 2 - - 4

Quarter 2 1 3 - - - - 4
Diagnosed with TB
Quarter 3 1 1 - 2 - 2 6

Quarter 4 - 6 - - - - 6

Quarter 1 - 2 - 2 - - 4

Initiated on TB Quarter 2 1 3 - - - - 4
treatment
Quarter 3 1 1 - 2 - 2 6

Quarter 4 - 6 - - - - 6

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 3,96,246

1.1. HIV sero-positive (%) 0.21

1.2. ICTC clients referred to NTEP 2,66,685

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 88,722 86,618 4,401 4,342 240 900

May-22 90,929 88,668 4,663 4,618 244 1,020

Jun-22 84,607 82,153 4,299 4,241 218 932

Jul-22 92,608 90,259 5,409 4,475 207 1,283

Aug-22 92,498 90,433 4,621 4,562 186 1,013

Sep-22 98,430 96,184 5,251 5,233 202 1,318

Oct-22 88,886 86,800 4,717 4,708 185 847

Nov-22 90,872 88,456 4,994 4,974 223 1,024

Dec-22 85,963 83,540 4,823 4,796 217 870

Jan-23 85,945 82,491 4,943 4,909 188 859

Feb-23 80,555 77,161 4,967 4,932 211 777

Mar-23 89,649 85,753 5,071 5,037 213 691

April 2022-March 2023 2,899 2,754

330 Sankalak: Status of National AIDS & STD Response (2023)

 TAMIL NADU

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Tamil Nadu

Rank 4
Sl. No.
Max Marks 120

Obtained Marks (%) 92 (77)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) Y
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) Y
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) Y
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 G
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 331

TELANGANA
TELANGANA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 1.22
2. IMR - - 0.50
3. Adult (15-49 yrs) HIV Prevalence (%) 0.47 0.43 0.45
4. Estimated people living with HIV 83,330 75,644 1,58,974
5. ART coverage (%) 55.6 71.0 63.3
6. Estimated children living with HIV 5,203 4,644 9,848
7. Annual new HIV infections 1,101 846 1,947
8. Annual AIDS-related deaths (ARD) 1,910 459 2,369
9. Change in annual new HIV infections since 2010 (%) -69.0 -69.39 -69.2
10. Change in annual ARD since 2010 (%) -80.2 -92.46 -84.9
11. EMTCT need - 1,062 1,062

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 75,381 - - 1.81
2. Men who have Sex with Men 16,427 - - 2.67
3. Injecting Drug Users 816 - - 0.4
4. Hijra/Transgender People 995 80.7 - 4
5. Migrants 75,601 - - 0.8
6. Truckers 47,000 - - 0.80
7. Prison inmates 82,917 88.2 0 2.50

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 30.5 30.7 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 30.3 32.9 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 65.4 61.9 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 70.4 58.9 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 4.4 0.4 -
5.1 Condom use during last higher-risk intercourse (%) 47.6 36.8 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 6.0 0.2 -
6.1 Condom use during last higher-risk intercourse (%) 32.3 50.0 -

2. Progress on 95-95-95 (2022-23)

88 87 85 86 87 86 85 84
93 Indicator (2022-23) Male Female Total
81 85
76 79 80 72
1. Estimated PLHIV size (2022) 83,330 75,644 1,58,974

2. PLHIV who know their HIV Status 53,829 59,651 1,14,077

3. PLHIV who know their HIV status and are on ART 46,328 53,739 1,00,570
PLHIV who know PLHIV who know PLHIV who are on 4. PLHIV who are on ART and tested for their viral load 36,943 39,114 76,285
their HIV status (%) their HIV status and ART and virally
are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 33,857 35,980 70,054
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 333

TELANGANA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 816
A. Information, Education, Communication,
2. Coverage (%) ≥95
Youth and Mainstreaming
3. Needles distributed 3,75,866
Indicator 2022-23 4. Syringes distributed 3,75,866
1. Schools with operational Adolescent Education 5. On OST 0
1,000
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,058
2. Colleges with operational Red Ribbon Clubs (RRC) 770 6.1. HIV sero-positive (%) 0.28
3. Persons trained under mainstreaming 1,650 6.1.1 Linked to ART 3
7. Tested for HIV (October 2022 -March 2023) 864
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.12
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 0
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 50 1. Estimated size 995
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) ≥95
2. Total STI/RTI 3. Condoms distributed 26,39,035
1,46,446 3,53,886 9,403 5,09,735
Clients managed 4. Tested for HIV (April 2022-September 2022) 1,588
3. RPR Tests 4.1. HIV sero-positive (%) 0.38
33,172 72,711 336 1,06,219
conducted 4.1.1. Linked to ART 5
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 2,418
1.64 0.31 7.44 0.75
seropositivity (%)
5.1. HIV sero-positive (%) 0.37
5.1.1. Linked to ART 8
4. Prevention of new HIV infections among 6. Clinic Visits 6,852
high-risk group and bridge population
7. STI/RTI treated 19
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 502
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 53 Indicator 2022-23
2. OST centres 0 1. Estimated size 75,601
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 32,098
Indicator 2022-23
3.1. HIV sero-positive (%) 0.04
1. Estimated size 75,381
3.2. Linked to ART 106
2. Coverage (%) ≥95
3. Condoms distributed 2,41,20,856 G. Truckers
4. Tested for HIV (April 2022-September 2022) 73,670 Indicator 2022-23
4.1. HIV sero-positive (%) 0.07 1. Estimated size 47,000
4.1.1. Linked to ART 54 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 91,823 3. Tested for HIV 3,552
5.1. HIV sero-positive (%) 0.17 3.1. HIV sero-positive (%) 0.11
5.1.1. Linked to ART 137 3.2. On ART 1
6. Clinic Visits 2,98,079
H. Prison Inmates
7. STI/RTI treated 1,676
Indicator 2022-23
8. Presumptive treatment 15,931
1. Total prisons 37
C. Men who have Sex with Men 2. Prisons covered under programme 37
Indicator 2022-23 3. Total inmates admitted 59,139
1. Estimated size 16,427 4. Inmates Covered (%) 72
2. Coverage (%) ≥95 5. Tested for HIV 29,335
3. Condoms distributed 53,28,916 5.1. HIV sero-positive (%) 0.39
4. Tested for HIV (April 2022-September 2022) 13,574 5.2. On ART (%) 89.57
4.1. HIV sero-positive (%) 0.21
I. Link Worker Scheme
4.1.1. Linked to ART 22
5. Tested for HIV (October 2022 -March 2023) 16,009 Indicator 2022-23
5.1. HIV sero-positive (%) 0.39 1. Districts covered under scheme 9
5.1.1. Linked to ART 51 2. Vulnerable population covered 77,644
6. Clinic Visits 54,828 3. Tested for HIV 56,420
7. STI/RTI treated 64 3.1. HIV sero-positive (%) 0.19
8. Presumptive treatment 2,068 3.2. Linked to ART (%) 99.1

334 Sankalak: Status of National AIDS & STD Response (2023)

 TELANGANA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres -
1.1. OSTC in Public Health Settings - Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 3
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories 2
2. IDU on OST -
2. Viral load testing conducted 77,077
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 90.3

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 1
3.1 Accredited NRL 1
Indicator 2022-23
1. HCTC facilities 1,195 4. State reference laboratories (SRL) 3
1.1. Stand-Alone 179 4.1 Accredited SRL 3
1.2. Facility integrated (Govt.) 827 5. CD4 testing conducted 56,747
1.3. Facility integrated (PPP) 131
6. External Quality Assessment of ICTC
1.4. CBS 58
1.5. SSK 9 6.1 Average Participation (%) 97.7
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 3,57,151 3,41,501 2,347 7,00,999
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
4,742 3,828 65 8,635
among tested A. HIV
3. HIV sero-positivity
(%) among tested
1.33 1.12 2.77 1.23 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 6,80,790
partner testing of
1,847 1,672 9 3,528 2. HIV testing among PW 7,13,858
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.06
5. No. of contacts with 4. HIV Positive PW (old + new detections) 946
‘at-risk’ population
1,112 1,409 9 2,530 4.1 On life-long ART 955
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 600

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 99.00
infected people 6. Babies tested HIV (6 week- 6 month) 590
A. Treatment facilities 6.1 Babies confirmed HIV Positive 4
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 23 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 468
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 13
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 10
3. Link ART Centres 74
4. Care Support Centres 13
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 6,53,775
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.01
1. HIV positive cases 3. Put on treatment 42
4,742 4,245 65 9,052
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 4,692 3,964 59 8,715 Stigma and Discrimination
centre
2.1 Initiated on ART 4,546 3,874 59 8,479 A. HIV
3. PLHIV alive and
46,328 53,739 503 1,00,570 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 77.0 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 8,851 7,811 77 16,739 2. State designated/appointed ombudsman -

Sankalak: Status of National AIDS & STD Response (2023) 335

TELANGANA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 2,07,882 37,651 2,838 4,947 58,821 2,208 3,14,347

Quarter 2 2,12,386 39,709 3,032 6,274 68,795 40,459 3,70,655

Screened for TB
Quarter 3 2,18,610 38,992 2,937 6,293 70,229 41,836 3,78,897

Quarter 4 2,27,417 41,723 2,875 4,666 70,968 39,434 3,87,083

Quarter 1 632 110 - 7 39 - 788

Quarter 2 507 78 3 2 16 - 606

Tested for TB
Quarter 3 452 95 1 4 12 - 564

Quarter 4 1,605 272 - 15 15 1 1,908

Quarter 1 6 13 - 1 - - 20

Quarter 2 2 1 2 - - - 5
Diagnosed with TB
Quarter 3 4 3 1 - - - 8

Quarter 4 19 6 - 1 - - 26

Quarter 1 5 5 - 1 - - 11

Initiated on TB Quarter 2 2 1 2 - - - 5
treatment
Quarter 3 7 7 1 - - - 15

Quarter 4 18 6 - 1 - - 25

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 25,158

1.1. HIV sero-positive (%) 4.91

1.2. ICTC clients referred to NTEP 34,990

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 51,548 48,427 1,127 1,033 171 870

May-22 58,850 55,445 1,101 1,059 178 1,718

Jun-22 72,436 52,162 1,115 1,073 165 938

Jul-22 57,565 53,405 1,020 981 149 817

Aug-22 57,565 53,405 1,020 981 149 817

Sep-22 69,162 63,530 1,090 1,054 144 877

Oct-22 75,271 68,848 917 891 146 898

Nov-22 73,557 68,010 1,134 1,116 141 961

Dec-22 76,769 70,833 1,025 991 142 889

Jan-23 74,015 66,541 930 888 99 1,110

Feb-23 69,453 61,944 1,095 1,068 114 280

Mar-23 78,012 72,266 1,470 1,453 167 416

April 2022-March 2023 1,865 1,717

336 Sankalak: Status of National AIDS & STD Response (2023)

 TELANGANA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Telangana

Rank 31
Sl. No.
Max Marks 120

Obtained Marks (%) 74 (62)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) G
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) Y
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) R
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) R
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) Y
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) R
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) Y
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) R
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) Y
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) Y
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 337

TRIPURA
TRIPURA

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 12.27
2. IMR - - 19.63
3. Adult (15-49 yrs) HIV Prevalence (%) 0.31 0.13 0.22
4. Estimated people living with HIV 4,277 1,802 6,079
5. ART coverage (%) 82.4 54.5 74.2
6. Estimated children living with HIV 333 210 543
7. Annual new HIV infections 526 220 746
8. Annual AIDS-related deaths (ARD) ≤50 ≤50 ≤50
9. Change in annual new HIV infections since 2010 (%) 301.5 300.00 303.2
10. Change in annual ARD since 2010 (%) 100.0 -16.67 46.2
11. EMTCT need - 56 56

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 6,242 54.7 0 2.9
2. Men who have Sex with Men 876 36 100 -
3. Injecting Drug Users 6,500 60.9 84.2 18
4. Hijra/Transgender People 159 - - -
5. Migrants 35,800 - - -
6. Truckers 1,000 - - -
7. Prison inmates 4,558 13.3 0 1.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 29.9 15.4 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 31.9 11.6 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 49.7 47.8 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 59.4 53.1 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 0.4 0.1 -
5.1 Condom use during last higher-risk intercourse (%) 7.6 0 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 0.5 0.3 -
6.1 Condom use during last higher-risk intercourse (%) 0.0 0.0 -

2. Progress on 95-95-95 (2022-23)

93 93 93 89 92 90 Indicator (2022-23) Male Female Total
80 80 85 78
70
61 1. Estimated PLHIV size (2022) 4,277 1,802 6,079
46 49 50
2. PLHIV who know their HIV Status 3,882 1,004 4,887

3. PLHIV who know their HIV status and are on ART 3,525 982 4,508
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 743 449 1,193
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 676 398 1,075
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 339

TRIPURA

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 6,500
A. Information, Education, Communication,
2. Coverage (%) 92
Youth and Mainstreaming
3. Needles distributed 9,97,760
Indicator 2022-23 4. Syringes distributed 9,97,760
1. Schools with operational Adolescent Education 5. On OST 1,064
400
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 3,598
2. Colleges with operational Red Ribbon Clubs (RRC) 31 6.1. HIV sero-positive (%) 12.03
3. Persons trained under mainstreaming 120 6.1.1 Linked to ART 370
7. Tested for HIV (October 2022 -March 2023) 3,871
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 8.06
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 249
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 18 1. Estimated size 159
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) -
2. Total STI/RTI 3. Condoms distributed -
21,560 20,463 34 42,057
Clients managed 4. Tested for HIV (April 2022-September 2022) -
3. RPR Tests 4.1. HIV sero-positive (%) -
17,567 16,635 - 34,202
conducted 4.1.1. Linked to ART -
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) -
0.39 0.14 - 0.27
seropositivity (%)
5.1. HIV sero-positive (%) -
5.1.1. Linked to ART -
4. Prevention of new HIV infections among 6. Clinic Visits -
high-risk group and bridge population
7. STI/RTI treated -
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment -
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 15 Indicator 2022-23
2. OST centres 10 1. Estimated size 35,800
2. Coverage (%) 63
B. Female Sex Workers
3. Tested for HIV 5,560
Indicator 2022-23
3.1. HIV sero-positive (%) 0.02
1. Estimated size 6,242
3.2. Linked to ART 111
2. Coverage (%) 76.52
3. Condoms distributed 5,65,849 G. Truckers
4. Tested for HIV (April 2022-September 2022) 2,726 Indicator 2022-23
4.1. HIV sero-positive (%) 0.22 1. Estimated size 1,000
4.1.1. Linked to ART 6 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 2,864 3. Tested for HIV 3,244
5.1. HIV sero-positive (%) 0.24 3.1. HIV sero-positive (%) 0.34
5.1.1. Linked to ART 7 3.2. On ART 11
6. Clinic Visits 11,056
H. Prison Inmates
7. STI/RTI treated 265
Indicator 2022-23
8. Presumptive treatment 697
1. Total prisons 13
C. Men who have Sex with Men 2. Prisons covered under programme 14
Indicator 2022-23 3. Total inmates admitted 4,683
1. Estimated size 876 4. Inmates Covered (%) 33
2. Coverage (%) 79 5. Tested for HIV 1,499
3. Condoms distributed 60,394 5.1. HIV sero-positive (%) 3.54
4. Tested for HIV (April 2022-September 2022) 364 5.2. On ART (%) 67.92
4.1. HIV sero-positive (%) 0.27
I. Link Worker Scheme
4.1.1. Linked to ART 1
5. Tested for HIV (October 2022 -March 2023) 496 Indicator 2022-23
5.1. HIV sero-positive (%) 1.61 1. Districts covered under scheme 2
5.1.1. Linked to ART 7 2. Vulnerable population covered 20,429
6. Clinic Visits 1,685 3. Tested for HIV 18,209
7. STI/RTI treated 11 3.1. HIV sero-positive (%) 0.72
8. Presumptive treatment 174 3.2. Linked to ART (%) 84.7

340 Sankalak: Status of National AIDS & STD Response (2023)

 TRIPURA

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 10
1.1. OSTC in Public Health Settings 6 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres 4 1.1 Accredited Viral load laboratories -
2. IDU on OST 1,064
2. Viral load testing conducted 1,187
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 89.2

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 187 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 24 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 136 5. CD4 testing conducted 1,321
1.3. Facility integrated (PPP) 9
6. External Quality Assessment of ICTC
1.4. CBS 18
1.5. SSK - 6.1 Average Participation (%) 100.0
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 96,355 48,467 4 1,44,826
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
1,692 114 2 1,808
among tested A. HIV
3. HIV sero-positivity
(%) among tested
1.76 0.24 50.00 1.25 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 59,310
partner testing of
155 143 - 298 2. HIV testing among PW 49,010
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.08
5. No. of contacts with 4. HIV Positive PW (old + new detections) 58
‘at-risk’ population
- - - - 4.1 On life-long ART 40
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 79

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 32
A. Treatment facilities 6.1 Babies confirmed HIV Positive 2
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 3 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 9
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months -
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 3
3. Link ART Centres 3
4. Care Support Centres 1
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 58,555
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.04
1. HIV positive cases 3. Put on treatment 23
1,692 151 2 1,845
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 1,543 133 1 1,677 Stigma and Discrimination
centre
2.1 Initiated on ART 1,539 133 1 1,673 A. HIV
3. PLHIV alive and
3,525 982 1 4,508 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 69.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 446 69 - 515 2. State designated/appointed ombudsman -

Sankalak: Status of National AIDS & STD Response (2023) 341

TRIPURA

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 3,107 234 3,855 - 1,310 464 8,970

Quarter 2 3,425 290 4,811 - 1,280 561 10,367

Screened for TB
Quarter 3 3,257 318 5,109 - 1,508 545 10,737

Quarter 4 3,485 335 5,653 - 1,576 286 11,335

Quarter 1 30 - 94 - - 5 129

Quarter 2 40 1 110 - - 1 152

Tested for TB
Quarter 3 48 3 103 - - - 154

Quarter 4 35 3 94 - - - 132

Quarter 1 - - 1 - - - 1

Quarter 2 - - 1 - - - 1
Diagnosed with TB
Quarter 3 - 2 3 - - - 5

Quarter 4 - - 1 - - - 1

Quarter 1 - - 1 - - - 1

Initiated on TB Quarter 2 2 - 1 - - - 3
treatment
Quarter 3 - 2 2 - - - 4

Quarter 4 - - - - - - -

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,479

1.1. HIV sero-positive (%) 2.37

1.2. ICTC clients referred to NTEP 2,234

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 796 789 32 30 1 97

May-22 1,025 1,017 28 24 1 107

Jun-22 1,549 1,545 34 28 2 99

Jul-22 1,589 1,582 26 24 - 48

Aug-22 1,680 1,676 27 26 3 43

Sep-22 1,817 1,814 22 18 - 50

Oct-22 1,417 1,414 31 25 3 70

Nov-22 1,895 1,889 23 21 - 16

Dec-22 1,738 1,733 21 20 1 70

Jan-23 1,733 1,728 21 18 - 156

Feb-23 1,689 1,685 21 18 1 91

Mar-23 1,935 1,930 21 14 - 78

April 2022-March 2023 51 48

342 Sankalak: Status of National AIDS & STD Response (2023)

 TRIPURA

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Tripura

Rank 24
Sl. No.
Max Marks 117

Obtained Marks (%) 79 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) R
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) Y
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) R
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) G
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) R
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) G
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) Y
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 343

UTTAR
PRADESH
UTTAR PRADESH

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 5.07
2. IMR - - 2.38
3. Adult (15-49 yrs) HIV Prevalence (%) 0.13 0.08 0.11
4. Estimated people living with HIV 1,21,055 73,847 1,94,902
5. ART coverage (%) 51.1 69.6 58.3
6. Estimated children living with HIV 11,588 6,328 17,916
7. Annual new HIV infections 6,543 3,340 9,883
8. Annual AIDS-related deaths (ARD) 1,870 355 2,225
9. Change in annual new HIV infections since 2010 (%) -12.2 -13.36 -12.6
10. Change in annual ARD since 2010 (%) -57.9 -81.86 -65.3
11. EMTCT need - 1,881 1,881

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 40,480 79.8 54.4 1.04
2. Men who have Sex with Men 19,668 40.8 28.6 1.1
3. Injecting Drug Users 35,412 18.7 82.6 5.45
4. Hijra/Transgender People 9,846 - - 3.6
5. Migrants 3,27,000 - - 0.67
6. Truckers 72,000 - - 0.70
7. Prison inmates 4,09,046 0 0 0.13

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 22.1 13.1 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 19.8 11.6 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 70 64.1 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 67.4 57.6 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 5.3 0.7 -
5.1 Condom use during last higher-risk intercourse (%) 58.5 70.5 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 8.7 1.3 -
6.1 Condom use during last higher-risk intercourse (%) 60.4 79.2 -

2. Progress on 95-95-95 (2022-23)

88 90 90 89 91 88 87 85 93 Indicator (2022-23) Male Female Total
78
64 1. Estimated PLHIV size (2022) 1,21,055 73,847 1,94,902
56 58 59 61

2. PLHIV who know their HIV Status 69,708 55,420 1,25,498

3. PLHIV who know their HIV status and are on ART 61,917 51,362 1,13,599
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally
4. PLHIV who are on ART and tested for their viral load 32,768 34,850 67,778
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 29,937 32,676 62,767
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 345

UTTAR PRADESH

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 35,412
A. Information, Education, Communication,
2. Coverage (%) 65
Youth and Mainstreaming
3. Needles distributed 97,51,176
Indicator 2022-23 4. Syringes distributed 51,77,197
1. Schools with operational Adolescent Education 5. On OST 2,237
Suspended
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 16,779
2. Colleges with operational Red Ribbon Clubs (RRC) 373 6.1. HIV sero-positive (%) 0.80
3. Persons trained under mainstreaming 290 6.1.1 Linked to ART 107
7. Tested for HIV (October 2022 -March 2023) 17,659
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.64
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 90
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 115 1. Estimated size 9,846
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 48
2. Total STI/RTI 3. Condoms distributed 11,31,318
5,09,068 8,06,944 24,388 13,40,400
Clients managed 4. Tested for HIV (April 2022-September 2022) 3,780
3. RPR Tests 4.1. HIV sero-positive (%) 0.26
1,18,132 2,05,762 3,194 3,27,088
conducted 4.1.1. Linked to ART 8
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 3,806
0.48 0.15 0.91 0.28
seropositivity (%)
5.1. HIV sero-positive (%) 0.37
5.1.1. Linked to ART 8
4. Prevention of new HIV infections among 6. Clinic Visits 14,719
high-risk group and bridge population
7. STI/RTI treated 181
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 537
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 86 Indicator 2022-23
2. OST centres 19 1. Estimated size 3,27,000
2. Coverage (%) 30
B. Female Sex Workers
3. Tested for HIV 12,282
Indicator 2022-23
3.1. HIV sero-positive (%) 0.15
1. Estimated size 40,480
3.2. Linked to ART 154
2. Coverage (%) 62.18
3. Condoms distributed 71,21,394 G. Truckers
4. Tested for HIV (April 2022-September 2022) 17,752 Indicator 2022-23
4.1. HIV sero-positive (%) 0.26 1. Estimated size 72,000
4.1.1. Linked to ART 38 2. Coverage (%) 79
5. Tested for HIV (October 2022 -March 2023) 19,575 3. Tested for HIV 19,168
5.1. HIV sero-positive (%) 0.16 3.1. HIV sero-positive (%) 0.10
5.1.1. Linked to ART 24 3.2. On ART 18
6. Clinic Visits 70,305
H. Prison Inmates
7. STI/RTI treated 1,753
Indicator 2022-23
8. Presumptive treatment 3,422
1. Total prisons 75
C. Men who have Sex with Men 2. Prisons covered under programme 74
Indicator 2022-23 3. Total inmates admitted 3,63,011
1. Estimated size 19,668 4. Inmates Covered (%) 86
2. Coverage (%) 65 5. Tested for HIV 2,70,780
3. Condoms distributed 28,67,042 5.1. HIV sero-positive (%) 0.41
4. Tested for HIV (April 2022-September 2022) 9,026 5.2. On ART (%) 91.03
4.1. HIV sero-positive (%) 0.75
I. Link Worker Scheme
4.1.1. Linked to ART 40
5. Tested for HIV (October 2022 -March 2023) 10,368 Indicator 2022-23
5.1. HIV sero-positive (%) 0.61 1. Districts covered under scheme 8
5.1.1. Linked to ART 46 2. Vulnerable population covered 1,22,062
6. Clinic Visits 36,853 3. Tested for HIV 72,884
7. STI/RTI treated 543 3.1. HIV sero-positive (%) 0.24
8. Presumptive treatment 1,932 3.2. Linked to ART (%) 89.5

346 Sankalak: Status of National AIDS & STD Response (2023)

 UTTAR PRADESH

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 19
1.1. OSTC in Public Health Settings 17 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories 3
1.3. No. of Satellite OST Centres 2 1.1 Accredited Viral load laboratories 2
2. IDU on OST 2,237
2. Viral load testing conducted 73,605
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 90.4

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 1
3.1 Accredited NRL 1
Indicator 2022-23
1. HCTC facilities 3,288 4. State reference laboratories (SRL) 9
1.1. Stand-Alone 456 4.1 Accredited SRL 9
1.2. Facility integrated (Govt.) 1,800 5. CD4 testing conducted 48,054
1.3. Facility integrated (PPP) 99
6. External Quality Assessment of ICTC
1.4. CBS 933
1.5. SSK 26 6.1 Average Participation (%) 70.2
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 0
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 12,73,363 12,21,526 3,184 24,98,073
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
9,978 4,761 117 14,856
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.78 0.39 3.67 0.59 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 67,91,420
partner testing of
3,636 3,556 22 7,214 2. HIV testing among PW 48,14,907
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 1,508
‘at-risk’ population
711 787 - 1,498 4.1 On life-long ART 1,569
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 916

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 1,051
A. Treatment facilities 6.1 Babies confirmed HIV Positive 23
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 55 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 715
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 35
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 37
3. Link ART Centres 32
4. Care Support Centres 27
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 30,85,549
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.02
1. HIV positive cases 3. Put on treatment 541
9,978 5,516 117 15,611
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 9,799 5,330 51 15,180 Stigma and Discrimination
centre
2.1 Initiated on ART 9,395 5,199 49 14,643 A. HIV
3. PLHIV alive and
61,917 51,362 320 1,13,599 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 80.2 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 3,370 1,479 21 4,870 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 347

UTTAR PRADESH

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 14,223 7,879 14,260 2,691 4,344 6,786 50,183

Quarter 2 15,212 8,521 14,752 3,089 5,210 7,051 53,835

Screened for TB
Quarter 3 15,447 8,826 15,037 3,031 4,823 7,475 54,639

Quarter 4 18,329 10,028 16,950 3,184 4,987 10,379 63,857

Quarter 1 325 161 266 27 30 10 819

Quarter 2 236 291 184 32 52 26 821

Tested for TB
Quarter 3 200 269 229 37 82 46 863

Quarter 4 332 293 383 113 7 68 1,196

Quarter 1 3 2 23 - 3 1 32

Quarter 2 7 7 13 1 3 1 32
Diagnosed with TB
Quarter 3 4 5 8 2 - - 19

Quarter 4 15 13 21 6 1 - 56

Quarter 1 3 3 21 - 3 1 31

Initiated on TB Quarter 2 7 9 12 1 3 - 32
treatment
Quarter 3 7 2 7 2 - - 18

Quarter 4 13 14 16 6 - - 49

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 1,45,126

1.1. HIV sero-positive (%) 1.14

1.2. ICTC clients referred to NTEP 70,392

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 60,333 60,167 1,529 1,494 170 1,105

May-22 62,298 62,188 1,571 1,534 183 1,085

Jun-22 62,169 61,914 1,564 1,523 187 1,138

Jul-22 64,474 64,317 1,490 1,479 163 1,233

Aug-22 64,474 64,317 1,490 1,479 163 1,233

Sep-22 74,744 71,783 1,577 1,530 176 1,336

Oct-22 79,933 79,746 1,424 1,414 108 1,590

Nov-22 81,701 81,701 1,677 1,673 123 1,596

Dec-22 81,259 81,259 1,592 1,587 154 1,279

Jan-23 77,920 77,920 1,556 1,551 132 1,031

Feb-23 76,348 76,348 1,762 1,754 170 1,031

Mar-23 83,403 83,352 1,949 1,946 187 1,362

April 2022-March 2023 2,991 2,866

348 Sankalak: Status of National AIDS & STD Response (2023)

 UTTAR PRADESH

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Uttar Pradesh

Rank 19
Sl. No.
Max Marks 117

Obtained Marks (%) 80 (68)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) R
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) Y
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) Y
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) R
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) NA
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) Y
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) Y
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 G
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 349

UTTARAKHAND
UTTARAKHAND

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 4.23
2. IMR - - 1.23
3. Adult (15-49 yrs) HIV Prevalence (%) 0.15 0.11 0.13
4. Estimated people living with HIV 7,184 5,040 12,224
5. ART coverage (%) 49.1 50.1 49.7
6. Estimated children living with HIV 586 389 975
7. Annual new HIV infections 310 207 517
8. Annual AIDS-related deaths (ARD) 200 127 327
9. Change in annual new HIV infections since 2010 (%) -40.5 -35.71 -38.7
10. Change in annual ARD since 2010 (%) -41.7 -18.59 -34.5
11. EMTCT need - 108 108

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 7,213 61 43.3 0.42
2. Men who have Sex with Men 2,883 65.7 20.3 2.68
3. Injecting Drug Users 3,835 28.0 93.2 9.77
4. Hijra/Transgender People 321 - - -
5. Migrants 90,000 - - -
6. Truckers 40,000 - - 2.10
7. Prison inmates 20,582 0 0 0.00

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 35.9 24.5 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 27.1 21.5 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 80.7 70.3 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 72.4 65.8 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 6.3 0 -
5.1 Condom use during last higher-risk intercourse (%) 61 - -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 13.2 0.0 -
6.1 Condom use during last higher-risk intercourse (%) 59.7 - -

2. Progress on 95-95-95 (2022-23)

84 82 86 86 86 81 Indicator (2022-23) Male Female Total
77 72 82
61 62 1. Estimated PLHIV size (2022) 7,184 5,040 12,224
52 56
45 50
2. PLHIV who know their HIV Status 4,459 2,961 7,448

3. PLHIV who know their HIV status and are on ART 3,529 2,524 6,078
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally 4. PLHIV who are on ART and tested for their viral load 2,204 1,573 3,795
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 1,726 1,349 3,092
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 351

UTTARAKHAND

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 3,835
A. Information, Education, Communication,
2. Coverage (%) 83
Youth and Mainstreaming
3. Needles distributed 11,65,435
Indicator 2022-23 4. Syringes distributed 5,81,766
1. Schools with operational Adolescent Education 5. On OST 494
2,349
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 2,211
2. Colleges with operational Red Ribbon Clubs (RRC) 100 6.1. HIV sero-positive (%) 0.81
3. Persons trained under mainstreaming 1,541 6.1.1 Linked to ART 12
7. Tested for HIV (October 2022 -March 2023) 2,703
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.81
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 22
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 27 1. Estimated size 321
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 52
2. Total STI/RTI 3. Condoms distributed 38,187
73,816 61,561 409 1,35,786
Clients managed 4. Tested for HIV (April 2022-September 2022) 141
3. RPR Tests 4.1. HIV sero-positive (%) 0.00
8,821 25,871 - 34,692
conducted 4.1.1. Linked to ART 0
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 146
1.12 0.12 - 0.37
seropositivity (%)
5.1. HIV sero-positive (%) 0.00
5.1.1. Linked to ART 0
4. Prevention of new HIV infections among 6. Clinic Visits 613
high-risk group and bridge population
7. STI/RTI treated 41
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 8
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 34 Indicator 2022-23
2. OST centres 5 1. Estimated size 90,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 28,005
Indicator 2022-23
3.1. HIV sero-positive (%) 0.06
1. Estimated size 7,213
3.2. Linked to ART -
2. Coverage (%) 69.60
3. Condoms distributed 12,39,809 G. Truckers
4. Tested for HIV (April 2022-September 2022) 4,630 Indicator 2022-23
4.1. HIV sero-positive (%) 0.06 1. Estimated size 40,000
4.1.1. Linked to ART 3 2. Coverage (%) ≥95
5. Tested for HIV (October 2022 -March 2023) 4,489 3. Tested for HIV 7,164
5.1. HIV sero-positive (%) 0.04 3.1. HIV sero-positive (%) 0.07
5.1.1. Linked to ART 1 3.2. On ART 4
6. Clinic Visits 17,359
H. Prison Inmates
7. STI/RTI treated 677
Indicator 2022-23
8. Presumptive treatment 687
1. Total prisons 11
C. Men who have Sex with Men 2. Prisons covered under programme 10
Indicator 2022-23 3. Total inmates admitted 21,037
1. Estimated size 2,883 4. Inmates Covered (%) ≥95
2. Coverage (%) 80 5. Tested for HIV 13,316
3. Condoms distributed 5,13,549 5.1. HIV sero-positive (%) 1.45
4. Tested for HIV (April 2022-September 2022) 2,116 5.2. On ART (%) 84.46
4.1. HIV sero-positive (%) 0.19
I. Link Worker Scheme
4.1.1. Linked to ART 4
5. Tested for HIV (October 2022 -March 2023) 2,136 Indicator 2022-23
5.1. HIV sero-positive (%) 0.23 1. Districts covered under scheme -
5.1.1. Linked to ART 4 2. Vulnerable population covered -
6. Clinic Visits 8,363 3. Tested for HIV -
7. STI/RTI treated 294 3.1. HIV sero-positive (%) -
8. Presumptive treatment 252 3.2. Linked to ART (%) -

352 Sankalak: Status of National AIDS & STD Response (2023)

 UTTARAKHAND

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 5
1.1. OSTC in Public Health Settings 5 Indicator 2022-23
1.2. OSTC in NGO Settings - 1. Viral load laboratories -
1.3. No. of Satellite OST Centres - 1.1 Accredited Viral load laboratories -
2. IDU on OST 494
2. Viral load testing conducted 4,318
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 81.0

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) -
3.1 Accredited NRL -
Indicator 2022-23
1. HCTC facilities 183 4. State reference laboratories (SRL) 1
1.1. Stand-Alone 51 4.1 Accredited SRL 1
1.2. Facility integrated (Govt.) 91 5. CD4 testing conducted 4,283
1.3. Facility integrated (PPP) 14
6. External Quality Assessment of ICTC
1.4. CBS 27
1.5. SSK 1 6.1 Average Participation (%) 83.5
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 1
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 1,94,222 1,29,321 171 3,23,714
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
902 272 1 1,175
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.46 0.21 0.58 0.36 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 2,18,460
partner testing of
190 233 - 423 2. HIV testing among PW 1,70,043
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.03
5. No. of contacts with 4. HIV Positive PW (old + new detections) 70
‘at-risk’ population
- - - - 4.1 On life-long ART 40
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 52

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 53
A. Treatment facilities 6.1 Babies confirmed HIV Positive -
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 6 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 42
2.1. Centre of Excellence (Adult) -
7.2 Babies confirmed HIV positive at 18 months 1
2.2. Centre of Excellent (Paediatric) -
8. HIV positive babies initiated on ART 1
3. Link ART Centres 32
4. Care Support Centres 2
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 1,97,641
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.04
1. HIV positive cases 3. Put on treatment 42
902 323 1 1,226
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 837 332 3 1,172 Stigma and Discrimination
centre
2.1 Initiated on ART 801 318 2 1,121 A. HIV
3. PLHIV alive and
3,529 2,524 24 6,078 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention -
- - - 78.7 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 915 474 5 1,394 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 353

UTTARAKHAND

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 4,594 2,052 1,448 154 11,039 9,298 28,585

Quarter 2 5,157 2,289 1,757 143 12,001 9,096 30,443

Screened for TB
Quarter 3 5,083 2,269 2,075 149 12,862 9,692 32,130

Quarter 4 4,951 2,233 2,312 177 12,302 9,707 31,682

Quarter 1 7 15 19 7 41 2 91

Quarter 2 72 29 48 8 38 3 198
Tested for TB
Quarter 3 63 32 37 9 42 - 183

Quarter 4 49 19 37 7 18 1 131

Quarter 1 2 - 1 - 17 2 22

Quarter 2 3 - 3 - 12 - 18
Diagnosed with TB
Quarter 3 - - 3 - 6 - 9

Quarter 4 3 1 3 - 8 1 16

Quarter 1 2 - 1 - 15 2 20

Initiated on TB Quarter 2 3 - 3 - 8 - 14
treatment
Quarter 3 - - 3 - 6 - 9

Quarter 4 3 1 3 - 6 1 14

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 10,826

1.1. HIV sero-positive (%) 1.30

1.2. ICTC clients referred to NTEP 3,209

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 3,216 2,956 98 55 19 33

May-22 3,012 2,686 81 43 13 38

Jun-22 2,864 2,752 90 46 16 47

Jul-22 2,820 2,582 94 65 26 24

Aug-22 2,820 2,582 94 65 26 24

Sep-22 - 2,908 91 63 14 33

Oct-22 3,051 2,788 72 58 11 20

Nov-22 2,622 2,551 64 43 15 214

Dec-22 2,971 2,760 84 50 15 32

Jan-23 2,534 2,519 77 53 5 46

Feb-23 2,694 2,522 80 49 12 89

Mar-23 2,514 2,415 92 49 12 122

April 2022-March 2023 180 152

354 Sankalak: Status of National AIDS & STD Response (2023)

 UTTARAKHAND

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT Uttarakhand

Rank 11
Sl. No.
Max Marks 120

Obtained Marks (%) 86 (72)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) R
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) R
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) Y
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) G
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) G
7 Status of state rules (G= Notified, R= Not notified) R
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) R
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) G
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) R
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) G
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) R
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) G
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) G
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) Y

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 355

WEST BENGAL
WEST BENGAL

1. Status of HIV/AIDS Epidemic

A. Epidemic Estimates (2022)
Indicator Male Female Total
1. IPR - - 3.59
2. IMR - - 1.89
3. Adult (15-49 yrs) HIV Prevalence (%) 0.09 0.08 0.08
4. Estimated people living with HIV 42,182 33,917 76,099
5. ART coverage (%) 74.3 67.1 71.5
6. Estimated children living with HIV 2,639 2,418 5,057
7. Annual new HIV infections 1,440 1,290 2,730
8. Annual AIDS-related deaths (ARD) 375 439 814
9. Change in annual new HIV infections since 2010 (%) -33.0 -32.07 -32.6
10. Change in annual ARD since 2010 (%) -85.1 -76.51 -81.5
11. EMTCT need - 563 563

B. High-risk population size (2021-22), safe practices (2015) and prevalence (2021)
Condom New Needle/ HIV
Population Group Estimated Size
Use (%) Syringe use (%) Prevalence (%)
1. Female Sex Workers 20,452 95.7 0 1.27
2. Men who have Sex with Men 3,532 42.4 24 4.36
3. Injecting Drug Users 2,334 62.0 94.6 7.4
4. Hijra/Transgender People 5,134 - - 9.15
5. Migrants 30,000 - - 3.2
6. Truckers 60,000 - - 2.01
7. Prison inmates 1,13,242 26.1 26.7 0.84

C. HIV/AIDS related knowledge, stigma and high-risk behaviour in general population (2019-21)
Indicator Male Female Total
1. Adults (15-49 yrs) with comprehensive knowledge about HIV/AIDS (%) 15.5 18.5 -
2. Youth (15-24 yrs) with comprehensive knowledge about HIV/AIDS (%) 14.3 17.4 -
3. Adults willing to care for a relative with HIV/AIDS in own home (%) 59.3 66.5 -
4. Adults willing to buy fresh vegetables from a shopkeeper or vendor who has HIV/AIDS (%) 56.7 64.2 -
5. Sexually active adults (15-49 yrs) having higher-risk sexual behaviour (%) 1.7 1 -
5.1 Condom use during last higher-risk intercourse (%) 63.6 52.4 -
6. Sexually active youth (15-24 yrs) having higher-risk sexual behaviour (%) 3.5 1.5 -
6.1 Condom use during last higher-risk intercourse (%) 67.9 62.5 -

2. Progress on 95-95-95 (2022-23)

90 87 85
84 86 89 90 87
95 Indicator (2022-23) Male Female Total
78 83 80
73 75
67
1. Estimated PLHIV size (2022) 42,182 33,917 76,099

2. PLHIV who know their HIV Status 36,736 25,831 62,962

3. PLHIV who know their HIV status and are on ART 31,349 22,759 54,424
PLHIV who know PLHIV who know PLHIV who are on
their HIV status their HIV status ART and virally
4. PLHIV who are on ART and tested for their viral load 13,614 18,251 32,015
(%) and are on ART (%) suppressed (%)
5. PLHIV who are virally suppressed 13,228 17,752 31,127
2018-19 2019-20 2020-21 2021-22 2022-23

Sankalak: Status of National AIDS & STD Response (2023) 357

WEST BENGAL

D. Injecting Drug Users

3. Prevention of new HIV infections among
general population Indicator 2022-23
1. Estimated size 2,334
A. Information, Education, Communication,
2. Coverage (%) 77
Youth and Mainstreaming
3. Needles distributed 9,86,049
Indicator 2022-23 4. Syringes distributed 4,93,684
1. Schools with operational Adolescent Education 5. On OST 900
2,950
Programme (AEP) 6. Tested for HIV (April 2022 -September 2022) 1,609
2. Colleges with operational Red Ribbon Clubs (RRC) 488 6.1. HIV sero-positive (%) 0.25
3. Persons trained under mainstreaming 5,656 6.1.1 Linked to ART 5
7. Tested for HIV (October 2022 -March 2023) 1,725
4. No. of calls received at helpline -
7.1. HIV sero-positive (%) 0.29
B. Sexually Transmitted Infections (STI)/Reproductive 7.1.1. Linked to ART 5
Tract Infections (RTI) Management
E. Hijra/Transgender person
Indicator 2022-23
Indicator 2022-23
1. NACO Supported 48 1. Estimated size 5,134
Designated STI/
RTI Clinics (DSRC) Male Female H/TG Total 2. Coverage (%) 46
2. Total STI/RTI 3. Condoms distributed 4,36,275
1,32,494 1,74,176 29,134 3,35,804
Clients managed 4. Tested for HIV (April 2022-September 2022) 1,532
3. RPR Tests 4.1. HIV sero-positive (%) 1.50
42,453 84,588 240 1,27,281
conducted 4.1.1. Linked to ART 23
4. Syphilis 5. Tested for HIV (October 2022 -March 2023) 1,962
3.47 0.62 21.67 1.61
seropositivity (%)
5.1. HIV sero-positive (%) 0.31
5.1.1. Linked to ART 6
4. Prevention of new HIV infections among 6. Clinic Visits 6,563
high-risk group and bridge population
7. STI/RTI treated 19
A. Targeted Intervention (TI) Projects and Opioid 8. Presumptive treatment 266
Substitution Therapy (OST)
Indicator 2022-23 F. Migrants
1. Targeted Intervention (TI) Projects 46 Indicator 2022-23
2. OST centres 11 1. Estimated size 30,000
2. Coverage (%) ≥95
B. Female Sex Workers
3. Tested for HIV 12,105
Indicator 2022-23
3.1. HIV sero-positive (%) 0.04
1. Estimated size 20,452
3.2. Linked to ART 239
2. Coverage (%) 94.02
3. Condoms distributed 57,87,884 G. Truckers
4. Tested for HIV (April 2022-September 2022) 13,559 Indicator 2022-23
4.1. HIV sero-positive (%) 0.16 1. Estimated size 60,000
4.1.1. Linked to ART 19 2. Coverage (%) 92
5. Tested for HIV (October 2022 -March 2023) 14,427 3. Tested for HIV 12,621
5.1. HIV sero-positive (%) 0.13 3.1. HIV sero-positive (%) 0.13
5.1.1. Linked to ART 19 3.2. On ART 16
6. Clinic Visits 54,219
H. Prison Inmates
7. STI/RTI treated 427
Indicator 2022-23
8. Presumptive treatment 688
1. Total prisons 60
C. Men who have Sex with Men 2. Prisons covered under programme 61
Indicator 2022-23 3. Total inmates admitted 1,34,334
1. Estimated size 3,532 4. Inmates Covered (%) 34
2. Coverage (%) 64 5. Tested for HIV 23,620
3. Condoms distributed 3,84,674 5.1. HIV sero-positive (%) 0.29
4. Tested for HIV (April 2022-September 2022) 1,638 5.2. On ART (%) 98.53
4.1. HIV sero-positive (%) 1.16
I. Link Worker Scheme
4.1.1. Linked to ART 18
5. Tested for HIV (October 2022 -March 2023) 1,862 Indicator 2022-23
5.1. HIV sero-positive (%) 1.13 1. Districts covered under scheme 11
5.1.1. Linked to ART 22 2. Vulnerable population covered 1,24,361
6. Clinic Visits 6,245 3. Tested for HIV 89,236
7. STI/RTI treated 17 3.1. HIV sero-positive (%) 0.28
8. Presumptive treatment 87 3.2. Linked to ART (%) 96.0

358 Sankalak: Status of National AIDS & STD Response (2023)

 WEST BENGAL

J. Opioid Substitution Therapy 7. Viral Suppression and laboratories

Indicator 2022-23 A. Laboratory facilities and service uptake
1. OST Centres 11
1.1. OSTC in Public Health Settings 7 Indicator 2022-23
1.2. OSTC in NGO Settings 1 1. Viral load laboratories 2
1.3. No. of Satellite OST Centres 3 1.1 Accredited Viral load laboratories 1
2. IDU on OST 900
2. Viral load testing conducted 34,867
5. Early detection of HIV infected people 2.1. Virally suppressed (%) 95.9

A. HIV Counselling and Testing Services (HCTS) 3. National reference laboratories (NRL) 2
3.1 Accredited NRL 2
Indicator 2022-23
1. HCTC facilities 1,015 4. State reference laboratories (SRL) 5
1.1. Stand-Alone 314 4.1 Accredited SRL 5
1.2. Facility integrated (Govt.) 583 5. CD4 testing conducted 30,721
1.3. Facility integrated (PPP) 35
6. External Quality Assessment of ICTC
1.4. CBS 83
1.5. SSK 13 6.1 Average Participation (%) 81.2
6.2. Average Discordance (%) 0.00
B. HIV testing among vulnerable population
(excluding pregnant women) 7. Quality Assurance Scheme for Basic Composite
Medical Laboratories (Entry Level)- M(EL)T
Indicator 2022-23 5
7.1 No. of ICTCs certified for M(EL)T certification
Male Female H/TG Total
1. Tested for HIV 12,31,503 9,77,596 4,660 22,13,759
8. Elimination of Vertical Transmission of
HIV & Syphilis
2. Found HIV Positive
4,212 1,607 91 5,910
among tested A. HIV
3. HIV sero-positivity
(%) among tested
0.34 0.16 1.95 0.27 Indicator 2022-23
4. Spouse/sexual 1. Estimated pregnant women (PW) 16,24,570
partner testing of
2,071 1,799 48 3,918 2. HIV testing among PW 12,74,917
HIV positive people
identified 3. HIV sero-positivity (%) among tested 0.02
5. No. of contacts with 4. HIV Positive PW (old + new detections) 494
‘at-risk’ population
- - - - 4.1 On life-long ART 500
through ‘Sampoorna
Suraksha Kendra’
5. Live births among HIV positive PW 399

6. Initiation and retention on ART of HIV 5.1 Babies given ARV Prophylaxis (%) 100.00
infected people 6. Babies tested HIV (6 week- 6 month) 334
A. Treatment facilities 6.1 Babies confirmed HIV Positive 2
Indicator 2022-23 (6 week- 6 month)
1. ART Centres 26 7. HIV exposed babies at 18 months
2. Centre of Excellence 7.1 HIV exposed babies tested at 18 months 291
2.1. Centre of Excellence (Adult) 1
7.2 Babies confirmed HIV positive at 18 months 8
2.2. Centre of Excellent (Paediatric) 1
8. HIV positive babies initiated on ART 7
3. Link ART Centres 52
4. Care Support Centres 13
B. Syphilis
B. Treatment uptake Indicator 2022-23
Indicator 2022-23 1. Syphilis testing among pregnant women (PW) 14,43,893
Male Female H/TG Total 2. Sero-positivity (%) among tested 0.04
1. HIV positive cases 3. Put on treatment 485
4,212 1,870 91 6,173
diagnosed (At ICTC)
2. New PLHIV 9. Elimination of HIV/AIDS related
Registered at ART 4,017 1,782 96 5,895 Stigma and Discrimination
centre
2.1 Initiated on ART 3,762 1,695 95 5,552 A. HIV
3. PLHIV alive and
31,349 22,759 316 54,424 Indicator 2022-23
on ART
1. State rules notified for HIV/AIDS Prevention and
4. 12 months retention Yes
- - - 84.9 Control Act (2017)
on ART (%)
5. Lost to follow-up cases 6,308 3,679 72 10,059 2. State designated/appointed ombudsman Yes

Sankalak: Status of National AIDS & STD Response (2023) 359

WEST BENGAL

10. HIV-TB Co-morbidities

A. HRG and Bridge Population

Indicator 2022-23

Indicator Quarter FSW MSM IDU H/TG Migrants Truckers Total

Quarter 1 12,857 1,195 733 1,529 3,340 8,452 28,106

Quarter 2 13,444 1,397 581 1,532 3,314 8,502 28,770

Screened for TB
Quarter 3 12,831 1,343 664 1,428 3,080 8,630 27,976

Quarter 4 13,676 1,555 804 1,973 3,463 8,616 30,087

Quarter 1 54 34 1 2 - 2 93

Quarter 2 147 15 1 1 - 4 168

Tested for TB
Quarter 3 72 14 - 2 - 2 90

Quarter 4 200 21 1 - - 1 223

Quarter 1 1 - 1 1 - - 3

Quarter 2 1 - 1 - - - 2
Diagnosed with TB
Quarter 3 - - - - - - -

Quarter 4 - 1 - - - - 1

Quarter 1 1 - - 1 - - 2

Initiated on TB Quarter 2 1 - 2 - - - 3
treatment
Quarter 3 - - - - - - -

Quarter 4 - 1 - - - - 1

B. HIV-TB Cross-Referral

Indicator 2022-23

1. In referral from TB programme 5,22,523

1.1. HIV sero-positive (%) 0.25

1.2. ICTC clients referred to NTEP 47,128

C. HIV-TB Coinfected at ART Centre

Indicator 2022-23

PLHIV PLHIV PLHIV with PLHIV PLHIV Co-infected Co-infected

PLHIV tested
attending underwent presumptive diagnosed initiated on enrolled at initiated on
for TB
ART Centre 4S screening TB with TB IPT ARTc ART

Apr-22 19,848 19,759 307 286 34 391

May-22 22,015 21,929 338 317 23 526

Jun-22 23,288 23,104 347 337 49 487

Jul-22 21,534 21,455 325 319 52 458

Aug-22 21,996 21,958 522 518 45 577

Sep-22 26,570 26,494 449 443 34 706

Oct-22 18,072 18,034 268 265 38 484

Nov-22 28,627 28,545 319 312 41 728

Dec-22 26,612 26,540 330 330 59 906

Jan-23 19,795 18,495 265 249 52 636

Feb-23 22,829 22,763 373 372 34 530

Mar-23 25,495 25,487 338 334 46 420

April 2022-March 2023 1,252 1,164

360 Sankalak: Status of National AIDS & STD Response (2023)

 WEST BENGAL

NATIONAL AIDS & STD CONTROL PROGRAMME

STATE/UT SCORECARD, FY 2022-23
State/UT West Bengal

Rank 11
Sl. No.
Max Marks 120

Obtained Marks (%) 86 (72)

1 First 95 (G=≥95%, Y= 80-94%, R=<80%) Y
2 Second 95 (G=≥95%, Y= 80-94%, R=<80%) Y
3 Third 95 (G=≥95%, Y= 80-94%, R=<80%) G
4 Frequency of social media updates (G=≥90%, Y= 89-75%, R=<75%) Y
5 Status of AEP integration in state school curriculum (G=Yes, R=No) G
6 Status of SCA (G= At least one meeting held since 2017, R= other than G) R
7 Status of state rules (G= Notified, R= Not notified) G
8 Status of ombudsman (G= Appointed, R=Not appointed) G
9 TI/LWS onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
10 OST onboarding (G=≥95%, Y= 90-<95%, R=<90%) G
11 HIV testing among HRG (HIV1 &HIV2) (G=≥95%, Y= 90-<95%, R=<90%) R
12 IDU on OST (G=≥95%, Y= 90-<95%, R=<90%) G
13 Viral load suppression among HRG & BP (G=≥95%, Y= 90-<95%, R=<90%) R
14 HIV testing among partners of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
15 HIV testing among spouse of HRG & BP (G=≥50%, Y= ≥40% to <50%, R=<40%) R
16 HIV testing among prisoners (G=≥50%, Y= ≥40% to <50%, R=<40%) R
17 Condom availability in months (G=≥3M, Y=1-2M, R=<1M) R
18 HIV testing against Target-GC % ((G=≥95%, Y= 80-94%, R=<80%) G
19 HIV testing against target-PW (G=≥95%, Y= 80-94%, R=<80%) G
20 % of pregnant women who initiated ART (G=≥95%, Y= 80-94%, R=<80%) G
21 % of TB suspected cases referred to NTEP (G=≥95%, Y= 80-94%, R=<80%) R
22 Clients managed at DSRC against the target (G=≥90%, Y= 75-89%, R=<75%) R
23 Clinic visit of HRGs at TI-Clinics (G=≥90%, Y= 75-89%, R=<75%) Y
24 Percentage of pregnant women screened for Syphilis (G=≥95%, Y= 80-94%, R=<80%) Y
25 Percentage of HRGs screened for Syphilis (G=≥90%, Y= 75-89%, R=<75%) Y
26 Progress on PLHIV alive on ART, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) G
27 LFU rate among new ART initiation, FY 2022-23 (G=<2%, Y= 2-4%, R=≥5%) G
28 ART Initiation, FY 2022-23 (G=≥95%, Y= 80-94%, R=<80%) Y
29 Status on establishment of CSC (G=≥95%, Y= 80-94%, R=<80%) G
30 % of SRL accredited (G=100%, Y= 80-99%, R=<80%) G
31 % participation of ICTCs in re-testing (G=≥95%, Y= 85-94, R=<85%) R
32 Orientation of SOPs on NACP Data Management & Sharing (G=Yes, R= No) R
33 No. of research projects undertaken in FY 2021-22 (G=4, Y= 2,3, R <2) G
34 No. of research priority areas finalised in FY 2022-23 (G=4, Y= 2,3, R <2) G
35 Institute mapped against all 4 research priority areas for FY 2022-23 (G=4, Y= 2,3, R <2) G
36 Utilisation with respect to funds released during FY 2021-22 (G=≥90%, Y= 85-<90%, R=<85%) R
Submission of EC/GB ratification for approval of Expenditure (FY 2020-21)
37 R
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
Submission of Utilization Certificate (in GFR 12A) for the FY 2021-22
38 Y
(G= by 30th June, Y= 30th Sept, R= beyond 30th Sept/not yet received)
39 Report Submission (BSD-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G
40 Report Submission (CST-SCM Report) (G=>90%, Y= 70-90%, R=<70%) G

Green=3 Marks Yellow=2Marks Red=1 Mark No Colour = Not Applicable

Sankalak: Status of National AIDS & STD Response (2023) 361

GLOSSARY
 S No Indicator Data Source Reference period Description Remarks

Domain: Prevention of new HIV/STI infection among high-risk group and bridge population
Targeted Number of targeted intervention
1 Interventions As on 31st March-2023 Exclusively for HRG and bridge population functional on 31 March for
(TIs) Based on facility data reported the reference period
through spreadsheet and
as received from States/UTs
[April 2022- March 2023] Number of OST centres
2 OST centres As on 31st March-2023 For Injecting Drug users functional on 31 March for the
reference period

Estimated Refers to estimated size of HRGs

Periodic size estimation
3 size of HRG 2021 & 2022 at the physical venues or with the
population network operators.

Refer to the HIV prevalence as

4 HIV Prevalence HIV Sentinel Surveillance 2021 - per the findings from periodic
sentinel surveillance under NACP

Numerator: Number of HRGs & bridge population reached

Based on facility data and by the programme in the reference period (Including
Programme Refer to the programme
5 periodic size estimation FY 2022-23 dynamic Population)
coverage (%) coverage
under the programme

Sankalak: Status of National AIDS & STD Response (2023)

Denominator: Estimated size of HRGs & bridge population

Number of free condoms distributed to HRGs & bridge

Condoms Refer to the number of condoms
6 FY 2022-23 population in the
distributed distributed
Based on facility data reported reference year
through spreadsheet and
as received from States/UTs Refer to the number of HRG,
[April 2022- March 2023] Number of HRGs,
bridge and other vulnerable
7 Tested for HIV FY 2022-23 bridge population and other vulnerable
population screened/tested for
population who tested for HIV in the reference year
HIV

363
 Refer to the number of HRG
Number of HRGs and bridge population and other
population, bridge population
8 Linked to ART FY 2022-23 vulnerable population who linked to the ART in the
and other vulnerable population
reference period

364
linked to ART centre

Numerator: Number of HRGs and bridge population who

detected HIV positive in the
HIV sero-
reference period Refer to the % of key population
9 positive FY 2022-23
Based on facility data reported detected HIV positive
(%)
through spreadsheet and Denominator: Number of HRGs and bridge population
as received from States/UTs tested for HIV in the reference period
[April 2022- March 2023]
Number of HRGs and bridge population visited clinic in the Refer to the number of HRG and
10 Clinic Visits FY 2022-23
reference period bridge population visited clinic

Number of HRGs Refer to the HRG population

11 STI/RTI treated FY 2022-23
diagnosed & treated for STI in the reference period diagnosed and treated for STI

Presumptive Number of HRGs provided presumptive treatment in the Refer to the number of HRGs
12 FY 2022-23
treatment reference period provided presumptive treatment

As on 31st December, Refers to the total number of

13 Total prisons Prison Statistics India 2021 Prison Statistics India of National Crime Records Bureau
2021 prisons in a State

Prisons
covered Consolidated monthly report format in SOCH reporting Refers to the total prisons
14 Based on facility data FY 2022-23
under system of NACP covered under NACP
programme

Refers to all inmates population

in prisons as on 31st December,
Total inmates
15 Prison Statistics India 2021 2021 Prison Statistics India of National Crime Records Bureau 2021 and all other prisoners
admitted
released during the year which
also includes detenues

Districts
covered Number of Link Worker Schemes functional on 31 March for Refer to the number of districts
16 Based on facility data FY 2022-23
under scheme the reference period covered under LWS
LWS

Sankalak: Status of National AIDS & STD Response (2023)

 Vulnerable
Vulnerable Population covered under the Link Worker Refer to the vulnerable
17 population FY 2022-23
Schemes in the reference period population covered
covered

Refer to the number of OST

OSTC in Public Number of main OST centres in public health settings in the
18 FY 2022-23 centres in the public health
Health Settings reference period
setting
Based on facility data reported
through spreadsheet and
OSTC in Number of main OST centres in NGO settings in the Refer to the number of OST
19 as received from States/UTs FY 2022-23
NGO Settings reference period centres in the NGO setting/DIC
[April 2022- March 2023]
Refer to the number of Satellite
No. of Satellite Number of satellite OST centers (linked with either public
20 FY 2022-23 OST Centres both in Public
OST Centres health or NGO main OST centres) in the reference period
Health and NGO setting

Refer to the number of IDU

21 IDU on OST FY 2022-23 Number of active clients on OST
population on OST

Domain: Management of Sexually Transmitted Infection/Reproductive Tract Infections

Number of NACO Supported designated Sexually
STI/RTI FY 2022-23 Transmitted Infections (STI)/Reproductive Tract Infections
22 -
Facilities (RTI) clinics (DSRC/Suraksha Clinics) functional on 31 March
for the reference period

Sankalak: Status of National AIDS & STD Response (2023)

Patients Number of patients managed for Sexually Transmitted
FY 2022-23
23 managed for Infections (STI)/Reproductive Tract Infections (RTI) at DSRC/ -
STI/RTI TI-NGOs in the reference period
Based on facility data reported
through spreadsheet and Number of RPR Tests conducted for syphilis screening
RPR tests as received from States/UTs FY 2022-23
24 among clients (excluding pregnant women) visited at DRSCs -
conducted [April 2022- March 2023] in the reference period

Numerator: Number of clients (excluding pregnant women)

who have tested Syphilis seropositive at DSRCs in the
reference period
Syphilis sero FY 2022-23
25 -
positivity (%)
Denominator: Number of RPR Test conducted for syphilis
among clients visited (excluding pregnant women) at DRSCs
in the reference period

365
 Domain: HIV Counselling and Testing Services

366
Included SA-ICTCs,
Number of HCTS facilities functional on 31 March for the F-ICTCs at Govt. Sector, PPP-
26 ICTC facilities FY 2022-23
reference period ICTC
and CBS

Number of SA-ICTC facilities functional on 31 March for the Functioning as HIV confirmatory
27 Stand-alone FY 2022-23
reference period facilities
Based on facility data reported
Facility
through spreadsheet and Number of F-ICTC Govt. facilities functional on 31 March for Functioning as HIV screening
28 integrated FY 2022-23
as received from States/UTs the reference period sites
(Govt)
[April 2022- March 2023]
Facility
Number of PPP-ICTC facilities functional on 31 March for the Functioning as HIV screening
29 integrated FY 2022-23
reference period sites
(PPP)

Functioning for HIV screening

Number of community- based screening site functional on
30 CBS FY 2022-23 among individuals who seldom
31 March for the reference period
uses health facilities

Included HIV testing conduced

Tested for HIV Number of HIV screening/testing done among ‘at-risk’
FY 2022-23 SA-ICTC, FICTCs, PPP-ICTCs and
(Total) clients (excluding pregnant women) in the reference period
31 CBS

Found HIV
positive among
‘at-risk’ clients Number of confirmed positive results at SA-ICTC Refers to the positive test results
FY 2022-23
(excluding (confirmatory site) in the reference period at confirmatory sites
32
pregnant
women)
Based on facility data reported
HIV sero- through spreadsheet and Numerator: Number of confirmed HIV positive results
positivity as received from States/UTs among samples tested from ‘at-risk’ clients (excluding
(%) among [April 2022- March 2023] pregnant women) in the reference period
‘at-risk’ clients FY 2022-23 -
33 (excluding Denominator: Number of HIV screening/testing done
pregnant among ‘at-risk’ clients (excluding pregnant women) in the
women) reference period

Spouse/sexual
partner testing Number of HIV screening/testing done among spouse or
of identified FY 2022-23 sexual partner of ‘at-risk’ HIV positive clients in the reference -
HIV positive period
34
people

Sankalak: Status of National AIDS & STD Response (2023)

 Domain: Initiation and retention on ART
HIV positive
Number of persons who have been detected HIV positive
35 cases FY 2022-23 -
At ICTC in a reference period
diagnosed

Number of ART centers functional on 31st March for the

36 ART Centres FY 2022-23 -
reference period

Link ART Number of Link ART Centers functional on 31st March for
37 Based on facility data reported FY 2022-23 -
Centres the reference period
through spreadsheet and
as received from States/UTs
Care Support [April 2022- March 2023] Number of CSC functional on 31st March for the reference
38 FY 2022-23 -
Centres period

Centre of
Number of Centre of Excellence (Adult) functional on 31st
39 Excellence FY 2022-23 -
March for the reference period
(Adult)

Centre of
Number of Centre of Excellence (Paediatric) functional on
40 Excellence FY 2022-23 -
31st March for the reference period
(Paediatric)

New PLHIV
Number of PLHIV who have been registered at ART centers

Sankalak: Status of National AIDS & STD Response (2023)

41 Registered at FY 2022-23 -
in a reference period
ART center

Initiated on Number of PLHIV who have been initiated on ART in the

42 As on 31st March 2023 -
ART reference period

PLHIV alive Cumulative number of PLHIV who are Alive and on ART as
43 As on 31st March 2023 -
and on ART on 31st March of reference period

Proportion of PLHIV on ART with no clinical contact or ARV

Based on facility data reported pick-up for 90 days or more since last due date (missed
Lost to follow- through spreadsheet and appointment) + PLHIV not initiated on ART and with no
44 as received from States/UTs As on 31st March 2023 -
up cases clinical contact or visit to health facility for more than or
[April 2022- March 2023] equal to 28 days from the date of registration at ART center
in reference period

Numerator: Number of PLHIV retained on ART after

completion of 12 months from the date of ART initiation in
12 months
Based on persons-based data During April-March the reference period
45 retention on -
in SOCH 2022-23
ART (%)
Denominator: Number of patients who were initiated on

367
ART during the reference cohort
 Domain: HIV-TB Co-infection Management

368
ICTC client
Number of HIV positive and HIV negative cases referred to
46 clients referred FY 2022-23 -
NTEP
to NTEP
Based on facility data reported
through spreadsheet and Numerator: Number of HIV positive results among samples
as received from States/UTs from referred TB cases in the reference period
HIV sero- [April 2022- March 2023] FY 2022-23
47 positive (%) -
Denominator: Number of HIV tests done among TB cases
(NTEP-ICTC)
referred from NTEP at confirmatory facility in reference
period

Domain: Laboratory Services

National
FY 2022-23 Number of National Reference laboratories under NACP
48 Reference -
functional on 31 March for the reference period
Laboratories

State
Based on facility data Number of State Reference laboratories under NACP
49 Reference FY 2022-23 -
functional on 31 March for the reference period
Laboratories

Viral Load Number of Viral load testing laboratories under NACP

50 FY 2022-23 -
testing Lab functional on 31 March for the reference period

Numerator: Number of valid viral load tests results with

<1000 copies per ml in
Viral Load (% Monthly report from Viral the reference period
51 FY 2022-23 -
Suppression load testing laboratories
Denominator: Number of viral load tests conducted in the
reference period

Numerator: Number of HIV reference laboratories/ICTC

Panel Testing participated in panel testing
52 (% FY 2022-23 -
Participation) Denominator: Number of HIV reference laboratories/ICTC
in the reference period
Bi-annual reporting by
ICMR-NARI
Numerator: Number of HIV reference laboratories/ICTC with
Panel Testing discordant result in panel testing
53 (% FY 2022-23 -
Performance) Denominator: Number of HIV reference laboratories/ICTC
participated in panel testing in the reference period

Sankalak: Status of National AIDS & STD Response (2023)

 Numerator: Number of ICTCs participated in Retesting
in the reference period
Re-testing (%
54 FY 2022-23 -
Participation)
Denominator: Number of ICTCs in the state in the
reference period
Quarterly reporting by SACS
Numerator: Number of ICTCs with discordant result in
retesting in the reference period
Re-testing (%
55 FY 2022-23 -
Performance)
Denominator: Number of ICTCs participated in Retesting
in the reference period

Viral Load
External Auto calculated through NACO
56 - FY 2022-23 -
Quality PRAYOG SHALA “tool”
Assurance

No. of ICTCs
Numerator: Number of ICTCs who have achieved
certified for
M(EL)T certificate
57 M(EL)T Quarterly reporting by SACS FY 2022-23 -
certification
Denominator: Target given to States in Annual Action Plan

Domain: Elimination of Vertical transmission of HIV and Syphilis (EVTHS)

Sankalak: Status of National AIDS & STD Response (2023)

Estimated
Estimated number of pregnant women in the reference
58 Pregnant National Health Mission (NHM) FY 2022-23 -
period
Women (PW)

Estimated Estimated number of HIV-positive women giving birth in

HIV Estimations 2022, NACO/
59 need for EVTH- 2022 calendar year and, therefore, in need of prophylaxis to -
NIMS (Biennial measurement)
related services prevent HIV transmission to the baby

HIV testing Number of HIV screening/testing done among pregnant

60 FY 2022-23 -
among PW women in the reference period

Pregnant
Number of pregnant women attending antenatal care (ANC)
61 Women tested FY 2022-23 Account for the repeat testing
Based on facility data reported clinic who were tested for HIV in the reference period
for HIV
through spreadsheet and
as received from States/UTs
[April 2022- March 2023] Numerator: Number of confirmed HIV test results among
HIV Positive pregnant women attending ANC clinic in the reference
among period Confirmed HIV positive out of
62 FY 2022-23
Pregnant tested (excluding known Positive)
Women (%) Denominator: Number of pregnant women attending ANC

369
clinic who were tested for HIV in the reference period
 Based on facility data reported HIV test done
through spreadsheet and Numerator: Number of pregnant women attending ANC
among
Coverage for as received from States/UTs clinic who were tested for HIV during pregnancy or already
Pregnant

370
HIV testing of [April 2022- March 2023] knew their HIV positive status in the reference period
63 FY 2022-23 women against
Pregnant
estimated
Women (%) Denominator: Estimated number of Pregnant women in the
need
reference period
National Health Mission (NHM)

HIV positive
Numerator: Number of Positive PW initiated/already on ART
PW initiated on
during the FY (Known + New)
ART for EVTHS
64 FY 2022-23 -
(%)
Denominator: Number of Positive PW newly diagnosed at
(Facility-level
ICTC and known positive registered ARTCs
denominator)

HIV positive
PW initiated on Based on facility data reported
Numerator: Number of Positive PW Initiated on ART
ART for EVTHS through spreadsheet and
treatment during the FY (Known + New)
65 (%) as received from States/UTs FY 2022-23 -
(Population [April 2022- March 2023]
Denominator: Estimated need for EVTH-related services
level
denominator)

Numerator: Number of HIV exposed babies initiated on

ARV prophylaxis in the reference period
Babies given
66 FY 2022-23 -
ARV Drug (%)
Denominator: Number of live birth to HIV positive pregnant
women in the reference period

Babies tested
Number of HIV exposed babies who have tested for TNA
for HIV (6
67 FY 2022-23 PCR test in between the age of 6 weeks to 6 months in the -
week-
reference period
6 month)

Numerator: Number of HIV exposed babies who have found

Babies HIV positive in TNA PCR test in the reference period
confirmed HIV
68 FY 2022-23 -
positive (6week Denominator: Number of HIV exposed babies who have
- 6month) tested for TNA PCR test in between the age of 6 weeks to 6
months in the reference period

Numerator: Number of babies initiated on ART who have

HIV positive
been found HIV positive in TNA PCR test in the reference
babies initiated
period
69 on ART (6 FY 2022-23 -
week- 6
Denominator: Number of babies who have found HIV
month))
positive in TNA PCR test in the reference period

Sankalak: Status of National AIDS & STD Response (2023)

 HIV exposed Number of HIV exposed babies who have tested for
70 babies tested FY 2022-23 Antibody test at 18 months for HIV confirmation in the -
at 18 months reference period

Numerator: Number of HIV exposed babies who have

confirmed HIV positive in Antibody test at 18 months in the
HIV positive reference period
71 babies at 18 FY 2022-23 -
months Denominator: Number of HIV exposed babies who have
tested for Antibody test at 18 months for HIV confirmation
Based on facility data reported in the reference period
through spreadsheet and
as received from States/UTs Numerator: Number of babies initiated on ART who have
[April 2022- March 2023] Confirmed HIV positive in 18 Months test in the reference
HIV positive
period
72 babies initiated FY 2022-23 -
on ART
Denominator: Number of babies confirmed HIV Positive
babies at 18 Months

Numerator: Number of pregnant women tested for syphilis

in the reference period
Syphilis testing
73 FY 2022-23 -
among PW
Denominator: Estimated number of pregnant women in the
reference period

Sankalak: Status of National AIDS & STD Response (2023)

Numerator: Number of pregnant women attending
antenatal care (ANC) clinic who were confirmed positive for
Syphilis Syphilis
Sero-positivity in the reference period
74 FY 2022-23 -
(%) among
tested Based on facility data reported Denominator: Total Number of pregnant women attending
through spreadsheet and antenatal care (ANC) clinic who were tested for Syphilis in
as received from States/UTs the reference period
[April 2022- March 2023]
Numerator: Number of Syphilis Reactive PW women
Put on receiving Syphilis treatment in the reference period
75 FY 2022-23 -
treatment
Denominator: Number of PW found Syphilis Reactive

371
“Sankalak - Status of National AIDS & STD
Response” is the evidence driven flagship
report of NACP, detailing the National AIDS
& STD Response toward the 2030 goal to end
the epidemic of HIV/ AIDS. ‘Sankalak’ reports
the robust programmatic and epidemic data
Nationally and by State/Union Territories (UT)
under NACP. In this fifth edition of Sankalak,
the progress across HIV care continuum for the
financial year 2022-23 is summarized”.